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Abstract 
Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an effective treatment for the 
motor symptoms of Parkinson’s disease, leading to substantial improvements in quality of life 
for most. However, a proportion of persons develop psychiatric symptoms in the postoperative 
period. These are typically linked to the titration of electrical stimulation and may be 
remediated by device reprogramming. However, even when transient, these psychiatric 
symptoms can be upsetting for the individual, stressful for close family members and limit 
gains in quality of life despite good postoperative motor outcomes. Given the importance of 
STN-DBS as an advanced therapy for Parkinson’s disease, methods to reduce the incidence 
and severity of these side effects would be of substantial clinical significance. 
 
Mood and personality changes are the most commonly reported adverse psychiatric sequelae 
of DBS. Phenomenologically, these changes are often marked by impulsivity: a tendency to 
act recklessly without due forethought. Impulsive decision-making is a major driver of 
financial, occupational and social harms, including postoperative relationship discord, 
relationship breakdown and even suicide. 
 
Clinicians undertaking DBS do not have a reliable method of predicting candidates ‘at risk’ of 
these complications. Instead, they rely on persons with Parkinson’s disease or their caregivers 
alerting them to these issues after discharge from hospital. Individuals may lack insight into 
the nature or severity of their personality change, delaying their presentation until after damage 
to finances, relationships and reputation has occurred.  
 
The overall goal of this investigation was to use a range of methods (quantitative, qualitative, 
neuroimaging and computational) to study impulsivity and other associated psychiatric 
symptoms after STN-DBS for Parkinson’s disease. The objective was to delineate effects on 
carer burden and examine the biological underpinnings of these symptoms, with the aim of 
predicting and preventing personality change in future cohorts. It was proposed that the site 
and distribution of the stimulation field, as well as the connectivity of the stimulation field with 
cortical regions of the brain, could be used as a predictor of post-DBS psychiatric symptoms 
and that reliable indicators of ‘safe’ stimulation could also be found.  
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The thesis begins with a broad introductory chapter on Parkinson’s disease and STN-DBS. The 
substantial impact of psychiatric symptoms in Parkinson’s disease upon caregiver burden is 
then reviewed. This is followed by an exploration of the specific neuropsychiatric symptoms 
germane to STN-DBS and the role of a psychiatrist in managing these difficulties. A particular 
case involving post-DBS neuropsychiatric complications is presented, with an initial analysis 
that suggests the site of stimulation and distribution of the stimulation field may have a role in 
the genesis of these symptoms.  
 
Subsequently, the longitudinal trajectories of neuropsychiatric symptoms and caregiver burden 
after STN-DBS are evaluated in a clinical cohort of participants, allowing inference upon the 
key drivers of burden and their temporal evolution. The meaning and significance of post-DBS 
neuropsychiatric symptoms is considered in a qualitative study including contributions from 
both persons with Parkinson’s disease and their caregivers.  
 
The methods introduced in the case study are then extended to a larger sample of participants, 
in whom the location and distribution of the subthalamic stimulation field iss modelled, 
revealing that psychiatrically ‘safe’ and ‘unsafe’ regions of the STN can be delineated and that 
these data can be used in a predictive fashion.  
 
A new behavioural assay is introduced: the ‘virtual casino’, in which participants can express 
a number of risk-taking behaviours in an ecologically-valid paradigm that overlaps with the 
spectrum of compulsive behaviours observed after STN-DBS. Using the virtual casino, 
estimates of environmental uncertainty (volatility) and stochasticity in belief-to-choice 
mapping are found to be linked to impulsive behaviour. Furthermore, estimates of uncertainty 
and stochasticity increase following STN-DBS and the magnitude of these changes is 
associated with postoperative impulsivity, implicating a role for the STN in the modulation of 
outcome certainty and offering a potential computational explanation of post-DBS impulsivity.  
 
Using high-resolution diffusion imaging, the structural connectivity of brain networks 
implicated in impulsivity are reconstructed. Prior to STN-DBS, impulsivity co-varies with 
structural connectivity of these intrinsic networks. Individuals with clinically-significant 
impulse-control behaviours (due to dopaminergic therapies) can be discriminated based on the 
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interaction of structural connectivity and gambling behaviour in the virtual casino. Following 
STN-DBS, the structural connectivity of the stimulation field with cortical regions is the key 
determinant of impulsivity. Individuals with clinically-significant neuropsychiatric symptoms 
can again be differentiated based on the interaction of structural connectivity and gambling, 
with a particular white-matter prefrontal tract implicated in this phenomenon.  
 
Finally, a manualised programme of psychotherapy is developed and introduced to a small 
group of caregivers reporting high levels of burden, with preliminary data on efficacy and 
acceptability.  
 
The findings of this investigation promise to improve the perioperative care of persons with 
Parkinson’s disease undertaking STN-DBS, through the proactive identification of candidates 
who are more likely to suffer impulsivity and personality change after surgery, as well as 
caregivers who are more likely to suffer burden. Furthermore, our examination of the 
anatomical and behavioural correlates of these phenomena shed light on the workings of the 
brain with applicability not only to Parkinson’s disease but also other psychiatric disorders 
accompanied by impulsivity. Future work will apply these data prospectively to guide DBS 
electrode implantation and stimulation titration to mitigate non-motor side effects.  
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Chapter 1 
1 Introduction 
‘During all these years of illness I was asleep. Now I am stimulated, stimulated to lead a different life.’ 
DBS patient, quoted in: ‘A Distressed Mind in a Repaired Body?’ (Schupbach et al., 2006). 
1.1 Parkinson’s Disease 
Parkinson’s disease is a progressive, incurable, neurodegenerative disorder characterised by 
motor symptoms: tremor, rigidity, bradykinesia, postural instability and gait disturbance. The 
neuropathology of Parkinson’s disease involves the intracellular aggregation of protein 
inclusions containing misfolded alpha-synuclein (Lewy bodies). This is most pronounced in 
the substantia nigra pars compacta of the brain, leading to the degeneration of dopaminergic 
neurons in the basal ganglia. The loss of cells in the substantia nigra is well established before 
the first manifestation of motor symptoms and neurodegeneration continues after diagnosis in 
other regions of the brainstem and cerebral cortex. Therefore, although in its early stages 
Parkinson’s disease may cause only mild functional disability, in later stages sufferers become 
profoundly dependent. The median time from onset to death from Parkinson’s disease is 
approximately nine to fifteen years (de Lau et al., 2005; Forsaa et al., 2010). 
 
Parkinson’s disease is the second most common neurodegenerative disease after Alzheimer’s 
disease, with median age-standardised annual incidence rates in high-income countries of 14 
per 100 000 people in the total population, and 160 per 100 000 people aged sixty-five years or 
older (Hirtz et al., 2007). The incidence of Parkinson’s disease increases rapidly with age after 
fifty, although a significant minority of individuals develop this condition in their thirties and 
forties. The male to female (M:F) incidence ratio is approximately 3:2. In Australia, it is 
estimated that over 64 000 individuals are currently living with Parkinson’s disease, equating 
to approximately 1 per 350 people (Deloitte Access Economics, 2015). Parkinson’s disease 
incurs a total financial cost (direct healthcare costs, lost productivity and informal care) per 
year of AUD 775 million. The lifetime cost of Parkinson’s disease per sufferer is similar to 
cancer (Deloitte Access Economics, 2015). The number of people living with Parkinson’s 
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disease is expected to increase by fifty percent by 2030, based on estimates of increased life 
expectancy, an ageing population and the strong association between age and onset of 
symptoms (Dorsey et al., 2007).  
 
Although age is the biggest risk factor for developing Parkinson’s disease, several other risk 
and protective factors have been identified (reviewed in Ascherio and Schwarzschild (2016)). 
Exposure to pesticides, high dairy consumption, methamphetamine use, traumatic brain injury 
and a diagnosis of melanoma increase the longitudinal risk of developing Parkinson’s disease. 
Tobacco use, caffeine use, non-steroidal anti-inflammatory use and vigorous exercise are 
protective against developing Parkinson’s disease. Genetic factors also make an important 
contribution to the risk of developing Parkinson’s disease. Monogenic forms of Parkinson’s 
disease include mutations in the genes SNCA, LRRK2 and parkin (Corti et al., 2011; 
Polymeropoulos et al., 1997), whilst single-nucleotide polymorphisms conferring an increased 
genetic risk of developing Parkinson’s disease have been identified from genome-wide 
association studies (Nalls et al., 2014). These common genetic variants may act synergistically 
with environmental risk factors; for example, the risk reduction conferred by caffeine use is 
mediated through single-nucleotide polymorphisms in the cytochrome P450 system 
responsible for caffeine metabolism (Popat et al., 2011). 
 
There is no test that permits definitive diagnosis of Parkinson’s disease at early stages of the 
disease. The gold standard remains the detection of Lewy body pathology at post-mortem 
examination. Clinically, the diagnosis is made using established consensus criteria, which 
comprise the presence of cardinal motor symptoms, the absence of symptoms suggesting 
another disorder and supportive features including unilateral onset, persisting asymmetry of 
symptoms, progression and responsiveness to levodopa (Hughes et al., 1992). Motor symptoms 
are heterogeneous and three major subtypes have been defined with differing prognostic 
implications (Jankovic et al., 1990): tremor-dominant Parkinson’s disease (with a relative 
absence of other motor symptoms); akinetic-rigid Parkinson’s disease (with a relative absence 
of tremor) and an intermediate mixed phenotype.  
   
Dopamine replacement therapy provides substantial relief from the motor symptoms of 
Parkinson’s disease. These drugs increase dopamine concentrations or directly stimulate 
dopamine receptors in the brain. They include levodopa, dopamine agonists, monoamine 
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oxidase inhibitors and catechol-O-methyltransferase (COMT) inhibitors. Unfortunately, for 
many persons the window of therapeutic benefit gradually narrows and individuals fluctuate 
between phases where motor control is good (‘on’) and periods without alleviation of 
symptoms (‘off’) in a dose-dependent fashion. Performance during ‘on’ periods may also be 
limited by abnormal involuntary choreiform or dystonic movements (dyskinesias) that 
associate in a peak or biphasic pattern with levels of levodopa. After five years of treatment 
with dopamine replacement therapy, forty percent of patients suffer from such complications 
(Ahlskog and Muenter, 2001). 
1.2 Deep Brain Stimulation 
Deep brain stimulation (DBS) provides a relatively constant and predictable improvement in 
the motor symptoms of Parkinson’s disease. In a surgical procedure, DBS electrodes are 
positioned within deep brain nuclei. These emit continuous, high-frequency stimulation that 
modulate disordered basal ganglia activity. Of four possible sites, the most common procedure 
is bi-hemispheric implantation in the subthalamic nucleus (STN). Randomised, controlled trial 
data indicate that bilateral STN stimulation increases ‘on’ time, reduces motor fluctuations and 
dyskinesias, enhances performance of activities of daily living and improves quality of life 
(Deuschl et al., 2006). The dose of dopaminergic medication is often substantially reduced 
(Williams et al., 2010). Guidelines exist to assist with the selection of patients who may benefit 
from DBS and referral to a DBS centre is recommended when satisfactory motor control 
becomes difficult (Silberstein et al., 2009). Contemporary evidence indicates that DBS 
provides superior benefits when compared to other available treatments (Schuepbach et al., 
2013). Its use in the treatment of Parkinson’s disease is set to grow as available data suggest 
benefits are greater when it is used relatively early in the course of the disease (Schuepbach et 
al., 2013). More than 100 000 individuals have had DBS for Parkinson’s disease since 1997 
(Medtronic data).  
  
DBS is a specialised treatment delivered in ‘quaternary-referral’ centres. The Asia-Pacific 
Centre for Neuromodulation (APCN) is a DBS centre based at St Andrew’s War Memorial 
Hospital in Brisbane, Australia. It specialises in the treatment of movement disorders, including 
Parkinson’s disease, essential tremor, dystonia and Tourette’s syndrome. The APCN is the 
largest DBS centre in Australasia and one of the largest worldwide, completing approximately 
one hundred cases per year. The clinical team at the centre includes two neurologists, a 
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neurosurgeon, two specialist nurses, a rehabilitation physician, a psychologist and two 
psychiatrists.  
 
Individuals with Parkinson’s disease are referred to the lead neurologist at the centre who 
evaluates their candidacy for DBS. The strongest predictor of an optimal motor response to 
DBS is the person’s response to dopaminergic therapy. In general, DBS provides a benefit 
equivalent to the best response to medication. Drug-resistant symptoms are unlikely to respond 
to DBS. Problems with speech and postural stability are also not well treated. Advanced age, 
severe cognitive impairment and unstable medical co-morbidities (particularly coagulopathies 
and ischaemic heart disease) are relative contraindications to neurosurgery. The neurologist 
outlines the surgical risks of the procedure, which include intracranial bleeding (<1 % risk) and 
infection of the device (~2 % risk). The latter complication is not usually life threatening but 
may necessitate explantation of the device and reinsertion after treatment with antibiotics.  
 
Subsequently, the liaison psychiatrist (this thesis author) reviews eligible surgical candidates 
in a ‘pre-DBS psychiatric assessment’ clinic, typically accompanied by a spouse or partner. 
This visit is an opportunity to screen again for major cognitive impairment and the presence of 
active, symptomatic psychiatric co-morbidities, which can be treated before the person 
proceeds to surgery. The psychiatrist discusses the risk, presenting features, significance and 
impact of psychiatric complications of DBS, which may include mania, depression, 
impulsivity, loss of empathy, apathy and suicidal behaviour. Surgical candidates are 
encouraged to consider prospectively how they would wish to be treated in the event of such a 
complication and are made aware of pathways to accessing urgent medical care at the centre.  
 
Consenting patients proceed to surgery after their psychiatric visit. Treatment with 
dopaminergic medication continues until the date of operation. The day prior to surgery, the 
person with Parkinson’s disease undertakes a Magnetic Resonance Imaging (MRI) brain scan, 
which allows the neurologist and neurosurgeon to visualise the subcortical targets for 
neuromodulation. Although the onset of motor symptoms in Parkinson’s disease is typically 
unilateral, almost all surgical candidates now have (or will soon develop) bilateral symptoms 
and thus one electrode is placed in each hemisphere of the brain. On the day of surgery, the 
neurosurgeon attaches a metal stereotactic frame to the skull of the patient and fuses a 
Computed Tomography (CT) brain scan (with the frame attached) to the existing MRI scan. 
This fused image is used to calculate the precise three-dimensional intra-cranial coordinates of 
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the surgical target. Under general anaesthesia the neurosurgeon drills a small burr hole on each 
side of the patient’s skull and passes a recording electrode along a pre-determined trajectory to 
the target structure. Accurate placement in the STN is confirmed using intra-operative 
microelectrode recording of local field potentials, and later by briefly rousing the patient from 
anaesthesia. At this time, the neurologist can assess the effect of intra-operative stimulation on 
the patient’s motor symptoms and screen for any unwanted motor or sensory effects (such as 
facial pulling, gaze deviation or paraesthesia). Once accurate placement is verified, permanent 
stimulating electrodes are inserted and their final position is verified using another CT brain 
scan.  
 
Professor Peter Silburn visualises the subcortical structures and determines the trajectory for the passing of the DBS electrode 
to the surgical target. 
 
Figure 1.1 | Targeting the Subthalamic Nucleus 
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Associate Professor Terry Coyne (left) inserts a DBS electrode using a stereotactic apparatus. Professor Peter Silburn (far 
right) monitors the response of the patient.  
 
The implanted stimulating electrodes are routed subcutaneously and connected to a pulse 
generator sited in the pectoral or abdominal fascia. Each electrode comprises between four to 
eight contacts, any number of which can be activated to deliver a square wave pulse of charge 
in the local neural elements. In the electrical circuit, the charge is delivered by means of at least 
one positive (anodal) and one negative (cathodal) terminal. Initially, the device is programmed 
with one contact as the cathode and the pulse generator as the anode, a configuration known as 
‘monopolar’. This gives rise to an approximately spherical field of charge with a relatively 
wide distribution within the local tissue. A configuration with both anode and cathode on the 
same electrode is known as ‘bipolar’ and delivers a more focussed stimulation field. Higher 
amplitudes are required to produce an equivalent distribution of charge in the bipolar 
configuration. Some stimulating electrodes are manufactured with ‘segmented’ contacts, which 
Figure 1.2 | Intraoperative Insertion of the DBS Electrodes 
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allows the clinician to activate only a portion of the ring of the selected contact, causing the 
electrical charge to be ‘directed’ towards the chosen target structure (referred to as current 
steering). The amount of charge delivered is a function of the stimulation amplitude and the 
impedance of the neural substrate. The amplitude can be modulated postoperatively and non-
invasively using a clinician programmer that communicates wirelessly with the pulse 
generator. Neurons close to the electrode are most likely to be activated by a given charge, as 
the activation threshold of a neuron increases as the square of the distance from a cathode 
(Bagshaw and Evans, 1976). 
  
The duration (or width) of the stimulation pulses also has a differential effect on neural 
elements. Larger neurons have a lower chronaxiae (i.e. they are more excitable and can be 
recruited at lower pulse widths). Therefore, for a given pulse width and stimulation amplitude, 
the volume of activation for large versus small neural elements differs, with smaller and less 
excitable neurons showing a more restricted pattern of activation closer to the cathode. As the 
pulse width is increased, a greater number of smaller elements are activated and the difference 
in activation radius equalises. Typical pulse widths used in the management of Parkinson’s 
disease range from 30-90 microseconds.  
 
At the level of the neuron and neurocircuit, the mode of action of DBS is complex and not fully 
understood. Negatively charged ions are injected into brain tissue and move in the extracellular 
space. These can have a variable effect on the membrane potential of individual neurons 
depending on their position and orientation with the stimulation field. Direct axonal activation 
may excite neurons or inhibit activity through activation of inhibitory afferents. Early 
assumptions that DBS creates a reversible lesion, or introduces a ‘correct’ pattern of neuronal 
discharges, have given way to the more sophisticated theory that DBS modulates pathological 
network activity such as the burst firing of STN neurons seen in animal models of Parkinson’s 
disease (Vila et al., 2000). For DBS to have clinically-significant effects, it is likely that a 
certain minimal volume of neural tissue must be activated. Preliminary work has approximated 
this to a radius of 2.5 mm around the active contact (Madler and Coenen, 2012; Maks et al., 
2009). 
 
At the APCN, the DBS device is activated at a low level intra-operatively and the patient is 
moved to the intensive care unit for twenty-four hours, before returning to the surgical ward. 
Although an optimal contact has been identified in theatre, the lead neurologist reviews the 
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patient several times per day during this time to corroborate the persistence of effective therapy 
and to trial alternative contacts if necessary. Excepting surgical complications, recovery from 
functional neurosurgery is relatively swift and persons with Parkinson’s disease are typically 
discharged home within five days of DBS device implantation.  
 
Persons with Parkinson’s disease return to the clinic weekly to fortnightly during the initial 
postoperative months and are reviewed by the DBS clinicians. Reduction of dopaminergic 
medication has begun following surgery and proceeds relatively swiftly as the device is 
manipulated to give greater stimulation amplitude at the chosen contact. Increases in 
stimulation are guided by the patient’s level of symptom relief and the emergence of side 
effects. Motor side effects may include dyskinesia (if stimulation titration is too rapid), 
worsening of dysarthria, blepharospasm and gaze palsy. Inadequate response to treatment at an 
adequate amplitude and pulse width, or the emergence of significant side effects, may prompt 
a switch to a bipolar stimulation configuration or selection of an alternative contact on the 
electrode. At this stage, the gross anatomical position of the electrodes can again be confirmed 
using CT brain imaging but their connection to more fine-grained neuroanatomical structures 
cannot be verified. Treatment is therefore empirical, with iterative feedback from the patient 
and their caregivers following programming changes that occur in the clinic. It may take six to 
twelve months to find the optimal stimulation parameters, with the slow accrual of motor 
benefits during this time. Educating the patient and their family about this relatively slow 
postoperative course is undertaken during the preoperative assessment process.  
 
The liaison psychiatrist (this thesis author) reviews all persons with Parkinson’s disease during 
the titration of neurostimulation, as this is the period during which emergent psychiatric 
symptoms are most likely to occur. The presentation and management of these symptoms is 
described in detail in Chapter 3 of this thesis.  
1.3 Objectives and Structure of this Thesis 
A significant proportion of persons with Parkinson’s disease undertaking STN-DBS develop 
postoperative psychiatric symptoms including impulsivity, mood and personality changes. For 
these individuals, quality of life after DBS may worsen rather than improve, associated with 
relationship breakdown and even suicide (Lewis et al., 2014; Lewis et al., 2015; Oyama et al., 
2014; Perozzo et al., 2001; Soileau et al., 2014; Voon et al., 2006; Voon et al., 2008). Clinicians 
Chapter 1  9 
 
   
do not have a reliable method of predicting which persons are ‘at risk’ of these symptoms. 
Instead, they rely on the person with Parkinson’s disease or their caregiver bringing these issues 
to the attention of the treating team after they have arisen. However, individuals may lack 
insight into the nature or severity of their personality change, delaying their presentation until 
after damage to finances, relationships and reputation has occurred.  
 
The overall goal of this investigation is to quantify, characterise, predict and prevent 
neuropsychiatric complications after STN-DBS for Parkinson’s disease. At present, it is not 
possible to foresee who will go on to develop postoperative neuropsychiatric problems from 
clinical characteristics at baseline. However, it is possible that a closer behavioural 
phenotyping of DBS candidates may improve the sensitivity and specificity of this approach. 
Additionally, clinical observation suggests that modulating the site and distribution of 
stimulation through adjusting the stimulation parameters has a direct and immediate role in the 
management of post-DBS personality change. This is supported by existing data on the 
anatomy of the STN, which suggests that differential modulation of discrete neural circuits 
may underlie psychiatric symptoms in a subpopulation of patients (Haynes and Haber, 2013; 
Lambert et al., 2012). Specifically, those persons who are impulsive may show strong 
connectivity between the stimulation site and the prefrontal cortex, with weaker connectivity 
between the stimulation site and the motor cortex. It is therefore conceivable that a major 
determinant of postoperative neuropsychiatric symptoms may be the interaction between brain 
anatomy and electrode position for a given individual, acting on a vulnerable neuroanatomical 
and neuropsychological substrate.  
 
The overarching investigation is a large multimodal study including quantitative, qualitative, 
computational and neuroimaging arms. Participants and their spouses were recruited 
consecutively from the movement disorders clinic during their passage from pre- to 
postoperative status. A unique aspect of this investigation is that it specifically examines the 
experience of and seeks information from the spouse or caregiver. This adds an extra dimension 
that has been largely neglected in investigations to date. Furthermore, this study evaluates 
participants longitudinally at multiple intervals, allowing a more complex interpretation of 
temporal dynamics than simple pre-post designs.  
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In the following thesis, two introductory review chapters cover the substantial impact of 
psychiatric symptoms in Parkinson’s disease upon caregiver burden (Chapter 2) as well as the 
specific neuropsychiatric symptoms germane to STN-DBS (Chapter 3). An illustrative case 
involving post-DBS neuropsychiatric complications is presented (Chapter 4), with an initial 
analysis that suggests the site of stimulation and distribution of the stimulation field may have 
a role in the genesis of these symptoms.  
 
The longitudinal trajectories of neuropsychiatric symptoms and caregiver burden after STN-
DBS are evaluated (Chapter 5), allowing inference upon the key drivers of burden and their 
temporal evolution. The meaning and significance of post-DBS neuropsychiatric symptoms is 
considered in a qualitative study including contributions from both persons with Parkinson’s 
disease and their caregivers (Chapter 6).  
 
The methods introduced in the case study are then extended to a larger sample of participants 
(Chapter 7), in whom the location and distribution of the subthalamic stimulation field is 
modelled, revealing that psychiatrically ‘safe’ and ‘unsafe’ regions of the STN can be 
delineated and that these data can be used in a predictive fashion.  
 
A new behavioural assay is introduced: the ‘virtual casino’, in which participants can express 
a number of risk-taking behaviours in an ecologically-valid paradigm that overlaps with the 
spectrum of compulsive behaviours observed after STN-DBS (Chapter 8). Using the virtual 
casino, estimates of environmental uncertainty (volatility) and stochasticity in belief-to-choice 
mapping are found to be linked to impulsive behaviour. Furthermore, estimates of uncertainty 
and stochasticity increase following STN-DBS and the magnitude of these changes is 
associated with postoperative impulsivity, implicating a role for the STN in the modulation of 
outcome certainty and offering a potential computational explanation of post-DBS impulsivity.  
 
Using high-resolution diffusion imaging, the structural connectivity of brain networks 
implicated in impulsivity are reconstructed. Prior to STN-DBS (Chapter 9), impulsivity co-
varies with structural connectivity of these intrinsic networks. Individuals with clinically-
significant impulse-control behaviours (due to dopaminergic therapies) can be discriminated 
based on the interaction of structural connectivity and gambling behaviour in the virtual casino. 
Following STN-DBS (Chapter 10), the structural connectivity of the stimulation field with 
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cortical regions is the key determinant of impulsivity. Individuals with clinically-significant 
neuropsychiatric symptoms can again be differentiated based on the interaction of structural 
connectivity and gambling, with a particular white-matter prefrontal tract implicated in this 
phenomenon.  
 
Finally, a manualised programme of psychotherapy is developed and introduced to a small 
group of caregivers reporting high levels of burden, with preliminary data on efficacy and 
acceptability (Chapter 11).  
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Chapter 2 
2 Caregiver Burden in Parkinson’s Disease 
‘My biggest fear... I can cope with absolutely anything, if he's quadriplegic it's fine, I can deal with that, but I 
can't deal with the psychiatric changes, it scares me too much. How he behaved…, I can't do that again.’ 
Spouse of a DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
2.1 Publication Details 
This chapter was published as: 
Mosley, P.E., Moodie, R. & Dissanayaka, N., 2017. Caregiver burden in Parkinson disease: a 
critical review of recent literature. Journal of Geriatric Psychiatry and Neurology. 30, 1-18. 
2.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, carried out the literature review, synthesised the 
data and wrote the manuscript. Ms Moodie contributed to the literature search and Dr 
Dissanayaka assisted with revisions to the manuscript.  
2.3 Abstract 
Burden is a negative psychological state induced in caregivers by the demands of providing 
care to a person with an illness or disability. Managing caregiver burden in Parkinson’s disease 
is significant because informal caregivers make a substantial contribution to the wellbeing of 
persons with this neurodegenerative disorder, incurring financial, social and personal losses. 
Failure to recognise and manage caregiver burden may lead to burnout and premature 
institutionalisation of the person with Parkinson’s disease. We conducted a comprehensive 
literature review to identify and summarise factors that may amplify burden, including motor 
and non-motor symptoms of Parkinson’s disease, caregiver psychiatric symptoms and 
caregiver coping style. We reviewed instruments designed to sample the construct of burden 
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amongst caregivers and evaluated interventions that may reduce burden, either by directly 
targeting caregivers or by treating symptoms of Parkinson’s disease associated with burden. 
We aim to provide a concise synopsis of these issues for the clinician or researcher working 
with this population in order to facilitate recognition of caregiver burden, as well as to enable 
accurate assessment of this construct, the administration of appropriate interventions and the 
stimulation of further research in this area.  
2.4 Introduction 
Caregiver burden can be operationalised as ‘the extent to which caregivers perceive that 
caregiving has had an adverse effect on their emotional, social, financial, physical and 
spiritual functioning’ (Zarit et al., 1986). It is a broad, multidimensional construct that reflects 
the unique experience of caregiving for individuals from different backgrounds, with differing 
levels of resilience and resources, facing distinctive illness-specific symptoms.  
 
The recognition of caregiver burden is important for the clinician who avows a holistic 
assessment of the person with Parkinson’s disease. Persistent burden may lead to strain, an 
enduring change in the caregiver’s sense of wellbeing that predisposes to burnout (Thornton 
and Travis, 2003). Not only does this create an ‘invisible patient’ in the patient-physician-
caregiver system, but it also diminishes the effectiveness of the caregiver and their ability to 
maintain their informal role as a partner in treatment. Beyond the health-related benefits to the 
person with Parkinson’s disease of having an effective caregiver, the economic benefits to 
society from informal caregiving are substantial. Delaying formal state-supported home care 
or avoiding premature institutionalisation is extremely cost-effective (Arno et al., 1999). In 
Australia, 2014 estimates suggest that Parkinson’s disease caregivers provide nineteen million 
hours of care, equivalent to AUD 78.2 million (USD 53.84 million) based on the opportunity 
cost estimation approach (Deloitte Access Economics, 2015). 
2.5 Parkinson’s Disease as a Source of Burden 
The nature of Parkinson’s disease engenders particular difficulties for the caregiver. Persons 
often develop Parkinson’s disease in the stage of life during which they are transitioning to 
retirement, with ensuing disruption to long-held plans and goals. If the caregiver is a spouse, 
they may also have to negotiate these developmental losses, as well as adapt to role changes in 
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a long-term, established relationship. Parkinson’s disease is progressive and incurable, such 
that the demands on the caregiver are likely to increase during later stages of the disease. Not 
surprisingly, the estimated cost of informal care is highest for persons in Hoehn and Yahr stage 
IV, with those persons in stage V likely to be institutionalised (Deloitte Access Economics, 
2015). The Hoehn and Yahr scale (Hoehn and Yahr, 1967) is a means of staging the progression 
of Parkinson’s disease, with stage V representing the most severe rating in which persons are 
bedridden or wheelchair bound unless aided.  
 
Parkinson’s disease is a complex disorder with motor and non-motor symptoms. It has been 
termed the ‘quintessential neuropsychiatric disorder’ (Weintraub and Burn, 2011). Persons 
with Parkinson’s disease may develop depression, anxiety, apathy, impulse-control disorders, 
psychotic symptoms, dementia and sleep disorders, in addition to problematic motor symptoms 
such as freezing of gait, falls and speech disturbance. All of these symptoms may amplify 
caregiver burden. Furthermore, some treatments for Parkinson’s disease, particularly the 
dopamine agonist medications and deep brain stimulation, may precipitate or worsen non-
motor symptoms. The caregiver of a person with Parkinson’s disease assumes many 
responsibilities, including care coordination, medication administration, prompting for self-
care, communication and advocacy on behalf of their loved one, surveillance of falls, provision 
of emotional support, whilst also playing an increasing role in directly assisting the person with 
activities of daily living as the disease advances. 
2.6 The Significance of this Review 
This review contributes to the existing literature by appraising predictors and correlates of 
caregiver burden in a framework that can be easily understood and integrated by the practising 
clinician working with persons with Parkinson’s disease. It also provides a thorough 
description of instruments that can be used to measure caregiver burden and a commentary on 
investigations that have been developed to address caregiver burden.  
 
Existing reviews have provided a cursory introduction to instruments and interventions 
(Martinez-Martin et al., 2012) or focussed on a psychological framework of caregiver burden 
(Greenwell et al., 2015). The present review benefits those in the medical and nursing 
professions, as well as psychologists, who often encounter caregivers of persons with 
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Parkinson’s disease. We believe our review also provides a solid foundation for clinician-
researchers to develop effective strategies for managing this significant clinical problem. 
2.7 Aims 
This review aims to provide an evidence-based, comprehensive and concise summary of the 
factors contributing to caregiver burden in Parkinson’s disease. Results from the literature 
review are grouped by theme and are clinically-oriented, so as to provide an accessible 
overview for the physician. A synopsis of the instruments that have been employed to quantify 
caregiver burden will be of interest to those planning future investigations of this construct. 
Finally, a treatment section examines interventions that may mitigate caregiver burden.  
2.8 Methods 
The nature of this review is similar in objective and design to a scoping study (Arksey and 
O'Malley, 2005), with the aim of summarising and disseminating research findings, as well as 
identifying gaps in the literature. Our target was the identification, assessment and management 
of caregiver burden in Parkinson’s disease. We excluded a small number of treatment studies 
with particularly severe methodological concerns (e.g. failure to adhere to study protocol). 
 
Our preliminary research questions were three-fold: 
 
i. What factors should prompt the clinician to look for caregiver burden when treating a 
person with Parkinson’s disease? 
ii. What instruments are available to measure caregiver burden and are there any key 
differences between them? 
iii. Are there any effective interventions that reduce caregiver burden? 
 
We consulted a librarian at the University of Queensland with expertise in searching databases 
in order to identify appropriate search terms and select appropriate electronic databases. The 
PubMed and PsychINFO databases were chosen to provide an optimum balance of breadth and 
specificity. The following search terms were used and captured articles published until the end 
of May 2017: 
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PubMed: ((Parkinson disease[mh]) AND caregivers[mh]) AND (burden OR anxiety OR 
depression OR stress OR strain) AND (Humans[Mesh] AND English[lang]). PsycINFO: 1) 
MeSH: depression, 2) MeSH: anxiety, 3) Any Field: burden, 4) Any Field: stress, 5) Any Field: 
strain, 6) 1 OR 2 OR 3 OR 4 OR 5, 7) MeSH: caregivers, 8) MeSH: parkinson disease, 9) 
Language: English, and 10) 6 AND 7 AND 8 AND 9. 
 
Copies of the full article were obtained for each returned result. One author produced a text 
summary of each study and these were discussed in a series of consensus meetings at which 
the original full texts were also examined. Studies were included if they reported a measure of 
burden amongst caregivers of persons with Parkinson’s disease, as assessed by a burden 
inventory, a quality of life measure or a proxy such as caregiver distress, depression or anxiety. 
This review included studies that correlated or modelled caregiver burden against individual, 
caregiver, disease or social factors. Qualitative investigations were also included. Review 
papers were returned from the initial search. References of these reviews were hand searched 
to discover additional papers. Further papers were identified after entering the search terms 
into Google Scholar. Studies were excluded if they did not report an analysis of caregiver 
burden or an appropriate measure of caregiver burden specific to Parkinson’s disease 
caregivers. Study proposals and papers judged to be of poor methodological quality as 
described above were also excluded. 
 
We developed a database of all included studies in order to group studies into relevant sections 
for the review, such as ‘neuropsychiatric factors associated with Parkinson’s disease’, 
‘measurement of caregiver burden’, ‘psychological treatments for caregivers’. The database 
summarised key elements from each included study, such as key findings, populations studied 
and outcome measures used. Database development was an iterative process, with refinements 
in terminology as the outline of the review took shape. 
 
We presented our data in a thematic manner, both in terms of the factors associated with 
caregiver burden in Parkinson’s disease as well as with interventions addressing caregiver 
burden. For example, we divided disease-related factors into motor symptoms and 
neuropsychiatric symptoms as this is a common distinction in clinical practice. We organised 
our interventions section according to treatment-modality (psychotherapy, rehabilitation) and 
recipient (person with Parkinson’s disease, caregiver). 
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Gaps in the literature were identified through comparing the results from our literature review 
with our clinical experience in a large movement disorders centre incorporating neurology, 
neurosurgery, neuropsychiatry, psychology and rehabilitation medicine (circa. 8000 persons 
with Parkinson’s disease).  
2.9 Results 
2.9.1 Summary of Search Results 
One hundred and fifty-nine papers were returned (excluding duplicates in both databases). 
Three review papers were returned from the initial search. Eight additional papers were 
discovered through hand-searching the references of these reviews. Eight additional papers 
were identified after entering the search terms into Google Scholar. One hundred and ten papers 
were selected for further analysis and summarised (Figure 2.1). Sixty-four papers examined 
factors associated with caregiver burden, thirty evaluated interventions that included caregiver 
burden as an outcome, thirteen described instruments used to measure caregiver burden, and 
three were review papers. 
2.9.2 Presentation of Results 
The following section begins with a summary of factors that are associated with burden 
amongst caregivers of persons with Parkinson’s disease. These factors are partitioned into 
disease-related factors, factors specific to treatments such as deep brain stimulation (DBS), 
factors pertaining to diagnosis or information and factors related to caregivers and their social 
circumstances. Disease-related factors are separated into motor and neuropsychiatric 
symptoms. There follows a summary of the instruments used to assess caregiver burden in this 
population and interventions that have sought to address burden amongst caregivers of persons 
with Parkinson’s disease.  
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2.9.3 Disease-Related Factors 
2.9.3.1 Motor Symptoms 
With progression of neurodegeneration and advancement into later stages of Parkinson’s 
disease, motor symptoms become more disabling, with the onset of motor fluctuations, 
dyskinesia, gait dysfunction, postural instability and falls, as well as increased time in an ‘off’ 
state. Expectedly, caregiver burden is positively correlated with these motor symptoms, overall 
disability and Hoehn and Yahr stage (Aarsland et al., 1999; Caap-Ahlgren and Dehlin, 2002; 
Figure 2.1 | Papers Selected for the Literature Review 
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Carod-Artal et al., 2013; Carter et al., 1998; Carter et al., 2008; Carter et al., 2012; Coelho et 
al., 2015; D'Amelio et al., 2009; Edwards and Scheetz, 2002; Fernandez et al., 2001; 
Goldsworthy and Knowles, 2008; Kelly et al., 2012; Leroi et al., 2012a; Leroi et al., 2012b; 
Lokk, 2008; Martinez-Martin et al., 2005; Martinez-Martin et al., 2007; Martinez-Martin et 
al., 2015; Martinez-Martin et al., 2008; Oguh et al., 2013; Onozawa et al., 2016; Ozdilek and 
Gunal, 2012; Peters et al., 2011; Razali et al., 2011; Rodriguez-Violante et al., 2015; Santos-
Garcia and de la Fuente-Fernandez, 2015; Sanyal et al., 2015; Schrag et al., 2006; Shin et al., 
2012a; Wallhagen and Brod, 1997). However, these three domains are not necessarily proxies 
for one another; advanced disease is also a risk factor for non-motor symptoms such as 
cognitive impairment, which may be an independent mediator of disability.  
 
In studies that have used qualitative approaches (Davey et al., 2004; McLaughlin et al., 2011; 
Roland et al., 2010; Tan et al., 2012), caregivers report mental burden attributable to 
maintaining surveillance for falls and repeatedly cueing for protective behaviours. The 
unpredictability of motor symptoms and the rigours of administering medications on schedule 
limit the capacity of caregivers to plan for activities outside of the home and contribute to 
reduced social interactions. These factors may influence the decision to institutionalise a person 
with Parkinson’s disease (Abendroth et al., 2012). 
2.9.3.2 Neuropsychiatric Symptoms 
Non-motor symptoms consistently make a greater contribution to caregiver burden than motor 
symptoms when the two are examined concurrently (Aarsland et al., 1999; Carter et al., 2008; 
Carter et al., 2012; Shin et al., 2012a). Non-motor symptoms may disproportionately magnify 
disability, increase the need for supervision and affect emotional aspects of the relationship 
with a caregiver.  
2.9.3.3 Depression 
Numerous studies link depressive symptoms in the person with Parkinson’s disease to 
caregiver burden (Aarsland et al., 1999; Aarsland et al., 2007; Caap-Ahlgren and Dehlin, 2002; 
Carod-Artal et al., 2013; Carter et al., 2008; Carter et al., 2012; Fernandez et al., 2001; Leiknes 
et al., 2010; Martinez-Martin et al., 2015; Meara et al., 1999; Ozdilek and Gunal, 2012; Santos-
Garcia and de la Fuente-Fernandez, 2015; Stella et al., 2009; Thommessen et al., 2002; Zhong 
et al., 2016). Depressive symptoms include sadness, lack of enjoyment, pessimism, guilt and 
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suicidality. Depression is likely to narrow the behavioural repertoire of the person with 
Parkinson’s disease and reduce warmth and reciprocity in the caregiving relationship. 
Depression amplifies fatigue and reduces motivation, effecting a further reduction in 
independence and the capacity to perform activities of daily living. Greater demands are placed 
on the caregiver and opportunities to experience positive aspects of care are limited. In more 
severe presentations, concern about the safety of the suicidal person may preoccupy the 
caregiver. 
2.9.3.4 Anxiety 
Anxiety in the person with Parkinson’s disease is commonly associated with caregiver burden 
(Aarsland et al., 2007; Carod-Artal et al., 2013; Leiknes et al., 2010; Ozdilek and Gunal, 2012; 
Viwattanakulvanid et al., 2014). Anxiety in Parkinson’s disease may present as panic disorder, 
social phobia, fear of falling, generalised anxiety or sub-syndromal symptoms of tension, 
irritability or stress (Dissanayaka et al., 2014). Anxiety often precipitates avoidance of 
triggering situations, manifesting as agoraphobia, which limits the capacity of caregivers to 
maintain their social network unless they leave the person with Parkinson’s disease at home. 
However, anxiety may also lead to excessive reliance on the caregiver for reassurance and 
supervision, a form of conditioned safety behaviour that is particularly draining for the 
caregiver. In extreme situations, persons with Parkinson’s disease are intolerant of being alone 
and become distressed when the caregiver is out of sight (Mercer, 2015).  
2.9.3.5 Apathy 
Some studies link apathy in the person with Parkinson’s disease to caregiver burden (Aarsland 
et al., 2007; Leiknes et al., 2010; Leroi et al., 2012a). Apathy includes both loss of motivation 
and loss of emotionality. This is manifest in diminished goal directed activity and reduced 
spontaneous or evoked emotional display (Starkstein and Leentjens, 2008). It overlaps with but 
is distinct from depression and dementia. Similar to those persons with depression, persons 
with Parkinson’s disease who display apathetic symptoms lack warmth and this may reduce 
the positive emotional feedback received by the caregiver. Persons who are more severely 
affected will require their caregivers to structure their daily routine and may even need 
prompting to complete basic tasks such as washing or brushing of teeth. Qualitative research 
suggests this aspect of caregiving is particularly taxing (Roland et al., 2010).  
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2.9.3.6 Cognitive Impairment 
Cognitive impairment in the person with Parkinson’s disease is consistently associated with 
caregiver burden (Aarsland et al., 1999; Aarsland et al., 2007; Carter et al., 2008; Carter et al., 
2012; Cifu et al., 2006; Coelho et al., 2015; Leroi et al., 2012b; Schrag et al., 2006; Stella et 
al., 2009; Thommessen et al., 2002). Persons with Parkinson’s disease dementia have 
functional impairment resulting from deficits in the domains of attention, language, memory, 
executive functioning and visuospatial orientation. These impairments lead to greater 
dependence on the caregiver. Additionally, many persons with Parkinson’s disease dementia 
have behavioural and psychological symptoms (BPSD) such as wandering, agitation, 
vocalisation and disinhibited behaviour (Aarsland et al., 2007). This may extend to 
inappropriate sexualised behaviour and physical aggression (Bruno et al., 2016). Psychotic 
symptoms are also common in this population (Aarsland et al., 2007).  
 
Isolated deficits in the executive functioning of persons with Parkinson’s disease are also 
correlated with caregiver burden (Kudlicka et al., 2014). Executive function comprises those 
neuropsychological abilities that underlie ordered, goal-directed and flexible behaviour, such 
as sustained attention, inhibition and planning. This can affect important daily tasks such as 
driving and medication adherence. Some persons with Parkinson’s disease show reduced 
awareness of their executive deficits and over-estimate their performance. Burden may arise 
when this assessment is discrepant with that of the caregiver (Kudlicka et al., 2013).  
2.9.3.7 Psychosis 
Psychosis in the person with Parkinson’s disease may be associated with caregiver burden 
(Aarsland et al., 2007; Marsh et al., 2004; Schrag et al., 2006). Psychotic symptoms include 
visual hallucinations and delusions. Hallucinations may be frightening for the person with 
Parkinson’s disease and are often worse at night, leading to agitation and sleep disturbance. 
Delusions may be particularly distressing if the caregiver is incorporated into the aberrant 
beliefs, such as in the case of delusional jealousy. In such cases the person with Parkinson’s 
disease believes their spouse is being unfaithful, may accuse the caregiver of infidelity and 
even attempt to restrict their movements.  
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2.9.3.8 Impulse-Control Behaviours (ICBs) 
ICBs, where present, may be associated with greater burden amongst caregivers (Leroi et al., 
2012a). Compulsive behaviours such as pathological gambling, hypersexuality, binge-eating, 
compulsive shopping and dopamine dysregulation are relatively common complications of 
Parkinson’s disease treatment (Weintraub et al., 2010). The behaviours themselves, even if 
transient, may have lasting financial, social and legal consequences that can add to the burden 
on a household. Hypersexuality, if associated with the use of pornography or with extra-marital 
affairs, can lead to a sense of betrayal in the caregiver. Furthermore, many persons with ICBs 
are secretive about their compulsions and may persist with their behaviours despite vowing to 
cease them, which fuels mistrust if they are subsequently discovered. Other persons with 
Parkinson’s disease lack insight into the harms associated with their ICBs and may avoid 
interventions or refuse to comply with clinical advice.  
2.9.3.9 Sleep 
Disrupted sleep in the person with Parkinson’s disease may be linked to caregiver burden 
(Carod-Artal et al., 2013; Cifu et al., 2006; Cupidi et al., 2012; Happe et al., 2002; Martinez-
Martin et al., 2008; Pal et al., 2004; Smith et al., 1997; Viwattanakulvanid et al., 2014). Persons 
with Parkinson’s disease may experience disturbed sleep in association with non-motor 
symptoms such as pain, depression and hallucinations, as a consequence of restless legs 
syndrome or rapid eye movement sleep behaviour disorder, as well as with motor symptoms 
such as nocturnal akinesia. Caregivers who share their bed with the person are also likely to 
have insufficient or poor-quality sleep. Caregivers who sleep separately may nonetheless need 
to assist the person overnight (Mercer, 2015). Up to ninety-five percent of Parkinson’s disease 
caregivers complain of sleep disturbance, which is a risk factor for the genesis of depressive 
symptoms (Cupidi et al., 2012; Pal et al., 2004; Smith et al., 1997).  
2.9.4 Deep Brain Stimulation (DBS) 
DBS is an advanced therapy for Parkinson’s disease that provides a relatively constant and 
predictable improvement in motor symptoms. Persons with motor complications of drug 
therapy that receive DBS may have a better outcome than those maintained on medication 
alone, expressed as an improvement in motor symptoms and a better self-rated quality of life 
(Schuepbach et al., 2013). However, the burden of the caregiver may not change and may even 
worsen (Lewis et al., 2014; Lewis et al., 2015; Oyama et al., 2014; Perozzo et al., 2001; Soileau 
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et al., 2014). This may be related to the persistence or worsening of existing non-motor 
symptoms such as ICBs and cognitive impairment, the incidence of new stimulation-dependent 
psychiatric symptoms such as impulsivity and hypomania, symptoms related to the withdrawal 
of dopaminergic drugs such as anxiety, depression and apathy, as well as to role changes 
associated with the sudden relief of disability in the person-caregiver dyad (Mosley and Marsh, 
2015a). 
2.9.5 Diagnosis and Information 
Qualitative studies suggest that some caregivers are distressed by delays in the diagnosis of 
Parkinson’s disease, especially if there is a lengthy wait to see a neurologist (McLaughlin et 
al., 2011). Difficulty accessing a neurologist has been identified as a potential barrier to the 
person with Parkinson’s disease receiving care (Lageman et al., 2015). There can be a 
perceived lack of information and communication in this early stage, with the caregiver feeling 
unskilled in their new role and uncertain about how to access information about the progression 
of the illness, medication and its side effects (McLaughlin et al., 2011; Mercer, 2015; Schrag 
et al., 2004a; Tan et al., 2012). Later in the disease, some caregivers express the need to know 
more about palliative services and their entitlement to benefits and government support 
(McLaughlin et al., 2011; Schrag et al., 2004a), or would more value more guidance regarding 
cognitive impairment and the person’s capacity to make decisions (Goy et al., 2008).  
2.9.6 Caregiver Factors 
2.9.6.1 Demographics 
Age, gender, education and social class of the caregiver are not related to caregiver burden in 
the majority of investigations (Greenwell et al., 2015), although three studies report greater 
burden and depressive symptoms in female caregivers (Calder et al., 1991; Lyons et al., 2009; 
Pasetti et al., 2003). Spousal and offspring caregiver burden was not significantly different in 
two investigations (Razali et al., 2011; Shin et al., 2012a), but greater amongst spouses in a 
third (Viwattanakulvanid et al., 2014). Burden scores were inflated in two samples of 
caregivers with very low income (Edwards and Scheetz, 2002; Viwattanakulvanid et al., 2014), 
with income being a predictor of burden in a longitudinal study (O'Connor and McCabe, 2011). 
Across investigations, the amount of hours spent caregiving does not correlate with burden 
(Martinez-Martin et al., 2007; Martinez-Martin et al., 2008; Shin et al., 2012a), correlates only 
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weakly with burden (Kim et al., 2007; Razali et al., 2011; Tew et al., 2013), or correlates 
moderately with burden (Sanyal et al., 2015; Zhong et al., 2016). It is possible that some 
caregivers who feel burdened may amplify the time they perceive as ‘caregiving’.  
2.9.6.2 Psychiatric Symptoms 
Depression and anxiety in the caregiver are strong predictors of burden (Caap-Ahlgren and 
Dehlin, 2002; Carod-Artal et al., 2013; Martinez-Martin et al., 2007; Martinez-Martin et al., 
2008; Meara et al., 1999; Ozdilek and Gunal, 2012; Schrag et al., 2006; Shin et al., 2012a; 
Shin et al., 2012b; Zhong et al., 2016). Most studies are cross-sectional, so the directionality 
of the association cannot be defined, although the existence of a reciprocal relationship seems 
likely. Depressive symptoms at baseline were predictive of lower quality of life amongst 
caregivers at twelve months (O'Connor and McCabe, 2011). Depression and anxiety elicit 
cognitive biases such as pessimism or the magnification of threat, such that the burden of 
caregiving may be overestimated. Conversely, the burden of caregiving is a chronic stressor 
with an added measure of prognostic uncertainty due to the nature of Parkinson’s disease with 
its fluctuating symptom profile and gradual progression. To the extent that caregiving is more 
burdensome, the risk of this role precipitating a psychiatric illness in the caregiver increases. 
When psychiatric symptoms in the caregiver are assessed, a significant proportion of caregivers 
(between twelve to fifty percent) reach the diagnostic threshold for anxiety and depressive 
disorders (Carod-Artal et al., 2013; Happe et al., 2002; Meara et al., 1999; Pal et al., 2004; 
Schrag et al., 2004a), or report exhaustion and depression tied to their caregiving role (as high 
as fifty percent) (Carod-Artal et al., 2013; Lokk, 2008; Schrag et al., 2006).  
2.9.6.3 Coping and Adaptation 
Appraising the challenge of caregiving is also influenced by personality style. Rather than the 
cognitive biases associated with an episodic mood or anxiety disorder, personality is a chronic 
and stable set of traits, expresses as a characteristic way of responding to and coping with stress. 
Neuroticism, a tendency to experience negative emotions such as worry, frustration and 
irritability, is associated with poorer psychological wellbeing in caregivers (Tew et al., 2013). 
Furthermore, pessimism in caregivers at baseline appears to be associated with a steeper 
longitudinal deterioration in caregiver physical health during follow up, highlighting an 
interesting potential link between caregiver physical and mental health (Lyons et al., 2004). 
Conversely, dispositional optimism appears to be protective against the future development of 
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caregiver burden (Lyons et al., 2009), perhaps because optimistic individuals are more likely 
to use effective coping strategies such as acceptance, positive reframing or humour. They may 
also be more capable of recruiting and retaining additional social support.  
2.9.6.4 Social Support 
As Parkinson’s disease progresses and the person becomes more disabled, the caregiver may 
progressively lose social contacts and outlets (Roland et al., 2010). The person with 
Parkinson’s disease may resist maintaining their social network due to difficulties managing 
group conversations or embarrassment with regards to eating in public, as well as a reluctance 
to reveal manifest Parkinson’s disease symptoms to those outside the family (Mercer, 2015). 
Transporting the person with Parkinson’s disease to and from medical appointments becomes 
a time-consuming activity (Deuel et al., 2010). On the contrary, the perception of ongoing 
social support may be protective (Edwards and Scheetz, 2002; Goldsworthy and Knowles, 
2008). 
2.10 Measurement of Caregiver Burden in Parkinson’s disease 
The optimal method of assessing caregiver burden in Parkinson’s disease is unclear. A 
heterogeneous range of self-report inventories and interviews have been employed in the 
scientific literature. Some have been adapted from the aged or cognitively impaired and 
specific validation in a Parkinson’s disease sample is reported where available. Others have 
been specifically developed with Parkinson’s disease caregivers in mind. Additionally, related 
measures such as caregiver physical health, anxiety and depression have been quantified as 
proxies of caregiver burden. Caregiver quality of life can also be a surrogate indicator of 
caregiver burden, but is broader in scope, examining general wellbeing in physical, 
psychological, social and spiritual dimensions.  
2.10.1 Instruments Adapted for Use in Parkinson’s Disease 
2.10.1.1 Zarit Caregiver Burden Interview (ZBI) 
A twenty-two item self-report inventory and the most commonly used measure in Parkinson’s 
disease (Zarit et al., 1980). Higher scores reflect greater levels of burden, with a two-factor 
structure comprising personal strain (e.g. ‘Do you feel embarrassed over your relative’s 
behaviour?’) and role strain (e.g. ‘Do you feel that your social life has suffered because you 
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are caring for your relative?’). The ZBI has been validated in a Parkinson’s disease sample, 
demonstrating high internal consistency and moderate to high convergent validity with related 
measures including anxious and depressive symptoms in the caregiver, the number of 
caregiving hours and the dependency of the person with Parkinson’s disease (Martinez-Martin 
et al., 2007). 
2.10.1.2 Caregiver Burden Inventory (CBI) 
A twenty-four-item self-report inventory developed for professional caregivers of persons with 
Alzheimer’s disease (Novak and Guest, 1989). Like the ZBI, higher scores indicate greater 
burden. The CBI aims to separate dimensions of burden into five subscales including ‘time-
dependency’, ‘developmental’, ‘physical’, ‘social’ and ‘emotional’ burden. It has not been 
validated in Parkinson’s disease, but it was demonstrated that total scores were sensitive to 
change in a psychotherapy intervention for Parkinson’s disease caregivers (Secker and Brown, 
2005).  
2.10.1.3 Caregiver Strain Index (CSI) 
A thirteen-item self-report inventory designed for use amongst informal caregivers of persons 
undertaking cardiac and hip surgery (Robinson, 1983). The CSI examines domains including 
employment, finances, physical effort, social restrictions, emotional distress and 
inconvenience. The CSI has not been validated in Parkinson’s disease but in the same 
psychotherapy study that reported pre- and post-intervention CBI data, CSI scores also showed 
sensitivity to change (Secker and Brown, 2005).  
2.10.1.4 Subjective and Objective Burden Scale (SOBD) 
The SOBD aims to parse ‘objective’ measures of burden (‘events, happenings and activities’) 
from ‘subjective’ aspects (‘feelings, attitudes and emotions’) in family caregivers of the aged 
(Montgomery et al., 1985). Objective burden is assessed with a nine-item inventory that 
evaluates the extent to which the caregiving role has changed elements of lifestyle including 
time, privacy, money, freedom and energy. Subjective burden is assessed using a thirteen-item 
inventory adapted from the personal strain factor of the ZBI (e.g. ‘I am afraid for what the 
future holds for my relative’). The psychometric properties of this scale have not been 
examined in Parkinson’s disease.  
Chapter 2  27 
 
   
2.10.1.5 Relatives’ Stress Scale (RSS) 
A fifteen-item scale developed for family caregivers of elderly relatives with dementia (Greene 
et al., 1982), comprising a two-factor structure including ‘personal distress’ (e.g. ‘Do you feel 
as though you can no longer cope with the situation?’ and ‘life upset’ (e.g. ‘Do you find it 
difficult to get away on holiday?’) The psychometric properties of this scale have not been 
examined in Parkinson’s disease. 
2.10.1.6 Family Caregiving Inventory (FCI) 
A structured interview developed for aged caregivers (Archbold et al., 1990). The FCI 
examines nine domains of caregiver role strain including ‘direct care’, ‘lack of resources’, 
‘worry’, ‘role conflict’, ‘economic burden’, ‘mismatched expectations’, ‘increased tension’, 
‘feelings of being manipulated’ and ‘global strain’. Procedures for scoring each item are 
available from the authors. Internal consistency has been reported in a sample of 380 
Parkinson’s disease caregivers with acceptable values for all domains excepting ‘mismatched 
expectations’ (Cronbach’s alpha 0.57) (Carter et al., 1998). 
2.10.1.7 Burden Index of Caregivers (BIC) 
An eleven-item scale developed in Japan for caregivers of individuals with neurological 
diseases including but not limited to Parkinson’s disease (Miyashita et al., 2006). The BIC 
discriminates overall burden into five factors including ‘time’, ‘emotional’, ‘existential’, 
‘physical’ and ‘service-related’ burden, the latter reflecting healthcare circumstances unique 
to Japan. 279 persons with Parkinson’s disease (646 overall) were part of a validation study 
confirming face validity, internal consistency and reliability. Concurrent validity with the ZBI 
was high .  
2.10.2 Instruments Designed for Use in Parkinson’s Disease 
2.10.2.1 Parkinson’s Disease Caregiver Burden Questionnaire (PDCB) 
An instrument developed from discussions with persons with Parkinson’s disease, their 
caregivers and clinicians, in order to elaborate Parkinson’s disease-specific themes and 
problems (Zhong et al., 2013). The PDCB is a twenty-item scale including subscales of 
‘physical burden’, ‘sleep disruption’, ‘symptoms’, ‘responsibility’, ‘medication management’, 
‘social burden’ and ‘effects on the relationship’. The psychometric properties of the PDCB 
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were examined in a sample of fifty persons with Parkinson’s disease and their caregivers. 
Internal consistency and concurrent validity with the CBI was high.  
2.10.2.2 Caregiving Distress Scale (CDS) 
An instrument developed from a cluster and factor analysis of existing scales administered to 
a sample of eighty persons with Parkinson’s disease and their caregivers (Cousins et al., 2002). 
The resulting CDS is a seventeen-item scale with subscales of ‘relationship distress’, 
‘emotional burden’, ‘carer-receiver demands’, ‘social impact’ and ‘personal cost’, which 
show high internal consistency. The test-retest reliability of the CDS was acceptable in a 
longitudinal analysis.  
2.10.2.3 Parental Illness Impact Scale (PIIS) 
A thirty-eight-item instrument quantifying the burden experienced by children of individuals 
with Parkinson’s disease, derived from semi-structured interviews with eighty-nine affected 
children (Schrag et al., 2004b). Subscales include ‘burden of daily help’, ‘communication and 
understanding’, ‘impact on personal future’, ‘impact on family functioning’, ‘friends’ 
reactions’ and ‘social development, independence and responsibility’. These subscales were 
internally consistent and showed concurrent validity with other measures of depression, self-
esteem and quality of life.  
2.10.2.4 Caregiver Strain Risk Screen (CSRS) 
A twenty-eight-item scale developed from qualitative interviews with family caregivers of 
persons with Parkinson’s disease (Abendroth, 2015). The CSRS has a four-factor structure 
including ‘self-preservation’, ‘nursing home consideration’, ‘coping through spirituality’, and 
‘coping through formal support’. The scale demonstrated high internal consistency in a sample 
of 217 Parkinson’s disease caregivers. Content validity was also supported by thirteen 
clinicians.  
2.10.3 Other Important Measures 
2.10.3.1 Positive Aspects of Caregiving (PAC) 
Caregiving may have rewarding consequences such as strengthening emotional ties, improving 
self-esteem, generating altruism and making financial savings. The PAC is a nine-item 
Chapter 2  29 
 
   
instrument developed and validated in a sample of Alzheimer’s dementia caregivers (Tarlow 
et al., 2004). It has not been examined in Parkinson’s disease.  
2.10.3.2 Caregiver Quality of Life 
Discussion of the available instruments assessing caregiver quality of life is beyond the scope 
of this review. A number of generic quality of life scales are reviewed in Martinez-Martin et al 
(Martinez-Martin et al., 2012). Two instruments have been designed specifically to assess 
quality of life in Parkinson’s disease caregivers, the PDQ-Carer (Jenkinson et al., 2012) and 
the BELA-A-(Spliethoff-Kamminga et al., 2003). 
2.11 Interventions 
2.11.1 Education and Psychotherapy 
A manualised educational program delivered over eight sessions to persons with Parkinson’s 
disease and their caregivers was developed to include coaching in pleasant activity scheduling, 
stress management, communication and strategies to reduce burden (Simons et al., 2006). The 
intervention was delivered separately to groups of persons with Parkinson’s disease and 
caregivers. Caregivers reported reduced burden after completing this program, as compared to 
study entry (A'Campo et al., 2010a). In a controlled trial versus ‘usual care’ (including forty-
six caregivers) burden also reduced (A'Campo et al., 2010b). Greater benefit was seen in 
caregivers of persons with maintained cognitive functioning (A'Campo et al., 2012).  
 
A course of cognitive behavioural therapy (CBT) was delivered to thirty Parkinson’s disease 
caregivers that identified as being ‘emotionally stressed’ by caring (Secker and Brown, 2005). 
A clinical psychologist delivered twelve-fourteen individual sessions covering modules such 
as accessing supports, relaxation, healthy sleep and challenging negative beliefs. Burden 
reduced compared to a control group of ‘usual care’. Benefits were maintained at six-months 
post-intervention. 
 
There is qualitative support for interventions that offer education and fellowship with other 
caregivers (McLaughlin et al., 2011; Roland et al., 2010; Schrag et al., 2004a; Tan et al., 2012), 
but thus far only a preliminary study of the utility of peer-support (Shah et al., 2015). The role 
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of mindfulness is yet to be adequately studied amongst Parkinson’s disease caregivers (Cash 
et al., 2016).  
2.11.2 Rehabilitation 
Interventions that foster independence of the person with Parkinson’s disease and improve 
physical functioning in the home environment would be expected to reduce caregiver burden. 
Persons with Parkinson’s disease who exercise regularly have caregivers that report less burden 
(Oguh et al., 2014). A program that coached caregivers to encourage exercise was qualitatively 
acceptable to caregivers and benefitted the mobility of the person with Parkinson’s disease 
(Pretzer-Aboff et al., 2011). Smoothing the motor fluctuations of advanced Parkinson’s disease 
with intestinal levodopa improved the capacity of individuals to perform their activities of daily 
living and reduced caregiver burden in a small open sample (Santos-Garcia et al., 2012), 
although improvement in caregiver stress was non-significant in a second small sample (Fasano 
et al., 2012).  
 
However, a course of intensive multidisciplinary rehabilitation delivered to the person alone 
(van der Marck et al., 2013; Wade et al., 2003), or the person and caregiver together (Trend et 
al., 2002), did not benefit caregiver burden or improve caregiver quality of life. A cueing 
training program that addressed freezing of gait in persons with Parkinson’s disease also did 
not show benefit for caregiver burden, although the overall effect on the primary outcome was 
small (Nieuwboer et al., 2007). Explicitly collaborating with the caregiver in order to translate 
interventions from the rehabilitation unit to the home may improve the caregiver’s sense of 
control and self-esteem. However, a ten-week domiciliary occupational therapy intervention 
that involved 180 caregivers did not significantly affect caregiver burden relative to a control 
group of no intervention, despite improvements in the perceived functioning of the persons 
with Parkinson’s disease (Sturkenboom et al., 2013; Sturkenboom et al., 2014).  
2.11.3 Treating the Non-Motor Symptoms of Parkinson’s Disease 
Treating psychiatric symptoms in persons with Parkinson’s disease is an intuitive strategy to 
reduce caregiver burden. Caregivers of persons with Parkinson’s disease dementia have 
reported reduced burden after treatment with cognitive enhancers, alongside neuropsychiatric 
benefits amongst the treated individuals (Leroi et al., 2014; Litvinenko et al., 2008; Oh et al., 
2015; Reading et al., 2001).  
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Some psychiatric symptoms in Parkinson’s disease are not so easily remediated with drug-
therapy. The management of ICBs is complicated by frequent intolerance of dopamine agonist 
withdrawal and a poor evidence base for other interventions (Zhang et al., 2016). Behavioural 
and psychological interventions are alternative treatments. In a randomised, controlled trial of 
CBT for forty-five individuals with ICBs, twelve sessions of manualised, individual CBT were 
delivered by a nurse therapist (Okai et al., 2013). Joint therapy with caregivers took place for 
some sessions, although the exact frequency of this was not reported. Compared to a waitlist 
control at six-months, some measures of ICB severity were reduced in the treatment group, 
although this was not reflected in a reduction of caregiver burden. However, as well as limited 
power from a small sample size, the failure to see an effect on caregiver burden here may well 
reflect the devastating impact of ICBs on relationship quality and caregiver wellbeing. More 
pervasive change may be necessary to effect a shift in this domain. Sleep disorders are also 
problematic non-motor symptoms for which behavioural interventions involving the caregiver 
may show promise (Leroi et al., 2010). 
 
Psychotherapy remains an important treatment modality for psychiatric symptoms including 
anxiety and depression. Here, pharmacotherapy may be only partially effective, complicated 
by side effects, or less acceptable to the person with Parkinson’s disease than a psychological 
approach. A small, uncontrolled trial of a six-session course of tailored CBT for twelve persons 
with Parkinson’s disease and anxiety led to a reduction in anxiety symptoms that was 
maintained at six-months (Dissanayaka et al., 2016). Caregivers attended the therapy sessions 
with their partner and were involved in the person’s treatment plan. Caregiver burden was 
reduced post-intervention. A larger, randomised, controlled trial of a ten-session course of CBT 
for eighty persons with Parkinson’s disease and depression also included caregivers in four 
separate educational sessions (Dobkin et al., 2011). These were designed to assist the caregiver 
with facilitating the person’s at-home practice of CBT. There was no significant change in 
caregiver burden following this intervention but interestingly caregiver participation in these 
education sessions was the only significant predictor of response to treatment by the person 
with Parkinson’s disease (Dobkin et al., 2012). This highlights the crucial role of caregivers as 
therapeutic allies that can enhance treatment response.  
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Preliminary evidence suggests that non-medication strategies may also be of benefit in the 
palliative setting. Caregivers of fifty-two persons with Parkinson’s disease and dementia 
associated with psychosis and high rates of physical and sexual aggression reported reduced 
burden subsequent to a three-month multidisciplinary intervention that including education, 
training in verbal de-escalation and behavioural therapy (Bruno et al., 2016). 
2.12 Conclusions 
Being a caregiver for a person with Parkinson’s disease is challenging. Caregivers assist the 
person with Parkinson’s disease to negotiate the stages of this progressive disorder, from 
diagnosis to palliative care, with its ensuing relational and lifestyle changes. The process of 
adaptation can be hampered by the unpleasant motor and non-motor symptoms of Parkinson’s 
disease, side effects of treatment, as well as by systemic issues such as healthcare organisation 
and financial resources. These factors may contribute to a perception of reduced wellbeing in 
the caregiver.  
 
Identifying and responding to caregiver burden is important for the clinician because informal 
caregivers make a major personal and societal contribution to the support of people with 
Parkinson’s disease. Burden is strongly connected to caregiver psychiatric symptoms, which 
appear to be highly prevalent. Ameliorating burden may mitigate these psychiatric symptoms, 
reduce the risk of caregiver burnout and prevent premature institutionalisation.  
 
Amongst the Parkinson’s disease -specific associations with caregiver burden, both motor and 
non-motor symptoms are represented, with major contributions from neuropsychiatric 
symptoms such as depression, anxiety, dementia, psychosis, apathy and impulse control 
behaviours. Depression and anxiety in the caregiver are particularly connected with perceived 
burden and a bidirectional relationship is likely to exist. Conversely, positive traits such as 
optimism may offer longitudinal protection against burden. 
 
A number of gaps in the literature can be identified. The effects of Parkinson’s disease speech 
impairment on caregiver burden has not been specifically examined. Speech abnormalities such 
as hypophonic dysarthria can limit effective communication between the person and caregiver, 
particularly if an ageing caregiver develops a hearing impairment. This may give rise to 
frustration and dissatisfaction in both parties. The physical wellbeing of Parkinson’s disease 
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caregivers has also not been systematically examined, outside of brief symptom checklists and 
self-rated physical quality of life. Psychological and psychiatric morbidity in caregivers is high 
and this increases the likelihood of physical co-morbidity. Male caregivers showed a higher 
all-cause mortality as compared to matched population controls in a Scandinavian sample 
(Nielsen et al., 2014). Finally, the functioning of the pre-morbid relationship is a further 
additional factor that may influence the prospective adaptability of the caregiver. The 
emotional quality of the person-caregiver relationship is relevant to the caregiver’s cross-
sectional estimation of burden (Tanji et al., 2008). This is a difficult construct to assess without 
the influence of a retrospective bias.  
 
One further gap is more general and relates to the cross-sectional design of most investigations 
included in this review. Cross-sectional studies demonstrate associations but the direction of 
causality and temporal evolution is more difficult, if not impossible to infer. More longitudinal, 
prospective studies are needed to accurately model and quantify the most significant predictors 
of caregiver burden amongst persons with Parkinson’s disease. A further benefit of this 
approach is the potential to identify strategies to mitigate burden before it becomes problematic 
for the caregiver (Santos-Garcia et al., 2016). 
 
When evaluating caregiver burden both general and Parkinson’s disease -specific instruments 
can be utilised. There are no comparative studies to suggest superiority of either a general or 
specific approach. The ZBI, FCI, and BIC are the only general measures to be validated in a 
Parkinson’s disease population and in practice the ZBI is most likely to be applicable in a 
clinical setting. The Parkinson’s disease-specific instruments require further investigation.  
 
A summary of the interventions that have addressed caregiver burden in Parkinson’s disease 
are presented in Table 2.1. Interventions with some evidence for reducing caregiver burden 
include education for the person with Parkinson’s disease and their caregiver, psychotherapy 
targeting psychiatric symptoms in the caregiver and the management of neuropsychiatric 
symptoms in the person with Parkinson’s disease through medication or psychotherapy. It is 
surprising that intensive outpatient or domiciliary rehabilitation did not ameliorate burden, 
although in this sample burden scores at baseline were relatively low and repeated cycles may 
be necessary to induce meaningful change. 
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The role of education and psychotherapy for Parkinson’s disease caregivers requires further 
investigation as the included trials do not include an active comparator, which limits 
conclusions about the specificity of the treatment effect. Future strategies for increasing the 
power of psychological interventions would be to target these at caregivers with established 
trait neuroticism, with current psychiatric symptoms or with current psychosocial difficulties. 
Clinicians may need to directly probe for these factors in the caregiver as they may not be 
elicited routinely.  
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Table 2.1 | Interventions that have Addressed Caregiver Burden in Parkinson’s Disease 
Psychotherapies for persons with Parkinson’s disease and caregivers  
Study Intervention Recipients Sample Size Mean H&Y Stage (SD) Design 
Caregiver 
Outcome 
Measures 
Results 
Secker & 
Brown (2005) 
CBT. 12-14 weekly sessions. 
Example session topics: pleasant 
activity scheduling, relaxation, 
sleep improvement, identifying and 
challenging negative thoughts. 
 
Caregivers reporting 
emotional stress 
n = 30 3.0 (±1.2) for 
intervention 
group, 2.5 (0.9) 
for control group 
Randomised, open-label, controlled trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation, end of 
treatment (3-months after randomisation 
for controls), and 6-months after 
randomisation. 
CBI, CSI 
 
 
 
 
Caregivers in the 
intervention group showed 
a significantly greater 
decrease in CBI scores 
(mean 29.8 (±20.1), p < 
.001) and CSI scores (mean 
4.1 (±4.2), p < .01) at 3-
months. Improvements 
maintained at 6-months. 
Leroi et al. 
(2010) 
Sleep therapy. Delivered over 6-
weeks. Number of sessions NR. 
Behavioural component: 
identification of maladaptive sleep 
behaviours and lifestyle changes to 
enhance sleep hygiene. Educational 
component: information on lifestyle 
and environmental factors that are 
detrimental to sleep. 
PwPD with sleep 
disturbances (identified 
using the SHORT-CARE 
sleep scale) and 
caregivers 
n = 15 (PwPD 
and caregivers) 
NR, but all PwPD ≤ stage 4 Randomised, open-label, controlled trial.  
Control group of basic sleep hygiene 
education. 
 
Measures taken at randomisation and 2-
weeks post-intervention. 
ZBI, NPI - 
total distress 
score 
No significant difference 
between the intervention 
and control group in ZBI or 
NPI total distress mean 
change scores. 
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Dobkin et al. 
(2011) 
CBT. 10 weekly sessions. Example 
session topics: behavioural 
activation, thought monitoring and 
restructuring, relaxation. Caregivers 
received 4 educational sessions 
providing them with skills to 
facilitate PwPD practice of CBT. 
Depressed PwPD (DSM-
IV criteria) and caregivers 
n = 80 (PwPD 
and caregivers) 
2.1 (±0.9) for 
intervention 
group, 2.2 (±0.8) 
for control group 
Randomised, open-label, controlled trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation, 5-
weeks (midpoint), 10-weeks (end of 
intervention), and 14-weeks post-
randomisation. 
CDS No significant group-by-
time effects for CDS scores. 
Okai et al. 
(2013) 
CBT. 12 weekly sessions. Example 
session topics: motivational 
interviewing, pleasant activity 
scheduling, feelings related to 
impulse control behaviours. 
PwPD with impulse 
control behaviours 
(identified using the QUIP 
and confirmed in clinical 
interview) and caregivers 
n = 42 (PwPD) 
and n = 36 
(caregivers) 
2.0 (±1.2) for 
intervention 
group, 2.4 (±1.2) 
for control group 
Randomised, open-label, controlled trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation and 6-
months after the intervention 
commenced. 
ZBI, NPI - 
total distress 
score 
No significant difference 
between the intervention 
and control group in ZBI or 
NPI total distress mean 
change scores. 
Cash et al. 
(2016) 
Mindfulness-based group 
intervention. 8 weekly sessions. 
Example session topics: 
mindfulness of bodily movements 
and sensations, noticing unpleasant 
events, the stress reaction cycle and 
responding vs. reacting to stress. 
PwPD and caregivers n = 29 (PwPD) 
and n = 10 
(caregivers) 
NR Open-label. No control group. 
 
Measures taken pre- and post-
intervention. 
PDQ-Carer No significant difference in 
PDQ-Carer scores pre- and 
post-intervention. 
Dissanayaka et 
al. (2016) 
CBT. 6 weekly sessions. Example 
session topics:  psychoeducation, 
symptom monitoring, calming 
techniques, progressive muscle 
relaxation and imagery, sleep 
hygiene, relapse prevention 
planning. 
PwPD with anxiety 
(DSM-IV criteria) and 
caregivers 
n = 12 (PwPD) 
and n = 10 
(caregivers) 
2.2 (±0.7) Open-label. No control group. 
 
Measures taken pre-intervention 
(baseline), immediately post-intervention, 
and 3 and 6 months from baseline. 
ZBI ZBI scores significantly 
decreased from pre-
intervention (mean 8.6 
(±7.6) to post-intervention 
(mean 5.6 (±6.9), p = .03.  
Improvement not 
maintained at 3 and 6-
months. 
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Education for Persons with PD and Caregivers 
Study Intervention Recipients Sample Size Mean H&Y Stage (SD) Design 
Caregiver 
Outcome 
Measures 
Results 
Simons et al. 
(2006) 
Education program. 8 weekly sessions. 
Example session topics: self-monitoring, 
health promotion, stress management, 
social support. 
PwPD and 
caregivers, but in 
separate groups 
n = 22 (PwPD) 
and n = 14 
(caregivers) 
NR, but range: 
stage 1-4 
Open-label. No control group. 
 
Measures taken pre- and post-
intervention. 
BELA-A-k No significant difference in BELA-
A-k ‘need for help’ or ‘bothered by’ 
scores pre- and post-intervention. 
 
A’Campo et al. 
(2010a) 
Education program. 8 weekly sessions. 
Example session topics: self-monitoring, 
health promotion, stress management, 
social support. 
PwPD and 
caregivers, but in 
separate groups 
n = 64 (PwPD) 
and n = 46 
(caregivers) 
2.4 (±1.0) for 
intervention 
group, 2.3 
(±0.7) for 
control group 
Randomised, open-label, 
controlled trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation 
and 1-week after the program 
ended. 
BELA-A-k Caregivers in the intervention group 
showed a significantly greater 
decrease in BELA-A-k ‘bothered by’ 
scores (mean 2.3 (±5.4), p < .01) and 
‘need for help’ scores (mean 5.1 
(±9.0), p < .01). 
A’Campo et al. 
(2010b) 
Education program. 8 weekly sessions. 
Example session topics: self-monitoring, 
health promotion, stress management, 
social support. 
PwPD and 
caregivers, but in 
separate groups 
n = 151 (PwPD) 
and n = 137 
(caregivers) 
2.0 (±0.8) Open-label. No control group. 
 
Measures taken pre- and post-
intervention. 
BELA-A-k BELA-A-k scores significantly 
decreased from pre- to post-
intervention.  
Mean ‘bothered by’ score pre-
intervention: 17.7 (±11.1), post-
intervention: 13.4 (±11.5), p = .006. 
Mean ‘need for help’ score pre-
intervention: 22.7 (±3.2), post-
intervention: 1.1 (±0.9), p < .001. 
Bruno et al. 
(2016) 
Palliative care. Number and duration of 
sessions NR. Included counselling, 
demonstration of de-escalation 
techniques, education regarding 
neurobehavioural changes, and 
medication management by the caregiver. 
Caregivers n = 52 
(caregivers) 
NR, but all 
PwPD ≥ H&Y 
Stage 3 
Open-label. No control group. 
 
Measures taken pre-intervention 
and 3-months later. 
ZBI ZBI scores significantly decreased 
from pre-intervention to 3-months. 
Mean ZBI pre-intervention: 41.9 
(±12.5), post-intervention: 35.3 
(±12.9), p < .01. 
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Multidisciplinary Rehabilitation  
Study Intervention Recipients Sample Size Mean H&Y Stage (SD) Design 
Caregiver 
Outcome 
Measures 
Results 
Trend et al. 
(2002) 
Multidisciplinary rehabilitation. 6 
weekly individualised sessions. 
Followed by group activities (such as 
PD education and relaxation). 
PwPD and 
caregivers 
n = 118 (PwPD) and 
n = 92 (caregivers) 
NR Open-label. No control group. 
 
Measures taken pre- and post-
intervention. 
HADS No significant difference in HADS 
scores pre- and post-intervention. 
Wade et al. 
(2003) 
Multidisciplinary rehabilitation. 6 
weekly individualised sessions. 
Followed by group activities (such as 
PD education and relaxation). 
PwPD n = 94 (PwPD) and 
n = 68 (caregivers) 
NR Randomised, open-label, controlled 
trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation 
and 6-months after the intervention 
commenced. 
CSI No significant difference between 
the intervention and control group in 
CSI change scores. 
Nieuwboer et 
al. (2007) 
Training in the use of a prototype cue-
ing device for freezing of gait. 
 
Participants received 9 30-minute 
treatment sessions over 3 weeks 
followed by 3 weeks of no training. 
PwPD n = 153 (PwPD) NR, but range: 
stage 2-4 
Randomised, single-blind, 
crossover design. 
 
Participants randomized to early or 
late intervention. 
 
Measures taken at baseline and 3, 6 
and 12-weeks after the intervention 
commenced. 
CSI No significant difference between 
the intervention and control group in 
CSI change scores. 
Van der Marck 
et al. (2013) 
Multidisciplinary care individually 
tailored for each PwPD. Number and 
duration of sessions NR. 
PwPD n = 301 (PwPD), n 
= 195 (caregivers) 
NR Non-randomised, controlled trial. 
 
Control group of no intervention. 
 
Measures taken pre-intervention 
and 4, 6 and 8 months after 
baseline assessment. 
BELA-A-k No significant difference between 
the intervention and control group in 
BELA-A-k scores. 
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Occupational Therapy 
Study Intervention Recipients Sample Size Mean H&Y Stage (SD) Design 
Caregiver 
Outcome 
Measures 
Results 
Sturkenboom et 
al. (2013) 
OT. Maximum of 16 sessions delivered 
over 10 weeks. PwPD were given 
strategies to improve task performance, 
advice on optimizing daily routines, 
simplifying activities and on appropriate 
aids and adaptations in the environment. 
Caregivers received information about 
possible care resources, aids and 
adaptations, and training in supervision 
skills. 
PwPD and 
caregivers 
n = 43 (PwPD and 
caregivers) 
NR Randomised, open-label, controlled 
trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation and 
3-months after randomisation. 
 
 
ZBI No significant difference between 
the intervention and control group in 
ZBI scores. 
Sturkenboom et 
al. (2014) 114 
OT. Delivered over 10 weeks, maximum 
16 hours. PwPD were given strategies to 
improve task performance, advice on 
optimizing daily routines, simplifying 
activities and on appropriate aids and 
adaptations in the environment. 
Caregivers received information about 
possible care resources, aids and 
adaptations, and training in supervision 
skills. 
PwPD and 
caregivers 
n = 191 (PwPD) 
and n = 180 
(caregivers) 
NR Randomised, open-label, controlled 
trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation, and 
3 and 6-months after randomisation. 
 
 
 
ZBI No significant difference between 
the intervention and control group in 
ZBI scores. 
Chapter 2  40 
 
Abbreviations: ZBI = Zarit Burden Interview 
 
 
Peer Support Groups 
Study Intervention Recipients Sample Size Mean H&Y Stage (SD) Design 
Caregiver 
Outcome 
Measures 
Results 
Shah et al. 
(2015) 
Telephone support group. 8 weekly 
sessions. 4 key components: education 
about caregiving, skills training, problem 
solving, support. 
Caregivers n = 7 3.1 (±0.7) Open-label. No control group. 
 
Measures taken pre-intervention and 
upon conclusion of the program. 
ZBI No significant difference in 
ZBI scores pre- and post-
intervention. 
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Drug Therapies  
Study Intervention Recipients Sample Size Mean H&Y Stage (SD) Design 
Caregiver 
Outcome 
Measures 
Results 
Reading et al. 
(2001) 
Use of rivastigmine (dose titrated to 6mg 
twice daily or maximum tolerated over 8 
weeks followed by 6 weeks of 
maintenance therapy). 
PwPD with 
psychotic 
symptoms 
n = 15 (PwPD 
and 
caregivers) 
NR Open-label trial. 
 
Measures taken at screening, 
baseline, after dose titration, after 
maintenance therapy and 
following withdrawal. 
NPI – total 
distress score 
NPI total distress scores were 
significantly reduced at the end of the 
maintenance phase of treatment, 
compared to baseline (p = .007). Means 
and standard deviations NR. 
Litvinenko et al. 
(2008) 
Use of galantamine for 24 weeks. 4mg 
twice daily for the first 4 weeks, 8mg 
twice daily for the following 20 weeks. 
PwPD with 
PD dementia 
(MMSE score 
< 25) 
n = 41 (PwPD 
and 
caregivers) 
3.2 (±0.5) for 
intervention group, 
3.3 (±0.6) for 
control group 
Randomised, open-label, 
controlled trial. 
 
Control group of no intervention. 
 
Measures taken at randomisation, 
and at weeks 4, 12, and 24 of the 
trial. 
NPI – total 
distress score 
NPI total distress scores were 
significantly reduced in the galantamine 
group by the ends of weeks 12 and 24, 
compared to the control group (p = .03 
and p = .007, respectively). Means and 
standard deviations NR. 
Santos-Garcia 
et al. (2012) 
Continuous duodenal levodopa infusion 
therapy (range: 23-42 months). 
Administered for at least 14 hours/day, 
initially by nasoduodenal infusion using a 
portable pump, and after 7 days by 
intraduodenal infusion through a 
transabdominal port. 
PwPD with 
motor 
fluctuations 
and 
dyskinesias 
n = 7 (PwPD 
and 
caregivers) 
3.7 (±0.5) Open-label trial. No control 
group. 
 
Measures taken pre-and post-
intervention. 
ZBI, CSI ZBI and CSI scores significantly 
decreased from pre- to post-intervention. 
Mean ZBI pre-intervention: 43.0 (±13.3), 
post-intervention: 20.7 (±12.1), p = .018. 
Mean CSI pre-intervention: 6.3 (±2.5), 
post-intervention 1.6 (±0.9), p = .018. 
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Fasano et al. 
(2012) 
Continuous duodenal levodopa infusion 
therapy (range: 6-52 months). 
Administered for at least 14 hours/day, 
initially by nasoduodenal infusion using a 
portable pump, and after 7 days by 
intraduodenal infusion through a 
transabdominal port. 
PwPD with 
motor 
fluctuations 
and 
dyskinesias 
n = 14 (PwPD 
and caregivers 
NR Open-label trial. No control 
group. 
 
Measures taken pre- and post-
intervention. 
RSS No significant difference in RSS scores 
pre- and post-intervention. 
Leroi et al. 
(2014) 
Use of memantine (20mg daily) for 16 
weeks. 
PwPD with 
PD dementia 
(DSM-IV 
criteria) 
n = 15 (PwPD 
and 
caregivers) 
3.3 (±0.8) for 
intervention group, 
3.5 (±0.9) for 
placebo group 
Randomised, double-blind, 
controlled trial. 
 
Measures compared to a placebo 
group. 
 
Measures taken at randomisation 
and 16-weeks post-
randomisation (end of drug 
treatment). 
ZBI Caregivers in the memantine group 
showed a significantly greater decrease in 
ZBI scores (mean change memantine 
group: -5.6 (±7.0), placebo group: 0.1 
(±6.6), p = .04). 
 
Oh et al. (2015) Use of rivastigmine (dose titrated over 4 
weeks followed by 20 weeks maintenance 
therapy). 20 PwPD received transdermal 
rivastigmine (mean dose 6.1mg) and 3 
PwPD received oral rivastigmine (mean 
dose 8.0mg). 
PwPD with 
PD dementia 
(MDS clinical 
diagnostic 
criteria) 
n = 23 (PwPD 
and 
caregivers) 
2.2 (±0.8) Open-label. No control group. 
 
Measures taken pre- and post-
intervention. 
NPI - total 
distress score 
and distress 
score for each 
subscale 
NPI total distress scores, and distress 
scores on the hallucinations, depression 
and dysphoria, apathy, and appetite 
changes subscales were significantly 
reduced from pre- to post-intervention. 
Mean NPI total distress score pre-
intervention: 8.1 (±6.4), post-
intervention: 5.4 (±7.4), p = .02. 
 
Full list of abbreviations: 
Abbreviations: NR = not reported; CBT = cognitive behavioural therapy; OT = occupational therapy; DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, 4th edition; MMSE = Mini-Mental State 
Examination; QUIP = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease; CBI = Caregiver Burden Inventory; CSI = Caregiver Strain Index; CDS = Caregiving Distress Scale; ZBI = Zarit 
Burden Interview; NPI = Neuropsychiatric Inventory; PDQ-Carer = Parkinson’s Disease Questionnaire – Carer; BELA-A-k = Questionnaire for Psychosocial Problems in Parkinson’s Disease; HADS = Hospital 
Anxiety and Depression Scale; MDS = Movement Disorder Society; SHORT-CARE = Comprehensive Assessment and Referral Evaluation (short version);  RSS = Relatives’ Stress Scale; PwPD = Persons with PD 
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Chapter 3 
3 Neuropsychiatric Symptoms after Subthalamic Deep Brain 
Stimulation for Parkinson’s Disease 
‘Before, when he was sick, we were a perfect couple. Now, he wants to live the life of a young man, go out, meet 
new people, all of that is intolerable! I would rather he be like he was before, always nice and docile!’ 
Spouse of a DBS patient, quoted in: ‘A Distressed Mind in a Repaired Body?’ (Schupbach et al., 2006). 
3.1 Publication Details 
This chapter was published as: 
Mosley, P.E. & Marsh, R., 2015. The psychiatric and neuropsychiatric symptoms after 
subthalamic stimulation for Parkinson’s disease. Journal of Neuropsychiatry and Clinical 
Neurosciences. 27, 19-26. 
3.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, carried out the literature review, synthesised the 
data and wrote the manuscript. Dr Marsh assisted with revisions to the manuscript.  
3.3 Abstract 
Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an established treatment for 
the motor symptoms of Parkinson’s disease. Non-motor features of Parkinson’s disease, 
however, may not improve with STN-DBS, and a specific constellation of neuropsychiatric 
symptoms may emerge in the postoperative period. Mania, impulsivity, depression, and apathy 
may curtail the potential gains from surgery. This paper discusses surgical candidacy, 
postoperative management of neuropsychiatric issues, and clinical dilemmas for the 
psychiatrist at the DBS centre. A paradigm that considers stimulation effects and dopamine 
replacement therapy to be key drivers of postoperative neuropsychiatric problems is presented. 
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3.4 Introduction 
Deep brain stimulation (DBS) is an established intervention that provides a more constant and 
predictable benefit than pharmacological treatment for Parkinson’s disease. Electrodes 
positioned within deep brain nuclei emit continuous high frequency stimulation that modulates 
disordered basal ganglia activity. The subthalamic nucleus (STN) is the most frequent surgical 
target and permits the greatest postoperative reduction in dopamine replacement therapy, 
although the internal segment of the globus pallidus (GPi) is a common alternative. Bilateral 
STN stimulation increases ‘on’ time (periods of mobility; contrasting with ‘off’ time where the 
person is immobile), reduces motor fluctuations and dyskinesias, enhances performance of 
activities of daily living and improves quality of life (Deuschl et al., 2006). Initially developed 
as a therapy for advanced disease, contemporary evidence indicates that STN-DBS provides 
superior benefits even in the early and mild stages of motor complications, which is likely to 
increase the extent of its use (Schuepbach et al., 2013).  
 
Parkinson’s disease has been described as the quintessential neuropsychiatric disorder 
(Weintraub and Burn, 2011). Non-motor complications generate an excess of functional 
disability, psychological morbidity and caregiver burden. The aetiology of these symptoms is 
diverse, with major contributions from neurodegeneration and dopaminergic stimulation, in 
addition to psychological and psychosocial changes arising in the setting of chronic disease. 
The psychiatrist may be consulted for issues such as depression, anxiety, apathy, impulse 
control disorders, psychotic symptoms and cognitive impairment, working collaboratively with 
the neurologist to reduce the impact of Parkinson’s disease upon patients and their families.  
 
The connection between STN-DBS and the neuropsychiatric features of Parkinson’s disease is 
complex. Even with a robust post-DBS improvement in motor disability, personal and social 
impairment may be unchanged (Houeto et al., 2006). Existing non-motor features may progress 
and new neuropsychiatric problems may also emerge, including mood disturbance, anxiety, 
apathy and impulsivity. These may impair postoperative functioning in non-motor domains. 
Relationship dysfunction may ensue (Schupbach et al., 2006). 
 
For most persons STN-DBS is a safe therapy. The rate of serious psychiatric complications 
following DBS for Parkinson’s disease is comparable to that amongst persons treated with 
dopaminergic therapies alone (Witt et al., 2008). At the group level, neuropsychological 
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measures of depression may even improve following DBS (Funkiewiez et al., 2004). However, 
a proportion of individuals experience transient neuropsychiatric symptoms attributable to 
DBS that are clinically significant (Voon et al., 2006). Mitigating these symptoms is likely to 
improve outcomes for this subset of persons. Unfortunately, evidence-based recommendations 
are sparse and clinical guidelines remain nascent. In this paper, we synthesise the available 
literature to provide a grounding for the psychiatrist in this field, noting domains that are yet to 
be robustly supported by data, or are controversial. We focus on STN-DBS, although some 
issues will also be applicable to other surgical targets.  
3.5 The Psychiatrist at the DBS Centre 
For those persons affected by neuropsychiatric complications, a range of factors will influence 
their incidence, persistence and severity. There is an interaction of biological aspects (such as 
electrode placement, stimulation dosing and the individual response to postoperative reduction 
in dopaminergic therapies) with more nebulous constructs (such as preoperative psychiatric 
vulnerabilities, personality style and social adjustment). The psychiatrist is well placed to 
assimilate biological, psychological and social variables into a unique understanding of each 
case that transcends neuropsychological inventories or rating scales. Nonetheless, STN-DBS 
is associated with neuropsychiatric phenomena largely specific to this procedure and not 
captured in standard psychiatric nosology. Furthermore, the character of the neuropsychiatric 
presentation is greatly influenced by the physiological manifestations of DBS, Parkinson’s 
disease and dopaminergic medication, which has direct implications for psychiatric 
management.  
3.6 Biological Aspects of Neuropsychiatric Complications 
3.6.1 Neurostimulation 
Consider the function of the basal ganglia in the selection and facilitation of movement, 
cognition and emotion. The STN has a regulatory role, providing an inhibitory ‘NO-GO’ signal 
in the cortico-subcortical networks of the basal ganglia (Volkmann et al., 2010). A gradient of 
representations exists within the STN, with motor activity located in the dorsolateral aspect of 
the nucleus, cognitive-associative circuits in the intermediate zone and limbic circuits in the 
ventromedial region (Lambert et al., 2012). Functional inhibition of the STN using high-
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frequency stimulation facilitates movement but may release cognitive and affective 
disinhibition in certain individuals. The small size of the STN means that current diffusion 
from accurately placed electrodes may still inadvertently modulate networks implicated in 
mood, thinking and reward, including the anterior cingulate cortex, the orbitofrontal cortex and 
the ventral tegmental area. Electrodes situated in the ventromedial STN (Chopra et al., 2012), 
or the substantia nigra (Ulla et al., 2011), seem more likely to produce these non-motor side 
effects.  
 
In Parkinson’s disease, variable patterns of cell loss within the basal ganglia also modify the 
outcome of DBS. Mesencephalic dopaminergic projections within motor and non-motor 
networks degenerate at different rates, (Kish et al., 1988), such that motor and non-motor 
responses may dissociate at a given level of stimulation. Following DBS, STN stimulation 
sufficient to restore functioning in a degenerated hypodopaminergic motor circuit may cause a 
functional imbalance in an adjacent non-degenerated non-motor circuit.  
 
The postoperative presentation of this syndrome resembles mania or hypomania, with a 
variable incidence of up to fifteen percent (Appleby et al., 2007; Daniele et al., 2003), although 
stimulation-induced reversible depressive symptoms have also been described following 
inadvertent electrode placement in the substantia nigra (Bejjani et al., 1999). Stimulation 
effects can be distinguished from intra-operative micro-lesioning by their persistence and 
temporal association with DBS adjustment. Clinically, the most common features are an 
elevated or irritable mood, racing thoughts, impulsivity and an increase in goal-directed 
activity. Insomnia and agitation may also be present. Some cases manifest attenuated 
symptoms, making the diagnosis more difficult to capture and potentially accounting for the 
discrepancy in reported incidence. Close family members such as spouses are nonetheless 
likely to detect these changes and commonly complain that the patient is no longer ‘himself’. 
Impulsivity is frequently noted and may be a common endophenotype in this cohort, defined 
informally as the tendency to act prematurely, without foresight. Some neuropsychological 
correlates of impulsivity are known to change after STN DBS, such as impaired response 
inhibition (Witt et al., 2004) and increased speed of decision making in situations of conflict 
(Frank et al., 2007).  
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3.6.2 Dopaminergic Medication 
Treatment with dopaminergic medication is also associated with neuropsychiatric 
complications that may persist or worsen after DBS. In these cases, exogenous dopamine 
disrupts the function of the basal ganglia in a manner that predisposes to impulse control 
behaviours (ICBs) such as pathological gambling, hypersexuality, compulsive shopping, binge 
eating and hobbyism (Weintraub et al., 2010). These disorders appear unified by the concept 
of compulsivity, namely a maladaptive perseveration of behaviour that is inappropriate to the 
situation and results in undesirable consequences. There is an overlap with impulsivity, with 
the two differentiated by their relevance to different aspects of response control: impulsivity to 
response initiation and compulsivity to response termination. Correspondingly, patients with 
ICBs also score highly on neuropsychological measures of impulsivity (Housden et al., 2010), 
are more likely to have a novelty-seeking temperament and to have experienced medication-
induced hypomanic symptoms (Voon et al., 2007). 
 
Pre-clinical evidence implicates the nucleus accumbens in the pathophysiology of these 
behaviours (Grace, 2008). A region of the ventral striatum that is vulnerable to dopaminergic 
destabilisation, the nucleus accumbens is associated with hedonic tone and reinforcement 
learning. Chronic dopaminergic stimulation (particularly provided by dopamine agonist 
medication) attenuates the regulatory drive of the prefrontal cortex to this region, with a 
predominance of appetitive limbic inputs and a loss of behavioural flexibility. This process is 
augmented by sensitisation of the ventral striatal neurocircuitry (Evans et al., 2006), as well as 
the affinity of dopamine agonists for D3 receptors that predominate in this region (Gerlach et 
al., 2003). Functional imaging indicates that patients with ICBs have a specific vulnerability 
to deactivation of frontal regulatory circuits (van Eimeren et al., 2010) and more recent work 
identifies a structural vulnerability to impulsivity in grey matter atrophy of fronto-striatal 
regions (O'Callaghan et al., 2013a). 
 
The relationship between STN-DBS and ICBs is controversial. By permitting substantial 
postoperative reduction in dopaminergic medication, STN-DBS has been considered a 
potential treatment for ICBs. However, this is not consistently supported in the literature, with 
70 % of patients with ICBs remaining unchanged or worsening after DBS in one series (Lim 
et al., 2009). New onset ICBs have also been reported after STN-DBS (Smeding et al., 2007). 
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If postoperative mania is caused by disinhibition of limbic and associative networks, then 
under-activation of these same non-motor circuits also produces characteristic neuropsychiatric 
sequelae. Substantial reduction of dopaminergic medication following STN-DBS is common 
practice as electrical stimulation in motor regions of the STN predominates. It may, however, 
unmask symptoms such as apathy, depression and anxiety in up to 50 % of persons (Thobois 
et al., 2010). For these individuals, dopaminergic medication has a psychotropic effect and 
withdrawal symptoms arise on discontinuation (Giovannoni et al., 2000), particularly in those 
treated with dopamine agonists (Rabinak and Nirenberg, 2010). The symptoms of this 
‘dopamine agonist withdrawal syndrome’ (DAWS) include anxiety, agitation, depression, 
irritability, insomnia and suicidal ideation, and respond to dopamine agonist repletion. DAWS, 
therefore, may also be a driver of postoperative neuropsychiatric complications after STN-DBS 
(Nirenberg, 2010). As medication withdrawal is not a problem for all individuals, the disease-
related denervation pattern may explain this hypo-dopaminergic vulnerability, with afflicted 
persons having greater mesocorticolimbic dopaminergic denervation than those without 
symptoms (Thobois et al., 2010). 
3.6.3 Summary 
We contend that many post-DBS neuropsychiatric disturbances have a biological basis in 
neurostimulation, dopaminergic tone and neurodegeneration. STN-DBS and the attendant 
alterations in dopaminergic therapy represent an acute insult to a compensated but brittle 
homeostatic system regulating movement, mood and cognition; already anatomically and 
physiologically disrupted prior to surgery. There may arise a postoperative dissociation 
between motor and non-motor outcomes as stimulation parameters and medication are 
optimised to restore degenerated motor circuits, with a resultant imbalance in topographically 
distinct functional networks.  
 
Despite the psychiatric sequelae of these complex disruptions to brain neurocircuitry, the 
natural history of post-DBS neuropsychiatric symptoms appears to trend to an attenuation of 
symptoms (including suicide risk) in the months and years that follow DBS. It is unclear 
whether this represents the progression of neurodegeneration or a slow recovery of stable 
homeostasis via preserved mechanisms of neuroplasticity. This process plays out in an 
individual with a unique temperament, specific constellation of psychiatric morbidity and a 
support network with a variable capacity to respond to disruption. It is particularly in the early 
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postoperative course that the psychiatrist’s expertise is relevant, when non-motor circuits seem 
at particular risk of dysregulation and the person at risk of an adverse outcome.  
3.7 Preoperative Issues 
3.7.1 Candidacy 
Suitability for STN-DBS can be considered from a psychiatric as well as a surgical perspective. 
This provides both clinical and ethical challenges for the psychiatrist. Neuropsychiatric 
symptoms may be present only at sub-clinical levels prior to DBS and it is difficult to identify 
those individuals who may suffer a postoperative deterioration. Alternatively, more florid 
behavioural problems may be concealed by surgical candidates and their families, fearful that 
psychiatric symptoms will affect surgical eligibility. It is difficult to conceive of denying 
surgery to persons identified as possessing risk factors, particularly if they have exhausted other 
treatment options and are capable of informed consent. The psychiatrist may be asked to stratify 
patients as high or low risk for poor non-motor outcome, but this is a complex matter shaped 
not only by the person’s psychiatric history but also by factors such as rapport with the 
psychiatrist and willingness to engage in close postoperative follow up. Hopefully this issue 
can be addressed in subsequent work. 
 
Should all candidates undergo a psychiatric assessment prior to STN-DBS? Neuropsychiatric 
symptoms are prevalent in the population presenting for surgery, even after screening by a 
neurologist (Voon et al., 2005). The advantages of preoperative engagement with the individual 
are that it allows assessment of the psychiatric ‘baseline’ and treatment of existing psychiatric 
problems. For example, having a history of a depressive disorder may be less important than 
being in remission at the time of surgery, such that the psychiatrist may delay DBS to allow 
the initiation of antidepressant therapy. 
 
The authority of the psychiatrist in the multidisciplinary team is not yet established. At what 
stage should the psychiatrist intervene to veto or delay DBS? Should the psychiatrist be able to 
suggest DBS of other brain nuclei that may be less likely to lead to neuropsychiatric 
complications? Clearly, navigating these issues demands a collegiate working relationship with 
the neurologist and neurosurgeon at the DBS centre.  
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3.7.2 Suicide 
The issue of suicide following STN-DBS for Parkinson’s disease was highlighted by a 
retrospective case series that found it to be a predominant cause of mortality in the first 
postoperative year (Voon et al., 2008), although the quality of this data is diminished by its 
retrospective nature. The only randomised, controlled trial to examine this issue did not find 
an increased rate of suicide in the DBS group at six months postoperatively (Weintraub et al., 
2013), although this study was arguably underpowered to detect a significant difference in such 
a rare event. Whilst DBS itself does not cause suicide, a constellation of downstream 
phenomena may make suicide more likely in vulnerable individuals. This is a nuanced concept 
that requires careful discussion with surgical candidates and their families.  
 
In the aforementioned retrospective series, postoperative depression was the factor most 
strongly associated with completed suicide and suicide attempts post-DBS (Voon et al., 2008). 
Identifying those patients likely to suffer postoperative depression is more difficult. Depression 
is one of the most common non-motor symptoms of Parkinson’s disease and a preoperative 
history of depression is thus relatively non-specific. In the absence of clear evidence, the 
psychiatrist might consider the duration, severity and treatment refractoriness of previous 
depressive episodes, as well as whether these appeared as a feature of Parkinson’s disease or 
as part of a premorbid history of major depressive disorder. Suicidal ideation is also relatively 
common in Parkinson’s disease (Nazem et al., 2008), but a past history of suicide attempts is 
of more concern. In one sample, severe depression at baseline predicted severe depression three 
years after DBS, emphasising the importance of treating active depressive symptoms prior to 
surgery (Funkiewiez et al., 2004). 
 
A history of the dopamine dysregulation syndrome or an ICB was also associated with a risk 
of attempted suicide post-DBS (Voon et al., 2008). This may be a marker of both impulsivity 
and a liability to develop a DAWS-induced depressive state, as co-morbidity of DAWS with 
ICBs is common. Prior to surgery, non-motor fluctuations in mood and anxiety, responsive to 
a levodopa challenge, also predict a postoperative vulnerability to DAWS (Thobois et al., 
2010). In clinical practice, however, identifying this phenomenon is hindered by the frequent 
disavowal of the non-motor effects of dopaminergic medication by persons with Parkinson’s 
disease, with ‘off’ period dysphoria often expressed in motor terms alone. It is conceivable that 
stimulation and DAWS could interact within the same individual to effect a dangerous 
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combination of depressed mood and impulsivity. This may be related to the observation that in 
this cohort, suicide attempts appeared more likely to result in death than other populations 
(Voon et al., 2008). 
 
The presence of a psychiatrist in the multidisciplinary team is evidently prudent, but may not 
mitigate the likelihood of suicide in all cases. Certain individuals may be reluctant to engage 
with the psychiatrist, for reasons of additional cost, stigma or alexithymia. This makes it 
substantially more challenging to accurately and effectively manage this group. As well as 
failing to report relevant features of the psychiatric history, such individuals can have a great 
aversion to accepting psychiatric care, despite the presence of suicidal urges. Even if the 
psychiatrist successfully identifies these cases, direct intervention may still be resisted. Here 
the psychiatrist faces a dilemma: can the patient be managed indirectly through other clinicians 
at the DBS centre or must the psychiatrist proceed with involuntary treatment under the 
provisions of the relevant local legislation? The latter course of action may be necessary in 
cases where the person lacks the capacity to make treatment decisions, but is likely to be a 
profoundly distressing experience that may compromise ongoing rapport and worsen 
engagement in the longer term. 
3.7.3 Impulsivity, Mania and ICBs 
At present, there is little evidence to guide identification of those patients at risk of 
postoperative impulsivity or manic symptoms. Major determinants of these phenomena are 
postoperative, such as inadvertent stimulation of the cognitive and limbic STN. Case reports 
(Voon et al., 2006), suggest that a personal or family history of bipolar disorder and a history 
of medication-induced mania may be risk factors. The significance of premorbid, sub-
syndromal bipolar traits is not established, but the concept of DBS unmasking a hitherto latent 
mood disorder bears consideration. The question of whether some patients have existing 
structural or functional vulnerabilities due to neurodegeneration or dopaminergic stimulation 
was raised in the preceding section, but it is not common practice to screen for these using 
neuroanatomical or neuropsychological methods and their connection to postoperative 
problems has not been established. 
 
The use of STN-DBS to treat preoperative ICBs is debatable. One group has demonstrated that 
abrupt cessation of dopamine agonists and marked reduction in dopaminergic medication after 
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surgery led to remission of baseline ICBs in their cohort (Lhommee et al., 2012). However, 
switching rapidly from a hyper-dopaminergic to a hypo-dopaminergic state brings its own 
complications, with emergent apathy and depression that may require rescue with 
recommencement of dopamine agonists. A higher rate of suicide attempts in this sample also 
supports the view that these individuals are more psychiatrically unstable candidates. If ICBs 
have been detected preoperatively, a gradual taper of dopamine agonists can begin prior to 
surgery, potentially smoothing the postoperative course. Whether severe preoperative ICBs 
should be a contraindication to STN-DBS is another question; there is not clear longitudinal 
data to guide clinicians. Persons with Parkinson’s disease should be warned that the ICB may 
persist or even worsen after surgery. In those individuals with compulsive use of dopaminergic 
medication, DBS is likely to treat motor symptoms but will not reduce the non-motor 
requirements for dopamine. Again, exposing these individuals to a staged dopaminergic 
withdrawal prior to surgery allows them to develop a tolerance to these non-motor ‘off’ states. 
The psychiatrist may advocate for GPi DBS in severe cases, based on the presumption that this 
target is associated with fewer neuropsychiatric complications. However, the outcome did not 
differ in one small retrospective series (Moum et al., 2012). 
3.7.4 Cognition 
Aside from effects on neuropsychological constructs of impulsivity, the most consistent effect 
of STN-DBS has been to impair semantic and phonemic verbal fluency (Voon et al., 2006)). 
For most persons, STN-DBS has no cognitive sequelae, but many clinical studies exclude 
individuals aged over seventy and those with significant pre-existing cognitive impairment, 
variously defined. There are cases of significant cognitive deterioration that occur soon after 
DBS and seem temporally linked to the procedure rather than to progression of Parkinson’s 
disease. Risk factors for this complication may include older age, total pre-surgical 
dopaminergic medication requirement and axial symptoms, potentially reflecting advanced 
disease (Daniels et al., 2010). Intra-operative variables are also potentially relevant, such as 
damage to cortical tissue during the passage of electrodes. 
 
The pre-surgical psychiatric assessment should routinely include an assessment of cognition. 
In Parkinson’s disease, this should include measures of visuospatial and executive function. 
Both the Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) and the 
Addenbrooke’s Cognitive Examination (Mathuranath et al., 2000) examine a distributed set of 
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cognitive domains, including verbal fluency, yet can be administered rapidly. Persons aged 
over seventy should be counselled about the potential, yet poorly quantified, risk of accelerated 
cognitive deterioration post procedure. Those with preoperative cognitive impairment should 
be warned that they may not benefit as greatly from STN-DBS on quality of life outcomes 
(Witt et al., 2011). The finding of pre-existing cognitive impairment should prompt an 
assessment of capacity to consent to DBS. Although DBS is generally contraindicated in cases 
of dementia, the psychiatrist should work with the multidisciplinary team on a case by case 
basis when this is advocated, contributing to the process of substitute decision making.  
3.7.5 Other Neuropsychiatric Symptoms 
Individuals with preoperative hallucinations and other psychotic symptoms linked to the 
neuropsychiatric toxicity of dopaminergic therapies may improve following STN-DBS with 
postoperative reduction of medication. However, the presence of psychotic symptoms signals 
advanced disease and should prompt a careful screen for significant cognitive impairment that 
might exclude surgery. However, in cognitively intact persons with psychotic symptoms, the 
outcome of STN-DBS appears favourable (Umemura et al., 2011). 
3.7.6 Preparing the Family System 
Parkinson’s disease classically disrupts the developmental transition from working life to early 
retirement. Long-held plans and goals are modified or given up. STN-DBS offers a chance for 
the person to recover the life that should have been, were it not for Parkinson’s disease. 
Typically, the individual with Parkinson’s disease exists in a family system, most often with a 
spouse or partner, in which roles are established to balance the restrictions of disability with 
the demands of everyday life. As part of the reversal of disability, roles in the marital and 
family system must now be renegotiated to take account of postoperative changes. The person 
and their spouse may have divergent opinions regarding the ideal outcome from surgery and 
how much the existing system should change. This process of adaptation can be disrupted by 
emergent neuropsychiatric symptoms, which alienate the person from his or her support 
network at a crucial point in the postoperative journey. A loyal partner is discarded in a 
euphoric behavioural activation as the person with Parkinson’s disease seeks to indulge a new-
found freedom from motor disability. Other spouses struggle to accept that DBS is not a cure 
for Parkinson’s disease and expect the depressed and apathetic individual to resume an entirely 
normal role within the family.  
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The psychiatrist generates a unique understanding of each case, including the internalisation of 
Parkinson’s disease as part of the person’s self-concept, associated negative cognitive 
distortions, coping styles and expectations of postoperative life. Negotiating a mutuality of 
expectations between the person with Parkinson’s disease, family and surgical team is an 
important step in mitigating the fantasy of cure or the unrealistic belief that DBS will resolve 
existing psychosocial difficulties. Families should also consider their capacity for increased 
forbearance in the immediate postoperative period during which neuropsychiatric symptoms 
are more common.  
3.7.7 Summary 
Though the psychiatrist can neither predict nor prevent all neuropsychiatric complications, 
screening for risk factors alerts the clinician to a potential worsening of neuropsychiatric 
symptoms. Certainly, the outcome after STN-DBS seems worse if preoperative ICBs go 
undetected (Lim et al., 2009). If known, risks can be addressed by ensuring that 
neuropsychiatric issues are treated at the time of surgery and the individual and family are 
educated about behaviours they may encounter following DBS. Unknown risks result from a 
preoperative denial of neuropsychiatric symptoms and the multiplicity of biological, 
psychological and social determinants that may contribute to a poor non-motor outcome 
following DBS. A key skill of the DBS psychiatrist is communicating these unknowns to the 
surgical candidate in a manner that increases capacity to make an informed decision about 
undertaking functional neurosurgery. 
3.8 Postoperative Issues 
3.8.1 Restoring the Balance of Dopaminergic Behaviours 
The psychiatrist’s role in the postoperative phase is to detect and manage neuropsychiatric 
symptoms before they substantially impair functioning and quality of life. It is neither 
necessary nor feasible to longitudinally follow all patients, so the psychiatrist relies on the 
patient and his support network for the prompt detection of behavioural disturbances. This 
highlights the importance of preoperative education to raise awareness of these issues. The 
psychiatrist is skilled in non-motor assessment and may be able to elicit non-motor symptoms 
that are overlooked by or concealed from other clinicians at the DBS centre.  
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With regards to treatment, the psychiatrist should also be familiar with adjustment of 
stimulation settings and comfortable with dosing dopaminergic therapies. These appear to be 
key interventions for post-DBS neuropsychiatric problems. Postoperatively, clinicians in the 
DBS team must balance titration of stimulation and withdrawal of medication, a process 
likened to walking a tightrope between the hyper-and hypo-activated clusters of non-motor 
symptoms. Tuning of the device and adjustment of medication to manage neuropsychiatric 
problems may necessitate the sacrifice of some motor response and thus requires collaboration 
with the treating neurologist and neurosurgeon. In refractory cases, the psychiatrist may also 
provide expertise in additional pharmacological and psychotherapeutic strategies, although the 
evidence base for these in the DBS population is limited.  
3.8.2 Impulsivity, Mania and ICBs  
These symptoms can be devastating, especially for families who were not forewarned about a 
potentially rocky postoperative course. The link between ICBs and carer burden in Parkinson’s 
disease is recognized (Leroi et al., 2012a). Even less florid disinhibition can be burdensome to 
the patient’s spouse, who is often ill-prepared to tolerate this ‘personality change’. Mood 
changes commonly appear to be stimulation dependent; switching to a dorsolateral stimulation 
contact, using bipolar rather than monopolar stimulation or reducing voltage can be helpful. 
When in bipolar mode, reversing the polarity of the active electrodes changes the shape of the 
stimulation field and also reduces diffusion to unwanted targets. However, effecting these 
changes may meet with resistance. Mood elevation is pleasant and a return to euthymia is often 
accompanied by substantial deterioration in motor performance. Managing this situation is 
challenging and demands a working alliance with the patient.  
 
Pharmacological treatment with an atypical antipsychotic or mood stabiliser may permit 
preservation of motor benefits (Schilbach et al., 2012), and is an option for refractory cases. 
Due to their rapid dissociation from the D2 receptor, quetiapine and clozapine are the 
antipsychotics of choice in Parkinson’s disease, being least likely to induce extrapyramidal 
symptoms. However, data for the efficacy of quetiapine for psychotic symptoms in Parkinson’s 
disease is inconclusive (Seppi et al., 2011), whilst clozapine is associated with considerable 
monitoring requirements to reduce the risk of myocarditis, cardiomyopathy and 
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agranulocytosis. Efficacy of either drug for the treatment of post-DBS neuropsychiatric 
symptoms has not been examined. 
 
The psychiatrist can be called upon to provide serial assessments of mental state during a phase 
of DBS reprogramming by the movement disorder specialist. This may also involve an opinion 
on capacity, safety and the need for hospitalisation to reduce the risk of misadventure or 
damage to reputation. Sensible behavioural management in this period includes placing 
temporary limits on financial transactions and restricting access to motor vehicles. Once these 
issues have abated, the psychiatrist can anticipate working with the family to process some of 
the grief and anger consequent to these behaviours, allowing the patient to re-establish his role 
in the family system. In the most severe cases, there may also be considerable legal, social and 
financial matters to address, such as criminal convictions, divorce, disputes over testamentary 
capacity and outstanding debts.  
3.8.3 Depression, Anxiety and Apathy 
In chronological order of appearance, depression can be ascribed to stimulation effects, 
levodopa withdrawal, psychological adjustment and non-motor progression of Parkinson’s 
disease. Direct stimulation-induced depressive symptoms are rare. When optimally placed, the 
immediate effects of stimulation seem to have a modest mood elevating effect (Wolz et al., 
2012). Depression and anxiety arising as a consequence of dopaminergic medication 
withdrawal are most likely to emerge in the initial postoperative months. In such patients, 
increasing levodopa or reintroducing a dopamine agonist reverses these mood changes. The 
role of pramipexole in the treatment of depression in Parkinson’s disease is established (Seppi 
et al., 2011). In the longer term, it is not clear whether reductions in medication should remain 
modest or whether neuropsychiatric symptoms are simply part of an unpleasant withdrawal 
syndrome that will abate in time. Antidepressant medication may address these symptoms 
although again the evidence base is inconclusive. In depressed Parkinson’s disease patients, 
there is more evidence for the efficacy of tricyclic antidepressants over selective serotonin 
reuptake inhibitors (Seppi et al., 2011), potentially reflecting the importance of noradrenergic 
reuptake inhibition; although the tricyclic antidepressants are less likely to be tolerated due to 
anticholinergic side effects. During this period, verbalised suicidality should be taken seriously 
in an impulsive population where attempts carry high lethality. The psychiatrist may again be 
required to closely monitor the patient’s mental state and consider inpatient treatment to 
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mitigate the risk of suicide. Where depression arises in the setting of a complicated adjustment 
to postsurgical life, the psychiatrist may take more of a psychotherapeutic role, revisiting the 
expectations of the patient and his family and investigating social determinants of wellbeing.  
 
Characterising the more distal effects of STN-DBS on mood is challenging. Variability in 
outcome is likely to be governed by such factors as personality, family support and adjustment 
to illness, with some evidence to suggest that persons who are poorly adapted at baseline 
continue to suffer psychosocial impairment (Kaiser et al., 2008). Post-DBS behavioural 
disorders may isolate the person with Parkinson’s disease. Non-motor disease progression is 
also relevant, given that the prevalence of depression in pharmacologically-managed persons 
with Parkinson’s disease is substantial. 
 
Apathy includes both loss of motivation and loss of emotionality. This is manifest in 
diminished goal-directed activity and reduced spontaneous or evoked emotional display 
(Starkstein and Leentjens, 2008). It overlaps with, but is distinct from, depression and 
dementia. Following DBS, apathy is relatively common in the setting of dopaminergic 
medication withdrawal and may be part of the spectrum that includes anxiety, depression and 
suicidal ideation. It responds to reintroduction of dopamine agonist medication (Czernecki et 
al., 2008), suggesting that apathy is a feature of DAWS in some persons. Apathy emerging 
later in the postoperative course is more likely to represent non-motor disease progression and 
addition of dopamine agonists in these individuals might lead to confusion rather than 
improvement. Behavioural measures such as prompting by caregivers or structured 
environmental stimulation are more suitable.  
3.8.4 Summary 
Biological aspects of post-DBS neuropsychiatric symptoms inform the psychiatrist’s 
management. Balancing stimulation with dopaminergic medication parallels the balancing of 
motor and non-motor outcomes. The psychiatrist will gather information from other clinicians 
in the DBS centre and the patient’s family to get a comprehensive picture of postoperative 
behavioural change. Working with families to contain neuropsychiatric disturbance is key, 
particularly when caregiver burden is onerous and relationship rupture seems imminent. 
Alliance with persons with Parkinson’s disease may be complicated by denial and preference 
for motor performance.  
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3.9 Conclusions 
We believe that a psychiatrist in the DBS centre adds value to non-motor outcomes by ensuring 
neuropsychiatric complications remain transient and self-limiting. The psychiatrist brings 
complementary skills to the DBS team including non-motor assessment and a capacity to work 
more closely with the family system. In this review, we have described a biological paradigm 
that underlies the disparate phenotypes in this post-DBS syndrome with a corresponding 
approach to candidacy and postoperative management.  
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Chapter 4 
4 An Illustrative Case of Mania after Subthalamic Deep Brain 
Stimulation for Parkinson’s Disease 
‘I've seen with this that people can change pretty quick just from a wire. Same person, same mind, or same 
brain, just shift a bit of voltage somewhere and a different person.’ 
Spouse of a DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
4.1 Publication Details 
This chapter was published as: 
Mosley, P.E., Marsh, R., Perry, A., Coyne, T. & Silburn, P., 2018. Persistence of mania after 
cessation of stimulation following subthalamic deep brain stimulation for Parkinson’s disease. 
Journal of Neuropsychiatry and Clinical Neurosciences. 30, 246-249. 
4.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, consented the participant, conducted the 
interviews, managed the psychiatric aspects of the participant’s care, analysed the 
neuroimaging and wrote the manuscript. Dr Marsh assisted with revisions to the manuscript. 
Dr Perry supervised the neuroimaging analysis. A/Prof Coyne and Prof Silburn implanted the 
DBS device.  
4.3 Abstract 
Mania following deep brain stimulation of the subthalamic nucleus (STN-DBS) for 
Parkinson’s disease may arise due to an imbalance of stimulation within motor and non-motor 
circuits of this nucleus. Postoperative management of mania has focussed on manipulation of 
stimulation. We report mood elevation subsequent to STN-DBS that was initially experienced 
as beneficial by the patient and his family. However, after activation of an additional contact 
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on the right DBS electrode, the patient developed a manic syndrome with psychosis. Despite 
cessation of stimulation, mania persisted for six weeks and necessitated psychiatric 
hospitalisation. We reconstructed the trajectory of the stimulating electrodes with reference to 
limbic, associative and motor subregions of the STN. We simulated a volume of activated 
tissue based on individualised stimulation parameters. These simulations suggested that limbic 
and associative stimulation predominated in the right STN. Our results provide further 
empirical support for the role of ventromedial STN stimulation in the pathogenesis of 
postoperative mania and report the novel finding of prolonged mania despite cessation of 
stimulation.  
4.4 Introduction 
The syndrome of mania or hypomania (mood elevation with psychomotor agitation, 
distractibility, pressure of speech, inflated self-esteem and impulsivity) may arise following 
deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson’s disease 
(Appleby et al., 2007; Voon et al., 2006). Previous reports have attributed the onset of mood 
changes to micro-lesional effects during neurosurgery (Romito et al., 2002), the amplitude 
(voltage) of stimulation (Chopra et al., 2011), or the position of the active electrode contact 
within the STN (Raucher-Chene et al., 2008). Remediation of mania has been described 
through reducing the amplitude of stimulation (Chopra et al., 2011), moving the active contact 
(Mandat et al., 2006; Raucher-Chene et al., 2008), delivering a more focussed stimulation field 
by using the electrode as the anode (Mandat et al., 2006), or the addition of mood-stabilising 
medication (Herzog et al., 2003). Here, we report a case of mania with psychotic symptoms in 
a person with Parkinson’s disease without a personal or family history of bipolar disorder, with 
persistence after prolonged cessation of stimulation (six weeks). To our knowledge, this is the 
first such case reported in the literature. This case also describes the phenomenon of a sustained 
mood change that was positively evaluated by the person and his family, with emergence of 
clinically-significant symptoms only after activation of an additional electrode contact nine 
months after device implantation. 
4.5 Case report 
The surgical candidate was a sixty-four-year-old married male working as a factory supervisor. 
He had a five-year history of Parkinson’s disease, manifest with rigidity and tremor of the left 
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upper limb, associated with generalised bradykinesis. His motor symptoms were levodopa-
responsive but treatment was limited by intolerable nausea on a range of agents including 
levodopa, a monoamine oxidase inhibitor and amantadine. He was referred to a movement-
disorders centre for consideration of STN-DBS due to significant functional impairment. 
 
In a pre-surgical assessment, the patient was evaluated by a movement-disorders neurologist, 
a neurosurgeon, a psychiatrist with experience in DBS for Parkinson’s disease, as well as a 
rehabilitation physician. The diagnosis of Parkinson’s disease was confirmed according to the 
United Kingdom Queens Square Brain Bank criteria (Hughes et al., 1992), with a Hoehn and 
Yahr scale score of 2 (Hoehn and Yahr, 1967). His Unified Parkinson’s Disease Rating Scale 
(UPDRS) Part III motor examination score was 47 (‘off’ medication). He had no other 
significant medical history. He was a non-smoker and imbibed alcohol infrequently. He gave 
a psychiatric history of a mild-moderate recurrent depressive disorder, without melancholic 
features and without any history of suicidality. His most recent episode of depression occurred 
in the setting of his movement disorder and was treated with escitalopram 20 mg under the care 
of his general practitioner. He denied a family history of psychiatric or neurological illness. 
His premorbid personality was described as gregarious, but with social withdrawal since the 
diagnosis of Parkinson’s disease. His Montreal Cognitive Assessment (MoCA) score was 
22/30. 
 
Subsequently, bilateral, stereotactic implantation of quadripolar Medtronic 3389 DBS 
electrodes was performed. The STN was identified as a midbrain structure on Fluid Attenuation 
Inversion Recovery (FLAIR) imaging. Intraoperative microelectrode recordings were 
employed to establish localisation within the STN and the patient was roused from anaesthesia 
to perform test stimulation. A computed tomograph (CT) scan confirmed satisfactory 
postoperative lead placement. Stimulation was commenced at contact 9 in the right STN and 
contact 1 in the left STN but subsequent electrode testing yielded the best motor outcome at 
contacts 11 and 1 (contacts are numbered 8-11 and 0-3 in the ventral-dorsal direction on the 
right and left DBS electrodes, respectively). The postoperative UPDRS Part III score was 12 
(‘on’ stimulation) and MoCA (alternate version) score was 28/30. Chronic monopolar 
stimulation parameters were 2.4 Volts (right STN) and 1 Volt (left STN) with a pulse-width of 
60 µs and frequency of 130 Hz. 
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The patient reported an immediate non-motor outcome from stimulation, manifest from the 
onset of active stimulation. He and his wife undertook a semi-structured interview six-months 
after his procedure: 
 
‘… the minute I opened my eyes my depression and anxiety have been lifted and I've never felt depressed and 
never felt anxious since that day, would you believe it? I wake up in the morning, I look forward to the day. I 
enjoy mixing with people now; I always used to shy away from people because I just couldn't get my thoughts 
and my words together.’ 
 
The patient was reviewed by a psychiatrist at each scheduled visit to the movement-disorders 
centre. He displayed a consistent mild elevation of mood with talkativeness. He denied any 
new impulsive or addictive behaviours. He admitted to episodic verbal irritability: 
 
‘It's probably made me a little bit more aggressive... I think it was always in me but I think it comes out a lot 
more now… I find it hard to control my words. Not to say that I've ever got into a fight… but I'm very vocal if I 
believe people are doing the wrong thing by me.’ 
 
Further adjustments to the DBS device were strongly resisted by the patient and his wife due 
to a concern about a return of depression and anxiety: 
 
‘I'm deadly worried about going back to being depressed and anxious… I don't know whether I'd be able to pull 
myself out.’ 
 
‘I was worried when he was at home all day… he'd be just sitting in front of the TV or lying in bed but now he's 
out all day either with friends or fishing. So that's a positive, isn't it?’ 
 
In order to address residual left-sided motor symptoms, contacts 10 and 11 in the right STN 
were activated concurrently during an inpatient stay nine-months after the initial surgery. There 
was no immediate change in mental status, but the patient’s family contacted the centre one-
week after discharge to report a new preoccupation with gambling and pervasive irritability. 
The patient refused to return for device adjustment but was apprehended by the police for 
dangerous driving. He was held for an emergency psychiatric assessment where he was judged 
to be floridly manic. He disclosed delusional beliefs that DBS clinicians were conspiring with 
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senior police officials to damage his reputation. He incorporated his wife into these persecutory 
beliefs and threatened to kill her.  
 
The DBS device was turned off with immediate return of motor symptoms but sustained 
persistence of mania with psychosis. He was admitted to a psychiatric ward and commenced 
on lithium, titrated to a serum level of 0.8 mmol/l. Quetiapine was initiated and titrated to a 
dose of 100 mg nocte. No oral dopaminergic therapies were introduced. Despite these changes, 
he required an extended admission as an involuntary patient due to persisting symptoms and 
poor insight. After six-weeks he was discharged on maintenance therapy with lithium. The 
patient and his family requested that the DBS device be re-activated and therapy was gradually 
re-titrated to his previous maintenance level with successful control of his motor symptoms. 
The patient regained his subjectively positive mood state without a return of mania or 
psychosis, but did not develop insight into the connection between his stimulation and his 
manic episode, nor did he believe that he had been psychiatrically unwell. He was able to return 
home with his wife and remains under the care of the movement disorders centre as well as a 
general psychiatrist.  
4.6 Anatomical Analysis 
Preoperative T1-weighted and FLAIR images were co-registered with a postoperative CT scan 
repeated at nine-months, using an affine transformation within FSL (FLIRT version 6.0) (Smith 
et al., 2004). These acquisitions were spatially normalized into ICBM 2009b nonlinear 
asymmetric space using a fast diffeomorphic image registration algorithm (DARTEL) as 
implemented in SPM12 (Ashburner, 2007). Electrodes were localised using the Lead-DBS 
toolbox (Horn and Kuhn, 2015) and projected onto the BigBrain histological atlas (Amunts et 
al., 2013). The positions of the electrode contacts were evaluated with reference to a 
tractographic parcellation of the STN into limbic, associative and motor subregions (Accolla 
et al., 2014). A simplified volume of activated tissue (VAT) was calculated based upon the 
patient’s stimulation parameters (Madler and Coenen, 2012). 
 
Visualisation (Figure 4.1) suggested that the left DBS electrode was positioned optimally in 
the motor aspect of the STN. However, the trajectory of the right DBS electrode appeared to 
pass through the associative STN, with contact 10 located on the border of the associative and 
limbic STN. The distances from contacts 9-11 to each subregion of the STN were compared 
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with the proportion of each STN subregion occupied by the VAT (Table 4.1). Although each 
selected electrode contact was close to all STN subregions, the volume of activated tissue 
appeared to preferentially include the limbic and associative zones. Given a previous report of 
mood changes induced by stimulation in the substantia nigra (Bejjani et al., 1999), we also 
extended our VAT analysis to this nucleus, using an atlas developed at high field-strength 
(Wang et al., 2016). Our findings suggest that the substantia nigra was not significantly 
implicated in this individual’s mood changes. 
 
 
A probabilistic parcellation of the STN is superimposed upon the BigBrain histological atlas in the midbrain. Within the STN 
atlas: yellow = limbic territory, blue = associative territory and maroon = motor territory. Figure 4.1A-1C: Coronal views of 
right electrode contacts 9 (A), 10 (B) and 11 (C); asterisk indicates the contact location. Figure 1D: Coronal view of the 
reconstructed electrode trajectories and position. Figure 4.1E: Sagittal view with illustrative VAT at contact 10 (2.4 Volts) on 
the right electrode (foreground) and contact 1 (1 Volt) on the left electrode (background).  
 
 
Figure 4.1 | Localisation of Electrode Contacts Using the Lead-DBS Toolbox 
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Table 4.1 | Anatomical analysis of the right hemispheric DBS electrode 
Distances from contacts 9–11 to each subregion of the subthalamic nucleus (STN) and the proportion of each STN subregion 
occupied by the volume of activated tissue (VAT). 
 
Contact on 
Right DBS 
Electrode 
Distance from 
Limbic STN 
(mm) 
Distance from 
Associative 
STN (mm) 
Distance from 
Motor STN 
(mm) 
Percentage of 
Limbic STN 
filled by VAT 
Percentage of 
Associative 
STN filled by 
VAT 
Percentage of 
Motor STN 
filled by VAT 
Percentage of 
Substantia 
Nigra filled by 
VAT 
9 1.92 1.56 1.11 14.48 7.66 8.23 4.96 
10 0.32 0.14 0.06 52.41 37.20 16.71 4.59 
11 0.76 0 1.48 84.83 70.68 12.59 3.94 
4.7 Discussion 
We describe the emergence of mood elevation subsequent to subthalamic DBS in an individual 
with Parkinson’s disease. This phenomenon was positively evaluated by the person with 
Parkinson’s disease and his spouse. Mania developed nine-months subsequent to initial DBS 
device implantation, secondary to the activation of an additional contact in the right STN. We 
employed a novel methodology for localising and quantifying the field of stimulation in the 
STN, supporting the role of ventromedial (limbic and associative) subthalamic stimulation in 
the pathogenesis of postoperative mania. Importantly, we also describe the persistence of mania 
for six-weeks after cessation of stimulation, implying that once established, this syndrome may 
not be responsive to stimulation manipulation.  
 
Existing evidence supports the significance of contact location within the STN. A tripartite 
functional organisation of the STN into limbic, associative and motor subregions is suggested 
by primate and human studies (Haynes and Haber, 2013; Lambert et al., 2012). Moving 
stimulation between the dorsal and ventral aspects of the nucleus can impair response inhibition 
(Hershey et al., 2010) and modulate behavioural symptoms (Mallet et al., 2007). Stimulation 
diffusion may also activate the medial forebrain bundle (Coenen et al., 2009), a dopaminergic 
tract that passes close to the STN as it ascends from the ventral tegmental area. 
 
The persistence of mania after prolonged cessation of stimulation is a novel finding and 
suggests a degree of plasticity in non-motor circuits modulated by stimulation. STN-DBS 
modifies the metabolism of cortical regions implicated in response inhibition (Ballanger et al., 
2009; Le Jeune et al., 2010; Thobois et al., 2007),   and decouples the STN from neural 
correlates of cognitive conflict (Cavanagh et al., 2011). A pathological decoupling of this 
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inhibitory network could underlie persistent mood elevation, with sub-syndromal changes 
present in our case for nine-months before mania developed. 
 
In our case, stimulation in the right STN appeared to underlie the patient’s psychiatric 
symptoms, given the onset of his manic episode after activation of an additional contact in the 
right DBS electrode, plus the relatively low stimulation intensity in the left electrode. 
Simulation of a VAT gave us additional data about the volume of each STN subregion 
influenced by stimulation and may help to explain the non-motor changes observed after DBS. 
Although anatomical localisation may have a role in the practice of DBS, preliminary findings 
such as this await replication in an appropriately-sized sample. We also note that we have not 
evaluated the modulation of subcortical-prefrontal fibre tracts such as the medial forebrain 
bundle or hyperdirect pathway. Accurate modelling of connectivity necessitates the 
preoperative acquisition of high angular resolution diffusion imaging, which was not available 
in this individual. The relative contribution of electrode localisation within the STN versus the 
connectivity profile of the stimulation seed is thus an additional research question to be 
addressed in future work. 
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Chapter 5 
5 The Longitudinal Trajectories of Caregiver Burden & 
Caregiver Ratings of Neuropsychiatric Symptoms after 
Subthalamic Deep Brain Stimulation for Parkinson’s 
Disease 
‘It's amazing technology, because you see... the moods, just so instantly from adjustments. He could be on a 
high and then you're just - it's like a robot being turned off and then you see them a couple of days later and 
then he's sort of all active again and feeling good in himself. It's so unbelievable how it can change so rapidly.’ 
Spouse of a DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b) 
5.1 Publication Details 
This chapter was published as: 
Mosley, P.E., Breakspear, M., Coyne, T., Silburn, P. & Smith, D., 2018. Caregiver burden and 
caregiver appraisal of psychiatric symptoms are not modified by subthalamic deep brain 
stimulation for Parkinson’s disease. NPJ Parkinson’s Disease. 4, 12. 
5.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, consented the participants, collected the data, 
implemented the analyses and wrote the manuscript. Dr Smith provided supervision of and 
assistance with statistical modelling, specifically including dimension reduction (LASSO), 
longitudinal clustering and hidden Markov modelling. Prof Breakspear provided critical 
revisions to the manuscript. A/Prof Coyne and Prof Silburn implanted the DBS devices for all 
participants with Parkinson’s disease. 
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5.3 Abstract 
Subthalamic deep brain stimulation (STN-DBS) is an advanced therapy that typically improves 
quality of life for persons with Parkinson’s disease. However, the effect on caregiver burden is 
unclear. We recruited sixty-four persons with Parkinson’s disease and their caregivers from a 
movement disorders clinic during the assessment of eligibility for STN-DBS. We used 
clinician, patient and caregiver-rated instruments to follow the patient-caregiver dyad from pre- 
to postoperative status, sampling repeatedly in the postoperative period to ascertain fluctuations 
in phenotypic variables. We employed multivariate models to identify key drivers of burden. 
We clustered caregiver-rated variables into ‘high’ and ‘low’ symptom groups and examined 
whether postoperative cluster assignment could be predicted from baseline values. Psychiatric 
symptoms in the postoperative period made a substantial contribution to longitudinal caregiver 
burden. The development of stimulation-dependent mood changes was also associated with 
increased burden. However, caregiver burden and caregiver-rated psychiatric symptom clusters 
were temporally stable and thus predicted only by their baseline values. We confirmed this 
finding using frequentist and Bayesian statistics, concluding that in our sample, subthalamic 
DBS for Parkinson’s disease did not significantly influence caregiver burden or caregiver-rated 
psychiatric symptoms. Specifically, patient-caregiver dyads with high burden and high levels 
of psychiatric symptoms at baseline were likely to maintain this profile during follow up. These 
findings support the importance of assessing caregiver burden prior to functional neurosurgery. 
Furthermore, they suggest that interventions addressing caregiver burden in this population 
should target those with greater symptomatology at baseline and may usefully prioritise 
psychiatric symptoms reported by the caregiver.  
5.4 Introduction 
Caregivers make a substantial contribution to the support of people with Parkinson’s disease. 
In 2014, Australian caregivers provided nineteen million hours of care, equivalent to AUD 78.2 
million (USD 59.5 million) (Deloitte Access Economics, 2015). The Parkinson’s disease 
caregiver may need to coordinate multidisciplinary treatment, advocate for additional services, 
administer medication, assist with personal care, prevent falls and provide emotional support. 
However, caregivers are at risk of burden, defined as ‘the extent to which caregivers perceive 
that caregiving has had an adverse effect on their emotional, social, financial, physical and 
spiritual functioning’ (Zarit et al., 1986). Burden is associated with adverse psychiatric 
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outcomes amongst caregivers (Carod-Artal et al., 2013; Martinez-Martin et al., 2008), and may 
reduce the effectiveness and tolerability of caregiving, resulting in earlier use of state-
sponsored services or premature institutionalisation.  
 
Parkinson’s disease is a complex disorder manifesting motor and non-motor symptoms, both 
of which may amplify caregiver burden. Psychiatric symptoms including depression, anxiety, 
apathy, psychosis, cognitive impairment and impulse-control disorders have consistently been 
associated with higher levels of burden (Mosley et al., 2017b). The cumulative prevalence of 
psychiatric and cognitive co-morbidity in Parkinson’s disease is estimated to be greater than 
fifty percent (Weintraub and Burn, 2011), with contributions from neurodegeneration, adverse 
effects of treatment and psychological reactions to progressive disability.  
 
Deep brain stimulation (DBS) is an advanced therapy for Parkinson’s disease that involves 
neurosurgery to position electrodes in deep brain nuclei. These produce continuous electrical 
stimulation to modulate disordered basal ganglia activity. Individuals with motor 
complications of drug therapy that receive DBS may have a better outcome than those 
maintained on medication alone, expressed as an improvement in motor symptoms, a reduced 
requirement for dopaminergic medication and a better self-rated quality of life (Schuepbach et 
al., 2013; Williams et al., 2010). However, DBS is not a treatment for psychiatric symptoms 
in Parkinson’s disease, which may continue to progress postoperatively. Furthermore, new 
psychiatric problems may also emerge, related to the titration of stimulation, the withdrawal of 
dopaminergic medication, and to the inevitable psychosocial adaptation that follows relief of 
disability in a patient-caregiver dyad (Mosley and Marsh, 2015a). (Note, although we prefer to 
use the term ‘person with Parkinson’s disease’, we occasionally employ the term ‘patient’ 
when this role is contrasted with that of ‘caregiver’). 
 
The subthalamic nucleus (STN) is the most common surgical target for DBS in Australasia. 
However, the anatomy of this nucleus confers vulnerability to stimulation-dependent cognitive 
and affective disinhibition (Cavanagh et al., 2011; Frank et al., 2007; Lambert et al., 2012). 
Accordingly, some persons with Parkinson’s disease become more impulsive and less empathic 
after DBS, acting recklessly without foresight or concern for others, potentially increasing 
caregiver burden (Mosley et al., 2018c). The incidence of this syndrome has been estimated at 
up to fifteen percent (Appleby et al., 2007; Daniele et al., 2003). 
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Early reports noted relational conflicts subsequent to STN-DBS, linked to perceived 
behavioural changes in the person with Parkinson’s disease, despite a good motor outcome and 
in the absence of significant relational difficulties prior to DBS (Perozzo et al., 2001; 
Schupbach et al., 2006). Prior research has suggested that as many as fifty percent of caregivers 
rate their wellbeing as negative following STN-DBS, despite positive patient-rated outcomes. 
Psychiatric symptoms are significant co-variates of negative caregiver ratings (Lewis et al., 
2015). Importantly, patient and caregiver ratings of postoperative affective changes are 
frequently discrepant (Lewis et al., 2014). Despite its clinical importance, the main factors 
influencing post-DBS caregiver burden, indeed whether burden increases or decreases after 
DBS, remain unclear. 
 
The objective of this study was to examine the trajectory and determinants of caregiver burden 
in a consecutive sample of persons with Parkinson’s disease referred for STN-DBS at one DBS 
centre in Australia. We employed a prospective, longitudinal design with repeated-measures 
sampling to capture fluctuations in motor and psychiatric symptoms as the patient-caregiver 
dyad progressed from pre- to postoperative status. A longitudinal investigation enables more 
accurate inference on the direction of causality and the temporal evolution of predictor 
variables. Furthermore, in this cohort, postoperative symptoms may be temporally connected 
to modulation of stimulation and withdrawal of dopaminergic medication, which may not be 
captured in a simple pre-post design. Additionally, in this investigation we specifically sought 
the perspective of the caregiver in rating psychiatric outcomes, motivated by clinical 
experience which suggests that persons with Parkinson’s disease may less aware of emerging 
affective and cognitive changes. We hypothesised that, in addition to postoperative motor 
symptoms, psychiatric symptoms would be significant determinants of caregiver burden. Of 
these, we conjectured that higher impulsivity and lower empathy would be the most significant 
psychiatric factors. Furthermore, we hypothesised that higher levels of burden would be present 
in caregivers of persons with Parkinson’s disease developing stimulation-dependent mood 
changes requiring intervention from a psychiatrist.  
5.5 Methods 
Sixty-four persons with Parkinson’s disease and their caregivers were consecutively recruited 
at the Asia-Pacific Centre for Neuromodulation, during the assessment of eligibility for STN-
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DBS. A movement disorders neurologist confirmed the diagnosis of Parkinson’s disease, 
according to the United Kingdom Queens Square Brain Bank criteria (Hughes et al., 1992). 
The laterality of disease onset and the Hoehn and Yahr stage (Hoehn and Yahr, 1967) at 
operation was recorded. The Parkinson’s disease subtype (tremor-dominant, akinetic-rigid, 
mixed-type) was established based on an analysis of the dominant symptoms elicited during 
the Unified Parkinson’s Disease Rating Scale (UPDRS) Part III Motor Examination (Spiegel 
et al., 2007). Exclusion criteria were the absence of an identified caregiver, DBS of deep brain 
nuclei other than the STN and dementia as defined by a Mini Mental State Examination Score 
(MMSE) of less than 25 or a clinical diagnosis of Parkinson’s disease dementia. The latter was 
defined according to the published Movement Disorder Society criteria (Emre et al., 2007). 
Caregivers were unpaid spouses or family members, residing with the person with Parkinson’s 
disease. Persons with Parkinson’s disease and their caregivers were required to be fluent in 
English in order to participate. Prior to DBS, all patients and their caregivers were assessed by 
a psychiatrist with experience in movement disorders, who recorded current and historical 
psychiatric symptoms. 
 
Persons with Parkinson’s disease underwent bilateral implantation of Medtronic 3389 or 
Boston Vercise electrodes in a single-stage procedure. The STN was identified as a midbrain 
structure on Fluid Attenuation Inversion Recovery (FLAIR) imaging and electrodes were 
targeted to this nucleus using a Leksell stereotactic apparatus. Intraoperative microelectrode 
recordings were employed to establish localisation within the STN and anaesthesia was down-
titrated to perform test stimulation. A computed tomography (CT) scan confirmed satisfactory 
postoperative lead placement. Stimulation was commenced immediately at low intensity and 
was titrated over the following week as an inpatient until motor symptoms were satisfactorily 
controlled. Post-discharge, persons with Parkinson’s disease returned to the movement 
disorders clinic for further neurological and psychiatric evaluation, with further DBS 
manipulation according to a set schedule of visits. The predominant criterion for DBS 
manipulation at each visit was manifest motor symptoms of Parkinson’s disease. However, if 
the patient, caregiver or clinician detected any new psychiatric symptoms (such as mood 
elevation, disinhibition or irritability) then a psychiatric review was initiated. Manipulation of 
the DBS device subsequently occurred if the symptoms were determined to be stimulation-
related (Mosley and Marsh, 2015a). 
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5.5.1 Measures 
Assessments took place prior to DBS and subsequently at two-weeks, six-weeks, thirteen-
weeks and twenty-six-weeks postoperatively, using the same battery of measures. Persons with 
Parkinson’s disease were ‘on’ medication and stimulation for all assessments. Participants were 
administered the following neuropsychological instruments, designed to capture the broad 
range of psychiatric symptoms observable in this cohort: the Barratt Impulsiveness Scale 11 
(BIS) and second-order factors attentional, motor and non-planning (Patton et al., 1995); the 
Beck Depression Inventory II (BDI) (Beck et al., 1961); the Empathy Quotient (EQ) (Baron-
Cohen and Wheelwright, 2004); the Geriatric anxiety inventory (GAI) (Pachana et al., 2007); 
the Questionnaire for Impulsive-Compulsive disorders in PD Rating Scale (QUIP-RS) 
(Weintraub et al., 2012); and the Apathy Scale (Starkstein et al., 1992). 
 
In addition to this psychiatric profile, impulsivity was assessed by administration of the 
following neuropsychological tests: the delay discounting task (Kirby et al., 1999); the 
Excluded letter fluency task (ELF) (Shores et al., 2006); and the Hayling test (Burgess et al., 
1997). The delay discounting task assesses delay aversion, the tendency to prefer sooner, 
smaller rewards over those that are larger but temporally more distant. It was designed to assess 
impulsivity in individuals with substance use disorders (Kirby et al., 1999), behaviours that 
share face validity with the impulse-control behaviours (ICBs) observed in a subset of persons 
with Parkinson’s disease. Both the Hayling and the ELF assess prepotent response inhibition, 
which is known to be modulated by STN-DBS (Obeso et al., 2013; Witt et al., 2008).  
 
Dementia was an exclusion criterion upon entry to the investigation, but it is conceivable that 
cognitive impairment could emerge over the course of the study as a consequence of disease 
progression, with associated burden (Leroi et al., 2012b). In order to assess basic cognitive 
status, the following additional cognitive tests were also administered: Mini-Mental State 
Examination (MMSE) (Folstein et al., 1975); and the	Montreal Cognitive Assessment (MoCA) 
(Nasreddine et al., 2005). 
 
Caregivers completed the Zarit Burden Interview (ZBI) (Zarit et al., 1980) and the Relationship 
Quality Index (RQI) (Norton, 1983) at each visit. In addition, a modified version of the BIS 
and EQ (caregiver-rated BIS and caregiver-rated EQ) assessed these behavioural domains from 
the perspective of the caregiver, given that impaired insight may affect patients’ own ratings. 
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This approach has previously been employed in studies involving Parkinson’s disease 
participants (O'Callaghan et al., 2013a). 
 
At each visit motor symptoms were assessed using the UPDRS Part III motor examination. 
Dopaminergic medication was recorded and converted to a levodopa-equivalent daily dose 
(LEDD) value (Evans et al., 2004). DBS parameters were also recorded (active contacts, 
amplitude, pulse-width, frequency).  
 
Persons with Parkinson’s disease remained under the care of a psychiatrist throughout the 
study. Those who developed clinically-significant mood or behaviour changes attributable to 
STN stimulation were defined as ‘cases’. This was operationalised as follows: the person with 
Parkinson’s disease, their caregiver or a clinician raised concern about new behaviours that 
were ‘out of character’. The person with Parkinson’s disease undertook a semi-structured 
psychiatric interview with attention to mood elevation, disinhibition, loss of empathy and 
irritability. If emergent symptoms were detected, the neurologist reduced the amplitude of 
stimulation or changed the position of the active electrode contact. If symptoms immediately 
remitted or substantially reduced upon repeated psychiatric assessment, then the symptoms 
were judged to be stimulation-related. All ‘cases’ subsequently underwent further DBS 
reprogramming to address these symptoms and remained under close follow up with the 
psychiatrist and neurologist until their psychiatric symptoms had entirely remitted. 
 
Table 5.1 | Full battery of tests and their acronyms 
Instrument Rater Acronym 
Apathy Scale Patient Apathy Scale 
Barratt Impulsiveness Scale Patient BIS 
Beck Depression Inventory II Patient BDI 
Empathy Quotient Patient EQ 
Geriatric Anxiety Inventory Patient GAI 
Questionnaire for Impulsive-Compulsive disorders in PD 
Rating Scale 
Patient QUIP-RS 
   
Barratt Impulsive Scale – Caregiver Version Caregiver Caregiver-rated BIS 
Empathy Quotient – Caregiver Version Caregiver Caregiver-rated EQ 
Relationship Quality Inventory Caregiver RQI 
Zarit Burden Interview Caregiver ZBI 
   
Delay Discounting Test Clinician Delay Discounting 
Excluded Letter Fluency Test Clinician ELF 
Hayling Test Clinician Hayling 
Mini-Mental State Examination Clinician MMSE 
Montreal Cognitive Assessment Clinician MoCA 
Unified Parkinson’s Disease Rating Scale Part III Motor 
Examination 
Clinician UPDRS 
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5.5.2 Statistical Analysis 
5.5.2.1 Sample Size Calculation 
For the assessment of caregiver burden using the ZBI, a difference of fourteen points on the 
ZBI was deemed clinically significant, as this was the difference in means reported by 
caregivers of Parkinson’s disease patients with ICBs (mean 30, ±14) and non-impulsive 
Parkinson’s disease patients (mean 16, ±11) (Leroi et al., 2012a). The phenotype of the 
psychiatric and behavioural change that may arise subsequent to subthalamic DBS overlaps 
with the construct of ICBs; thus, this study was selected as a reasonable proxy for the sample 
size calculation, noting that no equivalent quantitative data on caregiver burden after 
subthalamic DBS was available. 
 
A Hedges g was calculated, assuming a distribution of cases (as defined above) to non-cases 
of 20:80, to give an effect size of 1.2. Sample size was calculated using G*Power (version 
3.1.9.3) (Faul et al., 2009), assuming an independent two-sample t test, with an alpha of 0.05 
and a power of 0.90, yielding a total of 56 required participants. 
5.5.2.2 Longitudinal Determinants of Burden 
The study design included longitudinal assessments for participants and their respective 
caregivers. The objective was to elucidate the trajectory of the caregiver-reported data and 
identify associated factors with prognostic value. To achieve this, the longitudinal data analysis 
required estimation of the correlations between assessments for each patient-caregiver dyad. 
For each caregiver endpoint, we fitted a random intercept-slope mixed-effects longitudinal 
model and used variable selection techniques to assess associations with prognostic factors.  
 
Variable selection techniques identify the minimum set of prognostic factors and avoid 
overfitting in the multivariate longitudinal models. Two distinct variable selection methods 
were employed. The first was the Least Absolute Shrinkage and Selection Operator (LASSO) 
(Friedman et al., 2010). The tuning parameter (l) was defined by the conservative and 
parsimonious one-standard-deviation rule (Hastie et al., 2009). The second method was an 
exhaustive approach, which scanned a complete set of all combinations of candidate covariates; 
the model space was then scored and sorted by the Bayesian information criteria (BIC). Model 
space was optimised using a genetic algorithm to identify a reduced model space that included 
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sets of covariates with large effect sizes. Subsequently, after eliminating those models which 
included covariates with poor associations, an exhaustive search was performed on the reduced 
model space to consider all combinations of candidate covariates.  
  
Covariates in longitudinal mixed models assume approximately normal distribution for best 
performance. Several covariates showed positive skewness when summary statistics and 
histograms were inspected. These covariates included Hayling Errors, ELF Repetitions and 
Rule Violations, Delay Discount parameter k and LEDD. A natural logarithmic transformation 
of log (1 + covariate) was applied to these skewed covariates before they were included as 
candidate prognostic factors in the multivariate longitudinal mixed models. For convenience, 
we refer to these log-transformed covariates as Log0 covariate. 
 
Table 5.2 | Candidate variables included in multivariate modelling of longitudinal ZBI 
Patient-Reported Caregiver-Reported Clinician Acquired 
Apathy Total Caregiver-Rated BIS Total Age 
BIS Total Caregiver-Rated BIS Attentional Subscale Gender 
BIS Attentional Subscale Caregiver-Rated BIS Motor Subscale Total Hoehn & Yahr Stage 
BIS Motor Subscale Total Caregiver-Rated BIS Non-Planning Total Log0 LEDD 
BIS Non-Planning Total Caregiver-Rated EQ Total Tremor-Akinesia Subtype 
BDI Total RQI Total Log0 Delay Discount k 
EQ Total ZBI Total Log0 ELF Repetitions 
GAI Total 
 
Log0 ELF Rule Violations 
QUIP-RS - Buying Log0 Hayling Category A Errors 
QUIP-RS - Eating Log0 Hayling Category B Errors 
QUIP-RS - Gambling Log0 Hayling AB Error Score 
QUIP-RS - Hobbyism MMSE Total 
QUIP-RS - Medication Use MOCA Total 
QUIP-RS - Sex UPDRS Total 
QUIP-RS - ICD Total  QUIP-RS - QUIP Total 
 
5.5.2.3 Longitudinal Trajectories of Burden and Caregiver-Rated Psychiatric Symptoms 
The objective in this analysis was to model the longitudinal evolution of burden and psychiatric 
symptoms. A repeated-measures analysis of variance (ANOVA) was performed for all 
longitudinal variables but this approach did not account for the observed inter-subject 
heterogeneity in our sample and could not describe the longitudinal course of our subjects over 
time. Therefore, we employed more complex modelling of individual trajectories, focussing on 
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caregiver-rated variables for this analysis. Again, using two distinct statistical methods, 
variables were parsed into separate clusters based on their observed longitudinal trajectories.  
 
A frequentist longitudinal clustering method estimated the number of clusters and each 
participant’s cluster assignment using k-means criteria (Genolini and Falissard, 2011). In this 
implementation, relative indices of the Calinski-Harabasz metric were compared, applying a 
minimum of 3 redraws per fixed cluster number using vote-counting of the highest Calinski-
Harabasz metric to determine the optimal cluster number (Caliński and Harabasz, 1974). 
 
In a separate analysis, clusters were estimated using a Bayesian method, incorporating hidden 
Markov models and transition probabilities (Rabiner, 1989). Similar to the frequentist 
clustering approach, the number of clusters was first estimated using a series of steps to 
optimise an information criterion. Subsequently, the probabilities of switching between or 
remaining in each cluster were then estimated. Non-informative priors were assigned to the 
transition probabilities and posterior probabilities for cluster assignments were then estimated. 
This extends the frequentist longitudinal clustering analysis by estimating the posterior 
probability that a given caregiver or patient will be found in a given cluster at a given time 
point and also provides a measure of the relative stability of cluster assignment.  
 
We extended this analysis to find baseline factors that predicted for these longitudinal clusters 
amongst the caregiver-rated endpoints using generalized boosted regression modelling. In 
other words, we considered predicting for clusters using all available baseline factors, both 
patient and caregiver-rated. We used a training and testing validation approach to find 
appropriate factors. In the first set of analyses, we excluded the baseline numeric observations 
that corresponded to the endpoint. For example, we excluded the pre-DBS caregiver-rated BIS 
numeric observations when we tried to predict for caregiver-rated BIS clusters. This is strong 
control against collinearity. In the second set of analyses, we added in these observations as 
predictors. 
5.5.2.4 Data Availability 
All analyses took place in the R software environment (R Core Team, 2014), using the 
following packages: lme4 and nlme for longitudinal mixed models (Bates et al., 2015; Pinheiro 
et al., 2017), glmnet for lasso (Friedman et al., 2010), glmulti for genetic algorithm model 
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selection (Buckland et al., 1997; Burnham and Anderson, 2002), depmixS4 for hidden Markov 
models (Ingmar and Maarten, 2010), kml for longitudinal clustering (Genolini et al., 2015) and 
gbm for boosted regression modelling (Friedman, 2002). Across the complete data set, less 
than five percent of data was missing. Missing data was inferred using the pooled results of 50 
iterations of imputation by classification and regression trees, employing mice for longitudinal 
data imputation using Gibbs sampling (van Buuren and Groothuis-Oudshoorn, 2011).  
5.6 Results 
5.6.1 Demographic and Baseline Variables 
Sixty-eight eligible patient-caregiver dyads were approached between 2013 and 2017 and 
sixty-four subsequently consented to participate in the study. No participants withdrew from 
the investigation. The sample of persons with Parkinson’s disease (Table 5.3) was comprised 
of predominantly male (48 males, 16 females), predominantly middle-aged individuals with 
most being classified as the akinetic-rigid or mixed phenotype. Most had moderate motor 
symptoms at baseline despite being ‘on’ medication during UPDRS assessment. Persons with 
Parkinson’s disease displayed a large range in measures of impulsivity and empathy, but 
generally evidenced mild symptoms of depression, anxiety and apathy at baseline. Caregivers 
were predominantly female (48 females, 16 males) and were all informal family caregivers, 
residing with the person with Parkinson’s disease. Sixty-three caregivers were spouses and one 
was the adult child of the person with Parkinson’s disease. The mean age of caregivers was 
58.3 (±8.4). Caregivers also displayed a large range in their ratings of burden, relationship 
quality and psychiatric symptoms. 
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Table 5.3 | Characteristics of STN-DBS participants at baseline 
 Akinetic-Rigid Tremor Mixed Total 
Gender n % total n % total n % total n % 
Male 19 29.7 10 15.6 19 29.7 48 75 
Female 5 7.8 2 3.1 9 14.1 16 25 
 Mean (SD), Median (Range) 
Age (Years) 65.9 (±7.8), 68 (47 - 76) 
58.2 (±9.3), 
61 (35 - 67) 
60.7 (±10.1), 
62 (40 - 77) 
62.2 (±9.5), 
65 (35 - 77) 
Hoehn & Yahr Stage 2.7 (±0.5), 2.5 (2 - 4) 
2.5 (±0.5), 
2.5 (2 - 3) 
2.8 (±0.5), 
3 (1.5 - 4) 
2.7 (±0.5), 
2.5 (1.5 - 4) 
Years since 
Diagnosis 
8.8 (±5.3), 
7 (1 - 23) 
8.4 (±6.2), 
6 (2 - 22) 
9.4 (±4.9), 
8 (3 - 21) 
9.0 (±5.2), 
7 (1 - 23) 
Levodopa equiv. 
daily dose 
1136.8 (±632.2), 
1013 (458 - 3450) 
892.6 (±376.5), 903 
(75 - 1400) 
1079.6 (±542.3), 
1124 (0 - 2200) 
1066 (±551.8), 
1000 (0 - 3450) 
Patient-Rated BIS 60.2 (±9.9), 60 (43 - 87) 
59.1 (±7.5), 
60 (44 - 74) 
61.0 (±7.7), 
60 (45 - 76) 
60.3 (±8.4), 
60 (43 - 87) 
Caregiver-Rated BIS 56.0 (±13.2), 52 (40 - 90) 
62.4 (±10.1), 
64 (42 - 77) 
60.6 (±10.5), 
61 (44 - 90) 
59.2 (±11.7), 
59 (40 - 90) 
Patient-Rated EQ 42.5 (±13.3), 42 (17 - 68) 
43.0 (±13.5), 
41 (23 - 67) 
40.6 (±10.9), 
41 (16 - 62) 
41.8 (±12.2), 
41 (16 - 68) 
Caregiver-Rated EQ 41.2 (±13.1), 42 (13 - 61) 
35.8 (±18.0) 
29 (11 - 64) 
37.1 (±12.6), 
36 (13 - 57) 
38.4 (±13.9), 
39 (11 - 64) 
QUIP-RS Total 18.1 (±15.0), 16 (0 - 55) 
18.0 (±9.5), 
18 (0 - 35) 
24.5 (±16.0), 
21 (0 - 63) 
20.9 (±14.8), 
19 (0 - 63) 
Beck Depression 
Inventory 
11.4 (±5.3) 
12 (1 - 21) 
9.3 (±5.7), 
9 (1 - 20) 
12.2 (±4.5), 
13 (4 - 22) 
11.3 (±5.1), 
12 (1 - 22) 
Geriatric Anxiety 
Inventory 
3.9 (±3.7), 
4 (0 - 17) 
4.6 (±4.1), 
4 (0 - 12) 
5.5 (±4.6), 
5 (0 - 15) 
4.8 (±4.2), 
5 (0 - 17) 
Apathy Scale 11.4 (± 5.4), 12 (1 - 22) 
10.6 (±6.4), 
10 (1 - 23) 
11.9 (±5.4), 
11 (3 - 26) 
11.5 (±5.5), 
11 (1 - 26) 
Mini Mental State 
Examination 
28.1 (±1.6), 
28 (25 - 30) 
28.6 (±1.4), 
29 (25 - 30) 
28.6 (±1.4), 
29 (25 - 30) 
28.4 (±1.5), 
29 (25 - 30) 
Montreal Cognitive 
Assessment 
26.3 (±2.7), 
27 (21 - 30) 
26.1 (2.6), 
28 (21 - 29) 
25.8 (±3.2), 
27 (16 - 29) 
26.0 (±2.9), 
27 (16 - 30) 
Hayling AB Error 
Score 
11.5 (±11.9), 
7 (0 - 38) 
8.2 (±10.6), 
2 (0 - 33) 
9.8 (±11.8), 
4 (0 - 45) 
10.1 (±11.5), 
5 (0 - 45) 
Excluded Letter 
Fluency Rule 
Violations 
9.2 (±6.1), 
7 (3 - 24) 
8.6 (±6.5), 
8 (0 - 21) 
8.3 (±4.3), 
8 (2 - 17) 
8.7 (±5.4), 
8 (0 - 24) 
Delay Discount k 0.016 (±0.022), 0.0079 (0.00016 - 0.1) 
0.019 (±0.019), 
0.016 (0.00016 - 
0.064) 
0.041 (±0.076), 
0.0098 (0.00016 - 
0.25) 
0.027 (±0.054), 
0.0098 (0.00016 - 
0.25) 
UPDRS Part III 
Motor Examination 
33.3 (±13.6), 
31 (13 - 60) 
33.1 (±15.5), 
37 (10 - 51) 
42.6 (±18.7), 
39 (17-91) 
37.3 (±16.8), 
36 (10 - 91) 
Zarit Burden 
Interview 
19.0 (±13.6), 
18 (1 - 54) 
19.4 (± 15.4), 
19 (2 - 47) 
24.4 (±13.0), 
24 (0 - 49) 
21.4 (±13.7), 
21 (0 - 54) 
Relationship Quality 
Inventory 
39.8 (±5.7), 
42 (27 - 45) 
36.5 (±8.8), 
39 (16 - 45) 
36.7 (±7.0), 
37 (22 - 45) 
37.8 (±7.0), 
40 (16 - 45) 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, EQ = Empathy Quotient, QUIP-RS = Questionnaire for Impulsive-
Compulsive Disorders in Parkinson’s Disease Rating Scale, UPDRS = Unified Parkinson’s Disease Rating Scale.  
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5.6.2 Multivariate Modelling of Caregiver Burden 
We were interested in characterising those factors most predictive of caregiver burden (as 
measured by the ZBI) in our longitudinal sample. We performed an exhaustive multivariate 
analysis on all possible combinations of candidate co-variates in a longitudinal, mixed-effects 
model to identify those with prognostic value for longitudinal burden, with scores on the ZBI 
as the dependent variable. Our results demonstrated a substantial contribution of psychiatric 
symptoms to caregiver burden (Table 5.4). We found statistically-significant positive 
associations with ZBI for depressive symptoms (as rated by the BDI); caregiver-rated 
attentional impulsiveness (as assessed with the attentional subscale of the BIS); impaired 
prepotent inhibition (as measured by Hayling Category A Errors; a marker of significant 
disinhibition); hypersexuality (as measured by the sex subscale of the QUIP-RS); 
dopaminergic medication dose (as quantified by LEDD); and Parkinson’s disease motor 
symptoms (as rated by the UPDRS part III motor examination). Caregiver ratings of 
relationship quality (as measured by the RQI) had a negative correlation with ZBI, with higher 
levels of burden associated with lower relationship quality. Caregiver ratings of empathy (as 
measured by the EQ) also demonstrated a negative correlation, indicating that as empathy 
decreased, burden increased.  
 
Table 5.4 | Results of multivariate modelling for caregiver burden 
Variable Direction of Association Chi Square Value Significance 
RQI Total - 60.7 6.5 x 10-15 *** 
Caregiver-Rated BIS Attentional + 14.7 0.00013 *** 
BDI Total + 14.2 0.00016 *** 
QUIP-RS Hypersexuality + 9.0 0.0027 ** 
Caregiver-Rated EQ - 7.7 0.0057 ** 
Log0 LEDD + 6.0 0.026 * 
UPDRS Part III Total + 4.9 0.027 * 
Hayling Category A Errors + 4.5 0.035 * 
 
Abbreviations: BDI = Beck Depression Inventory, BIS = Barratt Impulsiveness Scale, EQ = Empathy Quotient, LEDD = 
Levodopa Equivalent Daily Dose (natural logarithm employed due to nonparametric distribution), QUIP-RS = Questionnaire 
for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale, RQI = Relationship Quality Index, UPDRS = 
Unified Parkinson’s Disease Rating Scale. Significance: *** p<0.001, ** p<0.01, * p<0.05  
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In a second approach, we also applied a variable selection and regularisation algorithm (the 
Least Absolute Shrinkage and Selection Operator) to identify the combination of prognostic 
co-variates that best predicted longitudinal ZBI without overfitting. Setting of a conservative 
regularisation term penalised model complexity. The LASSO showed agreement with the 
exhaustive multivariate analysis, although it included clinical subtype (akinetic-rigid with 
higher ZBI) and impulsivity as measured by ELF Rule Violations (a marker of disinhibition), 
whilst dropping LEDD. 
 
We noted the likelihood of complex interactions between predictors and extended the optimal 
multivariate models to test for interaction effects up to second-order. Our genetic algorithm 
reported on the top twenty candidate models and then we performed backwards elimination to 
reduce the number of parameters and interaction terms. Only one statistically-significant 
interaction term was identified, between the caregiver-rated BIS Attentional subscale and 
Hayling Category A Errors (p = 0.0088).  
5.6.3 Burden Associated with Stimulation-Related Psychiatric Symptoms 
We wished to test whether caregiver burden was increased by changes in mood and behaviour 
that can arise during the early postoperative phase of subthalamic DBS titration. We tested for 
differences in caregiver-rated burden and psychiatric symptoms between those persons with 
Parkinson’s disease who developed new psychiatric symptoms due to subthalamic stimulation 
(‘cases’) and those who did not (‘non-cases’). Classification of ‘caseness’ was undertaken by 
a psychiatrist and neurologist. We compared two epochs: from baseline versus two-weeks and 
baseline versus six-weeks. We employed ratings of caregiver burden (ZBI), caregiver-rated 
empathy (EQ) and caregiver-rated impulsiveness (BIS). We extended this analysis to a linear 
model that included clinical subtype as an interaction factor with cases.  Of these analyses, we 
found a statistically-significant difference in burden between cases and non-cases at six-weeks 
post-DBS (p = 0.0005, Figure 5.1). There was a similar trend towards a difference in caregiver-
rated EQ between cases and non-cases at six-weeks that did not reach significance (p = 0.0550). 
We found no significant differences between cases and non-cases from baseline to the second-
week and six-week follow-up times with respect to caregiver-rated BIS (p = 0.96 and 0.43 
respectively), nor were there any interactions between cases and Parkinson’s disease motor 
phenotype (p = 0.87 and 0.75 for akinetic-rigid and mixed phenotype versus tremor-dominant). 
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Developing psychiatric symptoms attributable to neurostimulation in the first six-weeks post-DBS is associated with 
significantly greater caregiver burden. Abbreviations: BL = Baseline, ZBI = Zarit Burden Interview. Thick bar = mean change 
in ZBI at six-weeks compared to baseline, box = standard deviation.  
5.6.4 Longitudinal Trajectories of Caregiver-Rated Variables 
We desired to investigate whether caregiver burden and caregiver ratings of psychiatric 
symptoms were longitudinally affected by their partner undertaking subthalamic DBS. We first 
employed a repeated-measures ANOVA (Table 5.5), which demonstrated an expected and 
significant longitudinal reduction in Parkinson’s disease motor symptoms and the requirement 
for dopaminergic medication. There was also a significant reduction in depressive symptoms 
in the person with Parkinson’s disease and a small, but significant, decrease in caregiver-rated 
relationship quality. There were no other significant longitudinal changes in patient, caregiver 
or clinician-rated variables at a group level.  There were also no significant group changes in 
relevant subscales (such BIS second order factors, or QUIP-RS subscales).  
 
  
Figure 5.1 | Stimulation-Induced Neuropsychiatric Symptoms Increase Caregiver Burden 
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Table 5.5 | Repeated-measures analysis of variance 
Instrument F Statistic Significance 
Apathy Scale 0.838 0.502 
BIS 0.757 0.554 
BDI 5.865 (decrease) 0.000146 *** 
EQ 0.273 0.895 
GAI 1.89 0.112 
QUIP-RS 1.383 0.24 
   
Caregiver-Rated BIS 0.768 0.546 
Caregiver-Rated EQ 1.291 0.273 
RQI 2.881 (decrease) 0.0229 * 
ZBI 0.276 0.894 
   
Delay Discount k 0.443 0.778 
ELF Rule Violations 0.104 0.981 
Hayling AB Error Score 0.81 0.519 
Mini-Mental State Examination 1.055 0.379 
Montreal Cognitive Assessment 0.454 0.769 
UPDRS Part III Total 13.5 (decrease) 5.54 x 10-10 *** 
LEDD 62.73 (decrease) 2 x 10-16 *** 
 
Abbreviations: BDI = Beck Depression Inventory, BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = 
Empathy Quotient, GAI = Geriatric Anxiety Inventory, LEDD = Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire 
for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale, RQI = Relationship Quality Index, UPDRS = 
Unified Parkinson’s Disease Rating Scale, ZBI = Zarit Burden Interview. Significance: *** p<0.001, ** p<0.01, * p<0.05 
 
However, suspecting considerable heterogeneity in our sample, we further examined individual 
participant-wise trajectories, focussing on caregivers. We selected the longitudinal trajectories 
of ZBI, caregiver-rated EQ and caregiver-rated BIS. We clustered individuals based on their 
longitudinal trajectories, using both a frequentist and a Bayesian approach. The advantage of 
the Bayesian approach was the estimation of posterior probabilities of cluster assignment for 
each caregiver rating at each time point, in addition to the likelihood of transition between 
clusters; i.e. how stable was a caregiver’s rating of burden and psychiatric symptoms as they 
moved through each postoperative interval? 
 
We considered the existence of up to five clusters.  According to both approaches, the optimal 
number of clusters was two across all caregiver endpoints. We categorised these as ‘High’ and 
‘Low’ clusters, noting that the ‘High’ cluster was simply the ranking relative to the ‘Low’ and 
as such might include normal or impaired functioning on a given instrument. The cluster 
assignments of the frequentist approach across six caregiver endpoints are shown in Figure 5.2. 
Note that ‘High’ and ‘Low’ clusters are well differentiated longitudinally with little egress of 
one cluster from its group trajectory into the path of another. The frequentist analysis of 
caregiver burden (ZBI score) identified a ‘High’ cluster with a longitudinal mean of 31.09 
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(±7.04) and a ‘Low’ cluster with a longitudinal mean of 10.83 (±5.88). The ninety-five percent 
confidence interval between ZBI scores across these clusters was 17.02-23.49 (t = 12.54, p = 
2.2 x 10-16). Descriptive statistics for caregiver-rated EQ and BIS are presented in Table 5.6.  
 
 
The line segments represent individual trajectories of each caregiver’s rating, and the thick lines are loess-smoothed cluster-
wise trajectories. The percentages are the proportion of caregivers assigned to each of the two clusters. Abbreviations: BIS = 
Barratt Impulsiveness Scale, EQ = Empathy Quotient, ZBI = Zarit Burden Inventory. 
 
Table 5.6 | Descriptive statistics for ‘High’ and ‘Low’ clusters 
Caregiver-Rated 
Variable 
‘High’ Cluster 
Mean (SD) 
‘Low’ Cluster 
Mean (SD) 
Difference in Means (95 % 
Confidence Interval) 
Significance 
Zarit Burden Interview 
(ZBI) 
31.09 (±7.04) 10.83 (±5.88) 17.03-23.49 p = 2.2x10-16 *** 
t = 12.54 
Caregiver-Rated 
Impulsiveness (BIS) 
71.17 (±6.30) 54.92 (±6.65) 12.9-19.5 p = 1.3x10-13 *** 
t = 9.85 
Caregiver-Rated 
Empathy (EQ) 
48.29 (±6.26) 27.03 (±8.12) 17.66-24.86 p = 2.2x10-16 *** 
t = 11.81 
 
Significance: *** p<0.001, ** p<0.01, * p<0.05 
Whereas cluster assignment in the frequentist approach is fixed, the Bayesian framework 
(through hidden Markov models) permits analysis of longitudinal cluster transition 
probabilities; that is, the probability of individuals changing clusters over time. Figure 5.3 
Figure 5.2 | Frequentist Clustering of Caregiver-Rated Variables 
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shows the posterior probabilities (‘High’ and ‘Low’) of cluster assignment per caregiver 
endpoint, with transition probabilities represented by direct arrows between clusters. The 
distribution of cluster assignment using the Bayesian framework showed general agreement 
with the posterior probabilities in the frequentist approach. However, for the caregiver-rated 
ZBI, EQ, BIS and subscales, transition probabilities between ‘High’ and ‘Low’ clusters were 
small. This implies that caregivers reporting high levels of burden prior to subthalamic DBS, 
as well as those caregivers reporting high levels of impulsiveness and low levels of empathy in 
their spouse, are unlikely to change this profile subsequent to subthalamic DBS. In other words, 
the pre-DBS score for a given variable is likely to be similar to the score post-DBS and during 
follow-up. 
 
 
For each variable, the posterior probability of cluster assignment (‘High’ vs. ‘Low’) is denoted below the variable heading. 
Transition probabilities for each cluster are represented by arrows. For example, for ZBI, 65 % of the sample are assigned to 
the ‘High’ cluster. Amongst that cluster, there is only a 10 % transition probability from ‘High’ to ‘Low’, indicating relative 
stability of ‘High’ cluster assignment for that variable. Abbreviations: BIS = Barratt Impulsiveness Scale, EQ = Empathy 
Quotient, ZBI = Zarit Burden Inventory. 
 
We strengthened this finding in a machine-learning model (gradient boosting) by looking for 
baseline factors that predicted for clusters ‘High’ or ‘Low’ across the ZBI, EQ, BIS and 
subscales using all available baseline factors, both patient and caregiver-rated. When we 
excluded the associated baseline numeric endpoints in our logistic models, there were no 
significant pre-DBS factors that predicted for clusters. When we included the relevant pre-DBS 
measure, these emerged as predictive for their respective cluster.  This implies that a caregiver 
Figure 5.3 | Hidden Markov Modelling of Cluster Assignment and Transition Probabilities 
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rating prior to DBS is generally reflective of that endpoint’s longitudinal cluster, regardless of 
all other factors.  
 
Given the negative correlation between RQI and ZBI score in the multivariate analysis, we 
were interested in whether relationship quality was an important moderating factor determining 
longitudinal assignment to a ‘High’ or ‘Low’ burden cluster. In a general linear model, there 
was a strong univariate relationship between RQI and ZBI cluster assignment (z = 3.2, p = 
0.0015). However, when other variables from the exhaustive multivariate modelling were 
added to the model, the contribution of RQI score became non-significant (z = 1.74, p = 0.082). 
Only adding baseline ZBI score to this multivariate model proved to be significant (z = -3.017, 
p = 0.0026), consistent with the gradient boosting analysis.  
 
To evaluate the contribution of RQI to a classifier of ZBI cluster, we examined the gradient 
boosting analysis more closely. When the ZBI baseline score was excluded from the 
classification model, RQI made a significant contribution to cluster assignment (18.8 %). 
However, the accuracy of this model at correctly classifying cluster assignment was poor (0.58, 
95 % confidence interval 0.34-0.80). When the ZBI baseline score was included, the 
contribution of RQI to cluster assignment halved (9.01%) but the accuracy of the model was 
superior (0.89, 95 % confidence interval 0.67-0.99). This suggests that, in this cohort, 
relationship quality (as assessed by the RQI) was not a dominant moderating factor influencing 
caregiver assignment to ‘High’ or ‘Low’ burden clusters. However, in a further analysis, we 
evaluated the likelihood of ZBI cluster assignment based on the raw RQI score. Participants 
had an approximately equal likelihood of ‘High’ or ‘Low’ ZBI cluster assignment with scores 
of 34 or above (maximum score 45). However, when the RQI score fell to 33 or below, the 
likelihood of assignment to the ‘High’ ZBI cluster rose to 0.8. This suggests that RQI may 
become an important moderating factor upon caregiver burden at lower values (Figure 5.4).  
  
Chapter 5  86 
 
 
 
Abbreviations: RQI = Relationship Quality Inventory, ZBI = Zarit Burden Interview. 
5.7 Discussion 
We present a longitudinal analysis of caregiver burden in a cohort of extensively-phenotyped 
individuals with Parkinson’s disease undertaking STN-DBS. Our data add to the relatively 
sparse literature in this domain, with the advantage of employing an iterative, longitudinal 
approach. This confers greater confidence in the direction of associations, as well as a more 
sophisticated analysis of the trajectories of caregiver-rated endpoints.  
 
At each assessment in the longitudinal investigation, a broad range of motor, neurocognitive 
and neuropsychological instruments were employed to phenotype persons with Parkinson’s 
disease. Subsequently, a multivariate analysis in a longitudinal, mixed-effects model identified 
a significant association between burden and co-morbid psychiatric symptoms. Caregiver 
burden and caregiver ratings of impulsiveness and empathy were subsequently selected for 
longitudinal analysis using a frequentist and Bayesian approach to identify whether DBS 
meaningfully altered their trajectories. 
Figure 5.4 | Likelihood of Assignment to the ‘High’ ZBI Cluster Against RQI Score 
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5.7.1 Determinants of Caregiver Burden 
We used an exhaustive, model-based approach to ascertain the minimum set of predictors of 
caregiver burden (ascertained with the ZBI). Consistent with our hypothesis, psychiatric 
symptoms made a substantial contribution, in addition to motor symptoms. Depressive 
symptoms, caregiver-rated empathy, caregiver-rated impulsivity and hypersexuality were 
significant predictors of ZBI score, whilst measures of prepotent response inhibition on the 
Hayling and Excluded Letter Fluency tests were also significant predictors. Our two methods 
for longitudinal multivariate modelling furnished similar results, suggesting the consistency of 
these findings. The onset of post-DBS stimulation-related psychiatric symptoms was also 
associated with significantly greater burden.  
5.7.2 Stability and Collinearity of Caregiver Cluster Assignment 
We used both a frequentist and a Bayesian method to provide complimentary analyses of the 
clustering of longitudinal trajectories of caregiver-rated variables and the stability of cluster 
assignment. We found that each individual variable was optimally parsed into two clusters, 
with a relatively low probability of switching between clusters during follow up. Furthermore, 
the only factor that predicted longitudinal cluster assignment was the numeric observation of 
that endpoint at baseline. This suggests that STN-DBS in this sample did not substantially alter 
the caregiver-rated psychiatric phenotype nor whether caregivers were classified into ‘High’ 
or ‘Low’ burden groups, despite considerable changes to medication and neurostimulation over 
the course of the investigation. Furthermore, longitudinal cluster assignment could not be 
predicted from the overall psychiatric profile at baseline without collinearity. The longitudinal 
means of these clusters were significantly different, suggesting their separation was not due to 
chance or measurement error, but representative of a cohort of caregivers with truly greater 
burden. Caregiver burden (as measured by the ZBI) in our ‘High’ burden group was of a similar 
degree to that reported by caregivers of persons with Parkinson’s disease with apathy and 
impulse-control disorders (Leroi et al., 2012a), as well as by caregivers of individuals with a 
Clinical Impression of Severity Index for Parkinson’s disease (CISI-PD) score of ‘severe’ 
(Martinez-Martin et al., 2008). This suggests that burden in this cluster is clinically-significant, 
consistent with prior reports amongst cohorts of significantly-impaired persons with 
Parkinson’s disease. Previous work has suggested a cut-off score of 24 or greater on the ZBI 
as indicative of caregivers at high-risk of clinically-significant depressive symptoms, requiring 
further assessment (Schreiner et al., 2006).  
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5.7.3 Conclusions 
Despite the effectiveness of STN-DBS in the treatment of motor symptoms of Parkinson’s 
disease and its benefits for patient-rated quality of life, its effect on caregiver burden is less 
clear. In this cohort, longitudinal levels of caregiver burden were not significantly altered post-
DBS. Psychiatric symptoms were significant drivers of post-DBS burden and included 
depression, impulsivity, compulsivity and impulsive responding on neuropsychological tests 
of prepotent inhibition. When clinically-significant levels of stimulation-dependent psychiatric 
symptoms emerged during the post-DBS period (as evaluated by a psychiatrist), caregivers of 
patients with these symptoms endorsed greater burden. This indicates a mechanism through 
which STN-DBS may transiently increase caregiver burden, until stimulation-dependent 
symptoms are managed with DBS manipulation. Overall, our findings add to the literature 
suggesting caregiver and patient-rated quality of life outcomes subsequent to STN-DBS may 
be discrepant.  
 
Our study is not the first to find caregiver burden unchanged after subthalamic DBS. Previous 
reports have utilised measures of caregiver strain or quality of life in a simple pre- and 
postoperative design, with sample sizes of between 12 and 25 (Lewis et al., 2015; Soileau et 
al., 2014). However, our investigation is the first to quantitatively examine longitudinal 
measures of caregiver burden in an adequately powered sample. This method of repeated 
sampling allows us to study the stability of burden and caregiver ratings of psychiatric 
symptoms, despite considerable changes to medication and neurostimulation over the course 
of the investigation. Additionally, we contribute a multivariate, longitudinal, analysis of those 
factors significantly associated with caregiver burden in this surgical cohort. 
 
Nonetheless, we acknowledge the moderate size of our sample and the single-centre nature of 
our investigation. However, our sample size is larger than comparable investigations 
employing such detailed phenotypic characterisation (Lewis et al., 2014; Perozzo et al., 2001; 
Soileau et al., 2014), and our calculation suggests our study is adequately powered to meet our 
primary objective. Additionally, the participants in our investigation are similar in terms of 
clinical severity, demographics and prior treatment to other large neurosurgical centres. 
Differences between centres in the postoperative prescribing of dopaminergic medication can 
influence the evolution of psychiatric symptoms, but we included levodopa equivalent dose as 
a variable in our multivariate modelling and we provide summary statistics describing 
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dopaminergic prescribing at each postoperative time point to aid comparison with other centres 
(Supplementary Table 5.7). Moreover, the striking separation and stability of cluster 
assignment, as evidenced by our frequentist and Bayesian statistics, suggest that the lack of 
longitudinal change in these variables is likely to be a true effect, rather than resulting from an 
underpowered cohort.   
 
Future work could incorporate more detailed characterisation of the caregiver, both in terms of 
demographic status and caregiver psychiatric morbidity. Depressive and anxiety symptoms in 
the caregiver are strongly associated with burden (Mosley et al., 2017b), and may strengthen 
the subsequent modelling of postoperative burden in surgical cohorts such as this. Furthermore, 
the number of years that caregivers have spent in this role may be an important mediating 
variable to consider. This will permit a more accurate definition of the profile of caregiver at 
high risk of burden, complementing the present identification of clinical factors in the person 
with Parkinson’s disease that are significantly associated with burden. Our finding that 
caregivers with poor relationship quality at baseline were highly likely to be assigned to the 
‘High’ burden cluster suggests a potential therapeutic target for intervention prior to functional 
neurosurgery. We suggest that caregivers reporting elevated burden and poor relationship 
quality at this stage may benefit from a structured psychotherapeutic intervention, beginning 
prior to DBS and continuing in the early postoperative period. The threshold for entry into the 
intervention could be determined by a psychiatrist conducting a formal preoperative psychiatric 
assessment, as part of an assessment of family functioning, in combination with formal rating 
scales. Cognitive, behavioural and environmental elements contributing to burden could be 
addressed in a series of modules, targeting such vulnerabilities as maladaptive coping styles, 
ineffective patterns of interpersonal communication and inadequate social support, all of which 
may impair patient-caregiver relational functioning. Comprehensive education regarding the 
role of DBS in the treatment of Parkinson’s disease should also be included, in order to prepare 
caregivers for potential neuropsychiatric complications and ensure that expectations about the 
benefit of DBS are realistic. We have developed such a manualized intervention, designed to 
be delivered by a psychologist or specialist nurse, which we are evaluating in a new cohort of 
caregivers. A similar intervention has been of benefit in caregivers of persons with Parkinson’s 
disease in a non-surgical cohort (A'Campo et al., 2010b; Simons et al., 2006). Such 
psychotherapies necessitate extra resources, but the results of this investigation suggest at-risk 
caregivers can be stratified at baseline, improving the specificity of the intervention. 
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In summary, caregivers that endorsed high levels of burden at baseline, as well as caregivers 
that reported high levels of impulsivity and low levels of empathy in their partners, generally 
maintained this profile during longitudinal follow up. The converse was also true. Therefore, 
STN-DBS neither amplified nor ameliorated caregiver burden, nor did it significantly alter 
caregiver ratings of psychiatric symptoms. Our statistical methods extend standard pre- versus 
post-test contrasts and allow inference upon individual trajectories, which strengthens our 
findings. This suggests that clinicians seeking to reduce caregiver burden in this population 
should identify and target those with high burden at baseline, as these caregivers are most likely 
to report ongoing burden during their postoperative journey. Furthermore, given the substantial 
contribution of psychiatric symptoms to postoperative burden, and the stability of psychiatric 
symptom clusters (as evaluated by caregivers in this paper), a preoperative psychiatric 
assessment of all surgical candidates is well placed to identify and manage these key variables.  
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5.8 Supplementary Data 
Supplementary Table 5.7 | Levodopa Equivalent Daily Dose (LEDD) at Each Interval 
Interval LEDD Mean (SD) LEDD Median (Range) 
Pre-DBS 1066 (±551.8) 1000 (0 – 3450) 
2-weeks post-DBS 416 (±243.5) 400 (0 -1210) 
6-weeks post-DBS 388 (±251.1) 375 (0 – 1463) 
13-weeks post-DBS 346 (±217.1) 346 (0 – 950) 
26-weeks post-DBS 346 (±208) 345 (0 – 1000) 
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Chapter 6 
6 Qualitative Accounts of Neuropsychiatric Symptoms after 
Subthalamic Deep Brain Stimulation for Parkinson’s 
Disease 
‘Well, I felt it was my freewill, but yeah, as I say, it's freewill, but driven by my brain, the stimulation of my 
brain, because that wasn’t me at all.’ 
DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic deep brain 
stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
6.1 Publication Details 
This chapter was published as: 
Mosley, P.E., Robinson, K., Coyne, T., Silburn, P., Breakspear, M. & Carter, A., 2019. A 
Qualitative Analysis of Neuropsychiatric Symptoms Following Subthalamic Deep Brain 
Stimulation for Parkinson’s Disease. Neuroethics. Published online ahead of print. 
6.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, consented the participants, collected the 
qualitative data, analysed the data and wrote the manuscript. Ms Robinson conducted a parallel 
analysis on the data as described in the methods section. Prof Breakspear provided critical 
revisions to the manuscript. A/Prof Coyne and Prof Silburn implanted the DBS devices for all 
participants with Parkinson’s disease. Dr Carter provided supervision in qualitative methods. 
6.3 Abstract 
Deep brain stimulation of the subthalamic nucleus (STN-DBS) for the treatment of Parkinson’s 
disease can lead to the development of neuropsychiatric symptoms. These can include harmful 
changes in mood and behaviour that alienate family members and raise ethical questions about 
personal responsibility for actions committed under stimulation-dependent mental states. 
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Qualitative interviews were conducted with twenty participants (ten patient-caregiver dyads) 
following subthalamic DBS at a movement disorders centre, in order to explore the meaning 
and significance of stimulation-related neuropsychiatric symptoms amongst a purposive 
sample of persons with Parkinson’s disease and their spousal caregivers. Interview transcripts 
underwent inductive thematic analysis. Clinical and experiential aspects of post-DBS 
neuropsychiatric symptoms were identified. Caregivers were highly burdened by these 
symptoms and both patients and caregivers felt unprepared for their consequences, despite 
having received information prior to DBS, desiring greater family and peer engagement prior 
to neurosurgery. Participants held conflicting opinions as to whether emergent symptoms were 
attributable to neurostimulation. Many felt that they reflected aspects of the person’s ‘real’ or 
‘younger’ personality. Those participants who perceived a close relationship between 
stimulation changes and changes in mental state were more likely to view these symptoms as 
inauthentic and uncontrollable. Unexpected and troublesome neuropsychiatric symptoms 
occurred despite a pre-operative education programme that was delivered to all participants. 
This suggests that such symptoms are difficult to predict and manage even if best practice 
guidelines are followed by experienced centres. Further research aimed at predicting these 
complications may improve the capacity of clinicians to tailor the consent process.  
6.4 Introduction 
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an effective treatment for 
the motor symptoms (tremor, rigidity, bradykinesia) of Parkinson’s disease. It involves surgery 
to position electrodes within this target that emit continuous high frequency stimulation to 
modulate dysfunctional basal ganglia activity. DBS is typically indicated when motor 
symptoms become difficult to manage with dopaminergic medication due to the development 
of motor fluctuations, dyskinesias, or medication-refractory symptoms. Bilateral STN 
stimulation increases ‘on’ time, reduces motor fluctuations and dyskinesias, enhances 
performance of activities of daily living and improves quality of life (Deuschl et al., 2006). 
The dose of dopaminergic therapy is often substantially reduced (Williams et al., 2010). DBS 
of the STN (STN-DBS) in Parkinson’s disease is set to grow as contemporary evidence 
suggests that earlier intervention produces superior results than best medical therapy 
(Schuepbach et al., 2013).  
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Approximately 10% of persons treated with STN-DBS develop unintended mood and 
behavioural changes as a consequence of electrical stimulation that disrupt post-surgical quality 
of life (Voon et al., 2006). These include euphoria, irritability, pathological gambling, 
hypersexuality and impulsivity, as well as more subtle changes in drive and empathy (Appleby 
et al., 2007; Chopra et al., 2011; Daniele et al., 2003; Herzog et al., 2003; Houeto et al., 2002; 
Mandat et al., 2006; Mosley and Marsh, 2015a; Raucher-Chene et al., 2008; Romito et al., 
2002; Thobois et al., 2010; Voon et al., 2006). Henceforth, these putative ‘stimulation-
dependent’ phenomena are referred to as ‘neuropsychiatric symptoms’, whilst recognising that 
more generally other symptoms in Parkinson’s disease such as anxiety, apathy, psychosis and 
cognitive dysfunction may also be encompassed by this term. The emergence of these issues 
may not be recognized by the person with Parkinson’s disease or not viewed as problematic. 
They may alienate the person with Parkinson’s disease from their support network, leading to 
estrangement or relationship separation. Such neuropsychiatric symptoms also raise ethical 
challenges, including the responsibility of the person for actions committed whilst under the 
influence of stimulation-dependent mental states (Bartlett et al., 2013; Sharp and Wasserman, 
2016). Personality change may lead family members to contend that the person is no longer 
themselves, stimulating debate about the effect of DBS surgery on personal identity (Baylis, 
2013; Klaming and Haselager, 2013; Witt et al., 2013). 
 
The occurrence of neuropsychiatric symptoms in Parkinson’s disease is certainly not unique to 
STN-DBS. Indeed, Parkinson’s disease has been referred to as the ‘quintessential 
neuropsychiatric disorder’ (Weintraub and Burn, 2011), such is the breadth of psychiatric and 
cognitive symptoms that may arise in the course of neurodegeneration. Dopamine replacement 
therapy (in particular dopamine agonist medication) has also been associated with the 
development of impulse-control disorders (Weintraub et al., 2010) and the rate of serious 
psychiatric side effects is similar amongst persons treated with STN-DBS as compared to 
matched individuals on best medical therapy (Witt et al., 2008). Clinicians are therefore 
challenged: the risks of psychiatric side effects as a component of STN-DBS should be 
communicated to patients and their families, but placed into appropriate context, given that 
persons with Parkinson’s disease may benefit greatly from the procedure and the alternatives 
are not without risk. 
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The stimulation-dependent nature of psychiatric symptoms has been contested by Gilbert et al. 
(2018), who suggest that they may reflect a worsening of pre-existing psychiatric disorders or 
aggravation of difficult family relationships in the setting of major surgery, less related to 
electrical stimulation than to premorbid psychiatric, personality and psychosocial functioning. 
In particular, these authors propose that debate regarding the neuroethical consequences of 
DBS relies largely upon speculative assumptions rather than empirical evidence. However,  
clinical experience indicates that a substantial proportion of psychiatric symptoms arise ‘de 
novo’ and in the absence of prior symptomatology, suggesting that there is not a clear ‘at-risk’ 
pre-surgical phenotype and that these symptoms may be an unintended consequence of the 
procedure (Cyron, 2016). Furthermore, the physiological role of the STN in decision-making 
lends biological plausibility to the view that modulation of this region may produce unintended 
cognitive and emotional side effects (Jahanshahi et al., 2015). A direct relationship between 
the adjustment of electrical stimulation and the onset or remission of psychiatric symptoms has 
been reported, suggesting that STN-DBS is a proximate cause in many cases (Chopra et al., 
2011; Herzog et al., 2003; Mandat et al., 2006; Raucher-Chene et al., 2008). Furthermore, the 
precise site of stimulation within this nucleus is associated with the onset of psychiatric 
symptoms, supporting the existence of a biological gradient related to the locus and amplitude 
of stimulation (Mosley et al., 2018d). Finally, the STN has been employed as a surgical target 
in DBS for obsessive-compulsive disorder (Mallet et al., 2008), indicating that this subcortical 
nucleus can be a nexus for psychiatric as well as movement disorders, helping to explain why 
psychiatric symptoms may arise as a consequence of STN-DBS for Parkinson’s disease. 
 
Complex changes in behaviour following STN-DBS are challenging to comprehensively assess 
with standard quantitative methods. Firstly, instruments that assess mood and personality only 
measure an operationalised subset of these phenomena; richer concepts such as ‘identity’ and 
‘autonomy’ are not captured in these scales. Secondly, affected individuals may show deficits 
in their awareness of these difficulties, which are only revealed after consulting with an 
informant. Qualitative investigations employ open-ended questions that allow participants to 
disclose more than pre-determined scales. Moreover, the inclusion of spousal informants 
provides a second perspective that may corroborate or contrast with the experience of the 
person with Parkinson’s disease. Qualitative methods also capture the participant’s ‘own 
voice’, meaning that issues relevant to the person with Parkinson’s disease are uncovered, 
assisting with the delivery of patient-centred care. Qualitative studies with people with 
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Parkinson’s disease (Hariz and Hamberg, 2014; Hariz et al., 2016) and their spouses (Haahr et 
al., 2013) have increased our understanding of living with a DBS device. However, there has 
been little research regarding the impact of subthalamic stimulation-induced neuropsychiatric 
symptoms on persons with Parkinson’s disease and their families (Gilbert et al., 2018).  
 
The goal of the present investigation was to explore the meaning and significance of 
stimulation-related neuropsychiatric symptoms amongst a sample of persons with Parkinson’s 
disease and their spousal caregivers. Here, participants and their spouses were purposively 
selected from a pool of consecutive surgical candidates based on the postoperative 
development of neuropsychiatric symptoms attributable to STN-DBS. Interviews were 
conducted six-twelve months postoperatively, after neuropsychiatric symptoms had been 
remediated following DBS manipulation. Findings from this study will enhance the capacity 
of clinicians to educate surgical candidates and respond to the emergence of neuropsychiatric 
symptoms in a manner that addresses the needs of the person with Parkinson’s disease and their 
family. This will be of increasing importance as subthalamic DBS becomes a more widely 
utilised intervention (Schuepbach et al., 2013).  
6.4.1 Terminology 
In the investigation that follows, a number of ethical and philosophical concepts are identified. 
To aid the clarity of subsequent discussion we first define what we take these terms to mean 
and how we take them to be inter-related. We recognise that these concepts have a rich history 
of debate in the bioethics literature and it is beyond the scope of this study to engage in this 
analysis. 
 
In order for an agent to be morally responsible for an act (or omission), the consequences of 
acting (or not acting) must be foreseeable, and the agent must possess autonomous control over 
her cognitive and volitional capacities. Acting deliberatively or purposely may enhance moral 
responsibility and blameworthiness. Autonomy is the exercise of a set of mental competences 
to make a judgement about one’s best action in a given situation. Autonomous agents reason 
consistently, reaching similar conclusions under similar environmental contingencies (i.e. they 
are sufficiently rational). Furthermore, an autonomous agent reasons and acts on the basis of 
authentic desires, i.e. the attitudes of the agent that move her to act are identified as her own, 
being consistent with the agent’s evaluation of her values (Wardrope, 2014). According to this 
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view, to act authentically and therefore responsibly is to do so in accordance with one’s ‘true 
self’. Selfhood is closely aligned with the concept of personal identity, a construct that is 
constitutive of responsibility. Broadly, there are two contrasting perspectives on personal 
identity and what constitutes someone’s ‘true self’: a view of selfhood as a form of reflective, 
self-generated autobiographical narrative (referred to as existentialist) (Schechtman, 2018), 
contrasted with an essentialist model that proposes the existence of a deeply immutable inner 
‘core’ of being (Pugh et al., 2017). In what follows we do not take a position on which 
conception of identity is correct. Identity and selfhood are distinct from personality, which 
refers to those temperamental or characterological traits that influence a distinctive array of 
behaviour within an individual.  
6.5 Methods 
Qualitative data was gathered from twenty semi-structured interviews conducted with persons 
with Parkinson’s disease (10) and their spousal caregivers (10) following subthalamic DBS.  
This study was part of a larger investigation of neuropsychological and neuroanatomical 
aspects of psychiatric symptoms (Mosley et al., 2018a; Mosley et al., 2018c; Mosley et al., 
2018d) after DBS. All participants received written information about the study and signed a 
consent form.  
6.5.1 Participants 
A larger cohort of persons with Parkinson’s disease (from which these participants were drawn) 
comprised surgical candidates consecutively recruited at the Asia-Pacific Centre for 
Neuromodulation between 2013-2017, during the assessment of eligibility for STN-DBS. The 
diagnosis of Parkinson’s disease was confirmed by a movement disorders neurologist 
according to the United Kingdom Queens Square Brain Bank criteria (Hughes et al., 1992). All 
persons with Parkinson’s disease completed a psychiatric and cognitive evaluation prior to 
surgery. Individuals without a spousal caregiver, proficiency in English, and those with 
cognitive impairment, as defined by a Mini Mental State Examination Score (MMSE) of 25 or 
less, or a clinical diagnosis of Parkinson’s disease dementia (Emre et al., 2007) were excluded 
from the study. Prior to consenting for surgery, persons with Parkinson’s disease and their 
spousal caregivers completed a sixty-minute education session run by a psychiatrist (PM) and 
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nurse specialist, which included information regarding the potential neuropsychiatric side 
effects of subthalamic stimulation. 
 
DBS electrodes were implanted in a single-stage procedure using a stereotactic apparatus, after 
the STN was identified via neuroimaging. Intraoperative microelectrode recordings were 
employed to establish localisation within the STN and intraoperative test stimulation was 
performed. Further imaging confirmed satisfactory postoperative lead placement. 
Postoperatively, stimulation parameters were adjusted non-invasively through an implanted 
pulse generator sited in the pectoral region. Stimulation titration began as an inpatient, with the 
amplitude of stimulation gradually increased as dopaminergic medication was slowly 
withdrawn. Persons with Parkinson’s disease returned to the clinic frequently during the first 
six postoperative months for routine neurological and psychiatric assessment, with further DBS 
manipulation undertaken according to motor symptoms.  
 
Identification of persons with Parkinson’s disease who developed psychiatric symptoms (that 
the investigators had grounds for believing were) attributable to subthalamic DBS used the 
same process as that reported in prior work (Mosley et al., 2018a; Mosley et al., 2018d).1 These 
persons were identified during a postoperative schedule of repeated neuropsychiatric 
assessments. A semi-structured diagnostic interview and mental state examination were 
conducted by the psychiatrist (PM) who had assessed all participants at baseline, with attention 
to mood elevation, disinhibition, compulsivity and loss of empathy. The contribution of 
neurostimulation to the presentation was confirmed if symptoms responded promptly to a 
reduction in the amplitude or change in the locus of stimulation, as assessed by serial mental 
state examinations and feedback from close family members. These individuals were invited 
to take part in a qualitative interview, which was also undertaken separately with their spousal 
caregiver. The present sample of ten patient-caregiver dyads was drawn from a total cohort of 
ninety-one recruited to the overarching investigation. Persons with Parkinson’s disease and 
their caregivers were only approached for interview after their psychiatric symptoms had 
definitively resolved, at an interval of six-twelve months post-DBS. No individuals declined 
participation.  
                                                
1 We acknowledge the bioethical debate regarding the attribution of these symptoms, e.g. Gilbert et al. 
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6.5.2 Interviews 
Interviews used a semi-structured template exploring common psychiatric symptoms 
attributable to subthalamic DBS and its impact on autonomy, identity and responsibility. The 
interview template is provided in Appendix B. Participants were encouraged to introduce topics 
that were not prompted by the interviewer. Persons with Parkinson’s disease and their spousal 
caregivers completed separate interviews to enable open disclosure and the expression of 
discrepant perspectives. Interviews were conducted face to face by PM with an approximate 
duration of sixty minutes. PM maintained field notes and a reflective diary. Audio-recordings 
of each interview were transcribed verbatim and checked for accuracy, with removal of all 
potentially identifiable information. All participants were informed verbally and in writing that 
the content of the interviews would not form part of their medical record. 
6.5.3 Data Analysis 
Deidentified transcripts were imported into NVivo qualitative analysis software (Mac version 
11.4.2, QSR International Pty Ltd, Doncaster, Australia) and analysed thematically (Braun and 
Clarke, 2006). Each transcript was read several times before extracts were coded to reflect the 
experience or perspective of the participants. Coding was an iterative and inductive process, 
with codes generated, refined and merged, and transcripts re-coded as the data corpus 
increased. Each transcript was re-coded until saturation, where no further excerpts could be 
identified. Both PM and KR carried out this initial coding step separately in order to generate 
diverse perspectives on the data. Discrepancies were discussed between PM and KR until a 
consensus was reached. Preliminary analyses of the transcripts were conducted in parallel to 
the interviews, to facilitate reflection during data collection. Subsequently, stable frameworks 
of codes were identified that cohered as themes, each describing a defined aspect of 
participants’ experience of psychiatric symptoms after subthalamic DBS.  
 
When coding, experience, preconceptions and bias were acknowledged. PM was a psychiatrist 
with involvement in over 400 cases of DBS for movement disorders. His position was that 
neurostimulation was causally responsible for the observed behavioural changes amongst these 
persons with Parkinson’s disease, rather than a psychological adjustment to the relief of 
disability or changing roles in the patient-caregiver dyad. KR was a provisional psychologist 
with no prior clinical experience or knowledge of the participants. In order to maximise the 
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transparency of subsequent findings the consolidated criteria for reporting qualitative research 
(COREQ) were employed (Tong et al., 2007).  
6.6 Results 
6.6.1 Participant Characteristics 
The data corpus consisted of twenty qualitative interviews, comprising ten persons with 
Parkinson’s disease (9 male, 1 female, mean age 59.4, range 36-71) and ten corresponding 
spousal caregivers (9 female, 1 male, mean age 57.9, range 35-70). The demographic and 
clinical characteristics of the persons with Parkinson’s disease selected for interview are 
summarised in Table 6.1. Persons with Parkinson’s disease were predominantly male, but with 
a broad range of age and variable degree of premorbid psychiatric history. Three had no prior 
psychiatric history, four had mild-moderate depressive or anxiety disorders and three had more 
severe behavioural addictions or psychotic symptoms related to dopaminergic therapies. 
Neuroimaging confirmed that the DBS electrodes were accurately targeted to the STN in all 
patients (Figure 6.1), with favourable motor outcomes from their procedure, manifested by a 
reduction in objective motor symptom scores and a reduction in the requirement for 
dopaminergic therapies. Quantitative data pertaining to these outcomes has been reported 
(Mosley et al., 2018a; Mosley et al., 2018d). 
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Table 6.1 | Demographic and Clinical Characteristics of the Sample 
Participant Age Gender Prior Psychiatric History DBS-Related Symptoms 
1 67 Male Nil Irritability, hypersexuality, pathological 
gambling, compulsive spending 
2 61 Male Depression (treated in 
primary care) 
Irritability, compulsive spending, alcohol 
dependence, aggression, suicide attempt 
3 62 Male Compulsive ‘hobbyism’ 
related to PD medication 
Impulsivity, dangerous driving, unwise business 
decisions, hypersexuality 
4 46 Male Nil Irritability, hypersexuality, compulsive spending 
5 67 Male Psychotic episode related to 
PD medication 
Hypersexuality, verbal disinhibition, leading to 
family discord 
6 64 Male Depression (treated in 
primary care) 
Manic episode with irritability, aggression, 
pathological gambling, dangerous driving, 
leading to involuntary hospitalisation 
7 36 Male Nil Hypersexuality, verbal disinhibition leading to 
family discord 
8 71 Male Non-motor fluctuations in 
anxiety 
Irritability, compulsive spending 
9 61 Female Anxiety (treated in secondary 
care) 
Irritability, compulsive spending 
10 54 Male Hypersexuality, compulsive 
spending, gambling related to 
PD medication 
Irritability, aggression 
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Using the Lead-DBS toolbox (Horn and Kuhn, 2015), preoperative T1 and T2-weighted images were co-registered with the 
postoperative CT scan and spatially normalised into ICBM_2009b nonlinear asymmetric space. Medtronic 3389 and Boston 
Vercise electrodes were manually identified, their spatial position was corrected for brainshift, and their trajectory was 
evaluated with reference to a recent parcellation of the STN (Ewert et al., 2018). The full pipeline has been described in prior 
work (Mosley et al., 2018d). A: coronal view of DBS electrodes, B: axial view of DBS electrodes. All electrodes were 
accurately targeted to the STN. 
6.6.2 Clinical Vignettes 
Brief clinical vignettes are summarised below to provide a narrative context for each patient.  
6.6.2.1 Person with Parkinson’s disease 01 
A sixty-four-year old male with an eleven-year history of tremor-dominant Parkinson’s 
disease. A retired senior government administrator with no personal or family history of 
psychiatric illness and no impulse control disorders despite long-term treatment with a 
dopamine agonist. One month after STN-DBS, he developed a coarsening of personality 
manifest with crude language, irritability and sexualised behaviour. He threatened to set up a 
rival DBS program, became preoccupied with sports betting and purchased a sports car on an 
Figure 6.1 | Localisation of Subthalamic Deep Brain Stimulating Electrodes 
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internet auction. His symptoms remitted at three-months postoperatively when his stimulation 
was moved to a more dorsal contact on both electrodes and a bipolar configuration (anode and 
cathode both localised to the electrode resulting in a more focussed stimulation field) was 
employed.  
6.6.2.2 Person with Parkinson’s disease 02 
A sixty-one-year old male with a five-year history of tremor-dominant Parkinson’s disease. A 
retired sales executive with a history of depression emerging as an early symptom of 
neurodegeneration, responsive to antidepressant medication. He developed an early 
postoperative hypomania characterised by euphoria and psychomotor agitation, which settled 
after one month. However, subsequent to an increase in stimulation five-months 
postoperatively, he abruptly became irritable, began drinking heavily, purchased $2000 of 
camping equipment, assaulted his wife and attempted suicide by jumping from a hotel window. 
His symptoms remitted with a switch to bipolar stimulation on both electrodes.  
6.6.2.3 Person with Parkinson’s disease 03 
A sixty-two-year old male with a twenty-three-year history of akinetic-rigid Parkinson’s 
disease. On long-term sickness benefits due to his movement disorder, he had developed 
dopamine dysregulation on a duodopa infusion and was manipulating his dose so as to engage 
in compulsive woodworking. This behavioural addiction resolved after STN-DBS, but three-
months later, his wife complained of impulsive behaviour: he was attempting to open a 
nightclub and was apprehended by the police driving his mobility scooter on a busy highway. 
His wife also described a new habit of fetishistic masturbation. His symptoms remitted with a 
reduction in stimulation amplitude. 
6.6.2.4 Person with Parkinson’s disease 04 
A forty-six-year old male with a four-year history of tremor-dominant Parkinson’s disease. 
Serving in the armed forces, he had no prior psychiatric history. Three months after STN-DBS, 
he developed an elevated mood with irritability, verbal disinhibition, compulsive spending and 
hypersexuality. He purchased expensive wine, paintings and solicited sex on the internet. His 
symptoms remitted with a switch to bipolar configuration, move to more dorsal electrodes and 
reduction in stimulation amplitude.  
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6.6.2.5 Person with Parkinson’s disease 05 
A sixty-seven-year old male with a thirteen-year history of tremor-dominant Parkinson’s 
disease. A former naval serviceman, he had developed a delusion of infidelity during treatment 
with a dopamine agonist. This had resolved following cessation of the drug, but was associated 
with a subsequent depressive episode, remitted at the time of DBS. He displayed euphoria and 
verbal disinhibition in the first week after STN-DBS, which settled spontaneously. However, 
subsequent to increases in stimulation amplitude during the following six months, he displayed 
abrupt changes in affect characterised by elation, irritability and hypersexuality, demanding 
sex from his spouse. These symptoms responded to moving the stimulation to more dorsal 
electrode contacts and a reduction in stimulation amplitude.  
6.6.2.6 Person with Parkinson’s disease 06 
A sixty-four-year old male with a five-year history of tremor-dominant Parkinson’s disease. A 
factory worker, he had a history of recurrent depressive disorder treated in primary care. 
Immediately after STN-DBS, he reported a non-motor effect of stimulation with resolution of 
his depressive symptoms, a phenomenon that was also positively received by his family. 
However, nine-months later a second contact was activated on the right electrode to manage 
residual motor symptoms, which led to the rapid development of a manic syndrome. This was 
associated with irritability, threats to his family, gambling and dangerous driving, eventuating 
in arrest and involuntary hospitalisation. His device was turned off and he was treated with 
mood stabilising medication and antipsychotics, with subsequent resumption of DBS under the 
initial postoperative settings. This case has previously been reported (Mosley et al., 2018c).  
6.6.2.7 Person with Parkinson’s disease 07 
A thirty-six-year old male with a five-year history of tremor-dominant Parkinson’s disease. A 
manual labourer, he had no prior psychiatric history and no background of impulse-control 
disorders despite treatment with a dopamine agonist. One month after STN-DBS, his wife 
described the emergence of a ‘forceful’ personality (previously he had been reserved) 
associated with a preoccupation with sex and agitation discernible on mental state examination. 
His symptoms remitted with a bipolar configuration and a move to more dorsal electrode 
contacts, but re-emerged at three-months subsequent to further stimulation increases and 
remitted again with a reduction in stimulation amplitude.  
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6.6.2.8 Person with Parkinson’s disease 08 
A seventy-one-year old male with a five-year history of tremor-dominant Parkinson’s disease. 
A retired scientist, he experienced non-motor fluctuations with cyclical anxiety symptoms in 
the inter-dose interval between doses of his levodopa. Two months after DBS, he developed 
an elevated mood in the irritable range after a stimulation increase. He presented with an 
uncharacteristically entitled affect and accused his treating clinicians of being incompetent. 
Upon admission, he attempted to buy artwork on the walls of the hospital and tried to give cash 
to the nursing staff. His family reported that he had bought artwork for them against their 
wishes. His symptoms remitted with a reduction in stimulation amplitude.  
6.6.2.9 Person with Parkinson’s disease 09 
A sixty-one-year old female with a five-year history of tremor-dominant Parkinson’s disease. 
A retired teacher, she had a history of generalised anxiety in the setting of her movement 
disorder and had been treated by a psychiatrist for these symptoms. In the first week after DBS, 
she became uncharacteristically irritable with outbursts of inappropriate anger directed towards 
her husband. She had poor insight into her changed behaviour and these outbursts persisted 
despite intensive DBS reprogramming. Her husband also reported compulsive spending. 
Eventually her right STN electrode was repositioned surgically and her symptoms remitted.  
6.6.2.10 Person with Parkinson’s disease 10 
A fifty-four-year old male with a five-year history of akinetic-rigid Parkinson’s disease. A 
retired postal officer, he had a history of impulse control disorders during treatment with 
dopamine agonist medication. These included pathological gambling, compulsive spending 
and hypersexuality comprising the compulsive use of internet pornography. His behavioural 
addictions remitted after STN-DBS corresponding with a reduction in his dopaminergic 
medication. However, two-months after surgery, he became irritable and his wife reported 
dangerous driving and threats of aggression. On mental state exam, he was agitated with 
pressure of speech and verbal disinhibition. His symptoms remitted with the use of a bipolar 
configuration and dorsal electrode contacts.  
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6.6.3 Coding and Themes 
A coding tree was developed from the data corpus, from which a network of primary and 
secondary themes was identified (Figure 6.2). Illustrative excerpts are provided in the text 
below and as Supplementary Material (available from https://doi.org/10.1007/s12152-019-
09410-x). 
 
 
6.6.4 Theme 1: Clinical Aspects of Neuropsychiatric Symptoms 
6.6.4.1 Caregiver Burden 
Stimulation-dependent neuropsychiatric symptoms were universally problematic for spousal 
caregivers. Caregivers spoke of their partner ‘no longer being the person I married’ and 
described a change in the spousal role to that of ‘parent’, ‘flatmate’, ‘nurse’ or even ‘sexual 
object’. Those with younger children struggled to explain behavioural changes to their 
offspring. Caregivers were troubled by verbal disinhibition and irritability, rating this as more 
burdensome than motor symptoms.  
 
‘My biggest fear... I can cope with absolutely anything, if he's quadriplegic it's fine, I can deal with that, but I 
can't deal with the psychiatric changes, it scares me too much. How he behaved, how he was when he was back 
there, I can't do that again.’ (Spouse 05) 
 
Even after resolution of neuropsychiatric symptoms, caregivers struggled to forgive their 
partners, particularly if DBS had revealed ‘skeletons in the closet’ or there had been lack of 
insight on the part of the person with Parkinson’s disease. 
Figure 6.2 | Primary and Secondary Themes Identified from the Data Corpus 
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‘We haven't done any counselling at all and I think we need to. As a spouse, you need to be prepared that these 
things can happen and that husbands or partners can turn feral [wild] and not to - we were told not to take it to 
heart - whatever is said is said out of - they can't help it. But in saying that, that's kind of not enough. You still 
hold - I mean, I do - I still hold on to things that were said and things that were done because it's ultimately 
affected our relationship. That's something that I have to move on from but it's really difficult.’ (Spouse 07) 
 
The connection of these symptoms to neurostimulation was problematic for some caregivers, 
who perceived themselves as helpless actors.  
 
‘This illness is something different. Everything else in your life you work harder, you tough it out, and whether 
it's a problem in a relationship or whatever, you work through it. This shit, it's all in someone else's hands. The 
most helpless feeling you'll ever have. It really is.’ (Spouse 09) 
 
6.6.4.2 Lack of Preparedness 
Almost all participants, both persons with Parkinson’s disease and their caregivers, reported 
being ill-prepared for the nature and impact of stimulation-dependent neuropsychiatric 
symptoms. This was despite the inclusion of an education session on the potential emergence 
of these symptoms for all participants during the preoperative multidisciplinary evaluation. 
Some participants denied ever receiving information about neuropsychiatric complications, 
whilst others acknowledged that their desperation to receive treatment for their motor 
symptoms clouded contemplation of this matter.  
 
‘I probably sort of looked on the bright side and thought, oh well, I'll be right… Maybe it wasn't their fault that 
they - they probably did say it but you know when you're sort of a bit desperate I guess you don't sit on that 
negative sort of thing.’ (Person with PD 08) 
 
Other participants recalled receiving education but were unable to reference the personal 
significance of this in the absence of any prior psychiatric history.  
 
‘It's a bit like childbirth [laughs]. It's kind of like no matter how much preparation you do, it's just something 
you've got to experience yourself… Truly we didn't think that - we sort of just hoped we'd skate through without 
having those kind of experiences.’ (Spouse 01) 
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Caregivers reported that this perceived lack of preparedness delayed them from seeking 
treatment for the person with Parkinson’s disease. 
 
‘Had they said to me he may have a change of personality, then I could have said well this has happened, and 
got on to it sooner. From my point of view, I've had to learn the hard way about the side effects.’ (Spouse 02) 
 
6.6.4.3 Evaluation and Service Enhancement 
Even after having experienced or witnessed neuropsychiatric complications, persons with 
Parkinson’s disease and their caregivers reported that they would still make the same decision 
to undergo neurosurgery and would cautiously recommend it to other individuals. This positive 
perspective was driven by the improvement in motor symptoms and reduction in medication 
requirements noted by participants. However, participants were forthcoming with suggestions 
about how the model of care could be improved for future surgical candidates. They expressed 
a preference for more education to improve their preparedness for emergent neuropsychiatric 
symptoms, through peer support and engagement with close family members.  
 
‘Make sure the whole family would be well and truly aware… again these adjustments on the DBS system are 
not just for an individual, the whole family need to be aware of it and how much adjustment and what's being 
done. Because from my own personal experience, I found out just how much it can affect you and not in a good 
way at all and that in turn reflects on the family and they’ve been through hell and back over this.’ (Person with 
PD 02) 
 
Some participants expressed a preference for the science of DBS to be developed to allow more 
accurate predictions of motor and neuropsychiatric outcome.  
 
‘I have a sense that while there's a lot of experience around, there's not a lot of firm, really solid knowledge 
about what happens once we start tweaking [adjusting the DBS]. It's very - there's a real trial and error aspect 
to it, which I probably thought would be less the case - that it would be more known, more rigorous if I can put 
it that way. I understand that it's a fairly new technology, so we're part of that developing of that rigour.’ 
(Spouse 01) 
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6.6.5 Theme 2: Philosophical Aspects of Neuropsychiatric Symptoms 
6.6.5.1 Attribution and Responsibility 
The language of participants revealed complex beliefs about the role of neurostimulation in 
precipitating observed behavioural changes. Many participants made statements that ascribed 
problematic behaviour to subthalamic stimulation, whilst maintaining a belief in personal 
responsibility for action.  
 
‘Where do you think those urges came from?’ (Interviewer) 
‘Largely out of my situation of boredom. I think they're an expression of my own freewill. It's just me thinking 
about it a lot more because my brain is more active. I'm the first to agree with that and I wouldn't want that any 
other way. So woe betides anybody who tries to turn me down.’ (Person with PD 01) 
 
‘Well, I felt it was my freewill, but yeah, as I say, it's freewill, but driven by my brain, the stimulation of my 
brain, because that wasn’t me at all.’ (Person with PD 02) 
 
One person with Parkinson’s disease credited subthalamic DBS with curing his longstanding 
depression but saw other behavioural changes as reflective of his unique personal history. 
 
‘The minute I opened my eyes [after the operation] my depression and anxiety had been lifted and I've never felt 
depressed and never felt anxious since that day… it has changed my character… Maybe buying a few presents 
for the kids, the grandkids, she might feel that I might overdo it at times. But there's a reason behind that too 
that she doesn’t understand. When I grew up, I grew up with nothing. My parents weren't very well off at all. I 
sort of felt I missed out, so I'm trying to probably give the grandkids a little bit more. I see a smile on their face, 
I get more enjoyment out of them getting that doll or that little motorised car or whatever it is, and what they 
get. So not DBS.’ (Person with PD 06) 
 
Even when participants held a very biological view of emergent neuropsychiatric issues, this 
did not necessarily affect their application of moral character to an action. 
 
‘I've seen with this that people can change pretty quick just from a wire. Same person, same mind, or same 
brain, just shift a bit of voltage somewhere and a different person … But I don't see why I should condone bad 
behaviour. Whether you're crook [ill] or not, bad behaviour is bad behaviour.’ (Spouse 09) 
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Some participants expressed a sense of bewilderment when attempting to disentangle this 
question of culpability. 
 
‘I don't know what's [the person with Parkinson’s disease] anymore and what's the DBS. I don't know if he's 
changed as a person or if a lot of it is the DBS. It's a hard one to answer, because I'm confused in my head of 
what's real and what's not real anymore.’ (Spouse 10) 
 
6.6.5.2 Authenticity 
Many participants viewed the emergence of neuropsychiatric symptoms as reflecting some 
aspects of the person’s ‘real’ self that Parkinson’s disease took away and which DBS allowed 
to re-emerge.  
 
‘I was very outspoken too, and - but a lot also was my personality coming back. Because I'd just [previously 
with Parkinson’s disease] let things go, whereas I'd always been very outspoken. I was sort of back to my old 
self in a lot of ways.’ (Person with PD 09) 
 
While the changes were seen as being consistent with their ‘real’ pre- Parkinson’s disease self, 
the degree of behavioural change was sometimes seen as exaggerated or a return to a much 
younger self.  
 
‘To some extent I think that they're probably - at least in [person with Parkinson’s disease’s] case kind of 
unique to him. They're not alien to what he used to be. They're exaggerations of how he would once have 
behaved anyway… it's just like everything with the knobs turned up or the volume turned up… we're back to the 
20-25-year-old personality that's not very nuanced and not all that willing to compromise.’ (Spouse 01) 
 
Participants who observed large positive changes in mental state subsequent to DBS 
adjustments were more likely to endorse a return to true selfhood.  
 
‘Yes, when first readjusted I was like my old self. I couldn’t believe how I felt. My wife and I could get on 
reasonably well… I felt my old self and that was what our children say, that we lost you at some stage, but now 
you're your old self again.’ (Person with PD 02) 
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However, the change to a less passive self caused problems for caregivers, particularly when 
the person with Parkinson’s disease was no longer willing to adhere to established roles within 
the family system. This appeared to be driven by changes in mood, rather than a simple 
reduction in disability due to the relief of motor symptoms.  
 
‘…he didn't want me looking after him and was calling me controlling, whereas normally it was - as I said, we 
were just a team. I don't call it controlling. I call it helping… it just triggered some… dark side.’ (Spouse 07) 
 
6.6.5.3 Control 
Participants who viewed neuropsychiatric symptoms as inauthentic, attributed behaviours to 
the DBS and perceived a loss of control or freewill.  
 
‘I knew I was saying it but I knew I shouldn't be saying it. See what I mean? It's just - you've just got no control. 
Yeah, it was no control, no filter. No circuit breaker, no - it was odd. It was…it just gets rid of all your 
inhibitions.’ (Person with PD 04) 
 
However, for some participants the surgery appeared to offer an additional and desirable ability 
to control personality and behaviour. 
 
‘We call him the Energizer Bunny and when the friends walk in, they'll say to him, are we switched on today, or 
switched up, because he's just got this energy. Then when you turn him down… in the afternoon he'd have to 
have a little nap. Well he doesn't like that. He likes to have this Energizer Bunny energy. Since he's had a taste 
of it, he really likes it. It's almost like an addiction actually… to me, it's almost like control.’ (Spouse 02) 
 
Participants who saw neuropsychiatric symptoms as authentic were less likely to perceive a 
loss of control. 
 
‘But I felt I was getting better each day, and I was very aware of what was happening. Physically there wasn't 
anything I could do about it, but with my verbal language and that I was starting to sort of think, this is no good, 
I've just got to stop it [being outspoken], and I was slowly getting better… I thought I was sort of getting control 
of it.’ (Person with PD 09) 
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However, the views of persons with Parkinson’s disease and spouses were sometimes 
discrepant on this matter. 
 
‘If she'd have seen a video of herself she'd have been surprised. In her mind, she thinks that she was fine, and 
she still believes that she was fine. But you understand from her point too because of where that wire was, she 
was high, for want of a better term, and feeling like a million bucks… that she's like superman. Almost like 
someone on drugs, but didn't believe that anything she was doing was wrong… It didn't get better. It just 
escalated. Every time they turned the unit, the voltage up she went up a level… You can't believe that a little bit 
of voltage would shift someone from there to there in that little bit of time.’ (Spouse 09) 
 
Participants (both spouses and persons with Parkinson’s disease) who observed this close 
relationship between stimulation changes and changes in mental state were more likely to view 
neuropsychiatric symptoms as inauthentic and uncontrollable. 
 
‘Then on Monday when it had been increased to three that was when I was sort of - something was happening 
that wasn't typical of me… I sort of felt irritable. Something was going on there... I was aware that I was like 
that, but I couldn’t seem to do too much about it. Then no, I don't understand what was happening or what was 
causing that. I was sort of over cooked, I was too stimulated, and maybe it had been increased too quickly.’ 
(Person with PD 08) 
6.7 Discussion 
The emergence of significant neuropsychiatric symptoms (such as mood changes, reckless 
decision-making and addictive behaviours) following STN-DBS can have a significant impact 
on the quality of life of both persons with Parkinson’s disease and their families. We know 
little about the way in which these individuals understand the causes and emergence of these 
behaviours, how they impact upon their lives and relationships, and what information or 
support they receive. This study provides a qualitative examination of these issues. Our study 
also enriches our understanding of the philosophical aspects of these phenomena, capturing 
how such symptoms, when they arise, impact on autonomy and identity.  
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6.7.1 Supporting Caregivers 
From a clinical perspective, emergent neuropsychiatric symptoms (as operationalised and 
identified by a psychiatrist) were particularly burdensome for caregivers, who reported changes 
in relational dynamics and enduring difficulties even after a recovered episode. In particular, 
caregivers often reported feeling helpless and overwhelmed by the changes observed in their 
partner. This finding is consistent with previous reports demonstrating that burden amongst 
Parkinson’s disease caregivers is highly correlated with comorbid psychiatric symptoms 
(Lewis et al., 2015; Mosley et al., 2017b). We suggest that the wellbeing of caregivers should 
be explicitly considered by clinicians who encounter these neuropsychiatric symptoms in their 
patients. The persistent distress reported by caregivers may require provision of psychological 
assistance even after neuropsychiatric symptoms have abated in order to facilitate relational 
readjustment. Future work will evaluate the effectiveness and acceptability of psychological 
care in this population. 
6.7.2 Enhancing Understanding 
These personal perspectives also highlight how neuropsychiatric symptoms are unexpected by 
persons with Parkinson’s disease and their families, despite prior education about the potential 
for behavioural changes. Most participants identified knowledge gaps in the psychiatric 
domain, with the majority able to recall accurate information regarding surgical complications 
of DBS and motoric benefits. Some participants disregarded information about psychiatric 
risks as they were preoccupied with addressing their motor symptoms, or they discounted the 
likelihood and impact of developing psychiatric symptoms, especially if they had no significant 
prior experience of psychiatric illness. However, it is important that surgical candidates and 
their families are explicitly prepared for this possibility, especially given that our participants 
perceived that ill-preparedness impaired their capacity to respond and cope with 
neuropsychiatric symptoms, and often delayed their help-seeking responses. Addressing this 
challenge may include the use of a structured instrument to deliver preoperative education. 
Further research is needed to develop such a tool, although the findings in this investigation 
will help identify knowledge gaps or when families are not likely to process information about 
the risk of behaviour change. Furthermore, clinicians may wish to employ a process of 
‘corrected feedback’ (Festinger et al., 2010) whereby the clinician can test the level of 
comprehension of imparted information. Corrected feedback also views the communication of 
important and complex clinical information as an ongoing process both prior and subsequent 
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to the relief of motor symptoms. Enhancing understanding may also necessitate greater 
clinician engagement with Parkinson’s disease support groups, which offer fellowship and 
advice to many persons with Parkinson’s disease. Perhaps it is easier for those persons who 
have some ‘lived experience’ of psychiatric symptoms to conceptualise themselves or their 
spouses receiving psychiatric care. 
6.7.3 Managing Unpredictability 
Given the relative unpredictability of postoperative psychiatric symptoms, it remains uncertain 
how forthcoming clinicians should be regarding the ‘unknowns’ of DBS. Unexpected and 
harmful neuropsychiatric symptoms may occur after STN-DBS, despite the oversight of a large 
and experienced movement disorders centre that follows best practice guidelines, including an 
embedded psychiatrist, preoperative psychiatric evaluation of all surgical candidates and a 
preoperative education programme delivered to spousal caregivers. It has previously been 
suggested that neuropsychiatric effects may be an integral, albeit unintended, consequence of 
STN-DBS for Parkinson’s disease (Cyron, 2016). Other nuclei in the basal ganglia, specifically 
the internal segment of the globus pallidus (GPi), have been advanced as a ‘safer’ target for 
DBS (Okun and Foote, 2005) but these outcomes have been contested (Krack and Hariz, 2013; 
Odekerken et al., 2013). Could the choice of target be adapted to favour the GPi in persons 
prone to psychiatric complications? However, based on information that can be derived from 
a standard clinical assessment and mental state examination, it seems unlikely that a 
psychiatrist can accurately predict an ‘at risk’ patient. Whilst false negatives are clearly a 
concern in this scenario, a false positive identification of an ‘at-risk’ individual may also harm 
a patient by implementing a bias towards a surgical treatment option that ultimately has a lesser 
benefit for their quality of life (Odekerken et al., 2013). Furthermore, it is also difficult to 
prospectively quantify the magnitude of future harm arising from subthalamic DBS. Although 
the cases reported in this investigation are clearly at the most severe end of the spectrum, there 
are a greater number of cases in which no neuropsychiatric symptoms arise or any emergent 
symptoms are detected quickly and addressed through prompt intervention with minimal or no 
enduring harm. What is the threshold of potential harm at which alternative targets should be 
considered? We agree with previous suggestions that the ultimate choice of target should be 
undertaken by the neurologist and neurosurgeon after a discussion with the surgical candidate 
and their family, during which the benefits and risks of stimulation at available targets can be 
considered (Cyron, 2016). 
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6.7.4 Contradictory Narratives of Causation and Control 
‘I regard the mind-body problem as wide open and extremely confusing’ 
Saul A. Kripke, Naming and Necessity (1980) 
Many of us invoke differing narratives to explicate our behaviour, which may comprise 
neuroscientific, psychological and social understandings (Pickersgill et al., 2011). Our 
participants also employed a diverse explanatory framework, utilising both deterministic and 
moral paradigms. As a result, their attempts to make sense of their experiences in the context 
of DBS were frequently contradictory. The attitude of some caregivers was reminiscent of 
Immanuel Kant’s assertion: ‘... although we believe that the action is thus determined, we none 
the less blame the agent’ (1946), describing behaviour as ‘bad’ or ‘childish’ despite endorsing 
a biological model of causation. This parallels findings in addiction, in which clinicians employ 
a neurobiological framework but retain a belief in the capacity of the individual to exercise 
control (Carter et al., 2014). It is also conceivable that the connection of neuropsychiatric 
symptoms with DBS titration, or the biological model espoused by treating clinicians, 
challenged existing attitudes held by participants, causing them to switch between determined 
and moral modes of explanation. It has been argued that neuromodulation confronts the ‘folk 
dualism’ of some persons (Mecacci and Haselager, 2014). Moreover, responsibility is not a 
unitary construct and can be seen as a syndrome of concepts, including causal relationships 
between intention, action and outcome, as well as moral judgements that an individual is 
blameworthy (Vincent, 2010). In addition, a distinction can be made between attributing moral 
character to an action and attributing moral responsibility for an action to an agent. This 
attributional ambiguity and complexity in the ways we tend to talk about responsibility may 
contribute to the distress experienced by many participants.  
 
One further possibility is that these contradictory narratives serve a purpose in providing moral 
justification for action. In parents of children with attention deficit hyperactive disorder 
(ADHD), definitions of authenticity shift according to prevailing cultural norms and 
developmental ideals (Singh, 2005). In our cohort, participants moved between particular 
frameworks of attribution and authenticity depending on their utility in explicating positive and 
negative behaviours. For example, behaviours that were evaluated negatively, such as 
irritability, disinhibition and relationship disruption, were often construed as arising from the 
exogenous and malign influence of stimulation. However, phenomena such as increased 
energy, generosity and extraversion were often seen as an opportunity to return to a more 
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authentic self, facilitated rather than imposed by DBS (see Supplementary Material for further 
excerpts).  
 
The perception of control exercised by participants with Parkinson’s disease over 
neuropsychiatric symptoms after STN-DBS was variable. Some (e.g. person with Parkinson’s 
disease 04) experienced a loss of autonomy manifest with lowered inhibitions and the 
perception of action contra to his identified values for normative behaviour. Others (e.g. person 
with Parkinson’s disease 09) recognised that her actions had been out of keeping with her pre-
surgical temperament but reasoned that she was able to exert voluntary suppression of those 
behaviours identified as problematic. Still others (e.g. person with Parkinson’s disease 02) 
actively sought out changes in mood engendered by higher levels of stimulation, reminiscent 
of other cases previously reported (Kraemer, 2013). In this latter excerpt, there is even a 
suggestion that the DBS is controlling the person with Parkinson’s disease.  
 
Interestingly, no participant (person with Parkinson’s disease or caregiver) raised concerns 
about a change of identity per se subsequent to STN-DBS. The language used by many 
participants evoked a notion of an essentialist ‘core’ self, which had been suppressed by 
Parkinson’s disease and released by DBS to a varying degree. However, DBS did not appear 
to disrupt the integration of these (sometimes radical) changes into the autobiographical 
narrative of the person with Parkinson’s disease, even when viewed from the caregiver’s 
perspective and even when acknowledging the causal role of brain manipulation in 
precipitating these changes (Baylis, 2013; Schechtman, 2009). Instead, when concerns were 
expressed by participants, these were primarily in the domain of autonomy, using phrases such 
as ‘on drugs’ or ‘no circuit breaker’. Again, this language seems to reflect a perception of a 
dysfunction in the cognitive machinery of autonomous decision making, leading to the 
expression of inauthentic behaviours rather than a shift in an underlying authentic selfhood.  
 
It appears that participants (both persons with Parkinson’s disease and caregivers) who noted 
a close relationship between stimulation changes and changes in mental status were more likely 
to conclude that these symptoms were inauthentic and uncontrollable. One could speculate that 
a close temporal association emphasises the connection between psychiatric symptoms and 
brain manipulation, which makes participants more likely to externalise this relationship. It is 
also possible that neuropsychiatric symptoms arising abruptly subsequent to stimulation 
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manipulation are more likely to be of a negative valence, reflecting a more severe phenotype 
of neuropsychiatric dysfunction.   
6.7.5 Limitations 
The biological model of PM was acknowledged and may have affected data gathering and 
analysis. Furthermore, the dual clinical and investigative role of PM may have limited 
information disclosed due to concerns regarding confidentiality. We endeavoured to overcome 
the first issue by developing an investigative team with clinical and non-clinical backgrounds, 
with a spectrum of prior knowledge about the participants, in order to allow diverse 
perspectives. Participants provided constructive criticism of the clinical team, suggesting that 
they were willing to offer opinions and that PM’s dual role did not prevent frank disclosure in 
this domain. Also, over ninety percent of participants in this investigation were male. This 
reflects a bias towards male gender in those accessing DBS at this centre (seventy-eight percent 
of all participants in the recruited cohort). Previous studies of drug addiction have identified 
gender differences in the attribution of control and responsibility (Hatgis et al., 2008). Further 
research is needed to determine whether these findings are also applicable to female patients. 
 
The emergence of neuropsychiatric symptoms after STN-DBS for Parkinson’s disease is a 
complex matter, with potential contributions from non-motor progression of 
neurodegeneration, dopaminergic therapies, as well as neurostimulatory effects (Mosley and 
Marsh, 2015a). However, in this investigation, our rigorous assessment schedule (Mosley et 
al., 2018a; Mosley et al., 2018d), involving a multidisciplinary neurological and psychiatric 
evaluation, increased the likelihood that observed symptoms were attributable to stimulation 
rather than other causes. However, we acknowledge that we are unable to definitively answer 
‘the causal question’ as posed by Gilbert et al. (2018) and discussed by Pugh et al. (2018). In 
our cohort, neuropsychiatric symptoms arose alongside clinically meaningful reductions in 
motor disability. Therefore, it remains possible that observed changes in mood, cognition and 
behaviour were indirect effects resulting from an amelioration of the participant’s condition. 
We suggest that our method of specifying stimulation-dependent neuropsychiatric symptoms 
increases the likelihood of a causal relationship: i.e. onset with adjustment of stimulation and 
offset with further adjustment of stimulation and we also point to the wealth of neuroscientific 
data implicating the STN in the genesis of psychiatric symptoms (Jahanshahi et al., 2015).  
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It is also important to acknowledge that STN-DBS has been shown to be of equivalent safety 
when compared with medical therapy (Witt et al., 2008), with some surgical centres reporting 
a postoperative reduction in problematic neuropsychiatric symptoms due to the reduction in 
dopaminergic medication afforded by neurostimulation (Lhommee et al., 2012). To some 
degree this is reflected in our sample, with a change in the behavioural phenotype of 
participants 3, 5 and 10, who all had significant pre-surgical neuropsychiatric difficulties 
attributable to dopaminergic therapies.  
6.7.6 Conclusions 
In this investigation, we have shown that stimulation-dependent neuropsychiatric symptoms 
following STN-DBS are often harmful and burdensome to persons with Parkinson’s disease 
and their spousal caregivers.2 Some participants did not fully integrate the information about 
potential psychiatric harms when it was delivered to them prior to surgery and further research 
will be important to identify new ways of preparing candidates in a way that is meaningful and 
memorable. Further work examining the neural basis of these symptoms may also assist 
clinicians to improve the informed consent process and deliver more reliable predictors of 
outcome, which at present remains affected by a degree of uncertainty. 
 
There is evidence to support a causal link between stimulation and the emergence of psychiatric 
symptoms in our participants, which corresponds with existing data in the quantitative domain. 
However, many persons with Parkinson’s disease did not hold an exclusively deterministic 
view and gave justified reasons for their (or their spouse’s) behaviour that did not rely on a 
biological model. Furthermore, some participants actively sought out changes in their mental 
state that were linked to stimulation, despite identifying that their behaviour under these 
conditions was markedly different from baseline. Whereas a ‘scientific’, neurobiological 
analysis of this phenomenon has many potential benefits, including improved understanding 
of neural mechanisms, prognostication, effective therapies and a reduction in stigma 
experienced by sufferers, further work is needed to clarify whether a bias towards deterministic 
or moral explanations helps or hinders the ability of participants to manage the burden and 
harms associated with neuropsychiatric symptoms. None of our participants considered that a 
                                                
2 We acknowledge that some participants appeared to welcome or seek out changes in mental state attributable 
to neurostimulation. However, this was often later associated with harmful sequelae, e.g. person with PD 02 – 
suicide attempt; person with PD 06 – arrest and involuntary hospitalisation. 
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change in identity had been precipitated by DBS, but some perceived that their autonomy (or 
that of their spouse) had been overridden by the device. This was most common for symptoms 
with negative consequences and for those symptoms with a close temporal connection to DBS 
manipulation. For these participants, inauthentic behaviour was considered to arise from a 
dysfunction in the competencies of autonomous decision making, rather than from a shift in 
authentically-held values. We hope that the empirical data that we have provided will 
contribute to further philosophical debate in this area.  
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Chapter 7 
7 The Site of Subthalamic Stimulation is a Key Determinant of 
Neuropsychiatric Symptoms after Deep Brain Stimulation 
‘Almost like someone on drugs… It didn't get better. It just escalated. Every time they turned up the unit… she 
went up a level… You can't believe that a little bit of voltage would shift someone from there to there in that 
little bit of time.’ 
Spouse of a DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
7.1 Publication Details 
This chapter was published as: 
Mosley, P.E., Smith, D., Coyne, T., Silburn, P., Breakspear, M. & Perry, A., 2018. The site of 
stimulation moderates neuropsychiatric symptoms after subthalamic deep brain stimulation for 
Parkinson’s disease. NeuroImage: Clinical. 18, 996-1006. 
7.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, consented the participants, collected the 
quantitative data and neuroimaging, performed the neuroimaging and statistical analyses and 
wrote the manuscript. Dr Smith provided supervision in machine learning techniques. A/Prof 
Coyne and Prof Silburn implanted the DBS devices for all participants with Parkinson’s 
disease. Prof Breakspear and Dr Perry provided supervision in statistical analyses. Dr Perry 
wrote the pipeline for threshold free cluster enhancement. 
7.3 Abstract 
Deep brain stimulation of the subthalamic nucleus for Parkinson's disease is an established 
advanced therapy that addresses motor symptoms and improves quality of life. However, it has 
also been associated with neuropsychiatric symptoms such as impulsivity and hypomania. 
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When significant, these symptoms can be distressing, necessitating psychiatric intervention. 
However, a comprehensive analysis of neurocognitive and neuropsychiatric outcomes with 
reference to the site of subthalamic stimulation has not been undertaken. We examined this 
matter in a consecutive sample of sixty-four persons with Parkinson’s disease undertaking 
subthalamic deep brain stimulation. Participants were assessed with a battery of 
neuropsychiatric instruments at baseline and at repeated postoperative intervals. A psychiatrist 
identified participants with emergent, clinically-significant symptoms due to stimulation. The 
site of the active electrode contact and a simulated volume of activated tissue were evaluated 
with reference to putative limbic, associative and motor subregions of the subthalamic nucleus. 
We studied anatomical correlates of longitudinal neuropsychiatric change and delineated 
specific subthalamic regions associated with neuropsychiatric impairment. We tested the 
ability of these data to predict clinically-significant symptoms. Subthalamic stimulation within 
the right associative subregion was associated with inhibitory errors on the Excluded Letter 
Fluency test at six-weeks (p = 0.023) and thirteen-weeks postoperatively (p = 0.0017). A cluster 
of subthalamic voxels associated with inhibitory errors was identified in the right associative 
and motor subregions. At six-weeks, clinically-significant neuropsychiatric symptoms were 
associated with the distance of the active contact to the right associative subregion (p = 0.0026) 
and stimulation within the right associative subregion (p = 0.0009). At thirteen-weeks, 
clinically-significant symptoms were associated with the distance to the right (p = 0.0027) and 
left (p = 0.0084) associative subregions and stimulation within the right associative subregion 
(p = 0.0026). Discrete clusters of subthalamic voxels associated with high and low likelihood 
of postoperative neuropsychiatric symptoms were identified in ventromedial and dorsolateral 
zones, respectively. When a classifier was trained on these data, clinically-significant 
symptoms were predicted with an accuracy of 79 %. These data underscore the importance of 
accurate electrode targeting, contact selection and device programming to reduce postoperative 
neuropsychiatric impairment. The ability to predict neuropsychiatric symptoms based on 
subthalamic data may permit anticipation and prevention of these occurrences, improving 
safety and tolerability. 
7.4 Introduction 
Subthalamic deep brain stimulation (STN-DBS) is an advanced therapy for Parkinson’s disease 
that reduces motor symptoms and improves quality of life (Schuepbach et al., 2013). However, 
the relationship between DBS and the neuropsychiatric features of Parkinson’s disease is 
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complex (Mosley and Marsh, 2015a). Some individuals become more impulsive and less 
empathic after DBS, acting recklessly without foresight or concern for others. The incidence 
of this syndrome has been estimated at up to fifteen percent (Appleby et al., 2007; Daniele et 
al., 2003). Predicting those persons who will develop this behavioural syndrome is a challenge 
for the clinician, given the wide spectrum of neuropsychiatric symptoms associated with 
Parkinson’s disease (Weintraub and Burn, 2011). Furthermore, the predictive value of 
preoperative neuropsychiatric symptoms is unclear.  
 
The emergence of postoperative impulsivity may be a neurostimulatory phenomenon related 
to the computational role of the STN in behaviour. In addition to its role as a relay nucleus that 
increases the inhibitory drive of the basal ganglia, the STN is a second input station to the basal 
ganglia, receiving direct cortical projections from the frontal lobe in the ‘hyperdirect’ pathway 
(Nambu et al., 2002). Here, the STN may ‘brake’ or ‘delay’ cognitive-associative circuits in 
the basal ganglia, suppressing impulsive and potentially error-prone responding. Functional 
and structural brain imaging support the role of this pathway in motor inhibition (Aron et al., 
2007; Rae et al., 2015). Following STN-DBS, persons with Parkinson’s disease demonstrate 
failures of motor inhibition (Hershey et al., 2004), action cancellation, (Obeso et al., 2013), as 
well as showing a failure of prepotent verbal inhibition (Thobois et al., 2007; Witt et al., 2004). 
Furthermore, when faced with a difficult choice, persons with Parkinson’s disease speed rather 
than slow their decision-making after STN-DBS (Cavanagh et al., 2011; Frank et al., 2007), 
where taking more time would be an optimal response in order to make an accurate decision. 
However, impulsivity is not the only behavioural symptom that has been reported subsequent 
to STN-DBS. Previous work has identified relationship discord precipitated by indifference to 
the emotional wellbeing of the partner of the person with Parkinson’s disease (Lewis et al., 
2015; Schupbach et al., 2006). One recent investigation has suggested a role for the STN in 
object valuation, which offers a potential mechanism for these more complex changes 
(Seymour et al., 2016).  
 
The anatomy of the STN confers vulnerability to stimulation-dependent neuropsychiatric 
changes. A tripartite functional organisation of the STN into limbic, associative and motor 
subregions is suggested by primate and human studies (Haynes and Haber, 2013; Lambert et 
al., 2012), although with considerable topological overlap and without lobar boundaries 
(Alkemade and Forstmann, 2014; Lambert et al., 2015). Yet, the small size of the STN means 
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that current diffusion from a stimulating contact in the dorsolateral sensorimotor region could 
modulate subthalamic regions with greater connectivity to fronto-striatal networks implicated 
in mood, decision-making and reward. The more ventral and medial the stimulating contact, 
the more likely these circuits are to be affected by DBS. Accordingly, moving stimulation 
between active contacts in the dorsal motor and ventral limbic aspects of the nucleus can impair 
response inhibition (Hershey et al., 2010) and precipitate manic symptoms (Mallet et al., 2007). 
One investigation has examined the influence of electrode position on psychiatric outcomes in 
a sample larger than a small case series (Welter et al., 2014). Here, the depth of the active 
contact in both the right and left hemispheres, relative to the inter-commissure plane, was 
associated with postoperative hypomania. However, this investigation only included one 
formal postoperative assessment after one year, at which time only depressive symptoms were 
evaluated. Other psychiatric symptoms, including measures of impulsive responding, were not 
assessed.  
 
The locus of subthalamic stimulation has been shown to affect motor outcomes after DBS for 
Parkinson’s disease. Accurate targeting of the stimulating contact to the lateral aspect of the 
STN significantly improves motor symptoms (Wodarg et al., 2012). Recently, Akram et al. 
(2017) modelled the extent of neural tissue activation in the subthalamic region and regressed 
these against motor outcomes, delineating discrete clusters of subthalamic and peri-
subthalamic voxels associated with maximal improvement in tremor, rigidity and bradykinesia. 
These were distributed in the posterior and superior aspects of the nucleus.  
 
The aim of our investigation was to identify if the locus of subthalamic stimulation moderates 
the evolution of postoperative neuropsychiatric symptoms. Tractographic parcellation of the 
STN into motor, associative and limbic regions furnished precise information on the position 
of each electrode contact relative to these STN subregions. We simulated a volume of activated 
tissue (VAT) for each hemisphere, for each participant, at each follow up. This enabled us to 
estimate the dispersion of charge within each STN subregion at a given time, and allowed us 
to evaluate the contribution of stimulation parameters to emergent symptoms during titration. 
Finally, we applied these data to delineate STN regions significantly associated with 
neuropsychiatric impairment and tested the predictive validity of our data. Our hypotheses were 
that the position of the active electrode contact and dispersion of charge in the associative and 
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limbic regions of the STN would be significant determinants of postoperative neuropsychiatric 
symptoms in individuals with Parkinson’s disease.  
7.5 Methods 
7.5.1 Participants 
Sixty-four participants were consecutively recruited at the Asia-Pacific Centre for 
Neuromodulation between 2013-2017, during the assessment of eligibility for STN-DBS. The 
diagnosis of Parkinson’s disease was confirmed according to the United Kingdom Queens 
Square Brain Bank criteria (Hughes et al., 1992). The laterality of disease onset and the Hoehn 
and Yahr stage (Hoehn and Yahr, 1967) at operation was recorded. The Parkinson’s disease 
subtype (tremor-dominant, akinetic-rigid, mixed-type) was established based on an analysis of 
the dominant symptoms elicited during the Unified Parkinson’s Disease Rating Scale (UPDRS) 
Part III Motor Examination, as described in Spiegel et al (2007). Candidates with cognitive 
impairment were excluded, as defined by a Mini Mental State Examination Score (MMSE) of 
25 or less or a clinical diagnosis of Parkinson’s disease dementia. The latter was defined 
according to published Movement Disorder Society criteria (Emre et al., 2007). All participants 
completed a psychiatric and cognitive evaluation prior to surgery. 
7.5.2 Image Acquisition 
A preoperative T1-weighted MPRAGE and a T2-weighted FLAIR sequence were acquired. 
For participants 1-26, this took place using a 3T GE Signa Hdx with a 32-channel head coil at 
St Andrews War Memorial Hospital. The acquisition parameters were as follows: T1: 1 mm3 
voxel-resolution, TR = 6.13 ms, TE = 2.01 ms, flip angle = 15°, matrix size = 256 × 256, FOV 
= 256 × 256 × 166; T2: 1 x 1 x 2 mm voxel-resolution, TR = 9502 ms, TE = 120.54 ms, flip 
angle = 90°, matrix size = 256 × 256, FOV = 256 × 256 × 75. Participants 27-64 were scanned 
using a 3T Siemens Prisma, with a 64-channel head coil at the Herston Imaging Research 
Facility. The acquisition parameters were as follows: T1, 1 mm3 voxel-resolution, TR = 2000 
ms, TE = 2.38 ms, flip angle = 9°, matrix size = 256 × 256, FOV = 256 × 256 × 192; T2, 1 x 1 
x 2 mm voxel-resolution, TR = 9500 ms, TE = 122.0 ms, flip angle = 120°, matrix size = 256 
× 256, FOV = 256 × 256 × 70. Postoperative CT images for all participants were acquired on 
a Siemens Intevo, with a resolution of 0.5mm3.  
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7.5.3 Surgery and Clinical Follow-Up 
Bilateral implantation of Medtronic 3389 (n = 48) or Boston Vercise (n = 16) electrodes took 
place in a single-stage procedure using a Leksell stereotactic apparatus, with the STN having 
been identified as a midbrain structure on Fluid Attenuation Inversion Recovery (FLAIR) 
imaging. Intraoperative microelectrode recordings (MER) were employed to establish 
localisation within the STN and intraoperative test stimulation was performed. A CT scan 
confirmed satisfactory postoperative lead placement. Contact selection for initial stimulation 
was based upon MER signals, with titration and evaluation of stimulation over the following 
week as an inpatient until motor symptoms were satisfactorily treated without adverse effects. 
All implanted electrode contacts were of the ring rather than segmented configuration and thus 
no current-steering was applied. Post-discharge, participants returned to the movement 
disorders clinic for further neurological and psychiatric evaluation, with further DBS 
manipulation according to a set schedule of visits. The predominant criterion for DBS 
manipulation at each visit was manifest motor symptoms of Parkinson’s disease. However, if 
the patient, caregiver or clinician detected neuropsychiatric symptoms (such as mood elevation, 
disinhibition or irritability) then a psychiatric review was initiated. Manipulation of the DBS 
device occurred immediately if neuropsychiatric symptoms were determined to be stimulation-
related and clinically-significant (e.g. precipitating interpersonal impairment). All participants 
received routine psychiatric follow up as part of multidisciplinary care.  
7.5.4 Neuropsychiatric Outcomes 
7.5.4.1 Neuropsychiatric Assessments 
Assessments took place prior to DBS and subsequently at two-weeks, six-weeks, thirteen-
weeks and twenty-six-weeks postoperatively, using the same battery of participant, caregiver 
and clinician-rated instruments, described in Mosley et al. (2017a). This investigation focussed 
on neuropsychiatric symptoms identified as significant drivers of caregiver burden in a 
multivariate analysis (Mosley et al., 2017a). Briefly, these included measures of impulsivity: 
the Barratt Impulsiveness Scale 11 (BIS) (Patton et al., 1995); the Questionnaire for Impulsive-
Compulsive disorders in PD Rating Scale (QUIP-RS) (Weintraub et al., 2012); the Excluded 
Letter Fluency task (ELF) (Shores et al., 2006); the Hayling test (Burgess et al., 1997); 
empathy: the Empathy Quotient (EQ) (Baron-Cohen and Wheelwright, 2004); and depression: 
the Beck Depression Inventory II (BDI) (Beck et al., 1961). In addition, a modified version of 
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the BIS and EQ (caregiver-rated BIS and caregiver-rated EQ) assessed these behaviours from 
the perspective of the caregiver, given that participant and caregiver ratings may be discrepant 
(Lewis et al., 2014).  
 
Furthermore, at each visit motor symptoms were assessed with the UPDRS Part III motor 
examination. Dopaminergic medication was converted to a levodopa-equivalent daily dose 
(LEDD) value (Evans et al., 2004). DBS parameters such as active contacts, amplitude, 
pulsewidth, frequency and impedance were recorded. Participants with Boston electrodes (n = 
16) had their stimulation amplitude converted from milliamps to volts using impedance 
measurements at the active contact. Participants were ‘on’ medication and stimulation for all 
assessments, in order to provide a naturalistic evaluation of symptom evolution.  
7.5.4.2 Neuropsychiatric ‘Caseness’ 
In addition to the above instruments, participants were assigned to the category ‘case’ or ‘non-
case’ depending on whether they developed clinically-significant neuropsychiatric symptoms 
attributable to DBS, necessitating device manipulation (hereafter referred to as ‘caseness’). 
This category was operationalised as follows: a participant was brought to the attention of the 
psychiatrist (who had assessed all participants at baseline) through self-referral, or via a relative 
or a clinician with concerns about the participant’s mood or behaviour. The psychiatrist 
conducted a semi-structured diagnostic interview and mental state examination with attention 
to euphoria, irritability, disinhibition, impulsivity, compulsivity and empathy. If the 
psychiatrist considered that a stimulation-related neuropsychiatric presentation was likely and 
was causing clinically-significant impairment or distress, the neurologist adjusted the 
participant’s DBS settings by moving to a new active contact or reducing the amplitude of 
stimulation. The psychiatrist then repeated the clinical assessment and sought collateral 
information from the participant’s relatives. If the neuropsychiatric symptoms responded 
immediately to device manipulation then the participant was defined as a case.  
 
A timeline displaying the sequence of assessments is presented in Figure 7.1A.  
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A: Timeline of participant assessments during the investigation. All participants underwent a multidisciplinary assessment at 
baseline prior to DBS, which included a psychiatric assessment. Participants also undertook a battery of neuropsychiatric 
instruments prior to DBS and at four postoperative intervals. Between postoperative assessments, participants received 
standard neurology and psychiatry follow up, with surveillance for the evolution of clinically-significant neuropsychiatric 
symptoms attributable to DBS. The interval of interest for this investigation was between the assessments at six and thirteen-
weeks post-DBS. B: Statistical flowchart illustrating the modelling of candidate neuropsychiatric and anatomical variables, 
controlling for disease and demographic factors, following by the identification of subthalamic voxel clusters significantly 
associated with neuropsychiatric impairment.  
 
7.5.5 Image Processing 
Preoperative MPRAGE and FLAIR images were co-registered with the postoperative CT scan 
using an affine transformation within FSL (FLIRT version 6.0, (Smith et al., 2004)). Each co-
registration was manually checked for accuracy (Figure 7.2A). The co-registered acquisitions 
were spatially normalized into ICBM_2009b nonlinear asymmetric space using a fast 
diffeomorphic image registration algorithm (DARTEL) as implemented in SPM12 (Ashburner, 
2007) (Figure 7.2B and 7.2C). Using the Lead-DBS toolbox (version 1.6.4.2 (Horn and Kuhn, 
2015)), (http://www.lead-dbs.org), electrodes were manually localised and corrected for 
Figure 7.1 | Timelines for Assessment and Analysis 
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brainshift by applying a refined affine transform calculated between pre- and postoperative 
acquisitions (Figure 7.2E). A volume of activated tissue (VAT), representing the dispersion of 
electrical charge in neural tissue, was estimated based upon individualised stimulation 
parameters (Madler and Coenen, 2012) at each assessment interval (Figure 7.2F). 
 
The spatial position of each electrode contact was evaluated with reference to a tractrographic 
parcellation of the STN into limbic, associative and motor subregions (Accolla et al., 2014). 
For both hemispheres we calculated: i) the distance of the electrode contact to the centroid of 
each STN subregion; ii) the distance to the nearest voxel of that volume; and iii) the extent of 
each subregion volume occupied by each participant’s simulated VAT. These variables are 
detailed in Table 7.1.  
 
 
Pipeline for the identification of electrode contact points and volume of activated tissue (VAT). A: MPRAGE, FLAIR and CT 
images were co-registered and manually checked for accuracy, with an accurately-sited electrode indexed in the right STN. B 
and C: Spatial normalisation into common template space using DARTEL. D: Coronal view of the active electrode contact 
(asterisk) with reference to the limbic (yellow), associative (blue) and motor (maroon) subregions of the STN. E: Axial view 
of both electrode trajectories with reference to the STN and its subregions. Within each STN limbic = yellow, associative = 
blue and motor = maroon subregions. F: Oblique sagittal view with simulated VAT in each hemisphere (red sphere). 
 
Figure 7.2  | Image Processing Pipeline 
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7.5.6 Statistical Analysis 
The emphasis of this investigation was on emergent neuropsychiatric symptoms attributable to 
subthalamic stimulation. By week twenty-six, any emergent neuropsychiatric symptoms linked 
to stimulation had attenuated following clinical intervention. No participants in this cohort 
became a ‘case’ between the thirteen and twenty-six-week assessment. The assessment at week 
two was discounted as residual lesion effects from electrode implantation could not be 
excluded. Therefore, the focus of this analysis was the assessments at six and thirteen-weeks, 
relative to baseline. 
 
At each assessment interval, data was z-normalised to account for the heterogeneity of and 
variance in assessment instruments. To calculate the rates of change for each neuropsychiatric 
outcome, normalized scores at baseline were subtracted from each follow-up assessment. 
Across the complete data set, less than 0.03 % was missing for any variable. Missing data was 
inferred using the pooled results of 50 iterations of longitudinal imputation by classification 
and regression trees, employing Gibbs sampling using mice in the R software environment. (R 
Core Team, 2014; van Buuren and Groothuis-Oudshoorn, 2011). The distribution of original 
and imputed data was checked for plausibility (Figure 7.3). At baseline and during follow up, 
the demographic and phenotypic characteristics of those participants who would become 
postoperative cases were contrasted with non-cases. Data with a non-Gaussian distribution was 
treated with the Kruskal-Wallis test. The Chi-squared test was employed for categorical 
variables. Prior to variable selection, a repeated-measures analysis of variance (ANOVA) was 
first employed to identify significant group-level longitudinal changes in neuropsychiatric 
assessment data. When multiple comparisons were undertaken, reported p-values were 
adjusted using the Benjamini and Hochberg method (1995) to control for the false discovery 
rate, with ! = 0.05.  
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The distribution of original and imputed data is compared to ensure plausible values are generated. The distribution of the 
original, non-missing data for each variable is displayed in blue and the results of five datasets of imputed values (each 
comprised of fifty iterations of imputation) are overlaid in red. The distribution of each imputed dataset is similar to the 
original, non-missing data, suggesting that imputed values are plausible. 
 
7.5.6.1 Variable Selection and Modelling 
To reduce the dimensionality of the dataset, comprising of many candidate anatomical and 
neuropsychiatric covariates, resolve unknown dependencies and remove redundant variables, 
a variable selection and regularisation algorithm (the Least Absolute Shrinkage and Selection 
Operator: LASSO) was employed to identify the combination of anatomical variables with the 
best predictive value for each neuropsychiatric outcome (Friedman et al., 2010). A 
conservative one-standard-deviation rule was chosen for the regularisation parameter (l) to 
protect against overfitting (Hastie et al., 2009). A binary model was employed for binary 
outcomes, a Gaussian model for parametric data and a Poisson model for nonparametric data.  
 
Figure 7.3 | Imputation of Missing Data 
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Subsequently, neuropsychiatric variables and their anatomical predictors as identified from the 
LASSO were modelled in a general linear model, with the model family defined by the nature 
of the dependent variable. Demographic and disease-related factors, including change in 
LEDD, were also entered as covariates. These analyses also took place in the R software 
environment, using glmnet for optimisation and glm for general linear modelling. A schematic 
of these steps is presented in Figure 7.1B. Scanning site was included as a covariate for all 
significant effects. 
 
Table 7.1 | Summary of Neuropsychiatric, Anatomical and Control Variables  
Neuropsychiatric Outcomes Anatomical Variables GLM Co-Variates 
Case versus Non-Case 
 
Patient-Rated BIS 
 
Caregiver-Rated BIS 
 
Patient-Rated EQ 
 
Caregiver-Rated EQ 
 
QUIP-RS 
Including subscales (Sex, 
Gambling, Eating etc.) 
 
Beck Depression Inventory 
 
Hayling Test 
Including: Category A & B 
Errors, AB Error Score 
 
ELF Task 
Rule Violations 
Distance to nearest voxel in each STN subregion: 
 
Distance to centroid of each STN subregion: 
 
Extent of each STN subregion occupied by simulated 
VAT: 
 
Ratio of simulated VAT: 
Right Associative:Motor STN 
Left Associative:Motor STN 
Age 
 
Gender 
 
Hoehn & Yahr Stage 
 
Clinical Subtype 
 
Years Since Diagnosis 
 
LEDD 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = Empathy Quotient, GLM = General 
Linear Model, LEDD = Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in 
Parkinson’s Disease Rating Scale, STN = Subthalamic Nucleus, VAT =- Volume of Activated Tissue 
 
7.5.6.2 Subthalamic Voxels Associated with Neuropsychiatric Symptoms 
In order to extend the findings from the general linear model, spatial clusters of subthalamic 
voxels associated with the neuropsychiatric outcomes were identified using threshold-free 
cluster-enhancement (tcfe) (Smith and Nichols, 2009). Here, hemispheric VAT’s for all 
participants at the intervals of interest were first concatenated into a 4-dimensional image and 
overlapping voxels within this image were thresholded to verify that the highest probability of 
stimulation was within the atlas-defined STN (Accolla et al., 2014). Each voxel within this 
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defined STN mask was entered into a general linear model against the demeaned 
neuropsychiatric outcome scores, with the tfce used as the test-statistic. Using FSL Randomise 
(Winkler et al., 2014), nonparametric permutation inference was then conducted upon each 
voxel to control for family-wise error (FWE), employing 5000 permutations to build up the 
null distribution. Voxels significantly associated with the neuropsychiatric outcome of interest 
were identified by α = 0.05 (FWE-corrected). FSL Cluster was employed for cluster-based 
inference and local maxima extraction. 
7.5.6.3 Classification of Clinically-Significant Symptoms 
Finally, the ability of these anatomical data to predict ‘cases’ at each interval was tested with 
a classifier employing an ensemble of weak-learners. In this Gradient Boosting method 
(Friedman, 2002), the cohort was split into a discrete training (75 %) and validation (25 %) set, 
employing 1000 trees with 10-fold cross-validation (R package gbm).  
7.6 Results 
7.6.1 Participant Characteristics 
The sample was predominantly male (18 females), predominantly middle-aged (mean age 61.7) 
with most being classified as the akinetic-rigid (37.5 %) or mixed phenotype (43.8 %). Most 
participants had moderate motor symptoms at baseline despite being ‘on’ medication during 
UPDRS assessment. Summary statistics for these and selected neuropsychiatric variables are 
presented in Table 7.2.  
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Table 7.2 | Demographic and Clinical Characteristics of the Study Cohort at Baseline 
Categorical Variable Total (n=64) 
Gender n % total 
Male 46 71.9 
Female 18 28.1 
Clinical Subtype n % total 
Akinetic-Rigid 24 37.5 
Mixed 28 43.8 
Tremor 12 18.8 
Continuous Variable Mean (SD), Median (Range) 
Age (Years) 61.7 (±9.3), 
64 (35 - 76) 
Hoehn & Yahr Stage 2.7 (±0.5), 
2.5 (1.5 - 4) 
Years Since Diagnosis 9.0 (±5.2), 
7 (1 - 23) 
Levodopa equiv. daily dose 1077.3 (±543.1), 
1008 (0 - 3450) 
Patient-Rated BIS 60.6 (±8.3), 
60 (43 - 87) 
Caregiver-Rated BIS 59.4 (±11.6), 
59 (40 - 90) 
Patient-Rated EQ 42.6 (±12.2), 
42 (16 - 68) 
Caregiver-Rated EQ 38.9 (±14.0), 
42 (11 - 64) 
QUIP-RS Total 20.5 (±15.0), 
18 (0 - 63) 
Beck Depression Inventory 11.1 (±5.1) 
11 (1 - 22) 
Hayling AB Error Score 10.1 (±11.2), 
6 (0 - 45) 
ELF Rule Violations 8.8 (±5.4), 
8 (0 - 24) 
UPDRS Part III Motor 37.0 (±16.6), 
36 (10 - 91) 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = Empathy Quotient, LEDD = 
Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
Rating Scale 
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7.6.2 Subthalamic Stimulation 
Analysis of the concatenated VAT volumes for the cohort demonstrated that the highest 
probability of stimulation was in the dorsolateral (motor) aspect of the STN, consistent with 
atlas-defined boundaries (Figure 7.4). The only variable demonstrating a significant change 
between assessment intervals was an expected increase in stimulation amplitude (right 
hemisphere: 95 % CI 0.17-0.58, p = 0.0005, left hemisphere: 95 % CI 0.17-0.60, p = 0.0005; 
Table 7.3). However, at each interval, some anatomical variables were significantly different 
between right and left hemispheres. At six and thirteen weeks the active contact was closer to 
the centroid of the right associative subregion (six weeks: 95 % CI 0.53-1.40 mm, p = 3.09 x 
10-4, thirteen weeks: 95 % CI 0.34-1.17 mm, p = 0.006), the nearest voxel of the right 
associative subregion (six weeks: 95 % CI 0.30-1.05 mm, p = 0.0016, thirteen weeks: 95 % CI 
0.14-0.91 mm, p = 0.026) and the VAT occupation of the associative subregion was greater in 
the right hemisphere (six weeks: 95 % CI 5.89-19.99 %, p = 0.0016, thirteen weeks: 95 % CI 
3.17-18.2 %, p = 0.02). At six weeks, the active contact was also closer to the centroid of the 
right limbic subregion (95 % CI 0.21-1.21 mm, p = 0.0016). 
  
Chapter 7  135 
 
 
  
Hemispheric VATs for each participant were concatenated and thresholded to identify the highest frequency of overlapping 
voxels at 6-weeks (A and B) and 13-weeks (C and D). The subthalamic atlas is overlaid on the BigBrain atlas (Amunts et al., 
2013). Within each STN limbic = yellow, associative = blue and motor = maroon subregions. A and C: Top 25% of overlapping 
voxels in the axial plane. B and D: Top 25% of overlapping voxels in the coronal plane.  
  
Figure 7.4 | Stimulation Predominates in the Dorsolateral Aspect of the STN Across the Cohort 
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Table 7.3 | Summary Statistics for Anatomical Variables at the 6-week and 13-week Postoperative Assessment Intervals 
All reported p-values have been adjusted for multiple comparisons using the Benjamini and Hochberg technique (1995) with ! = 0.05. Significance: *** p<0.001 ** p<0.01 * p<0.05.  
 
Anatomical Variable Mean (SD), Median (Range) 
6-weeks 13-weeks 
Right Hemisphere Left Hemisphere Right Hemisphere Left Hemisphere 
Stimulation Amplitude (Volts) 2.05 (±0.58), 
1.95 (1.1 - 3.4) 
2.00 (±0.59), 
1.90 (1.0 - 4.1) 
2.42 (±0.59), 
2.4 (1.5 - 3.6) 
2.39 (±0.64), 
2.45 (0.8 - 4.1) 
t-stat = 0.48 
p-value = 0.6 
t-stat = 0.32 
p-value = 0.8 
Distance to nearest voxel: 
Motor STN (mm) 
0.71 (±0.72), 
0.42 (0.015 - 2.61) 
0.67 (±0.74), 
0.30 (0.008 - 2.44) 
0.89 (±0.92), 
0.49 (0.015 - 3.41) 
0.79 (±0.72), 
0.61 (0.008 - 2.27) 
t-stat = 0.29 
p-value = 0.8 
t-stat = 0.5 
p-value = 0.79 
Distance to nearest voxel: 
Associative STN (mm) 
0.94 (±0.94), 
0.63 (0.019 - 4.14) 
1.61 (±1.20), 
1.44 (0.022 - 5.32) 
1.07 (±1.00), 
0.72 (0.023 - 4.14) 
1.60 (±1.18), 
1.32 (0.036 - 5.32) 
t-stat = 3.53 
p-value = 0.0016 ** 
t-stat = 2.73 
p-value = 0.026 * 
Distance to nearest voxel: 
Limbic STN (mm) 
3.04 (±1.41), 
3.11 (0.17 - 6.41) 
3.57 (±1.46), 
3.55 (0.51 - 7.52) 
3.46 (±1.43), 
3.34 (0.17 - 6.41) 
3.92 (±1.44), 
3.80 (0.68 - 6.47) 
t-stat = 2.09 
p-value = 0.06 
t-stat = 1.79 
p-value = 0.16 
Distance to centroid: Motor 
STN (mm) 
2.90 (±1.10), 
2.84 (0.90 - 5.00) 
2.59 (±1.12), 
2.84 (0.26 - 6.61) 
3.16 (±1.26), 
3.11 (0.86 - 6.57) 
2.80 (±1.17), 
2.84 (0.24 - 5.17) 
t-stat = 1.62 
p-value = 0.1 
t-stat = 1.68 
p-value = 0.16 
Distance to centroid: 
Associative STN (mm) 
3.13 (±1.25), 
2.96 (0.64 - 6.08) 
4.09 (±1.25), 
3.95 (1.78 - 7.69) 
3.33 (±1.16), 
3.11 (1.16 - 6.09) 
4.09 (±1.22), 
3.92 (1.72 - 7.69) 
t-stat = 4.35 
p-value = 3.09 x 10-4 *** 
t-stat = 3.59 
p-value = 0.006 ** 
Distance to centroid: Limbic 
STN (mm) 
5.11 (±1.49), 
5.07 (1.87 - 8.46) 
5.83 (±1.36), 
5.86 (3.27 - 9.40) 
5.45 (±1.46), 
5.26 (1.84 - 8.45) 
6.04 (±1.33), 
6.24 (3.47 - 8.46) 
t-stat = 2.84 
p-value = 0.0016 ** 
t-stat = 2.38 
p-value = 0.06  
VAT overlap: Motor STN (%) 31.2 (±23.1), 
27.2 (0.48 - 91.0) 
33.8 (±20.2), 
34.8 (0 - 74.2) 
33.0 (±24.9), 
30.5 (0 - 91.0) 
36.3 (±23.6), 
34.6 (0.24 - 80.8) 
t-stat = 0.67 
p-value = 0.6 
t-stat = 0.79 
p-value = 0.4 
VAT overlap: Associative STN 
(%) 
27.7 (±23.0), 
23.1 (0 - 86.2) 
14.8 (±16.8), 
10.0 (0 - 77.4) 
29.4 (±23.1), 
25.5 (0 - 81.2) 
18.7 (±19.8), 
10.8 (0 - 76.9) 
t-stat = 3.64 
p-value = 0.0016 ** 
t-stat = 2.82 
p-value = 0.02 * 
VAT overlap: Limbic STN 
(%) 
6.13 (±15.9), 
0 (0 - 91.7) 
3.09(±7.3), 
0 (0 - 31.5) 
5.42 (±16.0), 
0 (0 - 97.9) 
3.11 (±7.7), 
0 (0 - 35.4) 
t-stat = 1.39 
p-value = 0.2 
t-stat = 1.04 
p-value = 0.4 
Ratio: Associative-Motor VAT 
overlap 
2.08 (±3.67), 
0.83 (0.017 - 17.3) 
0.99 (±3.48), 
0.36 (0.016 - 27.9) 
2.70 (±7.09), 
0.98 (0.017 - 47.4) 
1.10 (±3.34), 
0.43 (0.019 - 26.3) 
t-stat = 1.73 
p-value = 0.09 
t-stat = 1.63 
p-value = 0.1 
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7.6.3 Neuropsychiatric Outcomes 
7.6.3.1 Assessment Data 
A repeated-measures ANOVA was employed to identify group-mean change amongst 
variables of interest across the chosen assessment intervals (baseline, six weeks and thirteen 
weeks). As expected, there was a significant decrease in motor symptoms (F = 10.38, p = 3.17 
x 10-4) and dopaminergic medication use (F = 79.59, p = 2.4 x 10-15) across the cohort. 
Controlling for age, gender, clinical subtype and dopaminergic medication use, this decrease 
in motor symptoms was related to the extent of the right subthalamic motor subregion occupied 
by the simulated VAT at six weeks (p = 0.029).  At thirteen weeks, by which time dopaminergic 
medication had been significantly reduced, raw scores on the UPDRS part III motor 
examination were also significantly associated with this anatomical variable (p = 0.0098). 
There were no other significant cohort-level longitudinal changes in neuropsychiatric variables 
that survived correction for false discovery rate (Table 7.4).  
 
Table 7.4 | Repeated-Measures ANOVA for Neuropsychiatric and Motor Outcomes Across Assessment Intervals  
All reported p-values have been adjusted for multiple comparisons using the Benjamini and Hochberg technique (1995) with ! = 0.05. Significance: *** p<0.001 ** p<0.01 * p<0.05. 
Outcome Measure F p 
Patient-Rated BIS 0.69 0.67 
Caregiver-Rated BIS 0.94 0.62 
Patient-Rated EQ 0.053 (decrease) 0.95 
Caregiver-Rated EQ 0.90 (decrease) 0.62 
QUIP-RS Total 1.20 0.6 
Beck Depression Inventory 4.23 (decrease) 0.064 
Hayling Category A Errors 0.29 0.9 
Hayling Category B Errors 1.3 0.6 
Hayling AB Error Score 1.24 0.6 
ELF Rule Violations 0.16 0.94 
LEDD 79.59 (decrease) 2.4 x 10-15 *** 
UPDRS Part III Motor 10.38 (decrease) 3.17 x 10-4 *** 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = Empathy Quotient, LEDD = 
Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
Rating Scale 
 
We next sought to identify anatomical variables that were predictive of individual variation in 
neuropsychiatric outcomes at follow-up assessments, as indexed by changes in scores from 
baseline. For each participant, standardised (z-scored) change values from baseline were 
calculated for each neuropsychiatric variable. These change scores were entered into a variable 
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selection and optimisation algorithm to identify anatomical variables of interest. These 
anatomical variables were then tested in a general linear model, controlling for relevant disease 
and demographic factors. Greater ELF Rule Violations at both follow-up assessments were 
predicted by the extent to which the simulated VAT occupied the right associative STN 
subregion. When controlling for clinical and demographic factors, increased ELF rule 
violations were observed to be related to greater VAT overlap for the right associative STN 
subregion at both six (t = 2.35, p = 0.023) and thirteen weeks (t = 3.3, p = 0.0017) (Table 7.5). 
The variable selection algorithm did not identify predictive anatomical variables for the other 
neuropsychiatric outcomes tested.  
 
Table 7.5 | Modelling of Anatomical Variables Relating to Neuropsychiatric Assessment Data 
Significance: *** p<0.001 ** p<0.01 * p<0.05  
 
ELF Rule 
Violations 
Anatomical Variables after 
Optimisation 
LASSO Coefficients (Fitted) General Linear Model 1 
Week 6 VAT Overlap: Right 
Associative STN 
Intercept = -0.65 
Coefficient = 0.0046 
t-stat = 2.349 
p-value = 0.023* 
Week 13 VAT Overlap: Right 
Associative STN 
Intercept = -0.087 
Coefficient = 0.0030 
t-stat = 3.30 
p-value = 0.0017** 
 
1 Controlled for age, gender, LEDD, clinical subtype, years since diagnosis 
 
These findings were extended by identifying clusters of STN voxels significantly associated 
with ELF inhibitory errors. At both six and thirteen weeks, clusters of subthalamic voxels in 
the right motor, as well as in the associative subregion, were significantly associated with an 
increase in inhibitory failure (p < 0.05, FWE-corrected) (Figure 7.5). Cluster statistics are 
presented in Supplementary Table 7.9. Thresholded statistical maps (extracted with FSL 
randomise) corresponding to the significant cluster-based inferences of change in inhibitory 
errors are provided for download (https://doi.org/10.1016/j.nicl.2018.03.009). 
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Within each STN limbic = yellow, associative = blue and motor = maroon subregions. At 6-weeks, a small cluster of FWE-
corrected subthalamic voxels significantly associated with ELF rule violations is observed in the right motor subregion (pink). 
At 13-weeks this cluster is larger and predominates in the right associative subregion, extending into the right motor subregion 
(blue). A: Axial view at 6-weeks, B: oblique view at 13-weeks, C: axial view at 13-weeks, D: coronal view at 13-weeks.  
 
7.6.3.2 Clinical Cases 
A total of twenty-six participants were identified as cases based on an operationalised 
assessment schedule by a psychiatrist (i.e. developed clinically-significant, stimulation-
dependent changes in mood, affect and behaviour) during postoperative follow up. The 
characteristics of cases and non-cases were compared at baseline, six weeks and thirteen weeks 
(Supplementary Tables 7.10-7.12). At baseline, in all demographic, disease-related and 
neuropsychiatric variables, there was no significant difference between groups (summarised in 
Supplementary Table 7.10). At the six week and thirteen week assessments, there were no 
significant differences between cases and non-cases amongst the neuropsychiatric assessment 
data (summarised in Supplementary tables 7.11 and 7.12). There were also no significant 
Figure 7.5 | Clusters of STN Voxels in the Right Associative and Motor Subregions Associated with Inhibitory Deficits 
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differences between groups in stimulation amplitude at either interval (left STN: p = 0.54 at 
six weeks and p = 0.60 at thirteen weeks; right STN: p = 0.29 at six-weeks and p = 0.93 at 
thirteen weeks).  
 
The factor ‘case’ versus ‘non-case’ was entered into a variable selection and optimisation 
algorithm to identify anatomical variables of interest. Again, these anatomical variables were 
tested in a general linear model, controlling for relevant disease and demographic factors. 
Anatomical variables with explanatory power were identified for caseness at both the six week 
and the thirteen week assessments. These then also proved highly significant when controlling 
for clinical and demographic covariates (Table 7.6). At six weeks, developing clinically-
significant symptoms was significantly associated with stimulation at a closer distance to the 
nearest voxel of the right associative STN subregion (z = -3.0, p = 0.0026), as well as with 
greater VAT overlap within this subregion (z = 3.31, p = 0.0009). At thirteen weeks, caseness 
was significantly associated with stimulation at a closer distance to the centroid of the right (z 
= -3.0, p = 0.0027) and left (z = -2.63, p = 0.0084) associative STN subregions, as well as with 
greater occupation of the right associative subregion by the simulated VAT (z = 3.0, p = 
0.0026).  
 
Table 7.6 | Modelling of Anatomical Variables Relating to Clinical Caseness after Subthalamic DBS 
Significance: *** p<0.001 ** p<0.01 * p<0.05  
Clinical Cases Anatomical Variables after 
Optimisation 
LASSO Coefficients (Fitted) General Linear Model 1 
Week 6 Distance: Right Associative 
STN Voxel 
Intercept = -0.72 
Coefficient = -0.11 
z-value = -3.00 
p-value = 0.0026** 
VAT Overlap: Right 
Associative STN 
Intercept = -0.72 
Coefficient = 0.016 
z-value = 3.31 
p-value = 0.0009*** 
Week 13 Distance: Right Associative 
STN Centroid 
Intercept = 0.19 
Coefficient = -0.29 
z-value = -3.00 
p-value = 0.0027** 
Distance: Left Associative 
STN Centroid 
Intercept = 0.19 
Coefficient = -0.049 
z-value = -2.63 
p-value = 0.0084** 
VAT Overlap: Right 
Associative STN 
Intercept = 0.19 
Coefficient = 0.0046 
z-value = 3.00 
p-value = 0.0026** 
 
1 Controlled for age, gender, LEDD, clinical subtype, years since diagnosis 
 
Clinical details of all identified cases are presented in Table 7.7, including the stimulation 
manipulation undertaken to remit symptoms. The occupation of the right associative STN 
subregion by the simulated VAT is contrasted at presentation and following stimulation 
manipulation. 
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Table 7.7 | Clinical Details of Identified Neuropsychiatric Cases 
ID Presenting Symptoms DBS Manipulation  Right associative 
STN occupied by 
VAT (%) Pre 
Right associative 
STN occupied by 
VAT (%) Post 
2 Irritability, reduced need for sleep, erratic 
driving, compulsive eating 
Amplitude in right STN electrode 
reduced 
46.39 66.74 
5 Irritability, compulsive spending (real-
estate), marital discord 
Active contact on both electrodes 
moved dorsally 
28.23 18.81 
6 Irritability, psychomotor agitation, rapid 
speech, marital discord 
Active contact on both electrodes 
moved dorsally 
22.32 2.62 
7 Irritability, emotional lability Amplitude in right STN electrode 
reduced 
53.83 53.61 
8 Hypersexuality, marital breakdown Active contact on both electrodes 
moved dorsally 
31.07 21.66 
9 Hypersexuality, reckless decisions (tried to 
open a nightclub), marital breakdown 
Amplitude in both electrodes reduced 33.70 16.19 
12 Irritability, psychomotor agitation Active contact on both electrodes 
moved dorsally & amplitude reduced 
43.54 4.60 
14 Mixed affective state with mood elevation, 
agitation, irritability & suicide attempt 
Active contact on both electrodes 
moved dorsally 
15.75 3.72 
15 Hypersexuality, verbal disinhibition & 
argumentativeness, marital breakdown 
Amplitude in both electrodes reduced 73.74 64.11 
17 Psychomotor agitation, reduced need for 
sleep, racing thoughts 
Active contact on both electrodes 
moved dorsally & amplitude reduced 
81.18 33.04 
18 Compulsive hobbyism (woodwork), 
reduced need for sleep, suicidal thoughts 
Active contact on both electrodes 
moved dorsally 
68.27 11.60 
23 Hypersexuality, marital breakdown Active contact on both electrodes 
moved dorsally 
68.05 11.59 
26 Verbal disinhibition, marital discord Active contact on both electrodes 
moved dorsally 
93.43 43.76 
28 Euphoria, uncharacteristic use of expletives Active contact on both electrodes 
moved dorsally 
73.96 71.77 
41 Euphoria, hypersexuality, loss of empathy, 
rapid speech, verbal disinhibition, marital 
discord 
Active contact on both electrodes 
moved dorsally & amplitude reduced 
31.94 13.34 
42 Irritability, hypersexuality, rapid speech, 
marital breakdown 
Active contact on both electrodes 
moved dorsally & amplitude reduced 
27.57 4.15 
47 Irritability, hypersexuality, distractibility, 
marital breakdown 
Amplitude in both electrodes reduced 42.23 23.63 
48 Reckless decision making (real-estate), loss 
of empathy, marital discord 
Active contact on right STN electrode 
moved dorsally & amplitude reduced 
11.59 19.47 
52 Irritability, compulsive spending (art) Amplitude in both electrodes reduced 43.32 23.19 
53 Irritability, verbal disinhibition, marital 
discord 
Amplitude in both electrodes reduced 46.82 28.88 
55 Irritability, psychomotor agitation, reduced 
need for sleep, rapid speech, aggression 
Active contact on right STN electrode 
moved dorsally 
56.45 3.93 
56 Irritability, hypersexuality Active contact on right STN electrode 
moved dorsally 
26.25 31.50 
57 Irritability, compulsive shopping (second-
hand goods), marital breakdown 
Active contact on both electrodes 
moved dorsally 
66.73 31.72 
60 Euphoria, left spouse for a new relationship Active contact on right STN electrode 
moved dorsally 
63.01 42.23 
61 Euphoria, irritability Active contact on right STN electrode 
moved dorsally 
26.03 0.65 
62 Irritability, psychomotor activation, 
reduced need for sleep 
Active contact on right STN electrode 
moved dorsally & amplitude reduced 
38.29 28.22 
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For each case, overlap of the left and right associative subregion by the simulated VAT was 
calculated pre- and post-intervention and tested for significant differences. This was repeated 
for the distance of the active electrode contact to the centroid of the associative subregion. 
Neuropsychiatric cases with active symptoms had a significantly greater volume of the right 
associative subthalamic subregion occupied by the simulated VAT than after remission of 
symptoms (95 % CI 8.98-32.48 %, t = 3.54, p = 0.00087). Likewise, neuropsychiatric cases 
with active symptoms had an active electrode contact significantly closer to the centroid of the 
right associative subthalamic subregion than after stimulation manipulation and remission of 
symptoms (95 % CI 0.045-1.24 mm, t = 2.17, p = 0.036), although this finding did not survive 
FDR correction. Interestingly, these findings were not replicated in the left STN (p = 0.15 for 
VAT overlap of the left associative subregion and p = 0.28 for distance to the left associative 
centroid).  
7.6.4 Predicting Caseness from Subthalamic Data 
A classifier applied to a training subset of the anatomical data showed broad agreement with 
the data acquired from the variable selection algorithm. In this classifier (Figure 7.6), the 
overlap of the simulated VAT with the associative subregion of the right STN had the greatest 
explanatory power at both six and thirteen weeks. At six weeks, this anatomical variable was 
the dominant factor in classification. At thirteen weeks, the distance of the active electrode 
contact to the right and left associative subregions were also important factors, similar to the 
data presented in Table 7.6. Using iterative cross-validation, the accuracy of the model at 
correctly classifying cases at six weeks was 79 % (95 % confidence interval 54.4-94.0 %, 
sensitivity 89 %, specificity 70 %, positive predictive value 73 %, negative predictive value 89 
%) and at thirteen weeks was 79 % (95 % confidence interval 54.4-94.0 %, sensitivity 71 %, 
specificity 83 %, positive predictive value 71 %, negative predictive value 83 %). 
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At both 6- and 13-weeks the overlap of the stimulation field in relation to the right associative STN subregion 
(VAT.Overlap.R.Assoc) has the greatest predictive power in the training set. A: at 6-weeks, this anatomical variable is the 
dominant factor in classification. B: at 13-weeks, the distance of the active electrode contact to the right and left associative 
subregions are also important factors. 
Figure 7.6 | Gradient Boosting Classification of Post-DBS ‘Cases’ Using STN Data 
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The spatial distribution of STN voxels significantly associated with the likelihood of being a 
‘case’ versus a ‘non-case’ were determined with a voxel-based analysis. The highest likelihood 
of being a ‘case’ and a ‘non-case’ was identified using the predicted probabilities of caseness 
in the machine-learning classifier trained on the whole dataset at thirteen weeks (accuracy 88 
%, 95 % confidence interval 76.9-94.5 %, sensitivity 90 %, specificity 86 %, positive predictive 
value 75 %, negative predictive value 95 %). Distinct clusters of voxels were identified in the 
dorsolateral STN corresponding to the highest likelihood of being a ‘non-case’, with clusters 
of voxels in the ventromedial STN corresponding with the highest likelihood of being a ‘case’ 
(Figure 7.7). Cluster Statistics are presented in Supplementary Table 7.9. Thresholded 
statistical maps (extracted with FSL randomise) corresponding to the significant cluster-based 
inferences of change in outcomes are provided for download 
(https://doi.org/10.1016/j.nicl.2018.03.009). 
 
 
Within each STN limbic = yellow, associative = blue and motor = maroon subregions. Green: a cluster of FWE-corrected 
voxels significantly associated with being a non-case can be identified in the dorsolateral aspect of the right STN. Red: a 
cluster of FWE-corrected voxels significantly associated with being a case are identified in the ventromedial aspect of both 
the right and left STN. Significant clusters are found in both the right and left STN, corresponding with the known anatomy 
of this nucleus, with motor representations in the dorsolateral aspect of this nucleus and cognitive-associative circuits in the 
ventromedial region. A: Axial view, B: Coronal view, C: Oblique view. 
 
Figure 7.7 | Distinct Clusters of STN Voxels Associated with High and Low Likelihood of Developing Clinically-Significant 
Neuropsychiatric Symptoms 
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7.6.5 Auxillary Analyses 
An additional analysis was carried out using scan group as an additional covariate for the 
significant findings detailed above. With the exception of ELF Rule Violations at 6-weeks post-
DBS, all findings remained significant (Supplementary Table 7.13), indicating that these 
findings were replicated across scanning conditions. Furthermore, we repeated the main 
analyses using the recently released DISTAL subthalamic atlas, which is precisely co-
registered to the ICBM nonlinear asymmetric MNI space and includes limbic, associative and 
motor subregions. Our findings were replicated in this atlas (Table 7.8). 
 
Table 7.8 | Main Analyses Repeated Using the DISTAL Subthalamic Atlas 
Significance: *** p<0.001 ** p<0.01 * p<0.05  
 
ELF Rule 
Violations 
Anatomical Variables after 
Optimisation 
General Linear Model 1 
Week 6 VAT Overlap: Right 
Associative STN 
t-stat = 2.151 
p-value = 0.036* 
Week 13 VAT Overlap: Right 
Associative STN 
t-stat = 3.30 
p-value = 0.0004*** 
 
Clinical Cases Anatomical Variables after 
Optimisation 
General Linear Model 1 
Week 6 Distance: Right Associative 
STN Voxel 
z-value = -3.00 
p-value = 0.0014** 
VAT Overlap: Right 
Associative STN 
z-value = 3.31 
p-value = 0.0082** 
Week 13 Distance: Right Associative 
STN Centroid 
z-value = -3.00 
p-value = 0.0045** 
Distance: Left Associative 
STN Centroid 
z-value = -2.63 
p-value = 0.012* 
VAT Overlap: Right 
Associative STN 
z-value = 3.00 
p-value = 0.0059** 
 
1 Controlled for age, gender, LEDD, clinical subtype, years since diagnosis 
7.7 Discussion 
We demonstrate the significance of the locus of subthalamic stimulation in the genesis of 
postoperative inhibitory dysfunction. We found that the spatial overlap between the inferred 
stimulation volume and the associative subregion of the right STN was significantly associated 
with inhibitory errors during the Excluded Letter Fluency (ELF) task. Rule violations in this 
task are a sensitive measure of inhibitory dysfunction in non-demented persons with 
Parkinson’s disease and are considered to represent goal-directed, selective inhibitory control. 
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It may be a more sensitive measure of disinhibition than the Hayling sentence completion task 
in this population (O'Callaghan et al., 2013b). We found a cluster of subthalamic voxels in the 
right STN associated with greater ELF rule-violations at six and thirteen weeks post-DBS. The 
inclusion of motor and associative zones in these clusters emphasises that the partitioning of 
STN subregions is not strictly delineated and is more likely to be represented by a gradient of 
sensorimotor-cognitive cortical connectivity.  
 
We also demonstrate that clinically-significant, stimulation-dependent neuropsychiatric 
symptoms (changes in mood, affect and behaviour from baseline, as assessed by a psychiatrist, 
responding immediately to stimulation manipulation) are also associated with the spatial 
overlap of the simulated VAT in the right associative STN, as well as the distance of the active 
contact from the nearest voxel of the associative subregion, and the centroid of the right and 
left associative subregions. We identify distinct clusters of voxels associated with high and low 
likelihood of stimulation-dependent neuropsychiatric symptoms and illustrate that 
postoperative ‘cases’ can be predicted with reasonable accuracy from these methods. 
 
Our study adds to the literature in the following ways. By using a larger sample size than many 
recent investigations, we were able to infer more accurately on the contribution of subthalamic 
stimulation to neuropsychiatric outcome. Secondly, our neuropsychiatric evaluation pre- and 
post-DBS was extensive and allowed us to discriminate between clinically-significant 
syndromes (such as mania and hypomania) and subclinical changes in dimensional constructs 
(such as impulsivity). Thirdly, by employing a voxel-wise analysis of the STN, we were able 
to report more detailed information about regions likely to be associated with neuropsychiatric 
impairment. Finally, we applied classification techniques to our dataset to quantify the ability 
of this information to predict clinical outcomes. 
 
We acknowledge several limitations of our approach. Firstly, the precise boundaries and 
orientation of the STN may display inter-subject heterogeneity, which introduces a potential 
source of error when using an atlas developed in a non-surgical population. However, accurate 
manual segmentation of the STN using standard acquisitions at 3-Tesla is challenging, prone 
to inter-rater variability and additional data, such as the functional topography of the nucleus, 
is lost. We addressed this concern by deforming individual acquisitions to a common space, 
but recognise that a bias may persist given that the subthalamic atlas was not defined in the 
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space used for nonlinear warps (Ewert et al., 2018). This could introduce a systematic bias in 
the subsequent analysis of subthalamic volumes. However, we repeated our main analyses 
using the recently released DISTAL subthalamic atlas, which is precisely co-registered to the 
ICBM nonlinear asymmetric MNI space (Ewert et al., 2018). All findings remained statistically 
significant, again weighted toward the right over the left STN. Furthermore, our finding that 
the topmost twenty-five percent of overlapping voxels in our group VAT volume overlay the 
motor territory of the STN in both hemispheres lends plausibility to our approach and suggests 
any errors induced by normalisation to a common space were not excessive, with electrode 
targeting and DBS programming most likely to eventuate in stimulation of the motor subregion 
of this nucleus.  
 
We have also used a simplified method for estimating each VAT, which fails to account for 
tissue inhomogeneity and the biophysics of axonal response to DBS  (Gunalan et al., 2017). 
However, the methods we employ benefit from being embedded in open-source rather than 
proprietary software and are not computationally demanding to implement.  
 
The use of two different MRI scanners for image acquisition introduces a further variable, but 
the acquisition protocol was not altered and we present key data from our analyses controlling 
for scan group in Supplementary Table 7.13. Overall, the correlation of anatomical variables 
with inhibitory deficits and neuropsychiatric ‘caseness’, derived from the general linear model, 
remains highly significant despite this additional covariate. The sole exception is ELF rule 
violations at six weeks, which is no longer significantly correlated with VAT overlap within 
the right associative subthalamic subregion. This was the finding of weakest significance in the 
original analysis. However, that the remaining results hold despite the addition of scan group 
to the model, arguably increases the generalisability of our findings.  
 
The proportion of neuropsychiatric ‘cases’ in our investigation (forty-two percent) is 
significantly higher than that reported in previous work (Voon et al., 2006). However, we 
emphasise that our definition of this syndrome did not require participants to meet criteria for 
a full manic episode. Rather, isolated symptoms such as impulsive decision-making or verbal 
disinhibition met our criteria, providing they arose de novo during stimulation titration, 
responded to stimulation manipulation and, whilst present, caused significant personal or 
relational distress. Formal pre- and postoperative psychiatric assessment within the movement 
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disorders centre likely enhanced sensitivity to detect attenuated symptoms. We also note that 
forty-four percent of caregivers in a recent investigation endorsed a negative postoperative 
‘personality change’ in their partners (Lewis et al., 2014). It is challenging to robustly 
operationalise this construct, but we argue that our criteria of linking symptom resolution with 
stimulation manipulation, as well as seeking collateral information from third parties, increases 
the reliability of assignment to the ‘case’ category.  
 
Aside from the ELF, no other anatomical variables showed explanatory power for other 
neuropsychiatric assessment instruments. This may also represent the reduced sensitivity of 
other instruments to change, as well as the complex role of other factors such as LEDD 
reduction and reduced participant insight into behavioural symptoms.  
 
Although our significant findings were biased to the right hemisphere, we cannot draw 
definitive conclusions regarding the laterality of any aetiologic mechanism, given the presence 
of significant inter-hemispheric differences between relevant associative and limbic variables 
(Table 7.3). However, this finding is intriguing, given previous work suggesting that executive 
control of inhibition is primarily a right-lateralised process (Aron et al., 2004; D’Alberto et al., 
2017; Possin et al., 2009). The STN forms a key node in a right-hemispheric network 
incorporating the inferior frontal gyrus and the pre-supplementary motor area, which subserves 
slowing and inhibition following the detection of cognitive conflict (Aron et al., 2007). This 
function is mediated through activation of the STN via the hyperdirect pathway, with the 
efficiency of inhibition correlated with the connectivity between these right-hemispheric nodes 
(Rae et al., 2015). Therefore, it is plausible that neurostimulation of the right STN in our 
subjects is more likely to induce disinhibition and suggests that the right hemisphere might be 
the first site to target when addressing stimulation-induced neuropsychiatric symptoms.  
7.7.1 Conclusions 
In sum, we have found empirical support for the hypothesised link between the site of 
subthalamic stimulation and the emergence of postoperative neuropsychiatric symptoms after 
STN-DBS for Parkinson’s disease. By simulating a volume of activated tissue for each 
participant, we were able to represent additional information about the spread of charge from 
the active electrode contact. Consistent with the known gradient of cortical representations 
within the STN, we demonstrated a connection between the associative subregion and 
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postoperative disinhibition, in addition to the emergence of clinically-significant 
neuropsychiatric symptoms. Across the whole STN, we were able to delineate distinct clusters 
of voxels associated with inhibitory impairment, as well as the likelihood of neuropsychiatric 
‘caseness’. Classification methods applied to our data were able to classify ‘cases’ with 
reasonable accuracy. Our findings suggest that electrode targeting within the STN and 
stimulation diffusion within more ventromedial aspects of this nucleus does have an important 
role in mediating neuropsychiatric outcome. This extends previous work on the importance of 
electrode targeting and stimulation titration for optimal motor outcome and corroborates 
existing data on the functional anatomy of this nucleus, derived from non-human primates and 
neuroimaging data in healthy subjects. We anticipate that data such as these could be used 
prospectively to guide DBS titration and enhance the safety profile of this clinically-effective 
therapy.  
 
Recently, several groups have employed diffusion imaging to characterise the connectivity 
profile of clinically-effective subthalamic stimulation (Accolla et al., 2016; Akram et al., 2017; 
Horn et al., 2017; Vanegas-Arroyave et al., 2016), although neuropsychiatric symptoms have 
not been formally examined in these approaches. Tractographic methods are able to incorporate 
white matter tracts adjacent to the STN, which may contribute to the balance of therapeutic 
versus adverse effects. Models of neural networks associated with favourable clinical outcomes 
offer insights into the mechanism of DBS and may, in the future, assist clinicians with selection 
of the optimal electrode contact and guide stimulation titration. Future work will evaluate if 
diffusion imaging surpasses other forms of data when predicting the evolution of postoperative 
neuropsychiatric symptoms.   
  
Chapter 7  150 
 
 
7.8 Supplementary Data 
Supplementary Table 7.9 | Cluster Statistics and Local Maxima from the Voxel-Based Analysis 
Cluster Hemisphere Volume (mm3) Coordinates of Local Maxima: ICBM_2009b 
nonlinear asymmetric space 
x y z 
ELF Rule Violations: 
Week 6 
R 3 14.5 -13.5 -7 
ELF Rule Violations: 
Week 13 
R 65 12.5 -12 -7.5 
Case: Week 13 R 244 11 -11 -7.5 
Case: Week 13 L 184 -10 -12 -9 
Non-Case: Week 13 R 47 13.5 -16.5 -8 
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Supplementary Table 7.10 | Characteristics of Participants Becoming  Postoperative ‘Cases’ Versus ‘Non-Cases’ at Baseline 
All reported p-values have been adjusted for multiple comparisons using the Benjamini and Hochberg technique (1995) with ! = 0.05.  
Significance: *** p<0.001 ** p<0.01 * p<0.05  
 
Categorical Variable Cases (n=27) Non-Cases (n=37) Case vs. Non-Case 
Gender n % total n % total Chi2 p-value 
Male 19 29.7 27 42.2 0 1 
Female 8 12.5 10 15.6 
Clinical Subtype n % total n % total Chi2 p-value 
Akinetic-Rigid 8 12.5 16 25 1.28 0.91 
Mixed 13 20.3 15 23.4 
Tremor 6 9.4 6 9.4 
Continuous Variable Mean (SD), Median (Range)  
Age (Years) 58.6 (±10.4), 
60 (35 - 76) 
64.0 (±7.9), 
65 (44 - 76) 
t-stat p-value 
2.28 0.35 
Hoehn & Yahr Stage 2.8 (±0.6), 
3 (2 - 4) 
2.6 (±0.5), 
2.5 (1.5 - 4) 
t-stat p-value 
-1.26 0.91 
Years Since Diagnosis 7.7 (±5.4), 
6 (1 - 23) 
10.0 (±5.0), 
8 (3 - 22) 
t-stat p-value 
1.72 0.59 
LEDD 1036.4 (±496.1), 1000 (0 - 
2200) 
1107.2 (±579.8), 1015 
(260 - 3450) 
Chi2 p-value 
0.0037 0.99 
Patient-Rated BIS 61.6 (±9.9), 
61 (44 - 87) 
59.8 (±7.0), 
60 (43 - 76) 
t-stat p-value 
-0.83 0.95 
Caregiver-Rated BIS 60.2 (±11.8), 
59 (42 - 90) 
58.7 (±11.6), 
58 (40 - 90) 
t-stat p-value 
-0.50 0.95 
Patient-Rated EQ 42.6 (±9.2), 
43 (23 - 66) 
42.6 (±14.1), 
40 (16 - 68) 
t-stat p-value 
-0.0086 0.99 
Caregiver-Rated EQ 38.8 (±14.2) 
42 (11 - 61) 
39.0 (±14.1), 
42 (13 - 64) 
t-stat p-value 
0.054 0.99 
QUIP-RS Total 19.3 (±13.4), 
17 (0 - 53) 
21.4 (±16.1), 
18 (0 - 63) 
t-stat p-value 
0.58 0.95 
Beck Depression Inventory 11.3 (±5.3), 
11 (1 - 22) 
11.0 (±5.1), 
11 (1 - 21) 
t-stat p-value 
-0.34 0.95 
Hayling AB Error Score 9.1 (±11.7), 
4 (0 - 45) 
10.8 (±10.9), 
7 (0 - 38) 
Chi2 p-value 
0.87 0.95 
ELF Rule Violations 8.7 (±5.4), 
7 (3 - 22) 
8.8 (±5.5), 
8 (0 - 24) 
Chi2 p-value 
0.12 0.95 
UPDRS Part III Motor 35.7 (±19.0), 
32 (10 - 91) 
38.0 (±14.9), 
38 (13 - 71) 
t-stat p-value 
0.51 0.95 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = Empathy Quotient, LEDD = 
Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
Rating Scale 
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Supplementary Table 7.11 | Neuropsychiatric Outcomes Amongst ‘Cases’ Versus ‘Non-Cases’ at 6-weeks 
There were 26 cases at this interval. 
All reported p-values have been adjusted for multiple comparisons using the Benjamini and Hochberg technique (1995) with ! = 0.05.  
Significance: *** p<0.001 ** p<0.01 * p<0.05  
Neuropsychiatric Variable Cases (n=26) Non-Cases (n=38) Case vs. Non-Case 
Mean (SD), Median (Range) 
LEDD 390.9 (±324.2),  
325 (0 - 1462.5) 
384.8 (±208.2),  
350 (0 - 850) 
Chi2 p-value 
0.12 0.96 
Patient-Rated BIS 59.6 (±9.9), 
58 (41 - 79) 
58.1 (±9.8), 
59 (39 - 82) 
t-stat p-value 
-0.60 0.96 
Caregiver-Rated BIS 63.3 (±12.4), 
61 (43 - 87) 
59.9 (±11.8), 
59 (39 - 87) 
t-stat p-value 
-1.07 0.96 
Patient-Rated EQ 42.0 (±13.2), 
42 (9 - 65) 
42.4 (±15.5), 
41 (11 - 69) 
t-stat p-value 
-0.0086 0.99 
Caregiver-Rated EQ 35.5 (±16.5) 
38 (10 - 61) 
37.1 (±15.0), 
39 (10 - 66) 
t-stat p-value 
0.37 0.96 
QUIP-RS Total 19.8 (±15.0), 
19 (0 - 55) 
17.7 (±16.0), 
15 (0 - 52) 
t-stat p-value 
-0.51 0.96 
Beck Depression Inventory 8.8 (±7.6), 
8 (0 - 33) 
7.4 (±5.8), 
6 (0 - 28) 
t-stat p-value 
-0.81 0.96 
Hayling AB Error Score 8.1 (±8.9), 
6 (0 - 31) 
6.6 (±9.8), 
5 (0 - 51) 
Chi2 p-value 
0.47 0.96 
ELF Rule Violations 9.2 (±8.1), 
7 (0 - 31) 
7.8 (±6.1), 
6 (1 - 27) 
Chi2 p-value 
0.09 0.96 
UPDRS Part III Motor 26.6 (±12.5), 
26 (6 - 63) 
26.4 (±14.9), 
26 (6 - 72) 
t-stat p-value 
-0.06 0.99 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = Empathy Quotient, LEDD = 
Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
Rating Scale 
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Supplementary Table 7.12 | Neuropsychiatric Outcomes Amongst ‘Cases’ Versus ‘Non-Cases’ at 13-weeks 
There were 20 cases at this interval. 
All reported p-values have been adjusted for multiple comparisons using the Benjamini and Hochberg technique (1995) with ! = 0.05.  
Significance: *** p<0.001 ** p<0.01 * p<0.05  
 
Neuropsychiatric Variable Cases (n=20) Non-Cases (n=44) Case vs. Non-Case 
Mean (SD), Median (Range) 
LEDD 338.9 (±240.3),  
300 (0 - 950) 
349.1 (±204.9),  
350 (0 - 825) 
Chi2 p-value 
0.38 0.93 
Patient-Rated BIS 59.7 (±9.6), 
60 (41 - 82) 
58.9 (±9.1), 
61 (40 - 74) 
t-stat p-value 
-0.35 0.93 
Caregiver-Rated BIS 64.5 (±13.6), 
66 (42 - 90) 
60.5 (±12.6), 
59 (35- 100) 
t-stat p-value 
-1.20 0.93 
Patient-Rated EQ 42.9 (±12.1), 
39 (22 - 64) 
41.1 (±14.7), 
37 (14 - 68) 
t-stat p-value 
-0.55 0.93 
Caregiver-Rated EQ 34.2 (±15.1) 
35 (10 - 58) 
36.8 (±13.5), 
37 (9 - 71) 
t-stat p-value 
0.73 0.93 
QUIP-RS Total 15.8 (±11.9), 
16 (0 - 55) 
17.0 (±16.1), 
9 (0 - 55) 
t-stat p-value 
0.34 0.93 
Beck Depression Inventory 9.4 (±5.9), 
8 (1 - 26) 
9.6 (±6.2), 
9 (2 - 29) 
t-stat p-value 
0.12 0.95 
Hayling AB Error Score 8.0 (±8.6), 
6 (0 - 27) 
8.7 (±11.5), 
4 (0 - 45) 
Chi2 p-value 
0.004 0.95 
ELF Rule Violations 8.9 (±5.5), 
8 (0 - 21) 
7.6 (±4.6), 
8 (1 - 18) 
Chi2 p-value 
0.77 0.93 
UPDRS Part III Motor 27.5 (±14.4), 
25 (3 - 60) 
28.8 (±12.7), 
30 (7 - 58) 
t-stat p-value 
0.39 0.93 
 
Abbreviations: BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, EQ = Empathy Quotient, LEDD = 
Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
Rating Scale 
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Supplementary Table 7.13 | Key Analyses Controlling for Scan Group as an Additional Covariate 
Significance: *** p<0.001 ** p<0.01 * p<0.05  
ELF Rule 
Violations 
Anatomical Variables after 
Optimisation 
General Linear Model 1 
Week 6 VAT Overlap: Right 
Associative STN 
t-stat = 2.349 
p-value = 0.070 
Week 13 VAT Overlap: Right 
Associative STN 
t-stat = 3.30 
p-value = 0.0075 ** 
 
Clinical Cases Anatomical Variables after 
Optimisation 
General Linear Model 1 
Week 6 Distance: Right Associative 
STN Voxel 
z-value = -3.00 
p-value = 0.0045** 
VAT Overlap: Right 
Associative STN 
z-value = 3.31 
p-value = 0.0027** 
Week 13 Distance: Right Associative 
STN Centroid 
z-value = -3.00 
p-value = 0.0033** 
Distance: Left Associative 
STN Centroid 
z-value = -2.63 
p-value = 0.0083** 
VAT Overlap: Right 
Associative STN 
z-value = 3.00 
p-value = 0.0036** 
 
1 Controlled for age, gender, LEDD, clinical subtype, years since diagnosis and scan group 
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Chapter 8 
8 Uncertainty, Impulsivity & Gambling after Subthalamic 
Deep Brain Stimulation for Parkinson’s Disease 
‘I think that it [the brain] controls everything; thinking, behaviour, addictions. I mean, now that he's got the 
electrodes on the brain, I think you've got control of it to a point... So, you must have control...’ 
Spouse of a DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
8.1 Publication Details 
This chapter was published as: 
Paliwal, S., Mosley, P.E.*, Breakspear, M., Coyne, T., Silburn, P., Aponte, E. & Stephan, K., 
2019. Subjective estimates of uncertainty during gambling and impulsivity after subthalamic 
deep brain stimulation for Parkinson’s disease. Scientific Reports. 9, 14795. 
*Co-first author and corresponding author 
8.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, consented the participants, collected the 
quantitative data and travelled to the Translational Neuromodeling Unit at ETH Zürich to 
conduct the statistical analyses with Dr Paliwal. The author and Dr Paliwal wrote the first draft 
of the manuscript collaboratively. Dr Paliwal and Prof Stephan developed the virtual casino 
employed in the task. The Hierarchical Gaussian Filter was developed by Prof Mathys. Prof 
Mathys and Dr Aponte contributed to model inversion and parameter estimation. A/Prof Coyne 
and Prof Silburn implanted the DBS devices for all participants with Parkinson’s disease. Prof 
Breakspear provided supervision in statistical analyses and critical revisions of the manuscript.  
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8.3 Abstract 
Subthalamic deep brain stimulation (STN-DBS) for Parkinson’s disease may modulate 
chronometric and instrumental aspects of choice behaviour, including motor inhibition, 
decisional slowing, and value sensitivity. However, it is not well known whether STN-DBS 
affects more complex aspects of decision-making, such as the influence of subjective estimates 
of uncertainty on choices. In this study, thirty-eight participants with Parkinson’s disease 
played a virtual casino prior to subthalamic DBS (whilst ‘on’ medication) and again, three-
months postoperatively (whilst ‘on’ stimulation). At the group level, there was a small but 
statistically significant postoperative decrease in impulsivity, as quantified by the Barratt 
Impulsiveness Scale (BIS). The gambling behaviour of participants (bet increases, slot machine 
switches and double or nothing gambles) was associated with this self-reported measure of 
impulsivity. However, there was a large variance in outcome amongst participants, and we 
were interested in whether individual differences in subjective estimates of uncertainty 
(specifically, volatility) were related to differences in pre- and postoperative impulsivity. To 
examine these individual differences, we fit a computational model (the Hierarchical Gaussian 
Filter, HGF), to choices made during slot machine game play as well as a simpler reinforcement 
learning model based on the Rescorla-Wagner formalism. The HGF was superior in accounting 
for the behaviour of our participants, suggesting that participants incorporated beliefs about 
environmental uncertainty when updating their beliefs about gambling outcome and translating 
these beliefs into action. A specific aspect of subjective uncertainty, the participants’ estimate 
of the tendency of the slot machine’s winning probability to change (volatility), increased 
subsequent to DBS. Additionally, the decision temperature of the response model decreased 
post-operatively, implying greater stochasticity in the belief-to-choice mapping of participants. 
Model parameter estimates were significantly associated with impulsivity; specifically, 
increased uncertainty was related to increased postoperative impulsivity. Moreover, changes 
in these parameter estimates were significantly associated with the maximum post-operative 
change in impulsivity over a six month follow up period. Our findings suggest that impulsivity 
in persons with Parkinson’s disease may be influenced by subjective estimates of uncertainty 
(environmental volatility) and implicate a role for the subthalamic nucleus in the modulation 
of outcome certainty. Furthermore, our work outlines a possible approach to characterising those 
persons who become more impulsive after subthalamic DBS, an intervention in which non-motor 
outcomes can be highly variable.  
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8.4 Introduction 
The subthalamic nucleus (STN) is a subcortical nucleus of central pathophysiological relevance 
for Parkinson’s disease. In Parkinson’s disease, STN neurons display abnormal patterns of 
burst firing (Vila et al., 2000) and low-frequency synchronisation of local field potentials 
(Brown et al., 2001). By modulating this pathological network activity, subthalamic deep brain 
stimulation (STN-DBS) improves motor symptoms such as bradykinesia, tremor and rigidity 
(Schuepbach et al., 2013). However, STN-DBS has also been linked to neuropsychiatric 
symptoms, particularly impulsivity (Jahanshahi et al., 2015; Mosley and Marsh, 2015a), an 
issue of substantial clinical importance. The STN is a second input station to the basal ganglia, 
receiving direct cortical projections from the frontal lobe (the ‘hyperdirect’ pathway) (Nambu 
et al., 2002). This route permits basal ganglia inhibitory tone to be directly modulated by 
cortical regions. Functional and structural brain imaging support the role of this pathway in 
motor inhibition (Aron et al., 2007; Rae et al., 2015). Following STN-DBS, participants with 
Parkinson’s disease make commission errors (in which participants execute an erroneous 
action) (Hershey et al., 2004) and take longer to cancel an action (Obeso et al., 2013), 
suggesting an impairment in action restraint.  Errors in the Stroop (Witt et al., 2004) and 
random number generation tasks (Thobois et al., 2007) suggest increased sensitivity to 
cognitive interference and impaired task-switching. When faced with decisional conflict, 
persons with subthalamic DBS speed up rather than slow down their decision-making 
(Cavanagh et al., 2011; Frank et al., 2007). These findings suggest a role for the STN in 
‘braking’ cognitive-associative circuits in the basal ganglia. It is not clear, however, whether 
such chronometric aspects of decision-making are sufficient to explain the complex picture of 
impulsivity after STN-DBS (Florin et al., 2013). For example, subthalamic DBS may modulate 
contingencies in reinforcement learning (Seymour et al., 2016; Wagenbreth et al., 2015), 
suggesting a role for the STN in valuation.  
 
A potential computational mechanism underlying impulsivity is the estimation of uncertainty. 
If the longer-term outcomes of actions are not (or do not seem to be) predictable, prospective 
thinking may be replaced by seeking immediately available outcomes, a policy that would 
manifest behaviourally as impulsivity (Patton et al., 1995). More specifically, subjective 
uncertainty about environmental dynamics, or the longer-term consequences of actions, has 
been associated with a tendency to reduce reflection and long-term planning, and favour short-
term over long-term outcomes (Averbeck et al., 2014; FitzGerald et al., 2015; Paliwal et al., 
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2014). For example, consider deciding how to invest a sum of money in order to maximise 
profit. In a dependable economic setting with a reliable government, low unemployment, 
steadily rising house prices and a stable stock market, one might be confident that a long-term 
investment in property, business or shares would pay off highly. However, if the long-term 
outlook was unpredictable, with the possibility of a military coup, high unemployment, 
crashing property market and volatile stocks, one might decide to spend the money now and 
enjoy its worth in the short-term. This connection between uncertainty and impulsivity is also 
seen in Parkinson’s disease. Persons with Parkinson’s disease and impulse control behaviours 
(ICBs) ‘jump to conclusions’ in an information collection task (the beads task) more quickly 
than participants without ICBs, a finding that relates informational uncertainty to impulsivity 
(Djamshidian et al., 2012). A computational modelling study of behaviour across three tasks 
commonly used to probe impulsivity (information sampling, temporal discounting and novelty 
bias) suggested that Parkinson’s disease participants with ICBs are more uncertain about the 
relationship between possible actions and future rewards than patients without ICBs (Averbeck 
et al., 2013). Based on these findings, we hypothesised that changes in impulsivity after STN-
DBS may also relate to estimates of environmental uncertainty about future rewards.  
 
A paradigmatic approach to inference and learning under uncertainty uses Bayes’ theorem to 
understand how prior knowledge (represented as a probability distribution known as the prior) 
is combined with new information from the environment (the likelihood) in order to update 
beliefs (the posterior). To obtain the posterior, a Bayesian agent inverts a ‘generative’ model 
(that describes how noisy sensory data result from environmental states); this corresponds to 
perception. Inferring environmental states from noisy sensory data allows the agent to plan 
actions that take into account the uncertainty of the environment (Daunizeau et al., 2010). 
Human behaviour often closely resembles those of Bayesian agents, for example, during low 
level sensory processing (Petzschner et al., 2015; Weiss et al., 2002), sensorimotor learning 
(Kording and Wolpert, 2004; Wolpert et al., 1995) and higher-level reasoning (Tenenbaum et 
al., 2006), although approximations to ideal Bayesian inference are likely required for most 
domains of cognition (Friston, 2009; Griffiths et al., 2010; Tenenbaum et al., 2011). 
 
Critically, a Bayesian perspective can accommodate multiple forms of uncertainty, beyond 
sensory noise. For example, the agent’s environment might change over time. In order to 
account for this environmental uncertainty (or volatility), Bayesian agents are able to modulate 
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the rate at which they learn (update their beliefs). This learning rate can be linked to an agent’s 
encoding of volatility (Behrens et al., 2007; Mathys et al., 2011; Mathys et al., 2014). For 
instance, in more volatile environments, estimates of uncertainty (and thus learning rate) should 
be higher so that more emphasis is given to very recent information; at the same time, 
predicting the longer-term consequences of actions becomes more difficult. Additionally, 
uncertainty around how to best translate an uncertain belief about the environment into the 
selection of an action that will eventually lead to a reward is yet another source of noise that 
could contribute to observed stochasticity in behaviour. This link between uncertainty and 
decision-making may be of crucial importance for impulsivity (Averbeck et al., 2013). 
Furthermore, individual differences in approximate Bayesian inference plausibly contribute to 
inter-individual variability in behaviour. Such differences can be quantified using models with 
participant-specific parameters concerning, for instance, the estimation of environmental 
volatility (Vossel et al., 2014), or the formation of unusually confident or ‘precise’ beliefs 
(Schwartenbeck et al., 2015).  
 
In prior work, we found that participant-specific parameter estimates encoding different aspects 
of uncertainty (such as an estimate of environmental uncertainty, the tonic volatility ") related 
to a clinical measure of impulsivity in a cohort of healthy individuals (Paliwal et al., 2014). 
This finding supported a mechanistic understanding of impulsivity from the perspective of 
uncertainty. Based on these results, we sought to assess whether similar relationships between 
computational measures of uncertainty and impulsivity were observed in a population of 
persons with Parkinson’s disease undertaking subthalamic DBS. Moreover, given the central 
role of this brain region in decision-making, we investigated whether receiving subthalamic 
DBS was associated with changes in the encoding of uncertainty that were connected to 
increases in impulsivity in certain persons. Finally, we assessed whether a perioperative 
computational characterisation of subjective aspects of uncertainty (estimates of environmental 
volatility and stochasticity of belief-response mappings) would be associated with longitudinal 
changes in impulsivity during clinical follow up. This latter question is clinically important as 
the non-motor outcomes from subthalamic DBS can be varied. Some centres advocate for the 
use of DBS to address impulsivity and compulsivity amongst persons with Parkinson’s disease 
on dopamine agonist medication, as subthalamic DBS allows these agents to be substantially 
reduced or even withdrawn (Lhommee et al., 2012). However, other centres report the 
emergence of harmful impulsivity subsequent to DBS, in persons with no prior history of 
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clinically-significant psychiatric symptoms (Amami et al., 2015; Halbig et al., 2009; Lim et 
al., 2009; Mosley et al., 2018c; Smeding et al., 2007). At present, there is little evidence to 
guide the identification of surgical candidates at risk of postoperative impulsivity (Mosley and 
Marsh, 2015a; Voon et al., 2006). 
 
In this analysis, we employed a similar computational framework to that previously reported 
(Paliwal et al., 2014), applying a hierarchical Bayesian model (the Hierarchical Gaussian Filter, 
HGF) to behavioural data from thirty-eight participants with Parkinson’s disease who played a 
virtual casino before and after subthalamic DBS. By allowing participants to vary their bet size, 
switch between slot machines and place double-or-nothing bets, we could estimate how 
participants not only inferred the trial-by-trial probability of winning, but also updated higher-
order beliefs about the fluctuations (volatility) of a slot machine’s winning probability. Similar 
to the rationale outlined in prior work (Paliwal et al., 2014), we believe that a naturalistic 
paradigm engenders increased behavioural engagement, allowing us to quantify behaviour that 
has a higher fidelity to ‘real world’ impulsivity. Additionally, model-based estimates derived 
from the computational framework may afford us an individual profile of how each participant 
represented (and responded to) environmental uncertainty. We assessed these findings against 
standard measures of impulsivity derived from clinical assessment and questionnaires, 
focusing our attention on self-reported impulsivity as measured by the Barratt Impulsiveness 
Scale (BIS). Our computational analysis examined how DBS changes the manner in which 
persons with Parkinson’s disease engage in Bayesian belief updating, and whether changes in 
participant-specific estimates of uncertainty before and after DBS relate to changes in 
impulsivity. 
8.5 Methods 
8.5.1 Participants 
Thirty-eight participants with Parkinson’s disease undertaking STN-DBS were consecutively 
recruited at the Asia-Pacific Centre for Neuromodulation in Brisbane, Australia. All 
participants met the UK Brain Bank criteria for Parkinson’s disease (Hughes et al., 1992). No 
participants met the Movement Disorder Society criteria for dementia (Emre et al., 2007). The 
Parkinson’s disease subtype and the Hoehn and Yahr stage at device implantation was recorded 
(Hoehn and Yahr, 1967). Participants underwent bilateral implantation of Medtronic 3389 or 
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Boston Vercise electrodes in a single-stage procedure. Stimulation was commenced 
immediately using microelectrode recording data to identify the optimal contact. Further 
contact testing took place over the following week as an inpatient, with participants returning 
to the DBS centre following discharge for further stimulation titration, guided by residual 
motor symptoms. Further details have previously been reported (Mosley et al., 2018a; Mosley 
et al., 2018d). 
8.5.2 Neuropsychiatric Assessment 
Impulsivity amongst participants was assessed with patient and clinician-rated instruments 
prior to STN-DBS and subsequently two-weeks, six-weeks, thirteen-weeks and twenty-six-
weeks postoperatively (Figure 8.1). A range of measures were obtained, to account for the fact 
that impulsivity is not a unitary construct. These included the Barratt Impulsiveness Scale 11 
(BIS) and second-order factors attentional, motor and non-planning (Patton et al., 1995); the 
Questionnaire for Impulsive-Compulsive disorders in PD Rating Scale (QUIP-RS) (Weintraub 
et al., 2012); the delay discounting task (Kirby et al., 1999); the Excluded letter fluency task 
(ELF) (Shores et al., 2006); and the Hayling test (Burgess et al., 1997).  
8.5.2.1 Barratt Impulsiveness Scale 
The BIS is one of the most widely used instruments for assessing trait impulsivity and is often 
the gold standard instrument against which other measures are compared. It is a thirty-item 
self-report questionnaire assessing the prevalence of impulsive behaviours. Respondents must 
rate each item (e.g. ‘I act on the spur of the moment’) from 1 to 4 according to the frequency 
of occurrence (i.e. rarely / never; occasionally; often; always / almost always). Higher scores 
indicate greater impulsivity. The mean BIS score is significantly greater in Parkinson’s disease 
participants with ICBs compared to non-impulsive persons with Parkinson’s disease (Isaias et 
al., 2008; Voon et al., 2007), suggesting that this instrument also has construct validity in the 
assessment of impulsivity in Parkinson’s disease. 
8.5.2.2 Questionnaire for Impulsive-Compulsive disorders in PD 
The QUIP-RS is a twenty-eight-item self-report questionnaire assessing the prevalence of ICBs 
including compulsive spending, hypersexuality, pathological gambling, binge eating, 
hobbyism, punding and dopamine dysregulation. Respondents much rate each item (e.g. ‘Do 
you have urges or desires for the following behaviours that you feel are excessive or cause you 
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distress?’) from 0 (never) to 4 (very often). The total sum obtained for each compulsive 
behaviour indicates the current severity of that behaviour. The instrument was designed for use 
in the Parkinson’s disease population and was previously validated against a semi-structured 
clinical interview (Weintraub et al., 2012).  
8.5.2.3 Hayling Test 
The Hayling Test is a sentence completion task, during which participants must insert a 
nonsense word at the end of a sentence, inhibiting the pre-potent stimulus to complete the 
sentence with a word that makes sense. The test assesses the construct of inhibition and is 
sensitive to frontal lobe dysfunction. For example, in the sentence: ‘the whole town came to 
hear the Mayor…’ a correct response could be ‘banana’. Participants would be penalised for 
completing the sentence with the clearly related words ‘speak’, or ‘talk’ (referred to as category 
A errors), as well as with words that are only partially connected such as ‘explode’ (referred to 
as category B errors). Parkinson’s disease participants make more category A and B errors than 
controls on this task (O'Callaghan et al., 2013a; Obeso et al., 2011).  
8.5.2.4 Excluded Letter Fluency Task 
The ELF is an additional measure of inhibitory control. Participants are given three trials of 
ninety seconds to produce as many words as possible that do not contain a specified vowel. 
Words must be longer than three letters and cannot be proper nouns or derivations of the same 
word stem. Scoring includes an overall correct total, the number of rule violations and the 
number of word repetitions. In a sample of fifty persons with Parkinson’s disease, the number 
of rule violations was previously shown to be significantly greater compared to age-matched 
controls and was highly correlated with anatomical changes in brain regions implicated in 
inhibition (O'Callaghan et al., 2013b).  
8.5.2.5 Delay Discounting Task 
An assessment of delay aversion, the tendency to prefer sooner, smaller rewards over those that 
are larger but temporally more distant. The task was designed to assess impulsivity in 
individuals with substance use disorders; behaviours that share face validity with the impulse-
control disorders (ICBs) observed in a subset of persons with Parkinson’s disease. Participants 
are presented with a series of twenty-seven choices between an amount of money distributed 
immediately and a larger sum after a specified delay. After the task is complete, participants 
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have the opportunity to win the amount of money they have chosen in a choice selected at 
random, either immediately or after a delay, depending on the choice they have made. 
Subsequently, the pattern of choices is analysed to calculate a discount parameter, or the point 
of indifference between delayed and immediate rewards for a given sum. Individuals with 
greater delay aversion have a higher discount parameter. The extent of delay aversion was 
previously shown to be greater amongst persons with Parkinson’s disease than healthy controls 
(Milenkova et al., 2011), as well as being greater amongst Parkinson’s disease participants 
with ICBs than non-impulsive persons with Parkinson’s disease (Housden et al., 2010; Voon 
et al., 2011b).  
 
Additional neuropsychiatric symptoms were captured with the Beck Depression Inventory II 
(BDI) (Beck et al., 1961); the Empathy Quotient (EQ) (Baron-Cohen and Wheelwright, 2004); 
the Geriatric anxiety inventory (GAI) (Pachana et al., 2007) and the Apathy Scale (Starkstein 
et al., 1992). For each self-report scale, participants were instructed to refer to ‘the last two 
weeks’, in order to obtain a measurement of current ‘state’. At each visit, Parkinson’s disease 
motor symptoms were assessed using the UPDRS Part III motor examination (Goetz et al., 
2007). Dopaminergic medication was recorded and converted to a levodopa-equivalent daily 
dose (LEDD) value (Evans et al., 2004). 
8.5.3 Design and Setting 
Participants completed the experimental task prior to DBS and at thirteen-weeks post-DBS. 
Participants were ‘on’ medication and stimulation for all assessments. We opted against a 
counterbalanced ‘off’ and ‘on’ DBS assessment at the same visit for several reasons. First, our 
aim was to provide a naturalistic insight into the subtle behavioural changes that emerge as 
patients transition from dopaminergic therapies to subthalamic stimulation; changes in 
levodopa equivalent daily dose were included as co-variates in our analyses. Second, our 
experience is that many patients would not tolerate the DBS ‘off’ state without severe 
discomfort. Thirdly, despite allowing DBS washout, plastic network effects of chronic DBS 
may persist and contaminate findings in an on-off design.  
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Persons with Parkinson’s disease were screened in a multidisciplinary clinic by a movement disorders neurologist, 
neurosurgeon, psychiatrist, and rehabilitation specialist prior to selection for subthalamic DBS. Prior to surgery, surgical 
candidates who consented to participate were assessed with a battery of neuropsychiatric instruments (see box). These 
instruments were repeated at 2-weeks, 6-weeks, 13-weeks and 26-weeks postoperatively. This methodology of iterative 
assessments was designed to capture fluctuations in neuropsychiatric symptoms as electrical stimulation was titrated and 
dopaminergic medication was reduced. The slot machine gambling paradigm was undertaken by participants prior to 
neurosurgery and at 13-weeks postoperatively. 
 
8.5.4 Virtual Casino  
We employed a modified version of an established slot machine gambling paradigm validated 
in healthy controls (Paliwal et al., 2014). The task was designed to have standard features 
normally attributed to slot machines (colours, sounds, banners), and its features were designed 
to mirror the specifications of Swiss and German slot machines (Figure 8.2). Due to its game-
like feel, the task successfully elicits impulsive, risk-taking and exploratory behaviour in 
participants. Task behaviour has been previously shown to correlate with standard measures of 
impulsivity (i.e. the BIS). Players began the slot machine with 2000 AUD in their account, and 
played through 100 trials. The trajectory of win-loss outcomes was predetermined, ensuring 
that participants’ experience of rewards and losses were comparable in order and quantity. The 
trajectory results in a positive outcome (net winnings) for most participants. At the end of the 
task, participants were awarded up to 30 AUD in real money based on the size of these virtual 
winnings.  
 
Figure 8.1 | Overview of Study Timeline 
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The task began with five training trials, after which the participant played through the main 
task, consisting of 100 trials. Only data from the main task were used for further analysis. For 
the main task, the win probability was 25 %, with wins split into big wins (12 % of trials) and 
small wins (88 % of trials). Players won when all three wheels showed the same symbols (e.g. 
all three wheels display an apple image). There were two possible types of losses. The first was 
a near-miss, in which the first two wheels of the slot machine displayed the same symbol, and 
the third was different (e.g. cherry, cherry, apple). The second was a true loss, in which all the 
wheels displayed different images (e.g. cherry, apple, orange). 
 
Game play proceeded as follows: at the onset of each trial, the main screen loaded, displaying 
the player’s account value. Players were then able to execute one of the following actions: place 
a bet (of unlimited magnitude – by loading the machine in increments of 5-10 AUD), switch 
slot machines, or ‘cash out’, which involved ‘exiting’ the casino and returning again on another 
virtual ‘day’. If the player chose to bet, after loading the machine, they pressed the ‘Pull’ button 
and watched as the wheels begin to spin. The player had the option of pressing the ‘Stop’ button 
at any time during wheel spin, ending the trial and subsequently revealing the outcome of the 
three wheels, Pressing the stop button had no effect on the trial outcome; though this was not 
told to the participant. In the absence of the stop button being pressed, the trial timed out after 
five seconds, and revealed the outcome to the player, with the first, second and third wheel 
stopping sequentially. For winning trials, there were ten possible reward amounts. Each 
possible reward was called a reward grade, and indicated a different multiple of the bet size 
placed (e.g. reward grade 1 indicated a reward amount that was double the bet amount placed).  
After each win trial, the player is offered a ‘double-up’ option, during which they were given 
three seconds to decide whether or not to engage in a ‘double-or-nothing’ option. The double-
or-nothing option had two possible outcomes: if the player won the double-or-nothing gamble, 
they doubled their win amount from that trial, if they lost the double-or-nothing option, they 
lost their entire win amount from the corresponding trial. If the player did nothing, or decided 
not to gamble, they are taken to the next trial. For losses, players were taken directly to the 
beginning of the next trial.  
 
In the context of the analyses presented, this version of the slot machine deviated from the 
version presented in Paliwal et al. (2014) in several important ways: here, players were given 
the ability to place unlimited bet sizes with the ability to increase their bets in increments of 5 
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or 10 AUD; there were no ‘fake win’ results, simply wins and losses; the task was considerably 
(fifty percent) shorter; and finally, the task was aesthetically remodelled in order to be more 
naturalistic.  
 
Each trial in the game followed a pre-programmed result sequence consisting of the following 
trial types: 
 
i. big wins: top three out of 10 reward grades 
ii. small wins: lower 7 out of 10 reward grades 
iii. near misses: when the same symbol appeared in wheel 1 and two, and a different symbol 
appeared in wheel 3 
iv. true losses (all three wheels showed different symbols). 
 
After all win trials, a participant was allowed to engage in a secondary double-or-nothing 
gamble, and had three seconds to decide whether or not to do so. A more detailed trial 
breakdown across the various types of wins and losses is listed below: 
 
i. 25 out of 100 trials were wins 
ii. 3 out of 100 trials were big wins 
iii. 22 out of 100 trials were small wins 
iv. 22 out of 100 trials were near misses 
v. 52 out of 100 trials were full losses. 
vi. All win trials contained a double-up option  
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The task consists of 100 trials. On every trial, players are able to place a bet of unlimited magnitude, switch slot machines or 
‘cash out’, exiting the casino and returning again on another virtual ‘day’. The overall win probability is 25 %, with wins split 
into big wins and small wins. The two possible types of losses are near-misses, in which the first two wheels are the same and 
the third is different (i.e. AAB) or a true loss, in which all the wheels are different (i.e. ABC). Game play proceeds as follows. 
Each trial begins with the slot machine main screen loading, displaying the player’s account value. The player then places a 
continuous-valued bet amount, incremented in units of 5 or 10 AUD. After the player has placed a bet, he or she presses the 
‘Pull’ button and watches as the wheels begin to spin. At any point, the player has the ability to press the ‘Stop’ button, ending 
the trial and subsequently revealing the outcome of the three wheels. Unbeknownst to the participant, pressing the stop button 
has no effect on the trial outcome. If the stop button is not pressed, the trial times out after 5 seconds, and the player sees the 
outcome of the first, second and third wheel sequentially. On trials in which the outcome is a win, there are ten possible reward 
grades (or multiples of the bet amount). After every win trial, players are offered a possible ‘double-up’ option, during which 
players are given 3 seconds to decide whether or not to engage in a ‘double-or-nothing’ option, thereby risking his or her entire 
win amount. If the player elects to engage in this gamble, a card flips over revealing the result, and subjects are taken to the 
next trial. If the player does nothing, or decides not to gamble, he or she is taken to the next trial. For each loss trial, players 
are taken directly to the beginning of the next trial. Again, the trajectory of win-loss outcomes is fixed, ensuring comparable 
inference upon perceptual and response parameters across participants.  
 
 
 
  
Figure 8.2 | Slot Machine Gambling Paradigm 
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8.6 Computational Modelling 
8.6.1 The Hierarchical Gaussian Filter (HGF) 
The HGF is a hierarchical Bayesian model (Mathys et al., 2011; Mathys et al., 2014) (Figure 
8.3) where each level of the hierarchy encodes distributions of environmental variables (in 
ascending complexity) that evolve as Gaussian random walks. The HGF is an extension of the 
model presented in Behrens et al. (2007) and describes an agent whose learning rate is a 
function of his or her uncertainty. In the HGF, an agent is assumed not only to represent current 
environmental contingencies, but also to track how these contingencies change over time 
(volatility), and to what degree volatility itself is constant (tonic volatility) or may change in 
time (phasic volatility). Importantly, the agent modelled in the HGF employs these 
representations to make predictions about emerging environmental fluctuations and future 
sensory feedback. Furthermore, the agent is able to encode the precision of each prediction and 
use these precision estimates to scale trial-wise updates of beliefs about the environment and 
its statistical structure. Each level of the HGF is coupled such that higher states determine how 
quickly the next lower state evolves, with the lowest hierarchical level representing sensory 
events. 
 
Inversion of this ‘perceptual model’ produces subject-specific parameter estimates that 
determine the nature of the coupling between levels of the HGF. Inverting this model under 
generic (mean-field) approximations results in analytical belief-update equations, in which 
trial-wise belief updates are proportional to prediction errors (PEs) weighted by uncertainty (or 
its inverse, precision). The subject-specific parameters shape an individual’s approximation to 
ideal Bayesian inference, specifically how phasic and tonic volatility impacts trial-wise 
estimates of uncertainty at all levels of the hierarchy. Posterior estimates of HGF parameters 
can thus be regarded as a compact summary of an individual’s uncertainty processing during 
an experiment.  
 
Furthermore, in a ‘response model’, trial-wise beliefs are probabilistically linked to observed 
trial-wise decisions. Inverting both perceptual and response models allows for estimating the 
parameters; this corresponds to Bayesian inference (of an observer) on Bayesian inference (of 
an agent) (Daunizeau et al., 2010).  
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 # $  represents binary observations (true wins=1, and losses=0, in the case of the slot machine). Binary inputs are represented 
on the first level, %&$ via a Bernoulli distribution, around the probability of win or loss, %'$ . In turn, %'$ 	is modelled as a 
Gaussian random walk, whose step-size is governed by a combination of %)$ , via coupling parameter *, and a tonic volatility 
parameter ". %)$  also evolves as a Gaussian random walk over trials, with step size + (meta-volatility). In this investigation, 
after observing trial-wise outcomes (win or lose), the gambler updates her belief about the probability of win on a given trial 
k (%'$ ), as well as how swiftly that slot machine is moving between being ‘hot’ (high probability of win) or ‘cold’ (low 
probability of win) %)$ . On any trial, the ensuing beliefs then provide a basis for the gambler’s response, which may be to 
increase the bet size, ‘double up’ after a win, switch to a new slot machine or leave the casino. 
 
  
Figure 8.3 | The Hierarchical Gaussian Filter (HGF)  
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8.6.2 The Perceptual Model 
The goal of the HGF is to infer how an individual subject learns about hierarchically coupled 
environmental quantities under different forms of uncertainty (including volatility). In our case, 
the first quantity, %&, represents trial-wise outcomes (wins or losses) in the slot machine. This 
derives, through a sigmoid transform, from a second-level variable, %' which represents, in 
logit space, the probability of winning (an indication of the slot-machine being ‘hot’ or ‘cold’ 
and likely (or not) to pay out). The variable %'  performs a Gaussian random walk trial by trial, 
with its step size (or variance) coupled to a higher level %) (the speed at which a machine 
fluctuates between ‘hot’ and ‘cold’ states), according to ƒ'(%)). The coupling between levels 
follows an expansion of log 2(%) to first order, with subject-specific parameters *, " that 
determine an individual’s approximation to ideal Bayesian inference (see Equation 5 below). 
Finally, the parameter + at the highest level denotes how quickly volatility itself is changing 
(meta-volatility). Generated observations, u, deterministically depend on x1, i.e., there is no 
sensory noise. A detailed derivation of the exact equations can be found in Mathys et al. (2014). 
 
For model inversion and estimating posterior distributions of states and parameters, the HGF 
employs a generic variational Bayesian approximation, assuming that the posterior 
distributions of the states are Gaussian at all levels of the hierarchy: 
 
 %4$ |# & , … , # $ , 7 ∼ 	9 :4$ , ;4$ <& , ( 1 ) 
 
where u is an observed input, :4$  is the mean at time point k for level i, and ;4$  is the 
precision, or inverse variance, of this distribution, and 7 ≝ *,", +  are subject-specific 
parameters. Updates to the posterior mean :4$ 	for level i have the general form: 
 
 >:4 ∝ ;4<&;4 @4<& ( 2 ) 
 
Thus, updates to the posterior mean at each level of the HGF are proportional to the prediction 
error (PE) at the level below, @4<&, weighted by a ratio of uncertainties (or their inverses, 
precisions). Specifically, this ratio consists of the precision of the prediction onto the level 
below, ;4<&, and the posterior precision at the current level, ;4$ .This equation reveals that the 
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precision ratio corresponds to a dynamic learning rate: the higher the precision (the lower the 
uncertainty) of a prediction on the level below, the more meaningful the input from the level 
below and the greater the impact of the PE on updating the posterior mean. Conversely, the 
more certain an agent is about the true value of %4, the smaller the impact of the PE. 
 
At the bottom of the hierarchy, the prediction error @A$  (= @B$ ) represents a value PE, the 
difference between the actual input u and the predicted input: 
 
 @B$ = 	 @A$ ≝ # $ − 	E :&$<&  ( 3 ) 
 
where s denotes the sigmoidal transform. At higher levels of the HGF, the PEs refer to volatility 
rather than value. A volatility PE (VOPE) integrates both predicted and observed, as well as 
informational and environmental uncertainty, 
 
 @4($) = 	 F4$ + (:4($) − 	:4($<&))'F4($<&) + 	H4($) − 1, ( 4 ) 
 
where 	H4($)	is defined as, 
 
 H4($) ≝ 	 J%K(*:4($<&) + ") ( 5 ) 
 
Here, informational uncertainty is given by F4($<&),	the variance of the posterior at trial k-1. 
Predicted total uncertainty is given by the denominator and includes both informational and 
environmental components. The environmental uncertainty represented by H4($) can be 
separated into phasic *:4($<&)  and tonic "  components, corresponding to ‘unexpected’ 
uncertainty related to environmental fluctuations. Additionally, H also affects the precision (or 
uncertainty) ratio (Equation 2) that defines the learning rate (for details, see Mathys et al. 
(2014)). Because the HGF can react sensitively to sudden shifts in environmental contingencies 
by adjusting the phasic component of its volatility estimate, it allows learning rates to be 
adjusted to the time-varying statistical structure of the environment. Individual differences in 
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this dynamic learning process are determined by the agent-specific uncertainty parameters *, " 
and +. 
 
More concretely, in the context of our study, parameters " and + at the second and third level 
of the hierarchy, respectively, encode different aspects of subjective estimates of uncertainty. 
Specifically, these estimates concern environmental uncertainty, i.e., hidden fluctuations 
(volatility) of environmental states (Mathys et al., 2014). These volatility estimates are 
potentially important for explaining the observed behaviour because they shape participants’ 
belief updates about the slot machine and their ensuing choices about gambling. Parameter " 
represents a participant’s estimate of tonic volatility, i.e., how quickly a slot machine could be 
moving from a state where it is likely to pay out (running ‘hot’) to a state where it is not 
(running ‘cold’) and vice versa. Parameter + encodes a participant’s estimate of meta-volatility, 
i.e., the tendency of volatility itself to change over time. Larger values of each parameter 
correspond to greater uncertainty in the participant’s perceptual inference process. 
8.6.3 The Response Model  
The response model maps a subject’s beliefs (obtained by inverting the perceptual model under 
given parameter values) to observed gambling behaviour. Here, we use a sigmoidal response 
model (Mathys et al., 2014). If this function is steep, there is a close relationship between 
current perceptual beliefs and betting behaviour. Conversely, a gentler sigmoidal slope results 
in a more stochastic mapping of beliefs to behaviour. This response function has a parameter, L, the decision ‘temperature' (also known as the inverse temperature), that determines the 
steepness of the sigmoid and thus the degree of stochasticity in the belief-to-choice mapping. 
The larger the value of L, the steeper the function, and the more deterministic is the relationship 
between a subject’s belief and their actions. In this paper, we test the following two variants of 
this response model:  
 
i. ‘Standard’ HGF:  L = 	MNOEPQOP, i.e., the mapping from beliefs to behaviour is fixed 
across the experiment. This parameter is estimated for each participant. 
ii. ‘Uncertainty-driven’ HGF: L = 	1/	F'($), where 	F'($) is the variance of the inferred 
probability of win on trial k. That is, the response behaviour dynamically adapts to the 
precision of the participants’ belief about the current probability of winning. 
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8.6.4 Perceptual Variable 
Based on previous work that examined different computational models of our slot machine 
paradigm (Paliwal et al., 2014), the perceptual variable used here was simple: a binary variable 
in which wins were represented by 1 and losses by 0 (Table 8.1). Although the task itself allows 
for continuous valued rewards, for this analysis, we look at wins and losses as binary outcomes 
(big wins and small wins are collapsed for the purpose of model fitting). We do so for the 
following reasons: first, we do not measure reward sensitivity on an individual basis, therefore 
creating a parametric multimodal reward variable that is consistent across the entire population 
is difficult. Secondly, measuring uncertainty-updating and impulsive responses in reaction to a 
binary win/loss event allows for a clearer interpretation of the model parameters and the 
correlational results. 
8.6.5 Response Variable 
The response variable used in the model is constructed from four key behaviours afforded to 
participants as they play the virtual casino: bet behaviour, machine switching, doubling up and 
cashing out. We identify four key indicators of risk-taking within these behaviours: 
 
i. Bet Increase (BI) 
- 1 = switching from a low to a high bet  
- 0 = staying at the same bet size 
ii. Double Up (DU)  
- 1 = engaging in the secondary double-or-nothing option 
- 0 = declining to engage in the secondary double-or-nothing option 
iii. Casino Switch (CS) 
- 1 = switching casino days 
- 0 = remaining in the current casino day 
iv. Machine switch (MS) 
- 1 = deciding to switch to a new machine 
- 0 = continuing to play on the same machine 
 
While these actions might at first glance appear to relate to different behaviours, they all share 
a common theme in that they enhance outcome variance and thus risk (compare the definition 
of risk in behavioural economics). For example, for a machine switch, regardless of whether 
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the player is performing well or poorly on the current machine, the decision to switch machines 
incurs the risk that the new machine chosen may be punishing or rewarding, thereby making 
the player vulnerable to the variance of the task. Similarly, a bet increase is a risk-inducing 
shift in the face of uncertainty, again making the player more susceptible to larger wins and 
losses. And in the same respect, casino switches and double-ups again expose players to the 
risk that their environment will change dramatically, and for the worst. Each of the above 
actions thus leads to greater outcome variance (risk), and risk-taking, in turn, is one critical 
component of impulsivity (Whiteside and Lynam, 2001). In order to combine these behaviours 
into a single representation of risk taking, we construct a trial-wise, binary response variable 
per participant by performing an OR operation over the four actions. If a subject performs one 
or more of these actions on a given trial, the response variable on that trial is a 1. If the subject 
did not engage in any of these actions on a given trial, the response variable on that trial is a 0.  
 
Table 8.1 | Composition of Perceptual and Response Models 
Composition of model 
variables 
Win 
Near-
miss 
True loss BI DU CS MS 
Perceptual variables 1 0 0 - - - - 
Response Variables - - - 1 1 1 1 
 
Variables are binary and composed on a trial-by-trial basis for each of combinations shown. BI = Bet increase; DU = double-
up; CS = casino switch; MS = machine switch. Wins are encoded as 1, losses as 0. 
 
8.6.6 Reinforcement Learning 
As an alternative model, we used a classical associative learning model, Rescorla-Wagner 
(RW), often used in reinforcement learning (RL) (Rescorla and Wagner, 1972). The RW model 
updates the probability of a win on trial k by combining the probability on trial k-1 with a PE 
weighted by a constant learning-rate:  
 
 S $ = S $<& + ! T $ − S $<&  ( 6 ) 
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where S $ is the state of the tracked variable, in our case, the win probability, at time k, S $<&  
is the state of the variable at time point k-1, !	is the learning rate and T $  is the actual outcome 
at time point k. 
 
Hence, in contrast to the HGF, the RW model does not have a dynamic learning rate over trials, 
nor can it account for different forms of perceptual uncertainty. Essentially, the RW model 
corresponds to an HGF with a fixed learning rate. Here, we combine the RW learning rule with 
the same sigmoidal response model described above, with free parameter L, that we estimate 
on a subject-specific basis. This results in a model that is (i) structurally not dissimilar but less 
complex than the HGF and (ii) almost identical to the RL model used in a prior investigation 
of learning after STN-DBS (Seymour et al., 2016).  
8.6.7 Model Inversion 
The HGF and RW models were inverted using population Markov-Chain Monte Carlo 
(MCMC) sampling (Aponte et al., 2016). Parameter estimation in the HGF is classically ‘fully 
Bayesian’ and requires a selection of priors, which influence parameter estimation to a lesser 
or greater degree. In order to minimise this influence, we used a novel empirical Bayesian 
inference scheme for the HGF where a Gaussian group-level distribution of parameters is 
constructed from samples across the group. This group-level empirical prior is then used to 
obtain posterior parameter estimates in each subject (Figure 8.4). Participant-specific point 
estimates for model parameters are calculated as the median value of the participant’s posterior 
distribution. 
 
Given the clinical constraints of our investigation (to reduce any burden on the participants, we 
only used 100 trials per episode of gambling, i.e., only half as many as in previous work) 
(Paliwal et al., 2014), it was important to ensure that parameter estimates were robust. 
Therefore, in order to verify that HGF parameter estimates reliably reflected participant-
specific characteristics of uncertainty-encoding and decision noise, we tested our ability to 
recover ground-truth parameter values from simulated response data. In order to assess 
parameter recoverability, we used three parameter values per parameter and generated a batch 
of thirty-eight synthetic response variables based on these assigned values, using the underlying 
trace of the slot machine as the perceptual variable. We then inverted the HGF and explored 
the relationship of the recovered parameter estimates, using the median of the posterior, with 
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the ground truth values. When estimating " and +, L was held fixed; conversely, when 
estimating for L, " and + were fixed. This process was repeated for ten batches across each 
parameter.  
 
 
Here, u represents the fixed perceptual variable that a participant observes during game play, and yi represents the response 
variable for participant i.	U4 = [*, ", +, L] is a participant-specific parameter vector consisting of the perceptual parameters 
shown in Figure 8.3 and the decision temperature, L. : and F are the mean and variance of the group-level empirical prior	that 
is constructed using observations from all N participants. This prior is simultaneously used to invert models on a participant-
specific level, for example, using u and y1, as the perceptual and response variables for Participant 1. In the notation used in 
this schematic, points indicate fixed parameters such as W or fixed data vectors such as u. Filled circles represent observed 
quantities, such as X4. Unfilled circles represent random variables that are estimated during model inversion. The 
hyperparameter for :, :B, is fixed to -3 for log" and -6 for log +, before inversion. The hyperprior on F is a gamma distribution 
with parameters Q and W, which are also fixed before inversion. As in previous work (Paliwal et al., 2014), we did not estimate * due to conditional dependencies with other parameters, but set it to unity. 
 
  
Figure 8.4 | Schematic of Hierarchical Model Inversion Using Population Markov-Chain Monte Carlo Sampling 
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8.6.8 Model Comparison 
As described above, we considered two competing hypotheses of how participants might 
incorporate uncertainty into their choice of actions, i.e., two different belief-to-choice 
mappings in the response model for the HGF (the ‘Standard’ and ‘Uncertainty-driven’ 
models). These two versions of the HGF were compared with the RW model. As we were 
primarily interested in the pre-DBS to post-DBS change, we selected the winning model for 
the pre-DBS measurements. We then evaluated if the parameter estimates of that winning 
model changed postoperatively. Estimates of the negative free energy (log model evidence) 
were computed using thermodynamic integration (Aponte et al., 2016). The negative free 
energy balances goodness of fit with a complexity penalty. Group-level free energy estimates 
were compared to select a winning model. 
8.6.9 Data Analysis 
8.6.9.1 General Considerations 
All computational modelling and model inversion was performed using MATLAB 
(Mathworks), employing custom scripts developed from the HGF toolbox 
(http://www.translationalneuromodeling.org/tapas/). Multiple regression analyses were 
performed using the regstats function in the MATLAB Statistics Toolbox. For all analyses 
involving multiple comparisons, native p-values are presented, accompanied by Holm-
Bonferroni correction at !=0.05. To test the significance of individual regressors in multiple 
regression models, post hoc t-tests were performed.  
 
Neuropsychiatric assessment data from baseline, prior to DBS, was compared with data 
gathered at thirteen-weeks post-DBS, when the gambling task was repeated. To test for 
differences in pre-DBS and post-DBS questionnaire scores and model parameter estimates, a 
paired t-test was employed when the data were normally distributed and the Wilcoxon signed-
rank test otherwise, where distribution was assessed using the Lilliefors test. Gambling 
behaviours (such as bet increases and machine switches) were also compared at both intervals. 
Gambling behaviours were regressed against clinical measures of impulsivity to determine 
significant relations. After determining the winning computational model, model parameter 
estimates were extracted for each participant and regressed against clinical measures of 
impulsivity to determine significant associations and predictors of postoperative impulsivity. 
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Based on previous work showing a significant association between BIS scores and both slot 
machine behaviour and HGF-based estimates of uncertainty encoding (Paliwal et al., 2014), 
we focused our analyses on the BIS and its subscales. Perceptual model parameters were 
extracted in log space: " and L are naturally estimated in log space, since they are part of 
exponential terms in their respective equations (see equation 5).	 
 
From a clinical perspective, we were interested in examining whether changes in the 
computational characterisation of individual uncertainty estimates pre- to post-DBS were 
associated with clinically-relevant changes in impulsivity at any time point after DBS. Our 
strategy to attempt prediction of clinical outcomes follows the ‘generative embedding’ 
approach, in which individual predictions are not derived from measured data but from 
parameter estimates obtained by a generative model (Brodersen et al., 2011; Brodersen et al., 
2014). Importantly, stimulation-dependent changes in impulsivity may evolve in an 
unpredictable manner subsequent to DBS, related to variations in DBS programming over time 
(with considerable adjustments to stimulation in the first six postoperative months). 
Furthermore, the optimal BIS cut-off score for clinically-significant impulsivity varies by age 
and disease (Stanford et al., 2009), with only one existing investigation specific to a 
Parkinson’s disease cohort (Voon et al., 2007). Therefore, we examined whether individual 
changes in parameter estimates associated with the maximum postoperative increase in 
impulsivity, as measured by the BIS, compared to baseline, across six months of longitudinal 
follow up.  
8.7 Results 
8.7.1 Participant Characteristics 
Participants were a predominantly middle-aged sample, with a bias towards male gender and 
akinetic-rigid/mixed phenotype over tremor (Table 8.2). Most participants had bilateral disease 
with consequent impairment of functioning in their activities of daily living.  
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Table 8.2 | Demographic and Clinical Characteristics of the Cohort 
Categorical Variable Total (n=38) 
Gender n % total 
Male 25 65.8 
Female 13 34.2 
Clinical Subtype n % total 
Akinetic-Rigid 13 34.2 
Mixed 18 47.4 
Tremor 7 18.4 
Continuous Variable Mean (SD), Median (Range) 
Age (Years) 61.9 (±9.3), 65 (35 - 76) 
Hoehn & Yahr Stage 2.7 (±0.6), 2.5 (1.5 - 4) 
Years Since Diagnosis 8.5 (±4.6), 7 (2 - 21) 
 
8.7.2 Neuropsychiatric Assessment Pre- and Post-DBS 
Concerning symptoms of primary interest (Table 8.3), there was a small but statistically-
significant group-level post-DBS decrease in impulsivity, as measured by the BIS Total, 
compared to baseline. There was also a significant reduction of motor symptoms assessed using 
the UPDRS Part III Motor Examination, with a corresponding significant reduction in the 
requirement for dopaminergic therapy (LEDD). There were no statistically-significant changes 
in other behavioural measures related to impulsivity, including the Hayling test, the Excluded 
Letter Fluency task and the delay discounting task. Comparable to the BIS, the QUIP-RS total 
score demonstrated a trend towards a reduction at thirteen-weeks post-DBS, but this did not 
reach significance. 
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Table 8.3 | Neuropsychiatric Assessment Data Pre- and Post-DBS 
‡Indicates significant native p-values, before multiple comparison correction  
Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-Bonferroni corrected for multiple comparisons with ! = 0.05. 
 
Behavioural Measure Pre-DBS Post-DBS Max Impairment Pre- vs. Post-DBS 
Gaussian Distribution Mean (SD), Median (Range) t-stat p-value Adj. p-value 
BIS 60.2 (±7.4), 60 (44 - 76) 
57.8 (±9.5), 
58 (40 - 75) 
2.3 (±6.4), 
3 (-14 - 17) 2.66 0.011 ‡ 0.033* 
BDI 11.1 (±5.1), 11 (1 - 22) 
8.4 (±6.6), 
6 (1- 29) 
1.3 (±7.1), 
0 (-12 - 18) 2.29 0.028
 ‡ 0.056 
QUIP-RS 21.4 (±15.7), 19 (0 - 63) 
17.2 (±15.8), 
14 (0 - 55) 
5.1 (±13.5), 
4 (-25 - 37) 1.78 0.084 0.084 
UPDRS Part III Motor 37.7 (±17.0), 37 (10 - 91) 
30.9 (±12.7), 
32 (8 - 60) N/A 3.47 0.001 ‡ 0.004** 
LEDD 1032.9 (±599.4), 988 (0 - 3450) 
334.9 (±199.8),  
329 (0 - 825) N/A 8.59 <0.001 ‡ <0.001*** 
Skewed Distribution Mean (SD), Median (Range) Chi-square p-value Adj. p-value 
ELF Rule Violations 9.7 (±5.3), 9 (0 - 24) 
8.4 (±5.0), 
8 (1 - 18) 
3.0 (±6.5), 
1 (-6 - 19) 20.2 0.12 0.360 
Hayling AB Error Score 11.4 (±11.1), 8 (0 - 38) 
9.4 (±11.3), 
5 (0 - 45) 
6.2 (±12.0), 
6 (-19 - 30) 23.6 0.13 0.360 
Delay Discount K 
0.034 (±0.067), 
0.016 (0.00016 - 
0.25) 
0.036 (±0.049), 
0.016 (0.00016 - 
0.25) 
0.041 (±0.077), 
0.0128 (-0.15 - 0.25) 12.6 0.18 0.260 
 
Abbreviations: BDI = Beck Depression Inventory, BIS = Barratt Impulsiveness Scale, ELF = Excluded Letter Fluency, LEDD 
= Levodopa Equivalent Daily Dose, QUIP-RS = Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease 
Rating Scale, UPDRS = Unified Parkinson’s Disease Rating Scale 
Max impairment refers to the maximum impairment for each outcome across all measurement intervals subsequent to DBS. 
 
For symptoms of secondary interest (and subscales), see Supplementary Table 8.12. There was 
considerable variance between subjects across assessment scores at each interval and within 
subjects across the course of longitudinal follow up (Supplementary Figure 8.8).  
 
The BIS and the BDI showed a significant positive correlation at each time point (YZ[\=0.46, 
p=0.003; YZ]^_=0.53, p<0.001), and both showed (near-)significant changes from pre- to post-
DBS (Table 8.3). Therefore, to rule out that impulsivity-related findings were driven by 
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changes in depression, the BDI was included as a covariate when regressing behaviour and 
model parameter estimates against BIS scores. Whilst the LEDD is conceivably related to 
impulsivity, it did not correlate with the BIS total (YZ[\=-0.126, p=0.450; YZ]^_=-0.042, 
p=0.799) and was therefore not included in these regression analyses. However, the QUIP and 
LEDD correlated strongly at both time points (YZ[\=0.42, p=0.008); YZ]^_=0.44, p=0.005), 
with LEDD decreasing significantly post-DBS. There were no significant correlations between 
LEDD and the other measures of impulsivity (ELF Rule Violations, Hayling AB Error Score 
and Delay Discount K). Based on previous work using this task and modelling framework 
(Paliwal et al., 2014), we focused our attention on exploring impulsivity as measured by the 
BIS.  
8.7.3 Gambling Behaviour 
8.7.3.1 Gambling Behaviour Pre- and Post-DBS 
At the group level, there were no significant differences in the behaviour of participants on the 
slot machine from pre- to post-DBS (Table 8.4). Due to subjects not engaging in the casino 
switch option, this variable was eliminated from regression analyses. 
 
Table 8.4 | Gambling Behaviour, Pre- and Post-DBS 
Gambling 
Behaviour 
Pre-DBS Post-DBS Pre- vs. Post-DBS 
Mean (SD, Range) t-stat (p-value) 
Bet Increases 39.732 (±42.98; 5-174.4) 54.896(±69.261; 5-339.75) -1.873 (0.069) 
Machine 
Switches 2.052 (±2.968; 0-12) 1.079 (±1.978; 0-10) 1.837 (0.074) 
Cashout 0.136 (±0.342; 0-1) 0 (±0; 0-0) N/A 
Double-up 10.736 (±9.841; 0-25) 13.132 (±9.510; 0-25) -1.483 (0.147) 
 
8.7.3.2 Pre-DBS Regression of BIS scores on Gambling Behaviour 
We studied the relationship between pre-DBS gambling behaviour and pre-DBS impulsivity 
as measured by the BIS (Table 8.5). The BDI was included in this regression in order to control 
for changes in clinical state attributable to depressive symptoms. The overall preoperative 
model including the BDI total was significantly associated with the BIS total score 
[` a,)) =3.024, p=0.031]. Post-hoc t-tests on task behaviour revealed that no behavioural 
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variable was significantly related to the BIS individually. When subscales of the BIS were 
examined, gambling behaviour associated significantly with the BIS Attentional subscale 
[` a,)) =4.094, p=0.008], where higher bet sizes corresponded to higher attentional impulsivity 
(P )b =2.303, p=0.028) (Supplementary Table 8.13). 
 
Table 8.5 | Pre-DBS Slot Machine Behaviour and Pre-DBS BIS 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variable Bet Size Machine Switch Double-up BDI cd F-stat p-value 
BIS Total 0.034 0.338 -0.077 0.821 0.268 3.024 0.0341* 
 
8.7.3.3 Post-DBS Regression of BIS scores on Gambling Behaviour 
The full model of postoperative gambling behaviour was also significantly associated with BIS 
total score [` a,)) =4.920, p=0.003] (Table 8.6). Again, post-hoc t-tests revealed that no task 
behaviour was significant on its own. When subscales of the BIS were examined, gambling 
behaviour correlated significantly with the BIS Attentional subscale [` a,)) =8.123, p<0.001]. 
Post-hoc t-tests revealed that higher bet sizes (P )b =2.604 p=0.014) and more frequent double 
or nothing gambles (P )b =2.589 p=0.014) corresponded to higher BIS Attentional scores 
(Supplementary Table 8.14).  
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Table 8.6 | Post-DBS Slot Machine Behaviour and Post-DBS BIS 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 
 Independent Variables (b)  
Dependent Variable Bet Size Machine Switch 
Double-
up BDI cd F-stat p-value 
BIS Total 0.018 0.128 0.263 0.712 0.374 4.920 0.003** 
 
Post-DBS, higher bets and more frequent machine switches were significantly associated with 
higher QUIP-RS scores (Supplementary Table 8.15). No other measures of impulsivity were 
significantly associated with pre- or post-DBS slot machine activity. 
8.7.3.4 Maximum BIS Increase and Perioperative Changes in Gambling Behaviour  
The change in gambling behaviours between the pre- and post-DBS time points were 
significantly associated with the maximum postoperative increase in BIS score. [` a,)) =3.516, 
p=0.017] (Table 8.7). Post-hoc t-tests revealed that the change in bet behaviour significantly 
was associated with maximum BIS increase (P )b =2.866, p=0.007). Additionally, the change 
in machine switch behaviour was also significantly associated with maximum BIS increase 
(P )b =2.219, p=0.034). In other words, changes in betting and slot machine switching 
behaviours after DBS indexed changes in impulsivity as assessed by the BIS. 
 
Table 8.7 | Pre-to-Post-DBS Slot Machine Behaviour and Max BIS Increase 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variable eBet Size eMachine Switch eDouble-up eBDI cd F-stat p-value 
Max BIS Increase 0.055^ 0.643^ 0.042 0.057 0.299 3.516 0.017* 
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8.7.4 Computational Modelling 
As described above, we were interested in evaluating the role of uncertainty and its association 
with postoperative changes in impulsivity in our cohort. We therefore first determined, using 
Bayesian model comparison, which of our three models best explained pre-DBS behaviour, 
before evaluating whether the parameter estimates of this winning model changed 
postoperatively and were associated with postoperative BIS scores. Bayesian model 
comparison selected the ‘standard’ HGF (with a participant-specific decision temperature in 
the response model) as the winning model, with a group-level Bayes factor of approximately 
12.5, compared to the next best model (the Rescorla-Wagner model) (Figure 8.5).  
 
 
Bayesian model comparison results across the Standard (Std), Uncertainty-driven (UD) and Rescorla Wagner (RW) models, 
pre- and post-DBS. Shown here are the group-level free energy values for the three models, Std, UD and RW. Pre-DBS model 
free energies are f`_g=-1994.54, h`i=-2005.82, and j`k=-1997.07. The winning model pre-DBS is the standard HGF. The 
group-level difference in free energy compared to the next best model (the Rescorla-Wagner model) is 2.53, corresponding to 
a Bayes factor of approximately 12.5. 
Figure 8.5 | Model Comparison Results 
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8.7.4.1 Parameter recoverability in the HGF 
We tested for parameter recoverability in the HGF, finding that ground truth parameter values 
for " and L could be recovered consistently, but we were unable to reliably recover + (Figure 
8.6). For this reason, we restricted the following analysis to parameters " and L when exploring 
the association between parameter values and questionnaire-based measures of impulsivity.  
 
 
The first plot above shows the mean of the recovered parameter values for "	across 10 inversions of the HGF on the y-axis, 
against the ground truth " values on the x-axis. The second plot shows the mean of recovered parameter values for + across 
10 inversions of the HGF on the y-axis, against the ground truth + values on the x-axis. The third plot shows the mean of the 
recovered parameter values for L across 10 inversions of the HGF on the y-axis, against the ground truth parameters for L on 
the x-axis. Error bars indicate the standard deviation of the recovered parameter estimates across 10 inversions. 
 
8.7.4.2 Changes in Model Parameter Estimates Pre- to Post-DBS 
Estimates of the HGF model perceptual parameter "	significantly increased postoperatively 
(P)b=-61.328, p<0.001), and estimates of L significantly decreased (P)b=2.124, p=0.04), 
implying larger subjective estimates of uncertainty (volatility) and greater stochasticity in the 
selection of responses after DBS (Table 8.8 and Figure 8.7). " represents a subject’s estimate 
about the tonic component of environmental volatility; i.e., how quickly the likelihood of 
winning on a given slot machine might be changing, while L represents the decision noise, or 
the stochasticity involved in the belief-to-choice mapping process. 
 
  
Figure 8.6 | Parameter Recoverability in the HGF 
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Table 8.8 | HGF Model Parameters, Pre- and Post-DBS 
Group means are reported with standard deviations and range in parentheses. Model parameters are reported in log space. 
Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-Bonferroni corrected for multiple comparisons with ! = 0.05.  
Parameter Pre-DBS Post-DBS t-stat p-value " -8.165 (0.207, -8.740--7.843) -5.491 (0.261, -6.187--4.952) -61.328 <0.001*** L 3.279 (2.802, 0.160-10.157) 2.218 (2.525, 0.096-9.721) 2.124 0.04* 
 
8.7.4.3 Pre-DBS Regression of BIS scores on Model Parameter Estimates 
The full regression model (including the estimates of preoperative perceptual and response 
parameters "	and L) was significantly associated with BIS total [ (`),)a)=3.372, p=0.03] (Table 
8.9). Post-hoc t-tests on model parameter estimates did not reveal any single parameter to be 
significantly related to the BIS on its own. When subscales of the BIS were examined, the full 
regression model associated significantly with the BIS Attentional subscale [` ),)a =3.314, 
p=0.031], but again no single parameter was independently significant (Supplementary Table 
8.16). 
 
Table 8.9 | Pre-DBS Model Parameters and Pre-DBS BIS 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variable l m BDI cd F-stat p-value 
BIS Total -5.306 -0.370 0.729 0.229 3.372 0.03* 
 
8.7.4.4 Post-DBS Regression of BIS scores on Model Parameter Estimates 
The full regression model was significantly associated with BIS total [` ),)a =10.906, p<0.001] 
(Table 8.10). Post-hoc t-tests revealed that " was a significant regressor (P )a =3.761, 
p=0.001). The positive regression coefficient for " implies that the greater the subjective 
estimate of uncertainty (tonic volatility), the higher the BIS score (Figure 8.7). In other words, 
although there was a group level decrease in BIS score pre-to-post DBS, at an individual level: 
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the greater postoperative estimate of uncertainty (i.e., the higher the estimated volatility of the 
slot machine’s winning probability), the greater the postoperative impulsivity. Thus, for 
participants with high subjective volatility estimates, there was likely to be a postoperative 
increase in BIS. When subscales of the BIS were examined, model parameter estimates 
correlated significantly with the BIS Attentional subscale [` ),)a =7.777, p<0.001] and the BIS 
Non-Planning subscale [` ),)a =7.642, p<0.001]. Post-hoc t-tests revealed that " was also a 
significant regressor in both of these associations (P )a =2.874, p=0.007 for BIS Attentional 
and P )a =2.561, p=0.015 for BIS Non-Planning) (Supplementary Table 8.17).  
 
Table 8.10 | Post-DBS Model Parameters and Post-DBS BIS 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variable l m BDI cd F-stat p-value 
BIS Total 17.434^ -0.007 0.943 0.49 10.906 <0.001*** 
 
8.7.4.5 Change in Model Parameters Associating with Maximum Change in BIS 
We were interested in whether individual pre- to postoperative changes in estimates of 
subjective uncertainty would correlate with the maximum postoperative change in impulsivity 
across six months of follow up post-DBS. The pre-to-post change in model parameter estimates 
was calculated as the preoperative minus the postoperative parameter estimate. In the case of ", postoperative parameter estimates were significantly higher than preoperative values (in the 
case of ", higher values imply higher uncertainty), therefore the Δ" value for each subject is 
negative and implies a post-operative increase in uncertainty. With regards to L, postoperative 
parameter estimate values were significantly lower than preoperative values (in the case of L, 
lower values imply greater stochasticity), therefore the ΔL value for most subjects is positive, 
implying a postoperative increase in the stochasticity of the belief-to-choice mapping. Changes 
in model parameter estimates were associated with the maximum post-operative increase in the 
BIS across all longitudinal assessments over six months [` ),)a = 3.987, p=0.015] (Table 8.11). 
Post-hoc t-tests revealed that ΔL was a significant regressor (P )a =3.312, p=0.002). The 
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positive regression coefficient here implies that a post-operative increase in decisional 
randomness related to a greater maximum increase in BIS (Figure 8.7). 
 
Table 8.11 | Max BIS Increase and Change in Model Parameters 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. Changes in " and L are calculated as the pre-DBS parameter estimate value minus the post-DBS 
parameter estimate value. Max BIS increase refers to the maximum impairment for impulsivity across all measurement 
intervals subsequent to DBS. 
 Independent Variables (b)  
Dependent Variable el em eBDI cd F-stat p-value 
Max BIS Increase 8.681 1.220^ -0.098 0.260 3.987 0.015* 
 
8.7.4.6 Supplementary Analyses 
We examined whether dopaminergic medication dosage expressed as a standardised unit 
(LEDD) was connected to computational model parameters and whether changes in drug doses 
postoperatively were connected to changes in uncertainty encoding. There was no significant 
relationship between pre-DBS model parameters and pre-DBS LEDD [` ',)o = 1.008, p=0.375] 
or post-DBS model parameters and post-DBS LEDD [` ',)o = 0.266, p=0.768]. Additionally, 
the pre-to-postoperative change in LEDD did not significantly relate to pre-to-postoperative 
change in BIS (Y=0.28, p=0.088). Also, the maximum decrease in LEDD across six months of 
follow up did not significantly relate to the postoperative maximum increase in BIS (Y=0.29, 
p=0.073),  
 
However, there was a significant relationship between the change in model parameter estimates 
and the maximum post-operative decrease in LEDD [` ',)o =4.032, p=0.027] (Supplementary 
Table 8.18). The BDI was not included in these regression models, as it is not a confound when 
examining a relationship between model parameter estimates and the LEDD. Post-hoc t-tests 
showed that ΔL was a significant regressor (P )a =2.832, p=0.008). The positive regression 
coefficient here implies that a post-operative increase in decisional stochasticity was observed 
in patients who had a larger post-operative decrease in LEDD. However, this relationship 
appeared to be driven by an outlier participant with a particularly large perioperative decrease 
in LEDD. When this participant was removed, the relationship was no longer statistically 
Chapter 8  189 
 
 
significant. We have removed the outlier in Figure 8.7 but a full plot including the outlier can 
be found in Supplementary Figure 8.9. 
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In the first row of figures, model parameter estimates for " and L, BIS scores and LEDD scores are displayed pre- and post-
DBS. For the box plots, the central line indicates the median of the distribution, and the top and bottom edges of the box 
represent the 25th and 75th percentiles respectively. The whiskers extend to the farthest data points that are included in the 
distribution and are not considered outliers. A paired t-test was performed to determine the pre-DBS vs. post-DBS difference 
in the distributions of ", L, the BIS and the LEDD. Significant differences were observed in estimates of parameter " (P )b =-
61.328, p<0.001) and in estimates of parameter L (P )b =-2.214, p=0.04) as shown in Table 8.8. Also shown is the change in 
BIS pre- and post-DBS (P )b =-2.66, p=0.033), as shown in Table 8.3. p-values are Holm-Bonferroni corrected for multiple 
comparisons with  = 0.05. The second row illustrates the relationship between pre-DBS " and pre-DBS BIS, pre-DBS L 
and pre-DBS BIS and the pre-to-post change in " with the max increase in BIS, as well as the max decrease in LEDD. The 
third row illustrates the relationship between post-DBS " and post-DBS BIS, post-DBS L and post-DBS BIS and the pre-to-
post change in L with the max increase in BIS. Here, we have removed the outlier in the plot relating the change in L to the 
max decrease in LEDD. These plots serve to better illustrate the results shown in Tables 8.10 and 8.11. Specifically, that 
greater volatility estimates (", the tendency of a slot machine’s winning probability to change) were associated with greater 
maximum postoperative BIS scores, and that greater stochasticity in belief-to-choice mapping (decision temperature - L) 
associated significantly with the maximum postoperative increase in BIS. 
 
Figure 8.7 | Computational Model Parameters, Pre- and Post-DBS 
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8.8 Discussion 
In this study, we employed a naturalistic gambling task and a hierarchical Bayesian model (for 
inference on participant-specific estimates of uncertainty) in order to investigate impulsive 
decision-making in participants with Parkinson’s disease undertaking subthalamic DBS.  
Gambling behaviour associated with a ‘gold-standard’ questionnaire (BIS) measure of 
impulsivity, with post-DBS changes in gambling behaviours indexing postoperative changes 
in impulsivity. We also found that parameter estimates representing subjective estimates of 
environmental uncertainty (volatility) changed significantly from pre- to postoperative 
conditions. In particular, there was a significant increase in ", that reflects a gambler’s estimate 
of how quickly the probability of winning on a given slot machine was changing (volatility), 
There was also a postoperative decrease in a second parameter, L, that captures the decision 
noise in a player’s belief-to-choice mapping. Notably, these model-based estimates of 
uncertainty related to postoperative impulsivity. The greater the postoperative estimate of ", 
the greater the postoperative BIS score. In other words, the more a participant perceived the 
pay-out tendency of a slot machine to be changing after DBS, the more impulsive they rated 
themselves. Additionally, the higher the pre- to postoperative decrease in estimates of L, the 
higher the postoperative increase in BIS score across six months of longitudinal follow up. In 
other words, the more a participant became indiscriminate in their belief-to-choice mapping 
after DBS, the more impulsive they rated themselves.  
 
Our gambling task utilised a multivariate response variable (bet increase, machine switch, 
casino switch and double-up) that captured different aspects of impulsivity and explorative 
behaviour. Furthermore, by employing a generative model that mapped observed responses to 
perceptual states, we were able to infer directly upon participant-specific parameters defining 
individual differences in uncertainty encoding. This is an important point of difference from a 
purely behavioural analysis, in which responses can have more than one (ambiguous) 
proximate cause. In the HGF, parameters are mathematically defined and have a concrete 
influence upon learning at different levels of the hierarchy (Mathys et al., 2011; Mathys et al., 
2014). 
 
What is the significance of individual differences in uncertainty encoding? Increased estimates 
of environmental uncertainty accelerate the rate of learning at higher hierarchical levels, which 
could engender maladaptive learning at lower levels of the hierarchy. A high learning rate 
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suppresses the influence of top-down expectations, and may impair learning about 
probabilistically aberrant events. In a recent investigation employing the HGF to model 
surprise about unexpected events, persons with autism learned more quickly about 
environmental volatility than controls without autism (Lawson et al., 2017). However, at lower 
levels of the hierarchy, the tendency to believe that environmental instability is unstable 
resulted in smaller prediction errors (surprise) when events violated expectations. In other 
words, when the world is judged to be unstable and unpredictable, an agent differentiates less 
between expected and unexpected outcomes. This offers a similar but computationally distinct 
account of the stimulation-related learning changes described in a previous study (Seymour et 
al., 2016), in which reduced positive and negative instrumental outcome sensitivity was 
reported as a consequence of neurostimulation. Similar to prior work, we found a positive 
relationship between model-based estimates of uncertainty and impulsivity (Averbeck et al., 
2013; Djamshidian et al., 2012; FitzGerald et al., 2015; Paliwal et al., 2014). A plausible 
computational account of impulsivity is that high subjective uncertainty leads to lack of 
predictability and thus increases a tendency for short-term reward seeking and exploration.  
 
We established that the ‘standard’ HGF best explained the gambling behaviour of our 
participants, in favour of a Rescorla-Wagner model or an ‘uncertainty-driven’ HGF. 
Importantly, the distinction between the standard and uncertainty-driven HGF models pertains 
only to the modelling of responses (the perceptual model is identical), in which the standard 
HGF employs a fixed decision temperature and the uncertainty-driven HGF a dynamic belief-
to-response mapping based on online estimates of uncertainty (of beliefs about winning 
probability). These model comparison results suggest that our participants incorporate 
estimates of volatility into their prediction of reward probability but do not vary the 
stochasticity of their responses in response to these estimates. This is an interesting point of 
difference from the findings amongst younger, healthy males who completed a similar (albeit 
much longer) version of this task (Paliwal et al., 2014) and future work will corroborate 
whether this finding of a static decision temperature is also observed amongst other 
neurodegenerative disorders. 
 
In our participants, neurostimulation may interact with the physiology of the STN and alter the 
computations it implements. A tripartite functional organisation of the STN into limbic, 
associative and motor subregions is suggested by primate and human studies (Haynes and 
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Haber, 2013; Lambert et al., 2012), with electrode implantation targeted to the dorsolateral 
sensorimotor region to address motor symptoms of Parkinson’s disease (Wodarg et al., 2012). 
Yet, the small size of the STN means that dispersion of electrical charge from a stimulating 
contact in this region could still modulate subthalamic regions with greater connectivity to 
fronto-striatal networks. The more ventral and medial the stimulating contact, the more likely 
these networks are to be affected by DBS. Previous investigations have suggested that the site 
of subthalamic stimulation can modulate cognitive (Hershey et al., 2010) and psychiatric 
symptoms (Mallet et al., 2007; Mosley et al., 2018d; Welter et al., 2014). How could STN-
DBS modulate uncertainty? From a computational perspective, the STN has been considered 
to implement a ‘delay’ on cognitive-associative circuits in the basal ganglia, allowing more 
information to be gathered to guide the most appropriate behavioural policy, suppressing 
impulsive and potentially error-prone responding (Cavanagh et al., 2011; Frank et al., 2007). 
It is possible that by modulating the decision threshold, STN-DBS could alter the bound for 
evidence accumulation and thus uncertainty in the representation of the reward environment 
(Herz et al., 2018; Pote et al., 2016). Further work employing drift diffusion modelling to 
quantify rates of evidence accumulation and decision boundaries after STN-DBS may be 
illuminating, having previously helped to elucidate the mechanisms underlying hallucinations 
in Parkinson’s disease (O'Callaghan et al., 2017). Further work is also required to determine if 
the site of stimulation affects the magnitude of changes in uncertainty estimation observed here 
and specifically if cognitive-associative or sensorimotor regions of the STN are most 
implicated in these shifts.  
 
We did not observe a cross-sectional relationship between dopaminergic medication (expressed 
as LEDD) and uncertainty encoding, nor did we observe a longitudinal relationship between 
LEDD and self-reported impulsivity. However, there was a longitudinal relationship between 
changes in model parameter estimates and the maximum reduction in LEDD during 
longitudinal follow up. Specifically, the greater the increase in decision noise (the greater the 
decrease in L), the greater the postoperative reduction in LEDD. It is difficult to be certain 
about whether this is a causal relationship and it may be an epiphenomenon of effective 
subthalamic DBS: One of the benefits of the STN (as opposed to other surgical targets in DBS 
for Parkinson’s disease such as the internal segment of the globus pallidus) is that it allows for 
significant postoperative reduction in dopaminergic medication. Therefore, this apparent 
relationship could well be mediated by the effect of electrical stimulation, increasing 
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indiscriminate responding and leading to a reduced requirement for dopaminergic therapy. 
Moreover, the finding that this relationship no longer held after the removal of an outlying 
participant decreases the confidence in this result. 
 
There are likely to be fundamental differences in the computational operations subserved by 
the STN and dopamine in decision-making and impulsive behaviour. We have discussed the 
chronometric role of the STN is setting a decision bound and delaying impulsive choice, 
whereas dopamine is likely to have an essential role in reinforcement learning and reward 
evaluation (Abler et al., 2006; Basar et al., 2010; Daw et al., 2006; Haber and Knutson, 2010; 
Kishida et al., 2016; Schultz et al., 1997; Tanaka et al., 2008; Wittmann et al., 2008). In a non-
surgical population, persons with Parkinson’s disease withdrawn from medication display a 
characteristic impairment in reward learning and may show enhanced punishment sensitivity 
(Frank et al., 2004). However, whilst dopamine replacement enhances the ability to learn from 
positive outcomes, learning from negative outcomes is impaired (Frank et al., 2004). Thus, if 
postoperative LEDD reduction were a principal driver of a change in behaviour subsequent to 
DBS, then a selective impairment in positive outcome representation would be expected. 
However, from the HGF perspective, an agent with increased uncertainty at higher levels would 
be expected to show both decreased reward and punishment learning, as surprise to both 
positive and negative unexpected outcomes would be reduced (Lawson et al., 2017). This 
suggests that LEDD changes may have a secondary role, but further careful experiments will 
be necessary to address this question. For example, the goal of this behavioural analysis was to 
relate a computational marker of uncertainty (over all trials) to impulsivity, but future 
neuroimaging investigations could model trial-wise positive and negative reward prediction 
errors and relate this to trial-wise brain activity. Participants could also be tested prior to STN-
DBS ‘on’ and ‘off’ medication (although in our cohort, participants were too impaired by their 
movement disorder to tolerate this and a group of less severely-affected individuals would be 
required).  
 
We did not observe significant correlations between behaviour or parameters inferred from slot 
machine play with other estimates of impulsivity including the excluded letter fluency task, the 
Hayling test and the delay discounting task. This reflects the multifaceted nature of impulsivity, 
which may implicate discrete subcortical and cortical regions and may evidence differential 
patterns of expression amongst impulsive endophenotypes (Nombela et al., 2014; Robbins et 
Chapter 8  195 
 
 
al., 2012). For example, the Hayling and ELF tasks are more commonly included amongst 
measures of task-switching and conflict interference, whilst the delay discounting task assesses 
impatience. Alternative paradigms may be required to capture participant-wise behaviour 
amongst these constructs.  
 
We acknowledge methodological limitations of our investigation. The lack of a 
counterbalanced on-off stimulation design means that we cannot directly infer that stimulation 
underlies the observed changes in perceptual modelling observed in our participants (rather 
than, for example, practice effects or time). Specifically, for our participants, the pre-DBS 
session was the first time they had performed the task, and so changes in postoperative 
behaviour could also be attributable to greater familiarity with the task and perhaps the inherent 
volatility of the reward structure. However, we suggest that a strength of our longitudinal 
design is that it is more reflective of the natural clinical course taken by persons with 
Parkinson’s disease in the clinic. Moreover, our participants simply would not have tolerated 
an extended DBS washout and we hypothesise that the younger age of participants in the study 
of Seymour et al may have facilitated their crossover design (Seymour et al., 2016). 
Nevertheless, it would be important to consider future experiments that could resolve this 
question, for example, selecting a cohort of younger Parkinson’s disease participants who could 
tolerate a washout of stimulation, or testing a cohort of participants without DBS twice, 
thirteen-weeks apart.  
 
Unfortunately, in this study, we were unable to utilise estimates of meta-volatility in our 
analysis as + could not be robustly recovered from simulated data. This failure to recover + 
might result from the limited number of trials (100) completed by each participant, which limits 
the amount of information that can be gathered to update estimates of this higher-level HGF 
parameter from the population prior. Again, the disability of our participant cohort prohibited 
a greater number of trials, as employed in previous studies using this paradigm (Paliwal et al., 
2014), but this could be considered in future studies using younger or less severely-affected 
participants.  
 
In summary, this study suggests that subjective estimates of uncertainty pertaining to 
environmental volatility and the stochasticity in belief-to-choice mapping change after 
subthalamic DBS for Parkinson’s disease and relate significantly to postoperative impulsivity. 
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Increased estimates of environmental uncertainty (volatility) and increased noise in the 
decision process may contribute to impulsivity as a clinically relevant form of maladaptive 
behaviour. Uncertainty elevates the learning rate and suppresses top-down expectations, which 
may blunt error signalling in a series of trial-wise outcomes. Similarly, a consistent decision 
rule with regards to acting on an internal model of the world is important to make appropriate 
decisions based on what has been learned. We therefore posit a cognitive mechanism for the 
genesis of impulsive behaviour in this population. Finally, our results demonstrate that a 
naturalistic assessment of gambling behaviour in a virtual casino is useful for investigating 
impulsivity in Parkinson’s disease. The potential of our model to explain changes in 
impulsivity through game play could be most valuable in this disorder, given the significant, 
but poorly quantified risks relating to surgical (neurostimulation) and medical (dopamine 
agonist) treatments. If those at a higher risk of neuropsychiatric harm could be identified, this 
would improve the nature of treatment choice and informed consent and the effectiveness of 
clinical follow-up. 
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8.9 Supplementary Data 
Supplementary Table 8.12 | Additional Neuropsychiatric Assessment Data Pre- and Post-DBS 
Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-Bonferroni corrected for multiple comparisons with ! = 0.05. 
 
Behavioural Measure 
Pre-DBS Post-DBS Max Impairment Pre- vs. Post-DBS 
Mean (SD), Median (Range) t-stat p-value 
BIS Attentional 16.1 (±3.2), 16 (10 - 23) 
15.0 (±3.4), 
15 (8 - 22) 
0.39 (±2.8), 
0 (-5 - 5) 2.64 0.06 
BIS Non-Planning 23.0 (±4.1), 23 (14 - 33) 
22.4 (±5.2), 
22 (15 - 36) 
2.3 (±3.7), 
2 (-6 - 9) 1.09 0.84 
BIS Motor 21.2 (±3.3), 21 (14 - 29) 
20.3 (±3.4) 
21 (13 - 30) 
1.2 (±3.5), 
1 (-7 - 14) 1.87 0.28 
Apathy Scale 11.5 (±5.7) 11 (1 - 26) 
11.3 (±5.5) 
11 (1 - 23) 
2.8 (±4.2), 
2 (-3 - 14) 0.30 1.54 
Empathy Quotient 40.7 (±13.1) 39.5 (16 – 68) 
40.4 (± 14.3) 
36 (14 – 68) 
-4.7 (±7.9), 
-5 (-26 - 13) 0.27 1.54 
Geriatric Anxiety 
Inventory 
4.9 (±4.3), 
5 (0 - 17) 
3.0 (±4.0), 
2 (0 - 20) 
0.55 (±3.4), 
0 (-5 - 11) 3.62 <0.001* 
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The participant-wise trajectories of key variables were inspected across all intervals in the investigation. Representative figures 
are presented below. Although mean changes were not significantly different at postoperative assessments, there was 
considerable inter-individual heterogeneity in postoperative course. 
BIS = Barratt Impulsiveness Scale, QUIP = Questionnaire for Impulsive-Compulsive Disorders in PD, ELF = Excluded Letter 
Fluency. Pre = Pre-DBS, FU1 = 2-weeks post-DBS, FU2 = 6-weeks post-DBS, FU3 = 13-weeks post-DBS, FU4 = 26-weeks 
post-DBS. 
 
  
Supplementary Figure 8.8 | Heterogeneity in Participant-Wise Trajectories 
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Supplementary Table 8.13 | Pre-DBS Slot Machine Behaviour and Pre-DBS BIS Subscales 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variables Bet Size Machine Switch 
Double-
up BDI cd F-stat p-value 
BIS Non-Planning 0.012 -0.028 -0.056 0.343 0.179 1.801 0.152 
BIS Motor -0.003 0.266 -0.046 0.138 0.094 0.858 0.499 
BIS Attentional 0.025^ 0.100 0.025 3.314 0.332 4.094    0.008** 
 
 
Supplementary Table 8.14 | Post-DBS Slot Machine Behaviour and Post-DBS BIS Subscales 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variables Bet Size Machine Switch 
Double-
up BDI cd F-stat p-value 
BIS Non-Planning 0.006 -0.237 0.031 0.439 0.303 3.588 0.016* 
BIS Motor -0.004 0.467 0.115 0.026 0.250 2.753 0.044* 
BIS Attentional 0.016^ -0.101 0.123^ 0.254 0.496 8.123 <0.001*** 
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Supplementary Table 8.15 | Post-DBS Gambling Behaviour and Post-DBS QUIP-RS 
The QUIP and LEDD correlated strongly at both time points (YZ[\=0.42, p=0.008; YZ]^_=0.44, p=0.005), with LEDD 
decreasing significantly post-DBS. LEDD was therefore included as a covariate when regressing against QUIP-RS total scores, 
in order to explain the remaining variance in QUIP due to gambling behaviour. This is consistent with a previous association 
of dopaminergic medication with compulsive behavioural disorders in PD (Weintraub et al., 2010). 
Higher bets (P )b =2.057, p=0.048) and more frequent machine switches (P )b =3.268, p=0.016) corresponded with higher 
QUIP scores. 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent 
Variable 
Bet Size 
Machine 
Switch 
Gamble LEDD cd F-stat p-value 
QUIP 0.073^ 3.268^ -0.137 0.004 0.248 2.727 0.046* 
 
 
Supplementary Table 8.16 | Pre-DBS Model Parameters and Pre-DBS BIS Subscales 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variables l m BDI cd F-stat p-value 
BIS Non-Planning -3.268 -0.056 0.326 0.172 2.351 0.090 
BIS Motor -1.222 -0.088 0.085 0.020 0.226 0.877 
BIS Attentional -0.817 -0.225 0.318 0.226 3.314 0.031* 
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Supplementary Table 8.17 | Post-DBS Model Parameters and Post-DBS BIS Subscales 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. 
 Independent Variables (b)  
Dependent Variables l m BDI cd F-stat p-value 
BIS Non-Planning 7.024^ 0.142 0.480 0.403 7.642 <0.001*** 
BIS Motor 5.259 -0.022 0.139 0.175 2.400 0.085 
BIS Attentional 5.150^ -0.127 0.324 0.407 7.777 <0.001*** 
 
 
Supplementary Table 8.18 | Max LEDD Reduction and Change in Model Parameters 
b values are standardized regression coefficients. Significance: *** p<0.001, ** p<0.01, * p<0.05, where p-values are Holm-
Bonferroni corrected for multiple comparisons with ! = 0.05. ^ Indicates significant t-statistics, Holm-Bonferroni corrected 
for multiple comparisons. Changes in " and L are calculated as the pre-DBS parameter estimate value minus the post-DBS 
parameter estimate value. Max LEDD decrease refers to the maximum postoperative reduction of dopaminergic medication 
across all measurement intervals subsequent to DBS. 
 Independent Variables (b)  
Dependent Variable el em cd F-stat p-value 
Max LEDD decrease 591.26 89.22^ 0.187 4.032 0.02* 
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Shown in the figure above is a version of Figure 8.7 in the main manuscript, with one change. Here, we have included the 
outlier in assessing the relationship between the pre-to-post operative change in L with the Max LEDD Decrease. As can be 
seen here, the outlier is driving the statistical relationship between these variables. The full figure is replicated here to provide 
the context of these analyses. 
 
 
 
 
Supplementary Figure 8.9 | Computational Model Parameters, Pre-and Post-DBS 
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Chapter 9 
9 The Structure of Discrete Brain Networks Underlies 
Impulsivity & Gambling in Parkinson’s disease 
‘Did neurologists tell you about side effects?’ (Interviewer) 
‘Only the caveat to - don't sue me. You'll let me know if you start having expansive thoughts and exaggerated 
thoughts about buying Lamborghinis or Ferraris. It was always Ferraris and Lamborghinis. That's probably 
because most neurologists probably aspire to them. But it might have tapped into their psyche and their needs. 
Might have small dicks or something I don't know. I hope that's in there [laughs].’ 
DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic deep brain 
stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
9.1 Publication Details 
This chapter was published as: 
Mosley, P.E., Paliwal, S., Robinson, K., Coyne, T., Silburn, P., Tittgemeyer, M., Stephan, K., 
Breakspear, M. & Perry, A., 2019. The structural connectivity of discrete networks underlies 
impulsivity and gambling in Parkinson’s. Brain. In press. 
9.2 Contribution to Authorship 
The author (Dr Mosley) conceived the project, consented the participants, collected the 
quantitative data, performed the neuroimaging and statistical analyses, and wrote the 
manuscript. Ms Robinson assisted with data collection. Dr Paliwal and Prof Stephan developed 
the virtual casino played by participants. A/Prof Coyne and Prof Silburn implanted the DBS 
devices for all participants with Parkinson’s disease. Prof Tittgemeyer shared a diffusion 
imaging sequence developed at the Max Planck Institute. Prof Breakspear provided supervision 
in statistical analyses and critical revisions of the manuscript. Dr Perry developed the diffusion 
imaging analysis pipeline and supervised neuroimaging analyses.  
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9.3 Abstract 
Impulsivity in Parkinson’s disease may be mediated by faulty evaluation of rewards or the 
failure to inhibit inappropriate choices. Despite prior work suggesting that distinct neural 
networks underlie these cognitive operations, there has been little study of these networks in 
Parkinson’s disease, and their relationship to inter-individual differences in impulsivity. High-
resolution diffusion MRI data were acquired from fifty-seven persons with Parkinson’s disease 
(19 females, mean age 62, mean Hoehn and Yahr stage 2.6) prior to surgery for deep brain 
stimulation. Reward evaluation and response inhibition networks were reconstructed with 
seed-based probabilistic tractography. Impulsivity was evaluated using two approaches: 
Firstly, neuropsychiatric instruments were used to assess latent constructs of impulsivity, 
including trait impulsiveness and compulsivity, disinhibition, and also impatience. Secondly, 
participants gambled in an ecologically-valid virtual casino to obtain a behavioural read-out of 
explorative, risk-taking, impulsive behaviour. Multivariate analyses revealed that different 
components of impulsivity were associated with distinct variations in structural connectivity, 
implicating both reward evaluation and response inhibition networks. Larger bet sizes in the 
virtual casino were associated with greater connectivity of the reward evaluation network, 
particularly bilateral fibre tracts between the ventral striatum (VS) and ventromedial prefrontal 
cortex (vmPFC). In contrast, weaker connectivity of the response inhibition network was 
associated with increased exploration of alternative slot machines in the virtual casino, with 
right-hemispheric tracts between the subthalamic nucleus (STN) and the pre-supplementary 
motor area (SMA) contributing most strongly. Finally, reduced connectivity of the reward 
evaluation network was associated with more double-or-nothing gambles, weighted by 
connections between the STN and vmPFC. Notably, the variance explained by structural 
connectivity was higher for behavioural indices of impulsivity, derived from clinician-
administered tasks and the gambling paradigm, as compared to questionnaire data. Lastly, a 
clinically-meaningful distinction could be made amongst participants with a history of impulse 
control behaviours (ICBs) based on the interaction of their network connectivity with 
medication dosage and gambling behaviour. In summary, we report structural brain-behaviour 
co-variation in Parkinson’s disease with distinct reward evaluation and response inhibition 
networks that underlie dissociable aspects of impulsivity (c.f. choosing and stopping). More 
broadly, our findings demonstrate the potential of employing naturalistic paradigms and 
neuroimaging techniques in clinical settings to assist in the identification of those susceptible 
to harmful behaviours.  
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9.4 Introduction 
Parkinson’s disease is generally viewed as a movement disorder characterised by slowing of 
action initiation, yet some individuals develop deficits in inhibitory-control and compulsive 
choice (Djamshidian et al., 2012; Gauggel et al., 2004; Kobayakawa et al., 2008; Milenkova 
et al., 2011; Nombela et al., 2014; Obeso et al., 2011). Approximately fifteen percent of those 
treated with dopamine replacement therapy develop a spectrum of impulse control behaviours 
(ICBs), including pathological gambling, hypersexuality, compulsive shopping and binge-
eating (Weintraub et al., 2010). However, other persons with Parkinson’s disease under the 
same treatment display no or less-pronounced impulsive biases without clinically-significant 
impairment, suggestive of underlying neurobiological differences in the susceptibility to ICBs. 
If these neurobiological determinants could be elucidated, enhanced identification of those 
vulnerable to ICBs would be possible. Furthermore, the understanding of other psychiatric 
conditions characterised by impulsivity and compulsivity (such as addiction) could be enriched 
(Robbins et al., 2012).  
 
Neurodegeneration and dopaminergic medication are two key biological mechanisms 
contributing to impulsivity in Parkinson’s disease. Degeneration of midbrain dopaminergic 
neurons is the neuropathological hallmark of Parkinson’s disease, most often affecting the 
ventral tier of neurons projecting to the dorsal striatum (Kish et al., 1988), precipitating motor 
symptoms. However, the dorsal tier of neurons projecting to the ventral striatum (the 
mesolimbic pathway) may also be vulnerable to neurodegeneration, even at diagnosis (van der 
Vegt et al., 2013). The ventral striatum (VS) is implicated in the integration of emotional, 
contextual and motivational information, with the ability to influence goal-oriented motor 
behaviour through feed-forward connections in the basal ganglia. For example, the VS is active 
during the experience of reward, and also during the anticipation of an appetitive stimulus, 
forming the basis of a reward prediction error signal (Knutson et al., 2001; O'Doherty et al., 
2002). Dopaminergic replacement therapy restores motor function in Parkinson’s disease but 
may disrupt the homeostatic role of midbrain dopaminergic neurons and modulate the 
regulatory input of the prefrontal cortex to the VS (Goto and Grace, 2005; Grace, 2008). The 
preservation of mesolimbic relative to nigrostriatal projections in Parkinson’s disease 
(Kumakura et al., 2010) means that dopaminergic transients in the VS encoding reward 
prediction errors may be biased by supplemental dopaminergic medication and result in 
exaggerated, ‘better than expected’ teaching signals, driving escalation of risky behaviours 
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with a tendency to discount losses (Voon et al., 2010a). Dopamine agonist medication also 
mediates elevated rates of reflection impulsivity (Djamshidian et al., 2013), but only increases 
temporal discounting (Voon et al., 2010b) and risk taking (Claassen et al., 2011; Voon et al., 
2011a) in persons with pre-existing ICBs. This suggests that dopaminergic medication in 
Parkinson’s disease is acting upon an ‘at-risk’ neural substrate rather than being a sufficient 
aetiological factor in isolation.  
 
Reward evaluation and response inhibition are two distinct neurocognitive mechanisms that 
likely underlie impulsive behaviour (c.f. making a choice versus suppressing an inappropriate 
choice). As aforementioned, reward evaluation (including appetitive learning and 
reinforcement) is underpinned by dopaminergic signalling within mesocorticolimbic networks 
(Haber and Knutson, 2010) and their connections with the orbitofrontal cortex (van Eimeren et 
al., 2010) and anterior cingulate cortex (Carriere et al., 2015; Cilia et al., 2011). These cortical 
regions are associated with the prediction and evaluation of behavioural outcomes, amongst 
other functions (Kolling et al., 2016; Rudebeck and Murray, 2014). Response inhibition is 
likely to be subserved by distinct neural networks in Parkinson’s disease (Antonelli et al., 2014) 
and healthy controls (Hampton et al., 2017). This ‘stopping network’ has been well 
characterised in non-clinical populations and is a predominantly right-lateralised network 
involving the inferior frontal gyrus (IFG), the pre-supplementary motor area (pre-SMA) and 
the subthalamic nucleus (STN) (Aron et al., 2007; Rae et al., 2015). The STN receives direct 
cortical projections from the IFG and pre-SMA in the ‘hyperdirect’ pathway, which serves to 
deliver a global ‘stopping’ signal to the basal ganglia in response to the detection of cognitive 
conflict (Aron, 2011). In Parkinson’s disease, the firing pattern of the STN increases in 
response to dopaminergic denervation (Vila et al., 2000), leading to bradykinesia, rigidity and 
tremor that can be successfully treated with deep brain stimulation (DBS) (Schuepbach et al., 
2013), signifying the central role of this nucleus in the pathophysiology of motor symptoms. 
However, the spread of electrical stimulation throughout discrete territories of the 
topographically-organised STN may underlie increased impulsivity subsequent to STN-DBS 
(Mosley et al., 2018d), supporting the role of this nucleus as a key node in non-motor aspects 
of response inhibition.  
 
Diffusion MRI (dMRI) is a neuroimaging technique that can be employed to characterise the 
architecture of white matter tracts in the brain (Jbabdi et al., 2015), which may provide new 
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insights into mechanisms of disease or therapy. For example, in Parkinson’s disease, the use of 
dMRI has revealed that structural connectivity of motor networks is predictive of clinically-
effective subthalamic stimulation (Accolla et al., 2016; Akram et al., 2017; Chen et al., 2018; 
Horn et al., 2017; Vanegas-Arroyave et al., 2016). However, there has been little study of 
cortico-subcortical networks with reference to impulsivity in Parkinson’s disease, although 
spatially-extensive white matter pathology in frontostriatal circuits may be present at early 
clinical stages (Rae et al., 2012). The presence of ICBs in Parkinson’s disease has been 
associated with reductions in Diffusion Tensor Imaging (DTI)-derived indices of white-matter 
‘integrity’ within frontal and mesolimbic tracts (relative to non-ICB patients) (Imperiale et al., 
2018). However, these investigations are typically constrained to between-group comparisons 
(i.e. ICB vs. non-ICBs), and hence the complex relationships between white matter changes 
and the multifaceted aspects of impulsivity remain poorly understood.  
 
Using a high-resolution dMRI acquisition, we sought to characterise the anatomical networks 
that underlie the different facets of impulsivity in Parkinson’s disease. We employed 
neuropsychiatric instruments and a novel task assessing gambling behaviour (Paliwal et al., 
2019), which we hypothesised would form a more ecologically-valid measure of impulsivity. 
We postulated that dimensional variations in impulsivity would relate to inter-individual 
differences in network connectivity and that different networks would be implicated in 
different aspects of impulsive responding. By elucidating the multi-faceted nature of 
impulsivity, spanning neuroanatomy and behaviour, during an ecologically-valid task, we 
aimed to create a behavioural read-out of impulsivity in Parkinson’s disease that could assist 
with diagnostic and prognostic assessment. In particular, we were interested in whether these 
measures would allow us to discriminate persons with clinically-significant ICBs. 
9.5 Methods 
9.5.1 Participants 
Participants were consecutively recruited at the Asia-Pacific Centre for Neuromodulation in 
Brisbane, Australia between 2016-2018. All participants met the UK Brain Bank criteria for 
Parkinson’s disease (Hughes et al., 1992) and at the time of recruitment were being assessed 
for subthalamic deep brain stimulation. All participants were at Hoehn and Yahr stage 2 or 
greater (Hoehn and Yahr, 1967) with motor fluctuations or other motor complications related 
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to dopaminergic therapy. No participants met the Movement Disorder Society criteria for 
dementia (Emre et al., 2007). The disease subtype was established based on an analysis of the 
dominant symptoms elicited during the Unified Parkinson’s Disease Rating Scale (UPDRS) 
Part III Motor Examination, as described in Spiegel et al (2007). Dopaminergic medication was 
converted to a levodopa-equivalent daily dose (LEDD) value (Evans et al., 2004). Further 
details regarding recruitment and baseline assessment have been previously reported (Mosley 
et al., 2018a). 
9.5.1.1 Sample Size Calculation 
A sample size calculation for a categorical assay of structural connectivity and impulsivity was 
informed by Imperiale et al. (2018), who compared the structural integrity of fronto-striatal 
white matter tracts by ICB status. Employing the reported differences in fractional anisotropy 
(0.03 ±0.03) and mean diffusivity (0.05 ±0.05) in these tracts, yielded an effect size of 1. 
Assuming a ratio of ICBs to no ICBs in our sample of 0.5:1, an independent two-sample t test, 
with an alpha of 0.05 and a power of 0.90, a total sample size of 50 was calculated using 
G*Power (version 3.1.9.3) (Faul et al., 2009). No prior work was available to inform a sample 
size calculation for a dimensional assessment of impulsivity in persons with Parkinson’s 
disease. However, in the study of Rae et al. (2015), the mean diffusivity of prefrontal-STN 
white matter tracts was correlated with action cancellation in a sample of healthy controls. 
Employing the positive correlation (r = 0.517) in these measures, a sample size of 36 was 
estimated.  
9.5.2 Assessment of impulsivity 
9.5.2.1 Neuropsychiatric Instruments 
Impulsivity was first assessed with a range of neuropsychiatric instruments, acknowledging the 
multidimensional nature of this construct. These included: trait impulsiveness: the Barratt 
Impulsiveness Scale 11 (BIS) and attentional, motor and non-planning subscales (Patton et al., 
1995); impulsive and compulsive behaviours (ICBs): the Questionnaire for Impulsive-
Compulsive disorders in PD Rating Scale (QUIP-RS) (Weintraub et al., 2012); impatience: the 
Delay Discounting task (Kirby et al., 1999); disinhibition: the Excluded Letter Fluency task 
(ELF) (Shores et al., 2006) and the Hayling test (Burgess et al., 1997). Broadly, these 
instruments could be distinguished by modality: the BIS and QUIP-RS are questionnaires 
completed by the participant, whilst the ELF, Hayling and Delay Discounting tasks are 
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administered by an examiner. Although the use of subscales has been criticised (Reise et al., 
2013), we opted to employ the BIS subscales based on their prior utility in explicating relevant 
behavioural features of Parkinson’s disease (Antonini et al., 2011; Smulders et al., 2014) and 
in order to maintain consistency with prior work (Mosley et al., 2018a). 
9.5.2.2 Gambling Paradigm  
In addition to these classical assessments of impulsivity, participants also gambled on slot 
machines within a virtual casino, which has been described and validated in healthy controls 
and persons with Parkinson’s disease (Paliwal et al., 2014; Paliwal et al., 2019). The motivation 
for this task was to provide a realistic simulation of impulsive behaviours. Participants started 
the casino with 2000 AUD (virtual money) in their account, and played through 100 trials 
where a gambling choice was required. In the casino, there were four slot machines to choose 
from; participants could move between machines at any time. Each slot machine had a unique 
visual appearance and soundtrack and participants were informed that different machines might 
have different outcome expectancies. On each trial, participants placed a bet that they were 
able to increase in increments of five or ten AUD with no maximum upper limit per bet. Once 
the bet was placed, a ‘Pull!’ button triggered three spinning wheels. After five seconds, the 
outcomes of the first, the second and third wheel were sequentially revealed. During this time, 
participants were also able to trigger an earlier reveal by using a ‘Stop!’ button. Win trials were 
signified by the nature of matching symbols across the three wheels. On all win trials, the 
participant was given the option to ‘Double-Up!’, engaging in a secondary double-or-nothing 
gamble, risking the total win amount (Figure 9.1). Notably, the trajectory of win-loss outcomes 
was predetermined, ensuring that participants’ experience of rewards and losses were 
comparable in order and quantity. The trajectory resulted in a positive outcome (net winnings) 
for most participants. At the end of the task, participants were awarded up to 30 AUD in real 
money based on the size of these virtual winnings. 
 
This naturalistic gambling task allowed for impulsive behaviour to be expressed in several 
ways on each trial: bet increases (in principle, of unlimited magnitude), exploratory slot 
machine switches, double-or-nothing gambles and cashouts. Keeping in mind that in the 
behavioural sciences ‘risk’ is typically defined in relation to the variance of choice outcomes 
(Johnson and Busemeyer, 2010), these actions are indicative of exploration and risk-taking as 
they increase the range of possible outcomes. For example, for a machine switch, regardless of 
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whether the player is performing well or poorly on the current machine, the decision to switch 
machines incurs the possibility that the new machine chosen may be more punishing or 
rewarding than the current machine, thereby making the player vulnerable to increased variance 
in outcomes. Similarly, a bet increase is a risk-inducing shift in the face of uncertainty, making 
the player more susceptible to larger wins and losses. In sum, each action implies a broadening 
of possible outcomes (risk), and may be understood as reflecting impulsivity. Further 
description of the gambling paradigm can be found in Paliwal et al. (2019).  
 
Participants completed the experimental tasks ‘on’ medication in order to protect participants 
against discomfort arising from ‘off’ states, which were generally severe in this peri-surgical 
population. LEDD was included as a covariate in subsequent analyses. Although dopamine 
agonists as a class are associated with an elevated risk of ICBs (Weintraub et al., 2010), we 
included all dopaminergic medication in the calculation of LEDD, given that ICBs are also 
more prevalent in persons on levodopa, as well as the substantial prior literature linking 
dopamine to changes in reward learning (and thus impulsivity) in preclinical models (Schultz 
et al., 1997), healthy persons (Abler et al., 2006) and persons with Parkinson’s disease (Frank 
et al., 2004). 
  
  211 
 
 
 
The task consists of 100 trials. On every trial, participants are able to place a bet of unlimited magnitude, switch slot machines 
or ‘cash out’, exiting the casino and returning again on another virtual ‘day’. The overall win probability is 25 %, with wins 
split into big wins and small wins. The two possible types of losses are near-misses, in which the first two wheels are the same 
and the third is different (i.e. AAB) or a true loss, in which all the wheels are different (i.e. ABC). For each loss trial, 
participants are taken directly to the beginning of the next trial. On all win trials, players are given 3 seconds to decide whether 
or not to engage in a ‘double-or-nothing’ option. If the participant elects to engage in this gamble, a card flips over revealing 
the result, and gamblers are taken to the next trial. If the player does nothing, or decides not to gamble, he or she is taken to 
the next trial. The trajectory of win-loss outcomes is fixed, ensuring that the participants are exposed to a comparable 
experience of sequential rewards and losses.  
 
 
   
Figure 9.1| Slot Machine Gambling Paradigm 
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9.5.3 dMRI Acquisition  
dMRI data were acquired using a 3T Siemens PRISMA scanner, with a 64-channel array head 
coil. For each scan, the diffusion-weighting was distributed in an isotropic manner (1.7 mm3 
voxel resolution) along 90 directions with a b-value of 3000s/mm2 (phase-encoding in anterior-
posterior direction), using a twice-refocused spin-echo planar imaging (EPI) sequence. Twelve 
non-diffusion-weighted images (b0) were acquired and interleaved throughout this sequence. 
An additional sequence of 8 non-diffusion weighted images were acquired in the opposite 
phase-encoding direction (posterior-anterior).  
 
A structural T1-weighted MPRAGE was also acquired with parameters as follows: 1 mm3 
voxel-resolution, TR = 2000 ms, TE = 2.38 ms, flip angle = 9°, matrix size = 256 × 256, FOV 
= 256 × 256 × 192. 
9.5.4 Diffusion Image Pre-Processing 
dMRI data were pre-processed using functions provided within MRtrix3 software (Tournier et 
al., 2019), (https://github.com/MRtrix3/mrtrix3/releases/tag/3.0_RC3), called from a pre-
processing pipeline developed in-house (https://github.com/breakspear/diffusion-pipeline). 
The dMRI data were first denoised (Veraart et al., 2016) and then corrected for motion, 
susceptibility, and eddy-current induced distortions within FSL eddy (Andersson and 
Sotiropoulos, 2016), leveraging the reverse phase-encoding acquisition to estimate the 
inhomogeneity fields. FSL eddy (using --repol) was also used to detect slice signal outliers due 
to bulk motion, corrected using a non-parametric replacement method (Andersson et al., 2016). 
Finally, bias-intensity correction was performed (Zhang et al., 2001). 
9.5.5 Intensity Normalization and Fibre Reconstruction 
To permit the comparison of fibre reconstruction and structural connectivity estimates across 
participants, group-average intensity normalization was performed. Briefly, fractional 
anisotropy (FA) maps were first calculated from the bias-corrected diffusion images of each 
participant (Figure 9.2A), and non-linearly registered to a generated population-average FA 
template (Figure 9.2B). The population template was subsequently used to derive an average 
white-matter mask (FA > 0.4), which was warped back into individual space, and then intensity 
normalization was performed on the dMRI data. This ensured that the median b0 white-matter 
value was uniform across study participants (Raffelt et al., 2012).  
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From the intensity-normalized diffusion data, the signal responses across different tissue-types 
(grey-matter, white-matter, CSF) were estimated (Dhollander et al., 2016; Dhollander et al., 
2018) and then averaged across all participants to obtain a group-wise response function. 
Through constrained spherical deconvolution (CSD) (lmax = 8, msmt_csd) (Jeurissen et al., 
2014) of the average white-matter signal contribution, fibre orientation distribution functions 
(fODF) were estimated for each participant (Figure 9.2C). The fODF provides local estimates 
of the apparent density of fibres as a function of angular orientation (Tournier et al., 2004; 
Tournier et al., 2007). CSD is able to resolve complex local fibre orientations and amplitudes 
at high-precision (Raffelt et al., 2015) and the acquisition protocol in this investigation was 
designed to maximise this capability.  
9.5.6 Fibre Reconstruction and Tractography 
The probabilistic streamline algorithm iFOD2 (Tournier et al., 2010) was used to reconstruct 
fibre-bundles within two networks that were defined a priori, based upon their involvement in 
reward evaluation and response inhibition (see below). Through sampling a probability density 
function of the fODF at each path point, the iFOD2 algorithm tracked the most plausible fibre 
propagations between seed and target regions, until 100 streamlines in total were reconstructed 
(Figure 9.2D). The default (for the acquired voxel resolution) tracking parameters were as 
follows: step size = 0.86 mm, minimum length = 8.56 mm, max length = 250 mm, 
seed/termination fODF threshold = 0.05, curvature constraint = 1 mm radius.  
 
All cortical and basal ganglia regions used in seed-based tractography were in MNI ICBM 
nonlinear asymmetric space. Parcellations were first transformed into individual anatomical 
space through non-linear co-registration of the skull-stripped T1 image and the ICBM template 
(Avants et al., 2008). Resultant parcellations (now in anatomical space) were then co-registered 
into diffusion space, applying a transformation matrix derived from boundary-based 
registration (Greve and Fischl, 2009) of the anatomical and mean b0 diffusion images.  
9.5.7 Apparent Fibre Density 
Estimates of structural connectivity between each seed and target region was derived from the 
apparent fibre density (AFD) (Raffelt et al., 2012), calculated by summing the fODF lobe 
integrals along each pathway of interest, approximating the total fibre volume. To correct for 
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differences in fibre length, the total fibre volume was divided by the mean streamline length to 
estimate the cross-sectional area of the fibre bundle, providing a measure of fibre ‘density’ 
independent of fibre length (Figure 9.2E). In two participants, the probabilistic streamline 
algorithm was unable to reconstruct fibre bundles between the VTA and VS in one hemisphere. 
For these two measurements, the AFD was consequently set at zero.  
 
AFD affords a more biologically-interpretable quantification of structural connectivity along a 
given bundle in comparison to traditional tensor-derived metrics such as fractional anisotropy 
(FA) and mean diffusivity (MD) (Calamante et al., 2015; Raffelt et al., 2012). Tensor-based 
metrics provide an average value across all voxels traversed by the pathway of interest and 
their biological interpretation in neurological disorders is contested, especially in tissue that 
contain crossing fibres (Raffelt et al., 2015; Riffert et al., 2014; Scheck et al., 2015). 
9.5.8 Reward Evaluation and Response Inhibition Networks 
Two discrete brain networks subserving reward evaluation and response inhibition were 
reconstructed with seed-based tractography. The reward evaluation network (Figure 9.2F) 
included streamline propagations connecting the ventral striatum (VS) with the ventromedial 
prefrontal cortex (vmPFC), the orbitofrontal cortex (OFC), the anterior cingulate cortex (ACC) 
and the ventral tegmental area (VTA). The connectivity of the STN with the vmPFC was also 
included in the reward evaluation network given the limbic connectivity of the STN (Haynes 
and Haber, 2013) and recent evidence suggesting changes in value sensitivity subsequent to 
STN-DBS for Parkinson’s disease (Seymour et al., 2016). The response inhibition network 
(Figure 9.2G) included tracts connecting the STN with the inferior frontal gyrus (IFG) and the 
pre-supplementary motor area (SMA).  
 
The cortical targets for these networks were selected from a gold-standard subdivision of the 
cortex based on multimodal MRI data (Glasser et al., 2016), which were initially projected 
onto volumetric MNI ICBM nonlinear asymmetric 2009a space (Horn, 2016). These included 
areas 10r and 10v (vmPFC), OFC and pOFC (OFC), a24 and p24 (ACC), 45 and 47l (IFG), 
6ma and 6mp (SMA). The basal ganglia parcellations (within 2009b space) that served as seeds 
within these tractography networks included the VS (Choi et al., 2012), the VTA (Pauli et al., 
2018), and the STN (Ewert et al., 2018). For VTA-VS connections, the VTA was defined as 
the seed-region.  
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A: High angular-resolution diffusion-weighted imaging was acquired along 90 directions using a 3T scanner and a 64-channel 
array head coil, with a b-value of 3000s/mm2 and voxel size of 1.7 mm3 isotropic. After denoising, and correction for motion, 
susceptibility, bias and eddy-current induced distortions, fractional anisotropy (FA) maps were calculated for each participant. 
B: FA maps were non-linearly registered to a population-average FA template, in order to derive an average white matter 
mask, which was then warped back into individual space to permit intensity normalisation on the diffusion data. This ensured 
that the median b0 white matter value was uniform across the study population. C: From the intensity-normalised diffusion 
data, signal responses across different tissue types (grey-matter, white-matter, CSF) were estimated and averaged across all 
participants to obtain a group-wise response function. Constrained spherical deconvolution of the average white-matter signal 
furnished fibre orientation distribution functions (fODF) for each participant. These functions provide local estimates of the 
density of fibres according to their angular orientation and can resolve complex organisations of crossing fibres more 
effectively than single tensor models. Our acquisition protocol incorporating 90 directions was designed to optimise this 
process. D: Fibre bundles were reconstructed using a probabilistic streamline algorithm, through sampling a probability density 
of the fODF at each path point, tracking the most plausible fibre propagations between seed and target regions. E: Quantitative 
estimates of structural connectivity between seed and target regions were derived from the apparent fibre density (AFD), 
calculated by summing the fODF lobe integrals along the pathway of interest and dividing by mean streamline length, to 
estimate the mean cross-sectional area of the fibre bundle. F & G: Two discrete networks subserving reward evaluation and 
response inhibition were defined based on previous work. Left panel: network models for each network. Right panel: 
illustrative streamlines (green) from one participant connecting seed (orange) and target (blue) regions for each tract in the 
network.  F: The reward evaluation network included white matter tracts connecting the ventral striatum with the ventromedial 
prefrontal cortex, the orbitofrontal cortex, the anterior cingulate cortex and the ventral tegmental area. It also included a tract 
connecting the subthalamic nucleus with the ventromedial prefrontal cortex (the limbic hyperdirect pathway). G: The response 
inhibition network included tracts connecting the subthalamic nucleus with the inferior frontal gyrus and the pre-supplementary 
motor area. ACC = anterior cingulate cortex, IFG = inferior frontal gyrus, OFC = orbitofrontal cortex, SMA = pre-
supplementary motor area, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal cortex, VS = ventral striatum, VTA 
= ventral tegmental area. Network models were visualised with the BrainNet Viewer (Xia et al., 2013).  
  
Figure 9.2 | Diffusion Processing Pipeline 
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9.5.9 Data Analysis 
9.5.9.1 Principal Components Analysis 
Amongst the neuropsychiatric instruments, principal components analysis (PCA) was first 
conducted. The motivation for this was to identify latent constructs of impulsivity across the 
questionnaires and clinician-administered tasks employed in this investigation. Components 
with eigenvalues greater or equal to one were retained. We did not include behaviours derived 
from the virtual casino in this dimension-reduction step on account of the qualitative difference 
in the collection of this data (i.e. derived from virtual gameplay) and therefore hypothesised to 
represent ‘purer’, more ecologically-valid metrics of an individual participant’s impulsivity. 
9.5.9.2 Path Modelling 
Partial least squares path modelling (PLS-PM) was employed to represent the multivariate 
relationships between anatomical and behavioural measures (McIntosh and Lobaugh, 2004; 
Shaw et al., 2016), controlling for relevant demographic and disease-related factors. PLS-PM 
is a form of structural equation modelling in which complex associations between multivariate 
data sets can be estimated. Each model specifies the linear weighting of one set of variables 
that best co-varies with a linear weighting of another. For example, in this investigation, 
anatomical variables were created from the reward evaluation and response inhibition networks 
as a weighted mixture of the connectivity of each tract within the network. Behavioural 
variables were formed from each neuropsychiatric instrument and each gambling output 
(although as these were assessed individually, the relationship between each behavioural 
variable and observed behaviour was monotonic). Each model then represented the path 
coefficients and corresponding significance values for the relationship between these 
anatomical and behavioural variables; in addition to describing the weighted contribution that 
each tract made to the anatomical variable. In each model, continuous measures including age, 
years since diagnosis of Parkinson’s disease and LEDD were also entered as co-variates, with 
disease subtype and gender examined with a permutation test (Figure 9.3). Interaction (or 
moderating) effects of these co-variates on the effect of connectivity on behaviour were also 
modelled. Confidence intervals for ‘out of sample’ effects were determined by bootstrapping, 
in which the data set was repeatedly sampled with replacement to create 10,000 independent 
bootstrapped data sets, with the sample size equal to the number of participants. Each PLS path 
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model was developed using a bi-hemispheric anatomical network, but results for each 
hemisphere in isolation are also reported.  
 
 
A PLS path model represents the relationship between structural network connectivity and impulsivity. An anatomical variable 
is constructed from the connectivity of each white matter tract in the anatomical network under investigation. The individual 
contribution of each tract to the anatomical variable is quantified by a ‘weight’ and the anatomical variable is formed as a 
linear mixture of the corresponding connectivity values that best co-varies with the behavioural variable under investigation. 
The relationship between the anatomical and behavioural latent variables is quantified in the path model by a path coefficient 
(that can be tested for statistical significance). Relevant demographic and disease-related co-variates are also represented in 
the inner model and path coefficients can be determined for these relationships. An interaction (moderating) effect can be 
modelled; in this case, the interaction of LEDD with the anatomical variable. Bootstrapping of the model yields 95 % 
confidence intervals for the path coefficients of interest. CI = confidence interval, LEDD = levodopa equivalent daily dose. 
 
For each outcome of interest, a number of alternative PLS path models of varying complexity 
could be proposed, with no consensus method for determining the optimal trade-off between 
model fit and model complexity (Henseler and Sarstedt, 2013). Therefore, model complexity 
was constrained a priori; each PLS path model included only one anatomical network and all 
included age, years since diagnosis and LEDD as covariates. One interaction term with the 
anatomical network was included (e.g. the interaction of LEDD or age with the reward 
evaluation network). The winning model from all permutations was selected based on the 
maximum R2 value prior to bootstrapping: in the setting of equivalent complexity of all 
estimated models, we thus use model fit (R2) as the single summary metric for comparing 
Figure 9.3 | Partial Least Squares Path Modelling  
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models. In order to demonstrate that there were convincing dissociations by network (reward 
evaluation versus response inhibition) in the explanation of variance, results from the best 
performing model using the alternative network were also reported for each outcome variable. 
For example, a winning model that included the reward evaluation network was compared with 
models employing the response inhibition network, in order to quantify the difference in 
variance explained by the two alternative networks. 
9.5.9.3 ICB status 
In contrast to the QUIP-RS, which provides a dimensional rating of compulsive traits, we also 
applied a semi-structured clinical interview to delineate ICB status in a categorical manner. 
This interview took place with the participant and spousal caregiver and was completed by an 
experienced neuropsychiatrist (PM). An ICB was defined by the clinical diagnosis of 
pathological gambling, binge eating, compulsive shopping, hypersexuality, hobbyism or 
dopamine dysregulation in the presence of clinically-significant impairment or distress. ICB 
status was then examined with a permutation test in the PLS-PM approach, performed upon 
the winning model for each behavioural variable of interest.  
 
In order to evaluate the performance of models that differentiated participants by their ICB 
status, a repeated k-fold cross-validation was performed to evaluate the null hypothesis of no 
difference in model performance. In this procedure, the data was randomly split into ten 
subsets. One subset was reserved and a regularised logistic regression model was trained on all 
other subsets of the data, with the model then tested on the reserved subset. This process was 
repeated until all subsets had served as the test set. The average of the prediction error across 
all subsets served as the performance metric and was employed to calculate a receiver operating 
curve (ROC), the area under the curve (AUC), sensitivity and specificity, for the categorisation 
of participants as ICB+ or ICB–. To define a null distribution (of a chance prediction) the same 
procedure was performed, but the assignment of the dependent variable (ICB status) was 
shuffled randomly across participants. This procedure was iterated 1000 times and the 
modelled data was compared with the null distribution to evaluate the null hypothesis of no 
difference in model performance.  
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Data analysis was performed in the R software environment (R Core Team, 2014), using the 
packages FactoMineR for PCA (Lê et al., 2008), plspm for PLS-PM (Sanchez, 2013), pls for 
PLS regression (Mevik, 2007) and caret for cross-validation (Kuhn, 2008).   
9.6 Results 
9.6.1 Participants 
Sixty-three surgical candidates were consented. Three were unable to obtain dMRI due to 
implanted prostheses incompatible with diffusion sequences, while one was excluded due to 
excessive motion artefact in the diffusion images (manifesting as signal dropout in connected 
slices). One candidate was excluded due to extensive cerebrovascular disease (Fazekas grade 
IV), and another was excluded after being unable to complete the virtual casino prior to surgery 
due to fatigue. Thus, fifty-seven participants proceeded to analysis (Table 9.1). Few 
participants (n = 7) engaged in the ‘cashout’ option within the virtual casino and this measure 
was therefore excluded from further analyses.  
 
Seventeen participants had a current or past history of an ICB and six participants had more 
than one ICB, when these were evaluated as part of a clinical interview. These comprised 
pathological gambling (n = 10), hypersexuality (n = 9), compulsive shopping (n = 3), dopamine 
dysregulation (n = 2), binge eating (n = 1) and hobbyism (n = 1). ICB+ individuals had 
significantly higher scores on the QUIP-RS (t = -4.31, corrected p = 0.003) but there were no 
other significant differences in disease-related, neuropsychiatric or gambling measures by ICB 
status (Table 9.1).  
9.6.2 Principal components analysis 
PCA of the neuropsychiatric instruments revealed four dimensions (components) of 
impulsivity with eigenvalues of one or greater, accounting for 77 % of the total variance in the 
data (Table 9.2, Supplementary Figure 9.7). Dimension 1 was comprised of equal contributions 
from the three subscales of the BIS and the QUIP-RS score, reflecting trait impulsiveness and 
compulsivity and reflecting questionnaire-derived rather than task-related data. Dimension 2 
reflected disinhibition, comprised primarily from ELF Rule Violations. Dimension 3 reflected 
impatience, being made up of the Delay Discounting constant p. Finally, Dimension 4 again 
reflected disinhibition, comprised primarily from the Hayling AB error score. The broad 
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alignment of these dimensions with separate neuropsychiatric instruments suggested that there 
was little redundancy in the multi-modal assessment of impulsivity in this investigation, aside 
from a distinction between questionnaire-based and examiner-administered measures. Given 
the equal contributions of the BIS subscales to Dimension 1 of the PCA, BIS total score was 
entered into the PLS path models. 
 
  
  222 
 
 
Table 9.1 | Demographic and Clinical Characteristics of the Cohort 
† FDR-corrected with Benjamini and Hochberg method (1995), with ! = 0.05. Significance: *** p<0.001, ** p<0.01, * p<0.05. 
 
Categorical Variable Total (n=57) Percentage Total 
Gender n % total 
Male 38 66.6 
Female 19 33.3 
Clinical Subtype n % total 
Akinetic-Rigid 19 33.3 
Mixed 27 47.4 
Tremor 11 19.3 
ICB Status n % total 
Yes 17 29.8 
No 40 70.2 
Continuous Variable Mean (SD), Median (Range) ICB+ vs. ICB-† 
Age (Years) 62.2 (±9.7), 
65 (35 - 77) 
t = 2.84 
corr. p = 0.059 
Hoehn & Yahr Stage 2.6 (±0.5), 
2.5 (1.5 - 4) 
t = -1.56 
corr. p = 0.22 
Years Since Diagnosis 8.2 (±4.1), 
7 (2 - 21) 
t = -0.80 
corr. p = 0.52 
Levodopa equiv. daily dose 1124 (±618.6), 
1025 (0 - 3450) 
t = -1.89 
corr. p = 0.21 
BIS Attentional 16.0 (±3.4), 
16 (10 - 26) 
t = -1.73 
corr. p = 0.22 
BIS Non-Planning 
 
22.6 (±4.1), 
23 (14 - 32) 
t = -0.54 
corr. p = 0.64 
BIS Motor 21.5 (±3.6), 
21 (14 - 30) 
t = -1.64 
corr. p = 0.22 
QUIP-RS Total 19.4 (±15.4), 
17 (0 - 63) 
t = -4.31 
corr. p = 0.003** 
Delay Discount q 0.037 (±0.063), 
0.016 (0.00016 – 0.25) 
t = 2.42 
corr. p = 0.076 
Hayling AB Error Score 13.8 (±13.1), 
9 (0 - 44) 
t = 1.00 
corr. p = 0.43 
ELF Rule Violations 8.4 (±5.5), 
8 (0 - 24) 
t = -0.47 
corr. p = 0.64 
UPDRS Part III Motor 39.6 (±15.2), 
39 (10 - 70) 
t = 1.34 
corr. p = 0.29 
Virtual Casino Mean (SD), Median (Range) ICB+ vs. ICB-† 
Average Bet Size (AUD) 41.8 (±44.6), 
27.2 (5 - 191.8) 
t = 0.39 
corr. p = 0.88 
Machine Switch (Percent) 1.5 (±2.7), 
0 (0 - 12) 
t = 1.09 
corr. p = 0.70 
Double or Nothing Gamble 
(Percent) 
17.0 (±20.5), 
15 (0 - 100) 
t = 2.05 
corr. p = 0.23 
     
BIS = Barratt Impulsiveness Scale; ELF = Excluded Letter Fluency Task; ICB = Impulsive Control Behaviours; QUIP-RS = 
Questionnaire for Impulsive-Compulsive disorders in PD Rating Scale; UPDRS = Unified Parkinson’s Disease Rating Scale 
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Table 9.2 | Principal Components Analysis of Neuropsychiatric Instruments 
Measure Representation 
Dimension 1 
Eigenvalue = 
2.10 
Dimension 2 
Eigenvalue = 
1.28 
Dimension 3 
Eigenvalue = 
1.04 
Dimension 4 
Eigenvalue = 
1.00 
BIS Attentional 
Contribution 30.7 % - - - 
Correlation 0.80 - - - 
BIS Non-Planning 
Contribution 25.7 % - - - 
Correlation 0.74 - - - 
BIS Motor 
Contribution 23.9 % - - - 
Correlation 0.71 - - - 
QUIP-RS 
Contribution 19.4% - - - 
Correlation 0.64 - - - 
Delay Discount q Contribution - - 60.7 % 28.6% 
Correlation - - 0.79 -0.53 
Hayling AB Error 
Score 
Contribution - 22.5 % - 56.8 % 
Correlation - 0.54 - 0.75 
ELF Rule 
Violations 
Contribution - 55.6 % - - 
Correlation - -0.84 - - 
 
BIS = Barratt Impulsiveness Scale; ELF = Excluded Letter Fluency Task; QUIP-RS = Questionnaire for Impulsive-
Compulsive disorders in PD Rating Scale 
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9.6.3 Path Modelling of Connectivity and Neuropsychiatric Instruments 
Path models employing the neuropsychiatric instruments are presented first, followed by 
behavioural read-outs from the gambling paradigm. The neuropsychiatric instruments are 
presented in the order in which they appeared amongst orthogonal dimensions of the PCA, with 
questionnaire measures first, followed by examiner-administered tasks. The network (reward 
evaluation or response inhibition) explaining the maximum variance differed by variable 
according to the construct under examination. For the gambling outputs, the variance explained 
by path models incorporating network indices was generally as high or higher than for the 
neuropsychiatric variables (Table 9.3). For most measures, distinctions by hemisphere were 
observed and a distinction by ICB status was observed for the gambling variable ‘bet size’. 
9.6.3.1 BIS 
We first assessed how variation in self-reported impulsiveness was related to the structural 
connectivity of our brain networks. The connectivity of the reward evaluation network and its 
interaction with LEDD best explained variations in this domain. The greater the connectivity 
of this network, the lower the self-reported impulsiveness (coefficient -0.44, K = 0.0021, Table 
9.3). The tracts weighted most strongly in the reward evaluation network were right VS-ACC 
and right STN-vmPFC (Supplementary Table 9.4, Figure 9.4A). The connectivity of the reward 
evaluation network explained 12.8 % of the total variance in BIS total score. The right (K = 
0.0028) hemisphere in isolation evidenced a significant effect. There was no significant 
difference by ICB status on the effect of connectivity (K = 0.41). 
9.6.3.2 QUIP-RS 
Last amongst the questionnaire measures, the connectivity of the reward evaluation network 
and its interaction with LEDD best explained variation in dimensional ratings of behavioural 
addictions such as gambling, sex, shopping and eating. The greater the connectivity of this 
network, the higher the rating of compulsivity (coefficient 0.34, K = 0.0045, Table 9.3). The 
tracts weighted most strongly in the reward evaluation network were right VS-OFC, left VS-
vmPFC and left VTA-VS (Supplementary Table 9.5, Figure 9.4B). The effects of age 
(coefficient -0.30, K = 0.033, younger age associated with greater compulsivity) and LEDD 
(coefficient 0.34, K = 0.040, higher dose of dopaminergic medication associated with greater 
compulsivity) were also significant. The connectivity of the reward evaluation network 
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explained 22.4 % of the total variance in QUIP-RS score. The right (K = 0.037) hemisphere in 
isolation evidenced a significant effect. There was no significant difference by ICB status (K = 
0.84) in the effect of connectivity. 
9.6.3.3 ELF rule violations 
First amongst the examiner-administered tasks, we assessed how variation in disinhibition (as 
expressed by ELF rule violations) was related to the structural connectivity of our brain 
networks. The connectivity of the reward evaluation network and its interaction with age best 
explained variation in this facet of impulsivity. The greater the connectivity of this network, 
the fewer inhibitory errors (coefficient -0.58, K = 1.5 x 10-5, Table 9.3). The tracts weighted 
most strongly in the reward evaluation network were right VS-vmPFC, right VTA-VS, right 
STN-vmPFC and left VS-ACC (Supplementary Table 9.6, Figure 9.4C). The connectivity of 
the reward evaluation network explained 32.7 % of the total variance in ELF rule violations. 
The right (K = 1.4 x 10-4) hemisphere in isolation evidenced a significant effect. There was no 
significant difference by ICB status (K = 0.14) in the effect of connectivity. 
9.6.3.4 Delay Discount k 
We then looked at delay discounting: the tendency to prefer sooner, smaller rewards over those 
that are larger but temporally more distant. This was best explained by the connectivity of the 
reward evaluation network and its interaction with age. The greater the connectivity of this 
network, the lower the impatience and the higher the ability to defer reward (coefficient -0.49, K = 8.0 x 10-4, Table 9.3). The tracts weighted most strongly in the reward evaluation network 
were right VS-vmPFC, right VS-OFC and left VTA-VS (Supplementary Table 9.7, Figure 
9.4D). The connectivity of the reward evaluation network explained 18.2 % of the total 
variance in the delay discount constant p. The right (K = 0.037) and left (K = 0.030) 
hemispheres in isolation evidenced a significant effect. There was no significant difference by 
ICB status (K = 0.24) in the effect of connectivity. 
9.6.3.5 Hayling AB error score 
Finally, the connectivity of the response inhibition network and its interaction with years since 
diagnosis of Parkinson’s disease best explained variation in disinhibition (as expressed by 
Hayling A or B errors). The greater the connectivity of this network, the fewer inhibitory errors 
(coefficient -0.54, K = 1.7 x 10-5, Table 9.3). The tract weighted most strongly in the response 
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inhibition network was left STN-SMA (Supplementary Table 9.8, Figure 9.4E). The 
connectivity of the response inhibition network explained 26.2 % of the total variance in 
Hayling AB Error Score. The right (K = 0.0095) and left (K = 1.7 x 10-4) hemispheres in 
isolation evidenced a significant effect. There was no significant difference by ICB status (K = 
0.11) in the effect of connectivity. 
9.6.4 Path modelling of Connectivity and Gambling Behaviours 
9.6.4.1 Bet Size 
A gambler’s variation in bet size was best explained by the connectivity of the reward 
evaluation network and its interaction with LEDD. The greater the connectivity of the reward 
evaluation network, the greater the impulsivity as measured by risk taking, expressed as higher 
bets in the casino (coefficient 0.42, K = 0.0038, Table 9.3). The most heavily weighted tracts 
in the reward evaluation network were right VS-vmPFC and left VS-vmPFC (Supplementary 
Table 9.9, Figure 9.5A). The connectivity of the reward evaluation network explained 29.7 % 
of the total variance in bet size. Both the right (K = 0.017) and left hemispheres (K = 0.0021) 
in isolation evidenced a significant effect. Notably, there was a significant difference by ICB 
status on the effect of connectivity (coefficient ICB+ = -0.87, coefficient ICB– = 0.45, K = 
0.0099). There was also a significant difference by ICB status in the interaction of LEDD with 
connectivity (coefficient ICB+ = -0.39, coefficient ICB– = 1.53, K = 0.030). 
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The association of structural connectivity with components of impulsivity derived from neuropsychiatric instruments. The left 
panel displays a bar plot displaying the relative weights of each tract in the winning network. Blue = negative weight, red = 
positive weight. ACC = anterior cingulate cortex, IFG = inferior frontal gyrus, OFC = orbitofrontal cortex, SMA = pre-
supplementary motor area, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal cortex, VS = ventral striatum, VTA 
= ventral tegmental area. L = left hemisphere, R = right hemisphere. The right panel shows illustrative streamlines (green) 
from an exemplar participant connecting seed (orange) and target (blue) regions for each heavily weighted tract in the network.   
 
9.6.4.2 Slot Machine Switch 
A gambler’s tendency to switch between slot machines in the virtual casino was best explained 
by the connectivity of the response inhibition network and its interaction with years since 
diagnosis of Parkinson’s disease. The greater the connectivity of the response inhibition 
network, the more likely a gambler was to prioritise exploitation over exploration (i.e. less 
likely to switch machines) (coefficient -0.38, K = 0.0027, Table 9.3). The interaction effect of 
years since diagnosis with connectivity was also significant (coefficient 0.29, K = 0.029). The 
most heavily weighted tracts in the response inhibition network were right STN-SMA and right 
STN-IFG (Supplementary Table 9.10, Figure 9.5B). The connectivity of the response 
inhibition network explained 21.7 % of the total variance in slot machine switch. Neither 
hemisphere in isolation evidenced a significant effect. There was no significant difference by 
ICB status on the effect of connectivity (K = 0.47).  
9.6.4.3 Double or Nothing Gambles 
A gambler’s tendency to accept double or nothing gambles was best explained by the 
connectivity of the reward evaluation network and its interaction with age. In contrast with bet 
size, the greater the connectivity of the reward evaluation network, the less explorative the 
gambler, with a lower likelihood of accepting a double or nothing gamble (coefficient -0.41, K 
= 0.0056, Table 9.3). Again, in contrast, the most heavily weighted tracts in the reward 
evaluation network were the left VS-OFC and left STN-vmPFC connections, whilst the 
bilateral VS-vmPFC tract weighted negatively (Supplementary Table 9.11, Figure 9.5C). The 
connectivity of the reward evaluation network explained 24.1 % of the total variance in double 
or nothing gamble uptake. The left (K = 0.027) hemisphere in isolation evidenced a significant 
effect. There was no significant difference by ICB status on the effect of connectivity (K = 
0.14). 
Figure 9.4 | Network Influences on Impulsivity 
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The association of structural connectivity with gambling behaviour derived from the virtual casino. The left panel displays a 
bar plot displaying the relative weights of each tract in the winning network. Blue = negative weight, red = positive weight. 
ACC = anterior cingulate cortex, IFG = inferior frontal gyrus, OFC = orbitofrontal cortex, SMA = pre-supplementary motor 
area, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal cortex, VS = ventral striatum, VTA = ventral tegmental 
area. L = left hemisphere, R = right hemisphere. The right panel shows illustrative streamlines (green) from an exemplar 
participant connecting seed (orange) and target (blue) regions for each heavily weighted tract in the network.   
 
  
Figure 9.5 | Network Influences on Gambling Behaviour 
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Table 9.3 | Detailed Output of Winning Models from PLS-PM Analysis 
Significance: *** p<0.001, ** p<0.01, * p<0.05 
 
Model Network Interaction R2 
Path 
Coefficient 
Significance 
95 % 
Confidence 
Interval 
Other Significant 
Co-variates 
Neuropsychiatric Instruments 
BIS 
Reward 
Evaluation 
Reward Evaluation 
x LEDD 
0.18 -0.44 K = 0.0021 ** -0.65 – -0.24 Nil 
QUIP-RS 
Reward 
Evaluation 
Reward Evaluation 
x LEDD 
0.37 0.34 K = 0.0045 ** 0.065 – 0.57 
i) Age 
coeff = -0.30 
95 % CI = -0.52 – -0.058 K = 0.014 * 
ii) LEDD 
coeff = 0.35 
95 % CI = 0.12 – 1.10 K = 0.040 * 
ELF Rule 
Violations 
Reward 
Evaluation 
Reward Evaluation 
x Age 
0.31 -0.58 K = 1.5 x 10-5 
*** 
-0.78 – -0.31 Nil 
Delay 
Discount q Reward Evaluation Reward Evaluation x Age 0.21 -0.49 K = 8.0 x 10-4 *** -0.75 – -0.19 Nil 
Hayling AB 
Error Score 
Response 
Inhibition 
Response Inhibition 
x Years Since 
Diagnosis 
0.37 -0.54 
K = 8.0 x 10-5 
*** 
-0.72 – -0.34 Nil 
Gambling Behaviours 
Bet Size 
Reward 
Evaluation 
Reward Evaluation 
x LEDD 
0.34 0.42 K = 0.0038 ** 0.15 – 0.65 Nil 
Slot Machine 
Switch 
Response 
Inhibition 
Response Inhibition 
x Years since 
Diagnosis 
0.30 -0.38 K = 0.0027 ** -0.60 – -0.15 i) Interaction coeff = 0.29 95 % CI = 0.075 – 0.50 K = 0.029 * 
Double or 
Nothing 
Gambles 
Reward 
Evaluation 
Reward Evaluation 
x Age 
0.33 -0.41 K = 0.0056 ** -0.68 – -0.055 Nil 
 
BIS = Barratt Impulsiveness Scale; ELF = Excluded Letter Fluency Task; QUIP-RS = Questionnaire for Impulsive-
Compulsive disorders in PD Rating Scale 
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9.6.5 Cross Validation of Bet Size by ICD Status 
The finding that ICB+ individuals could be distinguished by the effect of connectivity on 
gambling behaviour (bet size) was evaluated with repeated k-fold cross-validation. This model 
yielded a Receiver Operating Curve (ROC) Area Under the Curve (AUC) of 0.72, a sensitivity 
of 0.89 and a specificity of 0.38. When compared with a null (chance) model (Figure 9.6) there 
was a significant difference in ROC AUC (model = 0.72, null = 0.64 K = 2.2 x 10-15). There 
was also a significant difference in specificity (model = 0.38, null = 0.094 K = 2.2 x 10-16).  
9.6.6 Supplementary Analyses 
In order to evaluate the specificity of each network (response inhibition or reward evaluation) 
in explaining the variance of each construct under examination, findings for the best model 
from the alternative network are presented in Supplementary Table 9.12. Again, this was 
defined as the model with the maximum R2, allowing LEDD, age and years since diagnosis of 
Parkinson’s disease as an interaction effect with network connectivity. Findings demonstrated 
that the winning network model explained considerably more variance than the ‘second placed’ 
model using the alternative network. Furthermore, for the majority of constructs, the effect of 
connectivity for the alternative network did not reach statistical significance or the 
bootstrapped 95 % confidence intervals crossed zero.  
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A: The relationship between connectivity of the reward evaluation network and bet size in the virtual casino, plotted by ICB 
status. Shaded area = standard error. B: Distribution of the receiver operating curve (ROC) area under the curve (AUC) values 
for a repeated k-fold cross validation model, comparing a null model (with a shuffled dependent variable) against a model 
trained on the relationship between connectivity and bet size. 
Figure 9.6 | Cross-Validation of the Relationship Between ICB Status, Connectivity and Bet Size 
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9.7 Discussion 
We find that the structural connectivity of cortico-subcortical networks contributes 
significantly to variability in impulsivity and gambling behaviours amongst individuals with 
Parkinson’s disease prior to subthalamic DBS. The variance explained by connectivity was 
highest for behavioural indices of impulsivity, derived from clinic-based tasks and a naturalistic 
virtual casino. The contribution of each network and the relative influence of each hemisphere 
was dissociated by the neuropsychiatric construct or gambling behaviour under investigation, 
supporting the conceptualisation of impulsivity as a multifaceted construct. Furthermore, 
persons with a history of ICBs could be differentiated from those without ICBs in the virtual 
casino when the interaction of betting behaviour, dopaminergic dosage and structural 
connectivity was examined.  
 
Amongst the neuropsychiatric instruments, we identified distinct dimensions (components) of 
impulsivity based upon a comprehensive phenotyping of participants. Broadly, these 
orthogonal dimensions derived from the PCA mapped onto distinct neuropsychiatric 
instruments, suggesting that our battery assessed different facets of impulsivity in this cohort. 
However, it is also notable that the first dimension of the PCA was comprised of metrics 
derived from self-rated questionnaires, raising the possibility that this dimension represented 
response modality rather than impulsivity per se. This is interesting in the light of a recent 
comparable finding amongst persons with frontotemporal dementia, in which questionnaire 
measures separated from experimental tasks in the characterisation of impulsivity and apathy 
(Lansdall et al., 2017).  
 
When the neuropsychiatric instruments were examined individually, inter-individual 
variability in the BIS, the QUIP-RS, the Delay Discounting task and ELF rule violations were 
best accounted for by PLS path models incorporating the reward evaluation network – a 
network comprised of bilateral fibre tracts connecting the STN, VS, VTA, OFC, ACC and 
vmPFC. The most heavily weighted tracts within the reward evaluation network differed 
between each of these instruments. Moreover, the influence of connectivity differed in 
direction (positive or negative) amongst the different constructs. For instance, for QUIP-RS 
score, heavily weighted tracts involved the VS, VTA, OFC and vmPFC, with greater 
connectivity associated with greater impulsivity and a bias to the right hemisphere. However, 
for BIS score, ELF rule violations and Delay Discounting p, greater connectivity of the network 
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was associated with reduced impulsivity. This dissociation may be attributable to differences 
in the construct assessed in each task (such as the difference between impatience and 
compulsiveness), as well as to differences in the individual weightings of each tract within the 
reward evaluation network. For example, for BIS score and ELF rule violations, heavily 
weighted tracts included those connecting the STN with the prefrontal cortex, suggesting that 
the strength of the stopping signal exerted by the STN made a key contribution to the role of 
this network. These hyperdirect tracts may be a means through which the STN links reward 
evaluation and response inhibition networks (Haynes and Haber, 2013; Nambu et al., 2002). 
Again, right-hemispheric tracts were predominant in this measure of inhibitory control. This 
bias is interesting, given prior work suggesting that the executive control of inhibition is 
primarily a right-lateralised process (Aron et al., 2004; D’Alberto et al., 2017; Possin et al., 
2009) and that modulation of the right STN after DBS for Parkinson’s disease is most likely to 
induce disinhibition (Mosley et al., 2018d). 
 
Amongst the neuropsychiatric instruments, only inter-individual variability in the Hayling AB 
Error score was best accounted for by a PLS path model incorporating the response inhibition 
network – a network comprised of bilateral fibre tracts connecting the STN, SMA and IFG. 
The greater the connectivity of this network, the less impulsive were the participants according 
to this examiner-administered metric. The weighting of tracts in this model is consistent with 
the classic ‘stopping’ network (Aron et al., 2007; Rae et al., 2015) and accords with the nature 
of the behaviours represented in this task, where participants must suppress habitual 
responding.  
 
Although they both assess disinhibition, Hayling AB errors and ELF rule violations correlate 
in opposite directions on Dimension 2 and are influenced most strongly by different networks 
when examined independently. This parallels prior findings using voxel-based morphometry, 
which have implicated the IFG in Hayling inhibitory errors and the OFC and VS in ELF Rule 
Violations (O'Callaghan et al., 2013a; O'Callaghan et al., 2013b). This may be related to 
underlying differences in the fine-grained structure of each task. In the ELF task, participants 
must obey phonemic policies, whereas in the Hayling test, participants must monitor semantic 
rules and implement a strategy to avoid suppression errors. In addition, in order to produce rule 
violations in the ELF task, the participant must be sufficiently ‘energised’ to initiate and 
maintain the generation of words (phonemic verbal fluency), which presumably requires the 
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integrity of dopaminergic networks such as those involving the VTA and VS (Barker et al., 
2018; McAuley, 2003). Furthermore, in the Hayling test, participants can make both gross 
failures of inhibition (A errors) or more subtle errors of semantics (B errors). In lesion studies, 
phonemic word fluency deficits are associated with the left IFG (Robinson et al., 2012) and 
Hayling semantic errors with the right IFG (Robinson et al., 2015). However, in the present 
cohort, the tract connecting the left STN-SMA was most strongly implicated in inter-individual 
variability in the Hayling AB error score. Further work will clarify the contribution of these 
tracts to these aspects of response inhibition.  
 
As highlighted above, the brain-behaviour covariations were as high or higher for gambling 
behaviours in the virtual casino as compared to the clinician-administered tasks. The greater 
the connectivity of the reward evaluation network, the more explorative and the higher the bet 
size employed by participants, modulated by LEDD. Bilateral tracts connecting the VS to 
vmPFC were weighted most heavily in this model, upholding much prior work linking the VS 
with reinforcement learning and reward evaluation (Abler et al., 2006; Basar et al., 2010; Daw 
et al., 2006; de Wit et al., 2012; Haber and Knutson, 2010; Hampton et al., 2017; Kishida et 
al., 2016; Schultz et al., 1997; Tanaka et al., 2008; Wittmann et al., 2008). The amount wagered 
in a gamble is a parsimonious way to obtain a behavioural readout of impulsivity and it is 
interesting that this measure correlated significantly with our reward evaluation network 
measures.  
 
The tendency of gamblers to switch slot machines in the virtual casino was negatively 
correlated with the connectivity of the response inhibition network, modulated by years since 
diagnosis. Gamblers with reduced connectivity of the response inhibition network were more 
likely to be impatient and explore different slot machines and thus could be considered more 
impulsive on this measure, preferring to explore their current environment rather than exploit 
alternatives. Again, right hemispheric tracts were weighted most strongly within this network. 
Here, the effect of years since diagnosis may be related to progressive neurodegeneration and 
the vulnerability of connections between the STN and SMA, given that modulation of these 
connections is most likely to result in a therapeutic benefit after STN-DBS for Parkinson’s 
disease (Vanegas-Arroyave et al., 2016). 
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Finally, the lesser the connectivity of the reward evaluation network, the more likely gamblers 
were to accept double or nothing gambles. This appears at first paradoxical when evaluated 
against the results for bet size. Specifically, when double or nothing gambles are considered, 
participants with greater connectivity of the reward evaluation network are less likely to take 
risks. However, when the weightings of the network are examined (Figure 9.5), the distribution 
of weightings is quite different to the network evaluated for bet size. In the reward evaluation 
network for double or nothing gambles, the VS-vmPFC tracts are now negatively-weighted, 
with the most highly-weighted tract being the left VS-OFC. The tracts from STN to vmPFC 
are also upweighted (again, a means through which the STN links reward evaluation and 
response inhibition networks). Thus, the connectivity of the reward evaluation network may 
have dissociable effects on different aspects of impulsive behaviour, with associations in 
opposite directions depending upon the cognitive operation under study. This supports prior 
work demonstrating that greater frontostriatal connectivity is associated with the ability to 
delay gratification in young adults (Achterberg et al., 2016; Peper et al., 2013).   
 
Crucially, our paradigm was able to identify significant differences between participants by 
ICB status. Individuals with a history of an ICB differed in the effect of reward evaluation 
connectivity on bet size, and the interaction effect of LEDD with reward evaluation 
connectivity. This finding is in line with previous work demonstrating that individuals with 
ICBs differ in their neural response to dopaminergic medication (van Eimeren et al., 2010; 
Voon et al., 2011a) and that striatal dopaminergic transmission is altered in ICB+ persons 
(Stark et al., 2018). Our cross-validation results suggest this is not merely a chance effect, 
although we stress that we do not propose that our model (in its current form) could be 
employed to differentiate prospectively between ICB+ and ICB– individuals, given its low 
specificity and the likelihood of a high false-positive rate. Nevertheless, using a game-like 
assay to obtain a behavioural (and, in the future, possibly also neural) signature of impulsivity 
is an appealing prospect. To our knowledge this manuscript offers the first structural account 
of brain-behaviour co-variation in Parkinson’s disease.  
 
Limitations of this investigation include the cross-sectional design, which precludes causal 
inferences about the link between structural connectivity and impulsivity. Furthermore, the pre-
surgical nature of the sampled population means that these findings may not apply to all persons 
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with Parkinson’s disease; there may be cohort-level differences in impulsivity amongst those 
who proceed to neurosurgery for their movement disorder.  
 
A further limitation with the virtual casino task that we employ is its exclusive basis in 
gambling behaviour. Seven of our seventeen participants with clinically-significant ICBs did 
not express pathological gambling as a feature of their compulsive behaviours, whilst in the 
wider Parkinson’s disease population, pathological gambling is certainly not seen in all persons 
with ICBs. We endeavoured to mitigate this problem by including bright colours and noises in 
our virtual casino that would have a universally appetitive influence, but we cannot discount 
the possibility that there may be a more suitable ‘domain general’ behavioural paradigm that 
could be developed to encompass all persons with varied ICBs.  
 
In summary, significant dimensional variations in impulsivity and compulsive behaviours are 
seen amongst persons with Parkinson’s disease. However, it has been unclear if these relate to 
underlying differences in brain networks likely to be affected by neurodegeneration and 
dopaminergic therapies. Distinct reward evaluation and response inhibition networks may 
associate with dissociable aspects of impulsivity (c.f. choosing and stopping) according to the 
behaviour under investigation. In our cohort, we have shown that impulsivity can be 
decomposed into non-overlapping components with separate neural covariations, grounded in 
these aforementioned brain networks. Importantly, clinician-administered tasks and 
ecologically valid measures derived from a naturalistic gambling were more closely tied to 
structural connectivity measures than traditional neuropsychiatric questionnaires. During the 
gambling task, participants with a history of ICBs differed from other persons in the manner in 
which their connectivity strengths interacted with dopaminergic therapy and gambling 
behaviour. This raises the possibility of using similar methods in clinical settings, as a means 
to identify those at risk of harmful behaviour.  
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9.8 Supplementary Data 
 
Seventy-seven percent of the variance was accounted for by the first 4 dimensions of the PCA.  
 
 
  
Supplementary Figure 9.7 | Scree Plot of Variance Explained by the Principal Components Analysis of Neurocognitive 
Measures 
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Supplementary Table 9.4 | Connectivity Weights in Reward Evaluation Latent Variable BIS 
Fibre Tract Weight 
Left STN - vmPFC 0.015 
Left VS - vmPFC 0.18 
Left VS - OFC -0.11 
Left VS - ACC -0.14 
Left VTA - VS 0.31 
Right STN - vmPFC 0.49 
Right VS - vmPFC -0.74 
Right VS - OFC -0.42 
Right VS - ACC 0.83 
Right VTA - VS 0.18 
 
ACC = anterior cingulate cortex, OFC = orbitofrontal cortex, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal 
cortex, VS = ventral striatum, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.77) or disease subtype (K = 0.59). The right (K = 
0.0028) hemisphere in isolation evidenced a significant effect but the left (K = 0.52) did not.  
 
 
Supplementary Table 9.5 | Connectivity Weights in Reward Evaluation Latent Variable QUIP-RS 
Fibre Tract Weight 
Left STN - vmPFC -0.75 
Left VS - vmPFC 0.54 
Left VS - OFC -0.13 
Left VS - ACC -0.095 
Left VTA - VS 0.42 
Right STN - vmPFC 0.036 
Right VS - vmPFC 0.21 
Right VS - OFC 0.66 
Right VS - ACC -0.35 
Right VTA - VS -0.22 
 
ACC = anterior cingulate cortex, OFC = orbitofrontal cortex, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal 
cortex, VS = ventral striatum, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.73) or disease subtype (K = 0.59). The right (K = 0.037) 
hemisphere in isolation evidenced a significant effect but the left (K = 0.069) did not. 
  
  240 
 
 
Supplementary Table 9.6 | Connectivity Weights in Reward Evaluation Latent Variable ELF Rule Violations 
Fibre Tract Weight 
Left STN - vmPFC 0.12 
Left VS - vmPFC -0.28 
Left VS - OFC 0.18 
Left VS - ACC 0.40 
Left VTA - VS 0.31 
Right STN - vmPFC 0.51 
Right VS - vmPFC 0.63 
Right VS - OFC -0.43 
Right VS - ACC -0.34 
Right VTA - VS 0.53 
 
ACC = anterior cingulate cortex, OFC = orbitofrontal cortex, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal 
cortex, VS = ventral striatum, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.81) or disease subtype (K = 0.63). The right (K = 1.4 x 
10-4) hemisphere in isolation evidenced a significant effect but the left (K = 0.32) did not. 
 
 
Supplementary Table 9.7 | Connectivity Weights in Reward Evaluation Latent Variable Delay Discount p 
Fibre Tract Weight 
Left STN - vmPFC 0.088 
Left VS - vmPFC -0.59 
Left VS - OFC -0.15 
Left VS - ACC -0.56 
Left VTA - VS 0.60 
Right STN - vmPFC 0.037 
Right VS - vmPFC 0.80 
Right VS - OFC 0.40 
Right VS - ACC 0.22 
Right VTA - VS -0.52 
 
ACC = anterior cingulate cortex, OFC = orbitofrontal cortex, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal 
cortex, VS = ventral striatum, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.84) or disease subtype (K = 0.56). The right (K = 0.037) 
and left (K = 0.030) hemisphere in isolation evidenced a significant effect. 
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Supplementary Table 9.8 | Connectivity Weights in Response Inhibition Latent Variable Hayling AB Error Score 
Fibre Tract Weight 
Left STN - IFG -0.19 
Left STN - SMA 0.98 
Right STN - IFG -0.38 
Right STN - SMA 0.24 
 
IFG = inferior frontal gyrus, SMA = pre-supplementary motor area, STN = subthalamic nucleus 
For the winning model, there was no significant effect of gender (K = 0.86) or disease subtype (K = 0.96). The right (K = 
0.0095) and left (K = 1.7 x 10-4) hemisphere in isolation evidenced a significant effect. 
 
Supplementary Table 9.9 | Connectivity Weights in Reward Evaluation Latent Variable Bet Size 
Fibre Tract Weight 
Left STN - vmPFC -0.34 
Left VS - vmPFC 0.51 
Left VS - OFC 0.18 
Left VS - ACC 0.23 
Left VTA - VS 0.31 
Right STN - vmPFC -0.017 
Right VS - vmPFC 0.46 
Right VS - OFC -0.12 
Right VS - ACC -0.54 
Right VTA - VS -0.66 
 
ACC = anterior cingulate cortex, OFC = orbitofrontal cortex, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal 
cortex, VS = ventral striatum, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.63) or disease subtype (K = 0.22). Both the left (K = 
0.00087) and right hemispheres (K = 0.022) in isolation evidenced a significant effect. 
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Supplementary Table 9.10 | Connectivity Weights in Response Inhibition Latent Variable Slot Machine Switch 
Fibre Tract Weight 
Left STN - IFG -0.044 
Left STN - SMA -1.00 
Right STN - IFG 0.40 
Right STN - SMA 1.07 
 
IFG = inferior frontal gyrus, SMA = pre-supplementary motor area, STN = subthalamic nucleus 
For the winning model, there was no significant effect of gender (K = 0.10) or disease subtype (K = 0.30). Neither the right (K 
= 0.094) nor the left (K = 0.15) hemisphere in isolation evidenced a significant effect. 
 
 
Supplementary Table 9.11 | Connectivity Weights in Reward Evaluation Latent Variable Double or Nothing Gambles 
Fibre Tract Weight 
Left STN - vmPFC 0.63 
Left VS - vmPFC -0.20 
Left VS - OFC 0.71 
Left VS - ACC 0.35 
Left VTA - VS -0.28 
Right STN - vmPFC 0.21 
Right VS - vmPFC -0.22 
Right VS - OFC -0.35 
Right VS - ACC -0.020 
Right VTA - VS -0.072 
 
ACC = anterior cingulate cortex, OFC = orbitofrontal cortex, STN = subthalamic nucleus, vmPFC = ventromedial prefrontal 
cortex, VS = ventral striatum, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.97) or disease subtype (K = 0.74). The left (K = 0.027) 
hemisphere in isolation evidenced a significant effect but the right did not (K = 0.25). 
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Supplementary Table 9.12 | Detailed Output of Second-Placed Models from PLS-PM Analysis 
Model Network Interaction R2 
Path 
Coefficient 
Significance 
95 % 
Confidence 
Interval 
Other Significant 
Co-variates 
Neuropsychiatric Instruments 
BIS 
Response 
Inhibition 
Response Inhibition 
x Age 
0.11 -0.30 K = 0.033 * -0.52 – -0.073 Nil 
QUIP-RS 
Response 
Inhibition 
Response Inhibition 
x LEDD 
0.26 -0.16 K = 0.20 -0.39 – 0.080 Nil 
ELF Rule 
Violations 
Response 
Inhibition 
Response Inhibition 
x Age 
0.15 0.28 K = 0.046 * -0.0042 – 0.55 Nil 
Delay 
Discount q Response Inhibition Response Inhibition x LEDD 0.19 -0.39 K = 0.0038 ** -0.60 – -0.14 Nil 
Hayling AB 
Error Score 
Reward 
Evaluation 
Reward Evaluation 
x Age 
0.15 -0.23 K = 0.13 -0.50 – -0.0010 Nil 
Gambling Behaviours 
Bet Size 
Response 
Inhibition 
Response Inhibition 
x LEDD 
0.09 0.15 K = 0.28 -0.13 – 0.42 Nil 
Slot Machine 
Switch 
Reward 
Evaluation 
Reward Evaluation 
x LEDD 
0.12 -0.29 K = 0.061 -0.63 – 0.12 Nil 
Double or 
Nothing 
Gambles 
Response 
Inhibition 
Response Inhibition 
x Age 
0.23 -0.24 K = 0.082 -0.49 – 0.045 Nil 
 
Significance: *** p<0.001, ** p<0.01, * p<0.05 
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Chapter 10 
10 Impulsivity & Gambling in Parkinson’s Disease after 
Subthalamic Deep Brain Stimulation Correlates with 
the Structural Connectivity of the Stimulation Field 
‘We call him the Energizer Bunny and when friends walk in, they'll say to him, are we switched on today, or 
switched up, because he's just got this energy. Then when you turn him down… in the afternoon he'd have to 
have a little nap. Well he doesn't like that. He likes to have this Energizer Bunny energy. Since he's had a taste 
of it, he really likes it. It's almost like an addiction actually… to me, it's almost like control.’ 
Spouse of DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
10.1 Abstract 
Subthalamic deep brain stimulation (STN-DBS) for Parkinson’s disease treats motor symptoms 
and improves quality of life, but can be complicated by adverse neuropsychiatric side-effects, 
typically characterised by impulsivity. It is unclear whether ‘at-risk’ persons can be identified 
prior to DBS, whether the genesis of neuropsychiatric symptoms relates to the distribution of 
the stimulation field, and which brain networks are responsible for their evolution. Using a 
comprehensive neuropsychiatric battery and a virtual casino to assess gambling behaviour, 55 
persons with Parkinson’s disease (19 females, mean age 62, mean Hoehn and Yahr stage 2.6) 
were assessed prior to STN-DBS and three-months postoperatively. Reward evaluation and 
response inhibition networks were reconstructed with probabilistic tractography using the 
participant-specific subthalamic volume of activated tissue as a seed. We found that the greater 
the connectivity of the site of stimulation with these frontostriatal networks, the greater the 
postoperative impulsiveness and disinhibition as assessed by the neuropsychiatric instruments. 
Larger bet sizes in the virtual casino postoperatively were associated with greater connectivity 
of the site of stimulation with right and left orbitofrontal cortex, right ventromedial prefrontal 
cortex and left ventral striatum. For all behaviours, connectivity of reward evaluation and 
response inhibition networks at baseline was not associated with postoperative impulsivity, 
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suggesting that the site and distribution of stimulation was a greater determinant of outcomes. 
Notably, a distinction could be made amongst participants with clinically-significant, harmful 
changes in mood and behaviour attributable to DBS, based upon an analysis of connectivity 
and its relationship with gambling behaviour. Additional analyses suggested that this 
distinction may be mediated by the differential involvement of fibres in the limbic hyperdirect 
pathway and superolateral branch of the medial forebrain bundle. These findings identify a 
mechanistic substrate of neuropsychiatric impairment after STN-DBS and suggest that 
tractography could be used to reduce the incidence of adverse neuropsychiatric effects.  
10.2 Introduction 
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) in Parkinson’s disease is an 
established advanced therapy that treats motor symptoms (tremor, rigidity, bradykinesia), 
improves quality of life and permits reduction or cessation of dopaminergic therapies (Krack 
et al., 2003; Schuepbach et al., 2013; Williams et al., 2010). However, in a proportion of those 
treated with STN-DBS, stimulation may induce neuropsychiatric symptoms, most often 
characterised by impulsivity and mood elevation (Appleby et al., 2007; Daniele et al., 2003; 
Hershey et al., 2004; Hershey et al., 2010; Mallet et al., 2007; Mosley and Marsh, 2015b; 
Romito et al., 2002; Voon et al., 2006; Welter et al., 2014). Although these symptoms can be 
ameliorated with stimulation reprogramming, they may nonetheless be associated with lasting 
harm (Mosley et al., 2018c; Mosley et al., 2019b) and caregiver burden (Mosley et al., 2018b). 
The ability to predict those at risk of a poor non-motor outcome would be a significant benefit 
to clinicians delivering this therapy, affecting surgical candidacy and choice of target, with the 
internal segment of the globus pallidus advanced as a neuropsychiatrically ‘safer’ target (Okun 
and Foote, 2005) but with potentially less favourable motor outcomes (Odekerken et al., 2013). 
Unfortunately, most preoperative measures show poor sensitivity and specificity for this 
syndrome. Whilst impulse control behaviours (ICBs) related to dopaminergic therapy display 
the greatest phenomenological overlap with stimulation-induced neuropsychiatric symptoms, 
their presence is not predictive and their absence is not protective: persons with pre-DBS ICBs 
may remit after STN-DBS following medication reduction (Eusebio et al., 2013; Lhommee et 
al., 2012), whilst those on medication but with no history of ICBs may develop such behaviours 
after STN-DBS (Lim et al., 2009; Moum et al., 2012).  
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STN-DBS may facilitate movement in Parkinson’s disease by interrupting synchronous 
oscillations between STN and cortex (Eusebio et al., 2009; Eusebio et al., 2011; Shimamoto et 
al., 2013), particularly in the hyperdirect pathway (Akram et al., 2017; Nambu et al., 2002). 
However, there is evidence to suggest that neuropsychiatric side effects of this therapy may 
also be determined by modulation of activity in frontostriatal networks. The STN has an 
overlapping functional topography, with a motor subregion in the dorsolateral aspect of the 
nucleus, grading to cognitive-associative and limbic subregions in the ventromedial plane 
(Accolla et al., 2014; Ewert et al., 2018; Haynes and Haber, 2013; Lambert et al., 2012). Spread 
of the stimulation field around a DBS electrode can modulate these non-motor circuits. 
Previously, by localising the active DBS contact and modelling a stimulation field based on 
individualised parameters, we reported an association between stimulation of the cognitive-
associative STN subregion and postoperative disinhibition, in addition to the emergence of 
clinically-significant neuropsychiatric symptoms such as hypomania (Mosley et al., 2018d). 
The physiological underpinnings of this impairment may lie in the function of the STN as a 
‘stopping’ node in the indirect pathway of the basal ganglia. By inhibiting the output of cortico-
striatal circuits, healthy STN firing delays decision-making, allowing time for evidence 
accumulation and the formulation of an appropriate behavioural policy. Accordingly, 
overriding this function with DBS may unmask impulsive and error-prone responding 
(Cavanagh et al., 2011; Frank et al., 2007). More generally, dimensional variations in a range 
of non-motor symptoms after STN-DBS were found to covary with the spread of electrical 
stimulation (Petry-Schmelzer et al., 2019). However, beyond local effects of DBS, establishing 
an association between modulation of frontostriatal networks and the emergence of post-DBS 
neuropsychiatric symptoms requires establishing a relationship between impulsivity and the 
individualised connectivity of the subthalamic stimulation field. 
 
Through modelling the distribution of white matter tracts in the brain, diffusion MRI (dMRI) 
can be employed to investigate network-wide effects of DBS at the surgical target. As well as 
the impact of stimulation on the STN, dMRI can also represent white matter tracts adjacent to 
the nucleus, such as the medial forebrain bundle, which may also be important mediators of 
adverse events (Coenen et al., 2009; Coenen et al., 2012). Motor networks associated with 
clinically-effective STN-DBS have previously been delineated with dMRI (Accolla et al., 
2016; Akram et al., 2017; Chen et al., 2018; Horn et al., 2017; Vanegas-Arroyave et al., 2016) 
but until now neuropsychiatric symptoms have not been comprehensively examined.  
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Using a high-resolution preoperative dMRI acquisition, we reconstructed the distribution of 
subthalamic stimulation and its connectivity based on two frontostriatal networks recently 
shown to underlie dissociable aspects of impulsivity and gambling behaviour in persons with 
Parkinson’s disease prior to STN-DBS (Mosley et al., 2019a). These reward evaluation and 
response inhibition networks were drawn from the distinct neurocognitive mechanisms 
responsible for impulsivity: sensitivity to appetitive rewards and failure to suppress 
inappropriate choices. Multiple lines of evidence implicate separable anatomical substrates of 
these ‘choosing’ and ‘stopping’ behaviours (Antonelli et al., 2014; Aron et al., 2007; Haber 
and Knutson, 2010; Hampton et al., 2017; Rae et al., 2015; van Eimeren et al., 2010). In our 
previous study of persons with Parkinson’s disease, we demonstrated brain-behaviour co-
variation in impulsivity and connectivity of these frontostriatal networks, with the effect of 
connectivity showing a distinction by ICB status. Here, we sought to identify if similar patterns 
of brain-behaviour co-variation could be identified following STN-DBS and if the effect of 
connectivity differed amongst persons who developed stimulation-induced neuropsychiatric 
impairment. Finally, we also examined whether structural connectivity of these networks at 
baseline was predictive of postoperative impulsivity, which would have implications for 
estimating risk in surgical candidates.  
10.3 Methods 
10.3.1 Participants 
Participants were consecutively recruited at the Asia-Pacific Centre for Neuromodulation in 
Brisbane, Australia between 2016-2018. All participants met the UK Brain Bank criteria for 
Parkinson’s disease (Hughes et al., 1992) and at the time of recruitment were being assessed 
for subthalamic deep brain stimulation (DBS). All participants were at Hoehn and Yahr stage 
2 or greater (Hoehn and Yahr, 1967) with motor fluctuations or other motor complications 
related to dopaminergic therapy. No participants met the Movement Disorder Society criteria 
for dementia (Emre et al., 2007). Further details of recruitment and assessment are as 
previously reported (Mosley et al., 2018a; Mosley et al., 2018d; Mosley et al., 2019b; Paliwal 
et al., 2019).  
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In the present longitudinal investigation, clinical and phenotypic assessments took place at 
baseline, prior to DBS (‘on’ medication), and three months postoperatively (‘on’ stimulation’). 
With presurgical results already reported (Mosley et al., 2019a), this investigation focussed on 
postoperative behaviours. However, preoperative findings are necessarily referenced when 
correlations between pre- and postoperative behaviours are reported.  
10.3.2 Image Acquisition 
A preoperative T1-weighted MPRAGE, a T2-weighted FLAIR sequence and diffusion-
weighted imaging (DWI) were obtained at baseline, using a 3T Siemens Prisma and a 64-
channel head coil. The acquisition parameters were as follows: T1, 1 mm3 voxel-resolution, TR 
= 2000 ms, TE = 2.38 ms, flip angle = 9°, matrix size = 256 × 256, FOV = 256 × 256 × 192; 
T2, 1 x 1 x 2 mm voxel-resolution, TR = 9500 ms, TE = 122.0 ms, flip angle = 120°, matrix 
size = 256 × 256, FOV = 256 × 256 × 70; DWI, 90 directions, b-value = 3000s/mm2, voxel size 
= 1.7 mm3 isotropic. Twelve non-diffusion-weighted images (b0) were interleaved throughout 
this main sequence, while an additional sequence of 8 b0 images were also collected with the 
opposite phase-encoding (posterior-anterior) direction to allow for distortion correction. 
Postoperative CT images for all participants were acquired on a Siemens Intevo, with a 
resolution of 0.5mm3.  
 
The DWI data were pre-processed with MRtrix3 (https://github.com/MRtrix3/mrtrix3), using 
an in-house preprocessing pipeline (https://github.com/breakspear/diffusion-pipeline). 
Preprocessing steps were identical to Mosley et al. (2019a). Full details on DWI acquisition, 
preprocessing and fibre reconstruction are provided in the Chapter 9. 
10.3.3 Surgery & Follow Up 
After the STN was manually identified on FLAIR imaging, bilateral implantation of Medtronic 
3389, Boston Vercise or Abbott 6172 directional electrodes took place in a single-stage 
procedure using a Leksell stereotactic apparatus. Intraoperative microelectrode recordings 
(MER) were employed to identify the boundaries of the STN and intraoperative test stimulation 
was performed. Postoperative lead placement was confirmed with CT imaging. Subthalamic 
stimulation was commenced immediately with the initial choice of contact based upon MER 
signals. After discharge, participants returned to the clinic at set intervals for further titration 
of stimulation (including changes in stimulating contact) against motor symptoms until these 
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were satisfactorily treated without adverse effects. Dopaminergic medication was reduced or 
ceased postoperatively, with remaining treatment converted to a levodopa-equivalent daily 
dose (LEDD) value (Evans et al., 2004). 
10.3.4 Assessment of Impulsivity 
All participants were assessed for impulsivity at baseline and at follow-up, three-months after 
DBS surgery. Participants were phenotyped on both occasions using a combination of 
neuropsychiatric instruments and engagement in a naturalistic gambling paradigm. 
10.3.4.1 Neuropsychiatric Instruments 
Impulsivity was assessed with a range of neuropsychiatric instruments, noting the 
multidimensional nature of this construct (analogous to Mosley et al. (2019a). These included: 
trait impulsiveness: the Barratt Impulsiveness Scale 11 (BIS) (Patton et al., 1995); impulsive 
and compulsive behaviours (ICBs): the Questionnaire for Impulsive-Compulsive disorders in 
PD Rating Scale (QUIP-RS) (Weintraub et al., 2012); impatience: the Delay Discounting task 
(Kirby et al., 1999); disinhibition: the Excluded Letter Fluency task (ELF) (Shores et al., 2006) 
and the Hayling test (Burgess et al., 1997). Statistical analyses of differences in impulsivity 
between pre- and post-DBS assessments were corrected for multiple comparisons using the 
Benjamini and Hochberg method (1995), with ! = 0.05. 
10.3.4.2 Gambling Paradigm  
Participants gambled on slot machines within a virtual casino validated in healthy controls and 
persons with Parkinson’s disease (Paliwal et al., 2014; Paliwal et al., 2019). This naturalistic 
gambling task allowed for impulsive behaviour to be expressed as bet increases, exploratory 
slot machine switches and ‘double or nothing’ gambles. Full details of this task are given in 
Mosley et al. (2019a), Paliwal et al., (2019) and Chapter 8.  
10.3.4.3 Caseness  
Following DBS surgery, participants were assigned to the category ‘case’ or ‘non-case’ 
depending on whether they developed clinically-significant (i.e. impairment or distress) 
neuropsychiatric symptoms attributable to DBS, necessitating device manipulation (hereafter 
referred to as ‘caseness’). Identification of these persons used the same process as prior work 
(Mosley et al., 2018a; Mosley et al., 2018d; Mosley et al., 2019b). This category was 
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operationalised as follows: participants were evaluated at baseline and postoperatively by a 
neuropsychiatrist (PM). A semi-structured diagnostic interview and mental state examination 
was undertaken with attention to euphoria, irritability, disinhibition, impulsivity and 
compulsivity. The contribution of neurostimulation to the presentation was confirmed if 
symptoms responded promptly to a reduction in the amplitude or change in the locus of 
stimulation, as assessed by serial mental state examinations and feedback from close family 
members. Clinically-significant neuropsychiatric symptoms had remitted in all participants by 
the time of the postoperative reassessment of impulsivity and gambling.  
10.3.5 Electrode Localisation & Volume of Tissue Activation 
DBS electrodes were localized using the Lead-DBS toolbox (Horn and Kuhn, 2015) 
(https://github.com/netstim/leaddbs/tree/develop). Preoperative structural acquisitions were 
co-registered with postoperative CT imaging and then normalized into common ICBM 2009b 
nonlinear asymmetric space using the SyN approach implemented in advanced normalization 
tools (ANTs) (Avants et al., 2008). Electrode trajectories were reconstructed after correcting 
for brainshift in postoperative acquisitions by applying a refined affine transform in a 
subcortical area of interest calculated pre- and postoperatively. Rotation of directional 
electrodes was determined based on visualization of the artefact created by the orientation 
marker and directional electrode segments (Hellerbach et al., 2018). For each electrode, a 
volume of activated tissue (VAT) was estimated using a volume conductor model of the DBS 
electrode and surrounding tissue, based on each participant’s individualised stimulation 
settings and a finite element method to derive the gradient of the potential distribution (Horn 
et al., 2019). An electric field (E-field) distribution was also modelled (Vorwerk et al., 2018).  
10.3.6 Tractography & Apparent Fibre Density  
Using the preoperative DWI data, constrained spherical deconvolution (CSD) (Jeurissen et al., 
2014; Tournier et al., 2004; Tournier et al., 2007) was performed in each participant after 
group-average intensity normalization (Raffelt et al., 2012), generating voxel-wise estimates 
of fibre orientation distribution functions (fODF). Using each VAT as a seed, fibre tracts to 
target regions were reconstructed with the probabilistic streamline algorithm iFOD2 (Tournier 
et al., 2010). Estimates of structural connectivity between each seed and target region were 
derived from the apparent fibre density (AFD) representing the underlying intra-axonal volume 
averaged along tracts (Raffelt et al., 2012) (further details provided in Chapter 9).  
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10.3.7 Networks 
The influence of the site and distribution of stimulation on postoperative impulsivity and 
gambling was evaluated using two discrete brain networks supporting reward evaluation and 
response inhibition, which were adapted to include a subthalamic VAT as the seed for 
probabilistic tractography (Figure 10.1A). We chose to employ the same networks utilised in 
Mosley et al. (2019a), which were found to explain a considerable portion of the variance in 
impulsivity prior to DBS. This preoperative reward evaluation network connected VS with 
ACC, OFC, vmPFC and the VTA, as well as the STN with vmPFC. The response inhibition 
network connected the STN with IFG and SMA. These baseline networks were used to evaluate 
the influence of structural connectivity prior to DBS on postoperative impulsivity and 
gambling. 
 
Postoperatively, these networks were modified to incorporate the subthalamic VAT at their 
centre. The reward evaluation network included streamlines connecting the site of stimulation 
with orbitofrontal cortex (OFC), ventromedial prefrontal cortex (vmPFC), ventral striatum 
(VS) and the ventral tegmental area (VTA). To capture tegmental fibres for this latter midbrain 
region, the VTA served as the seed and the subthalamic VAT as the target. The response 
inhibition network included tracts connecting the VAT with the inferior frontal gyrus (IFG) 
and pre-supplementary motor area (SMA). Thus, the hub of the reward evaluation network was 
shifted perioperatively from the VS to the VAT/STN whilst the response inhibition network 
was alike across assessment intervals. 
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A: Two discrete networks subserving reward evaluation and response inhibition were specified based on previous work. The 
pre-DBS reward evaluation network was defined to include tracts connecting VS with vmPFC, OFC, ACC and VTA. It also 
included a tract connecting the STN with vmPFC (the limbic hyperdirect pathway). The response inhibition network included 
tracts connecting the STN with the IFG and the SMA. Postoperatively, these networks were adapted with the subthalamic 
VAT at their centre. Network models were visualised with the BrainNet Viewer (Xia et al., 2013).  
B: Cross lagged (latent change score) model which allows quantification of the relationship between preoperative structural 
networks and baseline phenotypic data to post-DBS networks and follow-up phenotypic data. Coefficients are modelled as 
follows: 1 represents brain-behaviour covariance at baseline (Brain_T1 ~ Behaviour_T1), 2 represents behaviour to brain 
coupling (Behaviour_T1 → ∆Brain_T1), 3 represents brain to behaviour coupling (Brain_T1 → ∆Behaviour_T1) and 4 is an 
estimate of correlated change in brain and behaviour (∆Brain_T1 ~ ∆Behaviour_T1). In the context of the present investigation, 
we were mainly interested in brain to behaviour coupling (3).  
ACC = anterior cingulate cortex, IFG = inferior frontal gyrus, LEDD = levodopa equivalent daily dose, OFC = orbitofrontal 
cortex, PCA = principal components analysis, SMA = pre-supplementary motor area, STN = subthalamic nucleus, vmPFC = 
ventromedial prefrontal cortex, VS = ventral striatum, VAT = volume of activated tissue, VTA = ventral tegmental area.  
  
Figure 10.1 | Modelling Brain-Behaviour Co-Variation 
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10.3.8 Data Analysis 
10.3.8.1 PLS Path Modelling 
Partial least squares path modelling (PLS-PM) was employed to identify specific patterns of 
structural connectivity explaining inter-individual variability in impulsivity and gambling 
behaviour after STN-DBS (McIntosh and Lobaugh, 2004; Shaw et al., 2016), controlling for 
relevant demographic and disease-related factors (Chapter 9). An anatomical variable was 
constructed from the connectivity of each white matter tract in the anatomical network under 
investigation. The individual contribution of each tract to the anatomical variable was 
quantified by a ‘weight’ and the anatomical variable was formed as a linear mixture of the 
corresponding connectivity values that best co-varied with the behavioural variable under 
investigation. The relationship between the anatomical and behavioural latent variables was 
quantified in the path model by a path coefficient and tested for statistical significance. 
Relevant demographic and disease-related co-variates were also represented and path 
coefficients were determined for these relationships. Bootstrapping of the model yielded 95 % 
confidence intervals for the coefficients of interest. The winning model from all possible 
permutations was selected based on the maximum R2 value prior to bootstrapping, in the setting 
of equivalent, constrained complexity of all estimated models. This approach is described in 
Mosley et al. (2019a) and Chapter 9. The influence of pre-DBS ICB status and post-DBS 
caseness on the association between connectivity and behaviour was examined with a 
permutation test in the PLS path model, performed upon the winning model for each 
behavioural variable of interest. 
10.3.8.2 Longitudinal Modelling 
Using the weighted network scores derived from PLS-PM, with pre- and post-DBS behavioural 
evaluations, a cross-lagged panel model was utilised to evaluate whether structural connectivity 
at baseline influenced impulsivity and gambling postoperatively (Figure 10.1B). These latent 
change score models assess longitudinal associations between two or more repeatedly sampled 
measures of brain and behaviour (Kievit et al., 2018; Lin et al., 2019; Muetzel et al., 2018). 
They quantify cross-domain coupling, capturing the extent to which change in one domain 
(impulsivity) reflects the baseline level in the other (connectivity). Here, a bivariate cross-
lagged model described four brain to behaviour relations of interest. These comprised: brain-
behaviour covariance at baseline (Brain_T1 ~ Behaviour_T1), brain to behaviour coupling 
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(Brain_T1 → ∆Behaviour_T1), behaviour to brain coupling (Behaviour_T1 → ∆Brain_T1) and 
an estimate of correlated change in brain and behaviour (∆Brain_T1 ~ ∆Behaviour_T1) after 
taking into account the coupling pathways. In the context of the present investigation, we were 
mainly interested in the ability of structural connectivity prior to DBS to predict cognitive 
change from pre- to post-DBS (Brain_T1 → ∆Behaviour_T1). Model fit metrics comprised the 
Comparative Fit Index (CFI - the degree to which the proposed model better fits the data than 
one in which no correlation exists between measurements) and the Root Mean Square Error of 
Approximation (RMSEA – a measure of the deviation between observed covariance and that 
predicted by the model). 
10.3.8.3 Linear Mixed-Effects Modelling 
For the gambling outcomes, random-intercept linear mixed-effects models were fit in order to 
provide an explicit longitudinal metric of change (e.g. in dollars wagered) by connectivity. 
These took the form: 
 
Gambling variableij ~ Connectivityij + LEDDi + Agei + Genderi + Years Since Diagnosisi + Timepointij + (1|ID) 
+ (1|Timepoint) 
 
With i denoting participant and j denoting timepoint.  
 
Models were adjusted for levodopa equivalent dose, age, gender, years since diagnosis of 
Parkinsons’ disease and timepoint (pre- or post-DBS), with random intercepts specified for 
each participant and each timepoint.  
  
The term in bold (the effect of connectivity on gambling variable) is the coefficient of interest. 
Hypothesis testing on a null model (omitting connectivity) was performed with the anova 
function in the lavaan package.  
10.3.8.4 Caseness 
Amongst individuals with clinically-significant, stimulation-dependent neuropsychiatric 
symptoms (‘cases’), supplementary analyses were undertaken to explore distinct patterns of 
connectivity in this group (Figure 10.2), where differential patterns of brain-behaviour co-
variation were identified. This required co-registration of individual participant data into a 
Chapter 10  255 
 
 
common anatomical reference. To achieve this, using the Lead-DBS toolbox, each participant’s 
VAT in each hemisphere was integrated with a normative structural connectome derived from 
90 persons with Parkinson’s disease (mean age 61.39 ± 10.42, 28 females) enrolled in the 
Parkinson’s Progression Markers Initiative (PPMI, www.ppmi-info.org), in which 20,000 
fibres were sampled per subject using a generalised q-sampling approach implemented in DSI-
Studio (Yeh et al., 2010), as described in more detail in Ewert et al. (2018) and Horn et al. 
(2017). Fibres traversing each participant’s VTA were selected from the group connectome 
based on the E-field gradient strength (i.e. fibres in peripheral VTA regions with a low E-field 
down-weighted) and projected to the volumetric surface of the ICBM 2009b nonlinear 
asymmetric brain in 1 mm isotropic resolution. A connectivity profile for each participant was 
expressed as the weighted number of fibre tracts between the stimulation site and each brain 
voxel. Subsequently, in order to visualise subcortical streamlines predictive of outcome, all 
fibres connected to VATs across the cohort were isolated from the normative connectome. For 
each fibre, change in the behavioural outcome of interest was compared between participants 
with and without connected VATs using a two-sided, two-sample P-test. This process yielded 
a ‘fibre P-score’, with high-values indicating that this fibre was strongly discriminative of 
clinical outcome (Baldermann et al., 2019). Only the top 20 % of fibres positively correlated 
with the behavioural variable were selected for analysis.  
10.3.8.5 Code Availability 
Data analysis was performed in the R software environment (R Core Team, 2014), using the 
packages FactoMineR for PCA (Lê et al., 2008), plspm for PLS-PM (Sanchez, 2013), pls for 
PLS regression (Mevik, 2007), lavaan for cross-lagged models (Rosseel, 2012)  and lme4 for 
linear mixed-effects models (Bates et al., 2015). 
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A supplementary analysis was undertaken to identify distinct patterns of connectivity between ‘cases’ and ‘non-cases’, where 
differential patterns of brain-behaviour co-variation were identified. A: Subthalamic electrodes were identified on 
postoperative imaging. B: Electrodes were localised in ICBM 2009b nonlinear asymmetric space using the Lead-DBS toolbox. 
C: Stimulation volumes were estimated for each participant based on individual stimulation parameters. D: A normative 
connectome from the Parkinson’s Progression Markers Initiative was integrated with the cohort. E: Fibres from this 
connectome passing through each stimulation volume were isolated. F: Measuring the behavioural variable, each fibre was 
tested across the cohort between participants with a stimulation volume that encompassed the fibre (connected) and those 
where the fibre did not traverse the volume (unconnected). If there was a significant difference between values of the 
behavioural variable between connected and unconnected VATs, then this fibre was identified as discriminative of outcome. 
The top 20 % of discriminative fibres were compared between ‘case’ and ‘non-case’ groups. 
  
Figure 10.2 | Identifying Fibres Discriminative of Behavioural Outcome 
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10.4 Results 
10.4.1 Participants 
Fifty-seven surgical candidates were consented and completed all baseline assessments. Two 
participants were unable to complete the postoperative assessments due to fatigue. Fifty-five 
participants thus proceeded to analysis (Table 10.1). Prior to surgery, seventeen participants 
had a current or past history of an ICB and six participants had more than one ICB. These 
comprised pathological gambling (n = 10), hypersexuality (n = 9), compulsive shopping (n = 
3), dopamine dysregulation (n = 2), binge eating (n = 1) and hobbyism (n = 1). Implanted 
devices comprised Medtronic 3389 (n = 21), Boston Scientific Vercise (n = 18) and Abbott 
6172 directional electrodes (n = 16). Directional electrodes were employed in five participants 
to steer current. Postoperatively, there was a significant decrease in UPDRS part III motor 
examination score (P = 3.80, corrected K = 0.0020) and levodopa equivalent daily dose (P = 
9.68, corrected K = 2.1 x 10-13). At a group level, there was also a significant decrease in 
disinhibition as assessed by the Hayling test (P = 2.60, corrected K = 0.044). There were no 
other significant pre-post group differences amongst the neuropsychiatric instruments or 
gambling behaviours (Table 10.1). Seventeen participants developed a postoperative elevation 
in mood and clinically-significant impulsive behaviour attributable to stimulation (‘cases’). 
Clinically significant psychiatric symptoms had remitted in these individuals at the time of 
postoperative assessment (described in Table 10.2). There were no significant differences in 
postoperative neuropsychiatric measures or gambling behaviours between case+ and case- 
participants. Neither were there significant differences by pre-DBS ICB status (Supplementary 
Table 10.5). Only seventeen participants utilised the machine switch option in the virtual casino 
and this measure was hence not analysed further.  
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Table 10.1 | Demographic and Clinical Characteristics of the Cohort 
† FDR-corrected with Benjamini and Hochberg method (1995), with ! = 0.05. Significance: *** p<0.001, ** p<0.01, * p<0.05. 
 
Demographic & Disease-Related Variables 
Categorical Variable Total (n=55) Percentage Total 
Gender n % total 
Male 36 65.5 
Female 19 34.5 
Clinical Subtype n % total 
Akinetic-Rigid 17 30.9 
Mixed 27 49.1 
Tremor 11 20.0 
ICB Status n % total 
Yes 17 30.9 
No 38 69.1 
Continuous Variable Mean (SD), Median (Range) 
Age (Years) 62.0 (±9.8), 65 (35 - 77) 
Hoehn & Yahr Stage 2.6 (±0.5), 2.5 (1.5 - 4) 
Years Since Diagnosis 8.2 (±4.2), 7 (2 - 21) 
Variables Assessed Pre- & Post-DBS 
Mean (SD), Median (Range) 
Assessment Instrument Pre-DBS Post-DBS Pre- vs. Post-DBS† 
Levodopa equiv. daily dose 1126 (±629.9), 1015 (0 - 3450) 
380 (±231.4), 
375 (0 - 825) 
t = 9.68 
corr. p = 2.1 x 10-13*** 
BIS Attentional 16.0 (±3.4), 16 (10 - 26) 
15.5 (±4.3), 
15 (8 - 31) 
t = 1.40 
corr. p = 0.25 
BIS Non-Planning 
 
22.6 (±4.1), 
23 (14 - 32) 
22.7 (±5.3), 
22 (14 - 37) 
t = -0.14 
corr. p = 0.92 
BIS Motor 21.5 (±3.7), 21 (14 - 30) 
20.7 (±3.8), 
21 (13 - 34) 
t = 1.99 
corr. p = 0.11 
QUIP-RS Total 20.0 (±15.3), 18 (0 - 63) 
18.6 (±16.6), 
15 (0 - 66) 
t = 0.80 
corr. p = 0.53 
Delay Discount q 0.038 (±0.064), 0.016 (0.00016 – 0.25) 0.028 (±0.031), 0.016 (0.00016 – 0.1) t = 1.59 corr. p = 0.19 
Hayling AB Error Score 14.2 (±13.1), 9 (0 - 44) 
10.0 (±10.6), 
5 (0 - 39) 
t = 2.60 
corr. p = 0.044* 
ELF Rule Violations 8.6 (±5.4), 8 (0 - 24) 
7.1 (±4.7), 
6 (1 - 22) 
t = 2.29 
corr. p = 0.072 
UPDRS Part III Motor 39.4 (±15.1), 39 (10 - 70) 
32.9 (±13.0), 
32 (8 - 60) 
t = 3.80 
corr. p = 0.0020** 
Virtual Casino Pre-DBS Post-DBS Pre- vs. Post-DBS† 
Average Bet Size (AUD) 42.2 (±45.2), 27.2 (5 - 191.8) 
61.4 (±78.0), 
25.7 (5 - 339.8) 
t = -1.87 
corr. p = 0.12 
Double or Nothing Gamble 
(Percent) 
17.1 (±20.7), 
15 (0 - 100) 
17.4 (±20.1), 
19 (0 - 100) 
t = -0.097 
corr. p = 0.92 
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BIS = Barratt Impulsiveness Scale; ELF = Excluded Letter Fluency Task; ICB = Impulse Control Behaviours; QUIP-RS = 
Questionnaire for Impulsive-Compulsive disorders in PD Rating Scale; UPDRS = Unified Parkinson’s Disease Rating Scale 
 
Table 10.2 | Details of Participants Developing Clinically-Significant Neuropsychiatric Symptoms (Cases) 
ID Gender Presenting Symptoms DBS Manipulation 
1*^ Male Euphoria, hypersexuality, loss of empathy, rapid speech, verbal disinhibition, marital discord 
Active contact on both electrodes moved 
dorsally & amplitude reduced 
2*^ Male Irritability, hypersexuality, rapid speech, marital breakdown 
Active contact on both electrodes moved 
dorsally & amplitude reduced 
3^ Male Irritability, hypersexuality, aggression, marital breakdown Amplitude in both electrodes reduced 
4^ Male Reckless decision making (real-estate), loss of empathy, marital discord 
Active contact on right STN electrode 
moved dorsally & amplitude reduced 
5^ Female Irritability, verbal disinhibition, marital discord Amplitude in both electrodes reduced 
6*^ Male Irritability, psychomotor agitation, reduced need for sleep, rapid speech, aggression 
Active contact on right STN electrode 
moved dorsally 
7^ Male Irritability, hypersexuality, divorced spouse Active contact on right STN electrode moved dorsally 
8*^ Female Irritability, compulsive shopping (second-hand goods), marital breakdown 
Active contact on both electrodes moved 
dorsally 
9^ Male Euphoria, left spouse for a new relationship Active contact on right STN electrode moved dorsally 
10^ Female Euphoria, irritability, compulsive shopping (internet) 
Active contact on right STN electrode 
moved dorsally 
11^ Female Irritability, psychomotor agitation, reduced need for sleep 
Active contact on right STN electrode 
moved dorsally & amplitude reduced 
12 Female Irritability, emotional lability, pressured speech, reduced need for sleep, compulsive internet use 
Active contact on right STN electrode 
moved dorsally & amplitude reduced 
13 Male Verbal disinhibition, hypersexuality, alcohol abuse Active contact on right STN electrode moved dorsally 
14 Female 
Increased goal-directed activity, compulsive 
shopping (motorbikes), hobbyism, reckless driving, 
obtained new tattoos 
Active contact on right STN electrode 
moved dorsally; current steering used in 
both electrodes to avoid medial STN 
15 Female Irritability, uncharacteristic swearing, compulsive shopping (furniture) 
Active contact on both electrodes moved 
dorsally 
16 Male 
Use of pornography & adult dating websites, 
impulsive travel overseas, impulsive financial 
decisions, marital breakdown 
Active contact on both electrodes moved 
dorsally 
 
17 Male Euphoria, impulsively left work to start own business leading to financial hardship Amplitude in both electrodes reduced 
 
*These participants reported in more detail in (Mosley et al., 2019b). 
^These participants included in (Mosley et al., 2018d). 
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10.4.2 Path Modelling of Connectivity and Impulsivity 
10.4.2.1 Overview 
Impulsivity was assessed using either neuropsychiatric instruments or gambling behaviours in 
a virtual casino. The variance in impulsivity explained by the structural connectivity of the 
subthalamic VAT was estimated using PLS path models. The variance explained by 
frontostriatal connectivity was higher for betting behaviour in the virtual casino, than for the 
neuropsychiatric instruments. Employing a cross-lagged model, postoperative changes in 
impulsivity and gambling were not signficiantly related to the structural connectivity of 
frontostriatal networks at baseline, prior to DBS. Finally, the effect of connectivity on bet size 
in the virtual casino differed amongst participants who developed postoperative, stimulation-
dependent neuropsychiatric symptoms (cases). 
10.4.2.2 BIS 
We first examined how variability in self-reported impulsiveness was related to the structural 
connectivity of networks incorporating the participant-specific stimulation field at each DBS 
electrode. The connectivity of the response inhibition network best explained variations in this 
construct. The greater the connectivity of the VAT with this network, the greater 
impulsiveness (coefficient 0.36, K = 0.010, Table 10.3). The tracts weighted most heavily in 
this network linked the VAT with left SMA and right IFG (Fig 10.3A, Supplementary Table 
10.6). There was no significant difference by preoperative ICB status (K = 0.57) or 
postoperative caseness (K = 0.33) on this effect. The connectivity of the VAT with the response 
inhibition network explained 15.4 % of the total postoperative variance in impulsiveness.  
 
We next used a cross-lagged model to assess the contribution of structural connectivity at 
baseline to postoperative impulsiveness. This construct was not significantly influenced by the 
structural connectivity of the response inhibition network prior to DBS (K = 0.071, Table 10.4). 
However, there was a significant cross-sectional association prior to DBS between 
impulsiveness and connectivity (coefficient -2.38, K = 0.017), with greater connectivity of this 
network linked to reduced impulsivity in this domain, the opposite of the post-DBS effect. 
There was also a significant correlated change in connectivity and impulsivity from the pre- to 
the postoperative interval (coefficient 1.74, K = 0.023), suggesting a co-occurrence of brain and 
behavioural changes (Supplementary Figure 10.5).  
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10.4.2.3 QUIP-RS 
There were no significant associations between dimensional ratings of behavioural addictions 
(such as gambling, sex, shopping and eating) and structural connectivity with the site of 
stimulation, either within the response inhibition or reward evaluation network.  
10.4.2.4 ELF Rule Violations 
We then evaluated how structural connectivity with the site of stimulation was related to 
disinhibition (as expressed by ELF rule violations). The connectivity of the reward evaluation 
network best explained variability in this facet of impulsivity. The greater the connectivity of 
the VAT with this network, the more inhibitory errors (coefficient 0.41, K = 0.0017, Table 
10.3). The tract weighted most heavily in this network linked the VAT with right vmPFC (Fig 
10.3B, Supplementary Table 10.7). There was no significant difference by preoperative ICB 
status (K = 0.62) or postoperative caseness (K = 0.78) on the effect of connectivity. The 
connectivity of the VAT with the reward evaluation network explained 16.9 % of the total 
postoperative variance in disinhibition.  
 
In the cross-lagged model, there was no significant effect of baseline structural connectivity on 
postoperative disinhibition (K = 0.12, Table 10.4). Again, prior to DBS there was a cross-
sectional association between connectivity and disinhibition (coefficient -0.51, K = 0.018), with 
greater connectivity in the reward evaluation network associated with fewer inhibitory errors, 
again the opposite of the post-DBS effect. There was also a significant co-occurrence of brain 
and behavioural changes after DBS (coefficient 0.34, K = 0.0050) (Supplementary Figure 10.6). 
10.4.2.5 Hayling AB Error Score 
The structural connectivity of networks incorporating the participant-specific stimulation field 
(both response inhibition and reward evaluation) did not associate with variation in 
disinhibition (as expressed by Hayling A or B errors).  
10.4.2.6 Delay Discount q 
Last amongst the neuropsychiatric instruments, we considered delay discounting: the tendency 
to prefer sooner, smaller rewards over those that are larger but temporally more distant. 
Postoperatively, behaviour on this task was best explained by the connectivity of the site of 
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stimulation within the reward evaluation network. The greater the connectivity of the VAT 
with this network, the lower the impatience and the greater the ability to defer reward 
(coefficient -0.31, K = 0.042, Table 10.3). The tracts weighted most strongly in this network 
were bi-hemispheric connections between the VTA and the site of stimulation (Fig 10.3C, 
Supplementary Table 10.8). There was no significant difference by preoperative ICB status (K 
= 0.15) or postoperative caseness (K = 0.14) on the effect of connectivity. The connectivity of 
the VAT with the reward evaluation network explained 3.3 % of the total postoperative 
variance in impatience.  
 
Using the cross-lagged model, postoperative impatience was not influenced by the structural 
connectivity of the reward evaluation network prior to DBS (K = 0.67, Table 10.4). At baseline, 
there was significant brain-behaviour covariance (coefficient -0.46, K = 0.020) with greater 
connectivity of the reward evaluation network also associated with a greater ability to defer 
reward. Brain and behavioural changes pre- to post-DBS were not significantly correlated (K 
= 0.85) (Supplementary Figure 10.7). 
10.4.2.7 Bet Size 
Inter-individual variation in bet size post-DBS in the virtual casino was best explained by the 
connectivity of the VAT with the reward evaluation network. The greater the connectivity of 
the VAT with this network, the higher the bets in the casino (coefficient 0.43, K = 0.0029, 
Table 10.3). Tracts weighted most heavily were those linking the stimulation field with right 
and left OFC, right VMPFC and left VS (Fig 10.3D, Supplementary Table 10.9). There was no 
significant difference by preoperative ICB status (K = 0.27) but there was a significant 
difference in postoperative caseness on the effect of connectivity (coefficient case+ = -0.90, 
case– = 0.56, K = 0.020). The connectivity of the VAT with the reward evaluation network 
explained 25.7 % of the total postoperative variance in bet size. In a linear mixed effects model, 
an increase in connectivity of 1 standard error increased bet size by AUD 31.1 (± 5.49, 72 (1) 
= 26.6, K = 2.5 x 10-7). 
 
Baseline connectivity of the reward evaluation circuit did not predict postoperative bet size (K 
= 0.78, Table 10.4). However, prior to DBS there was a significant relationship between pre-
DBS bet size and baseline connectivity (coefficient 0.53, K = 0.0050), with greater connectivity 
also associated with higher bets. There was no significant correlation in change between 
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gambling and structural connectivity pre- to post-DBS (K = 0.059) (Supplementary Figure 
10.8).  
10.4.2.8 Double or Nothing Gambles 
The likelihood of a gambler taking on a double or nothing gamble was not associated with the 
structural connectivity of the site of stimulation, when the reward evaluation and response 
inhibition networks were entered into the PLS path models.  
 
Table 10.3 | Detailed Output of Models from PLS-PM Analysis 
PLS-PM Analysis of Post-DBS Impulsivity & Gambling 
Variable Network R2 
Path 
Coefficient 
Significance 95 % C.I. 
Other Significant 
Co-variates 
Post-DBS Neuropsychiatric Instruments 
BIS 
Response 
Inhibition 
0.19 0.36 K = 0.010 * 0.062 – 0.58 Nil 
ELF Rule 
Violations 
Reward 
Evaluation 
0.27 0.41 K = 0.0017 ** 0.15 – 0.62 Nil 
Delay 
Discount q Reward Evaluation 0.14 -0.31 K = 0.042 * -1.00 – -0.049 
i) Years Since Diagnosis 
coeff = -0.33 
95 % CI = -0.55 – -0.092 K = 0.030 
Post-DBS Gambling Behaviours 
Bet Size 
Reward 
Evaluation 
0.30 0.43 K = 0.0029** 0.044 – 0.64 Nil 
 
Significance: *K < 0.05. **K < 0.01. ***K < 0.001 
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Table 10.4 | Cross-Lagged Model Results 
Cross-Lagged Model Results 
 Cross-Lagged Coefficients Cross-Sectional Coefficients Model Fit Indices 
Variable 
Brain_T1 → 
∆Behavior_T1 
Behaviour_T1 → 
∆Brain_T1 
Brain_T1 ~ 
Behaviour_T1 
∆Brain_T1 ~ 
∆Behaviour_T1 
CFI RMSEA 
Post-DBS Neuropsychiatric Instruments 
BIS 
coeff = 1.55 K = 0.071 coeff = 0.031 K = 0.026 * coeff = -2.38 K = 0.017 * coeff = 1.74 K = 0.023 * 1.0 0.001 
ELF Rule 
Violations 
coeff = 0.25 K = 0.12 coeff = 0.24 K = 0.10 coeff = -0.51 K = 0.018 * coeff = 0.34 K = 0.0050 ** 1.0 0.001 
Delay 
Discount q coeff = 0.033 K = 0.67 coeff = -0.11 K = 0.33 coeff = -0.46 K = 0.020 * coeff = -0.013 K = 0.85 1.0 0.001 
Post-DBS Gambling Behaviours 
Bet Size 
coeff = 0.045 K = 0.78 coeff = 0.35 K = 0.056 coeff = 0.53 K = 0.0050 ** coeff = 0.37 K = 0.059 1.0 0.001 
 
Significance: *K < 0.05. **K < 0.01. ***K < 0.001 
In the cross-lagged model:  
Brain_T1→∆Behaviour_T1 represents brain to behaviour coupling: the extent to which structural connectivity at baseline 
predicts change in impulsivity and gambling at follow up.  
Behaviour_T1→∆Brain_T1 represents behaviour to brain coupling: the degree of change in structural connectivity dependent 
on impulsivity at baseline.  
Brain_T1~Behaviour_T1 is brain-behaviour co-variance at baseline 
∆Brain_T1~∆Behaviour_T1 is an estimate of correlated change: reflecting the degree to which brain and behaviour changes 
co-occur.  
CFI = Comparative Fit Index, RMSEA = Root Mean Square Error of Approximation  
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For each aspect of postoperative impulsivity and gambling, the anatomical network with the greatest capacity to explain 
variance in this behaviour was defined with PLS path modelling. Left column: In each PLS path model, the anatomical variable 
representing structural connectivity was comprised of a weighted mixture of all tracts in the network. Right column: The most 
heavily weighted tracts. A: Barratt Impulsiveness Scale; B: ELF Rule Violations; C: Delay Discount Constant p; D: Bet Size.  
IFG = inferior frontal gyrus, OFC = orbitofrontal cortex, SMA = pre-supplementary motor area, vmPFC = ventromedial 
prefrontal cortex, VS = ventral striatum, VAT = volume of activated tissue, VTA = ventral tegmental area.  
Figure 10.3 | Fibre Tracts Weighted Most Strongly in the Association of Connectivity with Impulsivity 
and Gambling 
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10.4.3 Fibre Tracts Discriminative of Bet Size in Case+ and Case– Participants 
Finally, we employed a normative connectome derived from individuals with Parkinson’s 
disease to visualise white matter fibres connected to the stimulation field. We selected fibres 
that were predictive of gambling behaviour that discriminated between case positive and case 
negative participants. In case negative participants, streamlines predictive of increased bet size 
were visualised passing from the diencephalon lateral to the STN and onwards to right vmPFC 
and OFC, consistent with findings from the PLS-PM analysis. In the right hemisphere, a portion 
of these streamlines traversed the VTA. However, in case positive participants, right-
hemispheric fibres predominantly involved the OFC rather than vmPFC. Moreover, these 
fibres were situated medial to the right STN and appeared to terminate / originate in the STN 
rather than passing into the midbrain. 
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Fibres that were discriminative of bet size and looked for differences between case+ and case– groups. A greater proportion 
of fibres connecting the right STN with the right OFC were observed in case positive participants. Furthermore, these fibres 
appeared to run medial rather than lateral to the STN (shown in orange in lowest panel) and did not traverse the diencephalon 
or include the VTA (shown in blue in lowest panel).  
  
Figure 10.4 | Fibre Tracts Weighted Most Strongly in the Association of Connectivity with Impulsivity and Gambling 
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10.5 Discussion 
In persons with Parkinson’s disease undertaking subthalamic DBS, impulsivity and gambling 
behaviour covaried with the structural connectivity of frontostriatal networks (reward 
evaluation and response inhibition) incorporating the field of stimulation. The variance 
explained by connectivity was higher for a behavioural index of impulsivity derived from a 
virtual casino than for the neuropsychiatric instruments. The relative contribution of white 
matter tracts in each network differed for each measure, suggesting that impulsivity remains a 
multifactorial construct in this clinical group. Notably, structural connectivity of these 
networks at baseline (prior to DBS) did not associate with postoperative behaviour, suggesting 
a primary role for the locus and distribution of stimulation in explaining this variance. Finally, 
individuals who developed postoperative changes in mood and clinically-significant impulsive 
behaviour (cases) could be discriminated by the interaction of connectivity and betting 
behaviour in the virtual casino.  
 
Postoperatively, inter-individual variability in impulsiveness was best accounted for by a PLS 
path model incorporating the response inhibition network, comprised of bilateral fibre tracts 
connecting the subthalamic VAT with the SMA and IFG. The greater the connectivity of the 
site of stimulation in this network, the more impulsive and disinhibited were the participants. 
At baseline, the inverse relationship was observed between connectivity and impulsiveness, 
but structural connectivity of this ‘stopping’ network preoperatively (Aron et al., 2007; Rae et 
al., 2015) did not influence behaviour postoperatively. This finding suggests that if this 
structural network is incorporated into the stimulation field through placement of the DBS 
electrode or stimulation titration, the influence of STN-DBS may be to engender impulsivity. 
This accords with much prior literature connecting STN-DBS to impairment in action restraint 
(Hershey et al., 2004), action cancellation (Obeso et al., 2013) and task-switching (Witt et al., 
2004), and supports prior work providing a structural substrate through which this impairment 
may arise (Haynes and Haber, 2013). 
 
Inter-individual variability in disinhibition, as manifest with ELF rule violations, was best 
accounted for by a model incorporating the reward evaluation network – a network comprised 
of bilateral fibre tracts connecting the subthalamic VAT with the VS, VTA, OFC and vmPFC. 
The most heavily weighted tract in this network linked the right subthalamic VAT with vmPFC, 
suggesting that the strength of the stopping signal exerted by the STN makes a key contribution 
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to the behavioural role of this network. This ‘hyperdirect’ tract may be a means through which 
the STN links reward evaluation and response inhibition networks (Haynes and Haber, 2013; 
Nambu et al., 2002). Again, at baseline, the inverse relationship was observed between 
connectivity and behaviour. The weight of the right-hemisphere in the postoperative network 
is noteworthy, given prior work suggesting that the executive control of inhibition is primarily 
a right-lateralised process (Aron et al., 2004; D’Alberto et al., 2017; Possin et al., 2009). These 
results also support the previous finding that modulation of the right associative STN subregion 
after DBS for Parkinson’s disease is most likely to induce disinhibition (Mosley et al., 2018d), 
with this subregion most likely to show connectivity with the vmPFC in the topographically-
organised STN. 
 
Inter-individual variability in impatience was also best explained by the connectivity of the 
reward evaluation network. Here, there was no dissociation by valence pre- and post-DBS; at 
both intervals stronger network connectivity was associated with a greater ability to delay 
gratification in the service of a larger reward. However, the variance explained by connectivity 
was small for this measure.  
 
For two neuropsychiatric outcomes, the QUIP-RS and the Hayling AB Error Score, there was 
no significant relationship between inter-individual variability and structural network 
connectivity with the participant-specific stimulation field. For the QUIP-RS, it may be that 
the substantial postoperative reduction in dopaminergic medication affects measurement of this 
construct, given that STN-DBS (with its attendant reduction in LEDD) has been advanced as a 
treatment for compulsivity (Eusebio et al., 2013; Lhommee et al., 2012). In the Hayling test, it 
may be that the AB error score is too coarse a measurement of disinhibition, given that a finer-
grained analysis of this instrument has shown differing anatomical specificity of A and B errors 
(Cipolotti et al., 2016; Robinson et al., 2015). Further work will be necessary to understand 
these findings.  
 
Brain-behaviour covariations were stronger for betting behaviour in the virtual casino than for 
the neuropsychiatric instruments. The greater the connectivity of the subthalamic VAT with 
the reward evaluation network, the higher the bets made by participants, with an increase of 
one standard error in connectivity associated with an increased bet of AUD 31.1. The 
involvement of bilateral tracts connecting the site of stimulation with OFC is particularly 
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interesting given the role of this region in predicting outcomes after behavioural choices 
(Rudebeck and Murray, 2014) and contributing to prediction error signalling in ascending 
dopaminergic projections from the VTA (Takahashi et al., 2011). It also lends further support 
to the idea that spread of electrical stimulation into limbic regions of the STN can quantitatively 
influence impulsivity.  
 
An alternative explanation for these findings is that the subthalamic VAT modulates ascending 
dopaminergic fibres in the superolateral branch of the medial forebrain bundle (slMFB), which 
pass adjacent to the STN and onwards to vmPFC and OFC (Coenen et al., 2009; Coenen et al., 
2012). Lateral orbitofrontal branches of the slMFB traverse the VS via the anterior limb of the 
internal capsule, potentially explaining why the VS is also weighted heavily in the reward 
evaluation network for bet size (Coenen et al., 2018). Appetitive learning and reinforcement is 
underpinned by dopaminergic signalling within mesocorticolimbic networks (Haber and 
Knutson, 2010) and it is plausible that STN-DBS could directly affect the evaluation of reward 
in this manner outside of any direct effect on STN firing.  
 
The distinction observed between case-positive and case-negative participants in the effect of 
connectivity on bet size offers an insight into these alternative hypotheses. In case-negative 
individuals, the effect of connectivity has a strong positive valence, whilst visual inspection of 
individual discriminative fibres isolated from a normative connectome shows ascending tracts 
passing through the VTA and adjacent to the STN in the right hemisphere, distributed widely 
amongst vmPFC and OFC. Therefore, in such individuals, it is plausible that direct modulation 
of the slMFB is operating to mediate this relationship. However, in case-positive individuals, 
this relationship between connectivity and bet size is not observed, whilst visual inspection of 
discriminative fibres shows tracts between the STN and right OFC that do not extend into the 
diencephalon. These fibres conceivably represent ‘limbic hyperdirect’ projections, comprising 
direct cortical-STN connections that drive STN output and behavioural inhibition. These 
findings cohere with our previous work demonstrating that ventromedial dispersion of the 
stimulation field within the right STN was more likely to be associated with disinhibition and 
the development of clinically-significant hypomania and harmful impulsivity (Mosley et al., 
2018d).   
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A number of caveats need to be considered when interpreting these results. Firstly, our case-
positive participants were assessed after stimulation manipulation had taken place to remediate 
more florid neuropsychiatric symptoms. Therefore, the distribution of stimulation associated 
with clinical hypomania will have been slightly different to that recorded at the formal 
postoperative assessment. However, we could still discriminate these groups in our virtual 
casino even after resolution of clinically-significant symptoms. This suggests that our assay 
was relatively sensitive and arguably improves the robustness of our findings. Secondly, the 
methodology employed in the isolation of discriminative fibres from the normative 
connectome involved mass-univariate tests across many connected fibres without controlling 
for the false discovery rate and thus must be viewed with caution.  
 
In conclusion, STN-DBS is an established and valuable intervention for the motor symptoms 
of Parkinson’s disease. However, there are relatively frequent and important neuropsychiatric 
changes which appear to relate to the site and distribution of subthalamic stimulation. In 
particular, we have demonstrated that the structural connectivity of the site of stimulation with 
reward evaluation and response inhibition networks is a major determinant of postoperative 
impulsivity. Structural connectivity at baseline was not associated with postoperative 
neuropsychiatric outcomes, suggesting that electrode placement and accurate stimulation 
titration are key drivers of these non-motor outcomes, over-riding and even reversing 
preoperative effects. It further highlights the difficulty of identifying an ‘at-risk’ phenotype 
prior to neurosurgery. As more neurosurgical centres employ tractography to improve DBS 
electrode targeting, contact selection and current steering for Parkinson’s disease, we anticipate 
that these findings will assist with adapting these methods to address neuropsychiatric 
outcomes. 
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10.6 Supplementary Data 
Supplementary Table 10.5 | Postoperative Neuropsychological Variables and Gambling Behaviours by Post-DBS Caseness 
& Pre-DBS ICB Status 
† FDR-corrected with Benjamini and Hochberg method (1995), with ! = 0.05.  
Significance: *K < 0.05. **K < 0.01. ***K < 0.001 
 
Neuropsychological & Gambling Variables Assessed Post-DBS 
Assessment Instrument Case+ vs. Case– † ICB+ vs. ICB– † 
Levodopa equiv. daily dose t = -1.50 corr. p = 0.47 
t = -1.85 
corr. p = 0.24 
BIS Attentional t = 2.41 corr. p = 0.20 
t = -1.52 
corr. p = 0.25 
BIS Non-Planning t = -0.42 corr. p = 0.85 
t = -0.56 
corr. p = 0.67 
BIS Motor t = -0.051 corr. p = 0.96 
t = -1.52 
corr. p = 0.25 
QUIP-RS Total t = 1.16 corr. p = 0.54 
t = -2.37 
corr. p = 0.13 
Delay Discount q t = 0.68 corr. p = 0.83 t = 2.64 corr. p = 0.11 
Hayling AB Error Score t = -0.49 corr. p = 0.85 
t = -0.53 
corr. p = 0.67 
ELF Rule Violations t = -1.13 corr. p = 0.54 
t = -0.82 
corr. p = 0.60 
Virtual Casino Case+ vs. Case– † ICB+ vs. ICB– † 
Average Bet Size (AUD) t = 0.096 corr. p = 0.96 
t = -1.46 
corr. p = 0.25 
Double or Nothing Gamble 
(Percent) 
t = 2.07 
corr. p = 0.24 
t = -0.26 
corr. p = 0.80 
 
BIS = Barratt Impulsiveness Scale; ELF = Excluded Letter Fluency Task; ICB = Impulse Control Behaviours; QUIP-RS = 
Questionnaire for Impulsive-Compulsive disorders in PD Rating Scale; UPDRS = Unified Parkinson’s Disease Rating Scale 
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Supplementary Table 10.6 | Connectivity Weights in Response Inhibition Latent Variable BIS 
Fibre Tract Weight 
Left VAT - IFG -0.88 
Left VAT - SMA 0.76 
Right VAT - IFG 0.43 
Right VAT - SMA 0.15 
 
IFG = inferior frontal gyrus, SMA = pre-supplementary motor area, VAT = volume of activated tissue 
For the winning model, there was no significant effect of gender (K = 0.55) or disease subtype (K = 0.059). The left (K = 0.012) 
hemisphere in isolation evidenced a significant effect but the right (K = 0.58) did not.  
 
 
Supplementary Table 10.7 | Connectivity Weights in Reward Evaluation Latent Variable ELF Rule Violations 
Fibre Tract Weight 
Left VTA - VAT 0.52 
Left VAT - vmPFC 0.36 
Left VAT - OFC -0.0022 
Left VAT - VS 0.45 
Right VTA - VAT -0.11 
Right VAT - vmPFC 0.75 
Right VAT - OFC -1.00 
Right VAT - VS -0.0076 
 
OFC = orbitofrontal cortex, vmPFC = ventromedial prefrontal cortex, VS = ventral striatum, VAT = volume of activated 
tissue, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 1.0) or disease subtype (K = 0.74). Both the left (K = 
0.043) and the right (K = 0.046) hemispheres in isolation evidenced a significant effect. 
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Supplementary Table 10.8 | Connectivity Weights in Reward Evaluation Latent Variable Delay Discount p 
Fibre Tract Weight 
Left VTA - VAT 0.44 
Left VAT - vmPFC 0.016 
Left VAT - OFC -0.32 
Left VAT - VS 0.036 
Right VTA - VAT 0.79 
Right VAT - vmPFC 0.28 
Right VAT - OFC 0.30 
Right VAT - VS -0.56 
 
OFC = orbitofrontal cortex, vmPFC = ventromedial prefrontal cortex, VS = ventral striatum, VAT = volume of activated 
tissue, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.85) or disease subtype (K = 0.81). Neither the left (K 
= 0.40) nor the right (K = 0.071) hemispheres in isolation evidenced a significant effect. 
 
 
Supplementary Table 10.9 | Connectivity Weights in Reward Evaluation Latent Variable Bet Size 
Fibre Tract Weight 
Left VTA - VAT 0.33 
Left VAT - vmPFC -1.21 
Left VAT - OFC 0.52 
Left VAT - VS 0.47 
Right VTA - VAT 0.015 
Right VAT - vmPFC 0.54 
Right VAT - OFC 0.49 
Right VAT - VS -0.30 
 
OFC = orbitofrontal cortex, vmPFC = ventromedial prefrontal cortex, VS = ventral striatum, VAT = volume of activated 
tissue, VTA = ventral tegmental area 
For the winning model, there was no significant effect of gender (K = 0.53) or disease subtype (K = 0.054). Neither the left (K 
= 0.17) nor the right (K = 0.086) hemisphere in isolation evidenced a significant effect. 
 
 
-  
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Coefficients:  
1 = Brain-behaviour covariance at baseline (Brain_T1 ~ Behaviour_T1)  
2 = Behaviour to brain coupling (Behaviour_T1 → ∆Brain_T1)  
3 = Brain to behaviour coupling (Brain_T1 → ∆Behaviour_T1)  
4 = Correlated change in brain and behaviour (∆Brain_T1 ~ ∆Behaviour_T1) 
  
Baseline
Impulsiveness
Impulsiveness
Post-DBS
Baseline
Response Inhibition
Connectivity
Post-DBS 
Response Inhibition
Connectivity
∆	Impulsivity
∆	Connectivity
coeff: -2.38
p = 0.017 *
coeff: 1.74
p = 0.023 *
coeff: 0.031
p = 0.026 *
coeff: 1.55
p = 0.071
1
2
3
4
Supplementary Figure 10.5 | Cross-Lagged Model Results: BIS 
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Coefficients:  
1 = Brain-behaviour covariance at baseline (Brain_T1 ~ Behaviour_T1)  
2 = Behaviour to brain coupling (Behaviour_T1 → ∆Brain_T1)  
3 = Brain to behaviour coupling (Brain_T1 → ∆Behaviour_T1)  
4 = Correlated change in brain and behaviour (∆Brain_T1 ~ ∆Behaviour_T1) 
 
  
Baseline
Disinhibition
Disinhibition
Post-DBS
Baseline
Reward Evaluation
Connectivity
Post-DBS 
Reward Evaluation
Connectivity
∆	Impulsivity
∆	Connectivity
coeff: -0.51
p = 0.018 *
coeff: 0.34
p = 0.0050 **
coeff: 0.24
p = 0.10
coeff: 0.25
p = 0.12
1
2
3
4
Supplementary Figure 10.6 | Cross-Lagged Model Results: ELF Rule Violations 
Chapter 10  277 
 
 
 
Coefficients:  
1 = Brain-behaviour covariance at baseline (Brain_T1 ~ Behaviour_T1)  
2 = Behaviour to brain coupling (Behaviour_T1 → ∆Brain_T1)  
3 = Brain to behaviour coupling (Brain_T1 → ∆Behaviour_T1)  
4 = Correlated change in brain and behaviour (∆Brain_T1 ~ ∆Behaviour_T1) 
 
 
  
Baseline
Impatience
Impatience
Post-DBS
Baseline
Reward Evaluation
Connectivity
Post-DBS 
Reward Evaluation
Connectivity
∆	Impulsivity
∆	Connectivity
coeff: -0.46
p = 0.020 *
coeff: -0.013
p = 0.85
coeff: -0.11
p = 0.33
coeff: 0.033
p = 0.67
1
2
3
4
Supplementary Figure 10.7 | Cross-Lagged Model Results: Delay Discount k 
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Coefficients:  
1 = Brain-behaviour covariance at baseline (Brain_T1 ~ Behaviour_T1)  
2 = Behaviour to brain coupling (Behaviour_T1 → ∆Brain_T1)  
3 = Brain to behaviour coupling (Brain_T1 → ∆Behaviour_T1)  
4 = Correlated change in brain and behaviour (∆Brain_T1 ~ ∆Behaviour_T1) 
 
Baseline
Bet Size
Bet Size
Post-DBS
Baseline
Reward Evaluation
Connectivity
Post-DBS 
Reward Evaluation
Connectivity
∆	Impulsivity
∆	Connectivity
coeff: 0.53
p = 0.0050 **
coeff: 0.37
p = 0.059
coeff: 0.35
p = 0.056
coeff: 0.045
p = 0.78
1
2
3
4
Supplementary Figure 10.8 | Cross-Lagged Model Results: Bet Size 
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Chapter 11 
11 A Pilot Trial of Cognitive Behavioural Therapy for 
Caregivers after Subthalamic Deep Brain Stimulation for 
Parkinson’s Disease 
 ‘We haven't done any counselling at all and I think we need to. As a spouse, you need to be prepared that these 
things can happen and that husbands or partners can turn feral [wild] and not to - we were told not to take it to 
heart - whatever is said is said out of - they can't help it. But in saying that, that's kind of not enough. You still 
hold - I mean, I do - I still hold on to things that were said and things that were done because it's ultimately 
affected our relationship. That's something that I have to move on from but it's really difficult.’ 
Spouse of DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
11.1 Abstract 
Caregivers of persons with Parkinson’s disease may develop a negative psychological state, 
termed ‘burden’, in response to the demands of providing care and losses associated with the 
illness. Subthalamic deep brain stimulation is an established, advanced therapy that improves 
quality of life for people with Parkinson’s disease by treating motor symptoms of the disorder. 
However, evidence suggests that caregiver burden may not improve following deep brain 
stimulation and a group of persistently burdened caregivers has been identified in prior work. 
We developed an eight-session, manualised, program of cognitive-behavioural therapy (CBT) 
incorporating elements of education, stress management, thought-challenging, relaxation, 
training in assertive communication and lifestyle modification. This intervention was delivered 
to a pilot sample of ten caregivers (six females, mean age 60, age range 34-79). Primary 
outcome measures were caregiver burden assessed with the Zarit Burden Interview and 
caregiver quality of life assessed with the PDQ-Carer. Secondary outcome measures comprised 
ratings of depression and anxiety in the caregiver, in addition to relationship quality. Caregiver 
burden (t = 2.91 p = 0.017) and caregiver anxiety (t = 2.82 p = 0.020) symptoms were 
significantly reduced at completion of the program and these benefits were maintained three-
months later. Caregiver quality of life had significantly improved by the end of the intervention 
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(t = 3.02 p = 0.015) but this effect was not sustained after three-months. The longitudinal 
influence of participation in the program on caregiver burden was confirmed in a linear, mixed-
effects model (72 (3) = 15.1, K = 0.0017). The intervention was well received by participants 
and qualitative feedback was obtained. These results indicate that caregiver burden is 
modifiable in this cohort with a short course of CBT, that benefits are maintained after 
termination of the program and that psychotherapy is acceptable to participants. Larger, 
controlled trials are justified.  
11.2 Introduction 
Parkinson’s disease is a progressive and incurable neurodegenerative disorder that affects 
approximately 70,000 individuals in Australia. Informal spousal caregivers play a crucial role 
in the care of persons with Parkinson’s disease, including coordinating medical care, 
medication administration, communication and advocacy on behalf of their partner, 
surveillance of falls, provision of emotional support, and directly assisting with activities of 
daily living as the disease advances. In Australia, estimates suggest that informal Parkinson’s 
disease caregivers provide 19 million hours of care per year, with a cost equivalence of AUD 
78.2 million (USD 53.84 million (Deloitte Access Economics, 2015). However, being a 
caregiver for a person with Parkinson’s disease may affect psychological, social, financial, 
physical and spiritual wellbeing, leading to a negative emotional state termed ‘burden’ in the 
caregiver. Recognising caregiver burden is important because it reduces resilience and 
effectiveness, predisposing to psychiatric illness in the caregiver and premature 
institutionalisation of the person with Parkinson’s disease.  
 
Parkinson’s disease is a complex disorder with motor and non-motor symptoms. Motor 
symptoms include slowness, stiffness, tremor, freezing of gait and falls. Non-motor symptoms 
include depression, anxiety, apathy, impulse-control behaviours (ICBs), psychosis, cognitive 
impairment and sleep disorders (Weintraub and Burn, 2011). All of the symptoms of 
Parkinson’s disease may amplify caregiver burden, although non-motor symptoms are 
particularly problematic for caregivers when motor and non-motor symptoms are examined 
concurrently (Mosley et al., 2017b).  
 
Chapter 11  281 
 
 
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an advanced therapy for 
Parkinson’s disease that provides a relatively constant and predictable improvement in motor 
symptoms. Persons with Parkinson’s disease that receive STN-DBS may have a better outcome 
than those maintained on medication alone, expressed as an improvement in motor symptoms 
and a better self-rated quality of life (Schuepbach et al., 2013). However, the burden of 
caregivers may not improve and may even worsen subsequent to this procedure (Lewis et al., 
2014; Lewis et al., 2015; Oyama et al., 2014; Perozzo et al., 2001; Soileau et al., 2014). This 
may be related to the persistence or worsening of existing non-motor symptoms such as ICBs 
and cognitive impairment, the incidence of new stimulation-dependent psychiatric symptoms 
such as impulsivity and hypomania (Jahanshahi et al., 2015; Voon et al., 2006), symptoms 
related to the withdrawal of dopaminergic drugs such as anxiety, depression and apathy 
(Appleby et al., 2007; Thobois et al., 2010), as well as to role changes associated with the 
sudden relief of disability in the person-caregiver dyad (Mosley and Marsh, 2015a).  
 
Through clinical and research experience with this cohort, our group identified a group of 
caregivers that experience significant difficulties both before and after their spouse receives 
DBS. These caregivers typically report high burden at baseline, prior to DBS, which is 
primarily accounted for by non-motor symptoms including mood disorders and behavioural 
addictions. Unfortunately, the DBS procedure did not appear to modify longitudinal burden in 
a sample of these caregivers (Mosley et al., 2018a). We also conducted qualitative interviews 
with these individuals, which revealed enduring distress related to the non-motor symptom 
profiles of their partners (Mosley et al., 2019b). 
 
Existing data suggests that standardised psychotherapies may mitigate the burden of 
Parkinson’s disease caregivers (A'Campo et al., 2010a; A'Campo et al., 2010b; Secker and 
Brown, 2005; Simons et al., 2006). However, until now no intervention has been specifically 
developed to address the specific challenges faced by caregivers after STN-DBS. In this 
manuscript, we develop and test such a manualised psychological intervention. 
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11.3 Methods 
11.3.1 Participants & Recruitment 
Participants were spousal caregivers of persons with Parkinson’s disease who were undertaking 
or who had undertaken STN-DBS at St. Andrew’s War Memorial Hospital, Brisbane, 
Australia. All persons receiving STN-DBS at this centre are seen by a multidisciplinary team 
including a psychiatrist. The caregiver is encouraged to attend these appointments. Caregivers 
were consecutively recruited from psychiatry consultations based on a report of burden either 
before or after their spouse received DBS. The presence of at least mild to moderate burden 
was confirmed using a score of ³ 21 on the Zarit Burden Interview. Exclusion criteria included 
lack of proficiency in English, cognitive impairment (scoring < 25 on the Montreal Cognitive 
Assessment) and concurrent participation in alternative psychotherapies. Participants were 
allowed to continue antidepressant and anxiolytic medication if these had been commenced 
prior to the intervention.   
11.3.2 Intervention 
A CBT treatment manual was informed by published psychological interventions (Pasqualini 
et al., 2006). The complete study manual is available from the lead author on request and an 
abbreviated summary is reported in Table 11.1. Following a baseline assessment, participants 
completed an eight-session course of cognitive behavioural therapy at weekly intervals, 
including modules that addressed education, coping styles, stress management, relaxation, 
assertive communication, diet, exercise, sleep hygiene and social support. 
 
Each of the eight sessions were undertaken individually with the caregiver; the person with 
Parkinson’s disease receiving DBS did not participate. The duration of each session was 
approximately sixty minutes and followed a similar format, including a recap of the previous 
session, active exercises and the provision of homework and handouts. Face to face sessions 
took place in the clinic. If unable to attend in person, participants were able to complete sessions 
using internet videoconferencing software. The DBS centre in Brisbane services the state of 
Queensland, which is a large geographical area over twice the size of the US state of Texas. 
Therefore, facilitating access in this manner was important for the acceptability of this study to 
potential participants. The first session was completed with an experienced neuropsychiatrist 
(PM, RM) and the remaining sessions with a clinical psychologist (DP) or a provisional 
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psychologist under the supervision of DP. If caregivers enrolled prior to DBS, the first session 
of the program was arranged to coincide with the week of DBS device implantation.  
11.3.3 Assessment 
Primary outcome measures were burden, assessed with the Zarit Burden Interview (ZBI) (Zarit 
et al., 1980) (higher scores indicate greater burden) and quality of life, assessed with the 
Parkinson’s Disease Questionnaire – Carer (PDQ-Carer) (Jenkinson et al., 2012) (lower scores 
indicate greater quality of life). For the latter outcome measure, a single summary score was 
reported (Morley et al., 2013), although changes in domains scores were also reported if 
statistically-significant. Secondary measures included depressive symptoms, assessed with the 
Geriatric Depression Scale (GDS) (thirty item version) (Yesavage et al., 1982), anxiety 
symptoms, assessed with the Geriatric Anxiety Inventory (GAI) (Pachana et al., 2007) and 
relationship quality, assessed with the Relationship Quality Index (RQI) (Norton, 1983). 
Assessments took place at baseline, after the fourth session (midpoint), after the final session 
(endpoint) and three months subsequent to the final session (to assess for the persistence of 
therapeutic effects). At baseline, personality was evaluated using the Big Five Inventory (John 
et al., 2014), given the connection between trait neuroticism and caregiver burden in 
Parkinson’s disease (Tew et al., 2013). 
 
11.3.4 Statistical Analysis 
Data analysis was performed in the R software environment (R Core Team, 2014). The 
difference in caregiver burden, quality of life, relationship quality and psychiatric symptoms 
from baseline to program endpoint and from baseline to three months after program completion 
were examined using a paired two-sample t-test, after testing for normality with a Shapiro-
Wilk’s test. In order to explicitly characterise the longitudinal effect of participation in 
psychotherapy on burden and quality of life, a linear mixed-effects model was fit across all 
measurement intervals using lme4 (Bates et al., 2015). This model took the form: 
 
Outcome variableij ~ Timepointij + Agei + Neuroticismi + (1|ID) 
 
With i denoting participant and j denoting an interval from baseline to three-months post-
intervention. Models were adjusted for age and neuroticism at baseline, with random intercepts 
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specified for each participant. The term in bold (the effect of longitudinal progression through 
the intervention on outcome) is the coefficient of interest. Hypothesis testing on a null model 
(omitting timepoint) was performed with the anova function in the lavaan package (Rosseel, 
2012). Mixed effects models are preferred to a repeated-measures analysis of variance because 
of their ability to flexibly model time effects, infer upon the pattern of change in variability 
over time and represent complex patterns of covariation (Gueorguieva and Krystal, 2004).  
11.3.5 Participant Feedback 
At the end of the program, participants were asked to rate the content of each session on a 
Likert scale and provide an overall assessment of the intervention. In free-text responses, 
participants were asked: ‘What aspects of the therapy did you find most beneficial?’, ‘How will 
your approach to caregiving change as a result of this program?’ and ‘What would you like to 
see changed in the future?’. 
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Table 11.1 | Outline of the Cognitive Behavioural Therapy Intervention 
Session Summary Homework 
1: Introduction 
An overview of the program was provided. A semi-structured 
discussion with the caregiver recorded individualised sources of burden 
in the caregiving relationship and these were linked to specific 
interventions delivered later in the program. The psychiatrist provided 
education about motor & non-motor symptoms of PD, in addition to 
information about STN-DBS. Examples of common PD and DBS-
related stressors were used to check participants’ understanding.  
The participant was given 
a worksheet to assist with 
pleasant activity 
scheduling. 
2: Coping with 
Caregiving 
The concept of ‘burnout’ was introduced and the participant was 
encouraged to identify personalized cognitive, emotional and 
behavioural signs that could serve as ‘warning signs’ for this state.  
Helpful and unhelpful examples of emotion-focused and problem-
focused coping styles were discussed and the participant was asked to 
identify their predominant coping strategies. Finally, the participant 
generated some examples of positive coping strategies to address 
emergent warning signs of burnout. 
The participant was asked 
to review their 
predominant stressors 
related to caregiving and 
develop a target list, 
including a specific 
example of a stressful 
situation. 
3: Challenging Thoughts 
The cognitive model was introduced, highlighting the relevance of 
thought patterns on the caregiver’s ability to cope. The highlighted 
stressor from the preceding homework was used as a thought 
monitoring exercise. The participant was taught how to challenge 
automatic negative thoughts and given examples of thought 
challenging scripts to practice.  
The participant was 
instructed to record 
positive & negative 
cognitions in a real-world 
stressful scenario. 
4: Managing Stress 
The cognitive model was extended to show that stress can be 
moderated by the manner in which caregivers respond to stressful 
situations. Stress cycles (the connection between thoughts, feelings, 
sensations and responses) were used to illustrate how positive self-talk 
can remediate stress. The participant was trained to replace negative 
cognitions with positive alternatives. A brief introduction to problem-
solving was also completed.  
The participant 
transferred one of the 
positive alternative 
thoughts they created to a 
cue card, reading it 
whenever a stressful 
situation arose.  
5: Relaxation 
The participant was introduced to mindfulness, progressive muscle 
relaxation, controlled breathing and guided imagery. One form of 
relaxation was selected by the participant to explore in detail, which 
involved scripted relaxation guided by the facilitator and the provision 
of written guidelines.  
The participant committed 
to practicing their selected 
relaxation every day 
during the forthcoming 
week. 
6: Sleep, Exercise & 
Nutrition 
The prevalence and implications of disturbed sleep in PD caregivers 
was discussed and this was linked to sleep hygiene and PD-specific 
sleep disorders such as restless legs and rapid eye movement sleep 
behaviour disorder. A sleep diary was used to identify sleep problems 
and a plan was developed to address individual barriers to effective 
sleep. Medical co-morbidities in the caregiver were appraised and steps 
were taken to meet any outstanding health needs. Goals were set to 
increase physical activity and any dietary deficits were reviewed.  
The participant 
implemented a plan to 
address one aspect of 
sleep, exercise or 
nutrition. 
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7: Support & 
Communication 
The participant charted their extended support network and identified 
key personal, professional and institutional supports. Assertive 
communication was introduced to the participant and assertiveness was 
modelled during facilitated role play in various demanding scenarios. 
The participant agreed to 
ask for help using 
assertive language in the 
forthcoming week. 
8: Review & Relapse 
Prevention 
Key learning points from each session were recapped and the 
participant identified areas in which they had improved, as well as 
issues that required further attention. Early warning signs (thinking 
styles, behaviours and situations) indicative of relapse were identified 
and actions to take under these circumstances were agreed.  
- 
 
11.4 Results 
11.4.1 Participants 
Ten participants (Table 11.2) were recruited in this pilot phase (six females). Caregivers ranged 
in age from young adults to elderly, with a mean age of 60. On average, subthalamic DBS had 
been performed twelve months previously, although there was significant variability (0-84 
months). The sample was moderately burdened by caregiving, with a moderate impairment in 
quality of life and moderate levels of depression and anxiety. Sources of burden endorsed by 
caregivers at baseline during the semi-structured interview comprised motor and non-motor 
symptoms, communication difficulties, financial stressors and perceived lack of support 
(Figure 11.1). All participants completed the eight-session course and no data was missing.  
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11.4.2 Effect of Intervention on Primary and Secondary Outcomes 
11.4.2.1 Primary Outcomes 
Compared to baseline, caregiver burden was reduced at completion of the intervention (t = 2.91 
p = 0.017) and this was maintained three-months following the intervention (t = 2.85 p = 0.019). 
Caregiver quality of life improved by the end of the program (t = 3.02 p = 0.015) and this effect 
was driven by a significant reduction in the domain of stress (t = 2.39 p = 0.041). However, 
three-months subsequent to the completion of psychotherapy this effect was not maintained (t 
= 1.30 p = 0.23).  
11.4.2.2 Secondary Outcomes 
There was a significant reduction in anxiety symptoms at the end of psychotherapy (t = 2.82 p 
= 0.020) and this effect was maintained three-months after completion of the program (t = 2.96 
p = 0.016). There were no significant changes in depressive symptoms or relationship quality.  
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Figure 11.1 | Sources of Caregiver Burden at Baseline 
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11.4.2.3 Longitudinal Modelling 
In a linear mixed-effects model including age and baseline neuroticism there was a significant 
effect of progression through the psychotherapy program on caregiver burden (72 (3) = 15.1, K 
= 0.0017) but not on caregiver quality of life (72 (3) = 6.1, K = 0.11). Age and neuroticism did 
not moderate caregiver burden but a statistically-significant (although small) interaction was 
seen between age and quality of life (Table 3). The effects at each measurement interval (Table 
3) can be interpreted alongside visualised longitudinal trajectories for each participant (Figure 
2). For caregiver burden, this visualisation demonstrates that two participants did not respond 
to the programme of psychotherapy. These participants had very high levels of burden at 
baseline and significant co-morbid depressive and anxiety symptoms (Participant 06: GDS = 
27, GAI = 13, Participant 07: GDS = 18, GAI = 15).  
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Table 11.2 | Demographic and Clinical Characteristics of the Cohort 
Demographic Variables 
Total, Percentage 
Categorical Variable Total (n = 10) Percentage Total 
Gender n % total 
Male 4 40.0 
Female 6 60.0 
Continuous Variable Mean (SD), Median (Range) 
Age (Years) 60 (±16.6), 
67.5 (34 - 79) 
Time Since STN-DBS (Months) 21.3 (±26.6), 
12 (0 - 84) 
Big Five Inventory Openness: 3.3 (±0.57), 3.4 (2.1 - 4.1) 
Conscientiousness: 3.6 (±0.66), 3.6 (2.2 - 4.6) 
Agreeableness: 3.9 (±0.56), 3.8 (3.1 - 4.6) 
Extraversion: 3.3 (±0.56), 3.2 (2.6 - 4.4) 
Neuroticism: 3.2 (±1.02), 3.3 (1.3 - 4.9) 
Outcome Variables  
Mean (SD), Median (Range) 
Primary Outcomes Baseline CBT Completion 3 Months Post-CBT 
Zarit Burden Interview 41.1 (±10.6), 
42 (25 - 58) 
33.6 (±13.6), 
32 (17 - 57) 
34.9 (±12.7), 
35 (16 - 56) 
Change from Baseline - t = 2.91 
p = 0.017 * 
t = 2.85 
p = 0.019 * 
Parkinson’s Disease 
Questionnaire: Carer 
45.8 (±15.8), 
41.8 (24.1 - 75.9) 
38.3 (±15.0), 
35.8 (19.8 - 62.1) 
41.4 (±15.0), 
44.4 (14.7 - 61.2) 
Change from Baseline - t = 3.02 
p = 0.015 * 
t = 1.30 
p = 0.23 
Secondary Outcomes Baseline CBT Completion 3 Months Post-CBT 
Geriatric Depression Scale 12.1 (±8.5), 
10 (3 - 27) 
10.7 (±6.7), 
11 (1 - 22) 
9.1 (±5.6), 
9 (1 - 18) 
Change from Baseline - t = 1.01 
p = 0.34 
t = 1.72 
p = 0.12 
Geriatric Anxiety Inventory 8.8 (±6.1), 
10 (1 - 16) 
5.8 (±5.1), 
4 (0 - 14) 
5.4 (±5.4), 
4 (0 - 13) 
Change from Baseline - t = 2.82 
p = 0.020 * 
t = 2.96 
p = 0.016 * 
Relationship Quality Index 30.4 (±9.4), 
33 (11 - 40) 
31 (±9.3), 
34 (15 - 44) 
30.8 (±9.7), 
34.5 (14 - 41) 
Change from Baseline - t = -0.41 
p = 0.69 
t = -0.40 
p = 0.70 
 
Significance: *K < 0.05. **K < 0.01. ***K < 0.001 
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Table 11.3 | Linear Mixed-Effects Modelling of Primary Outcomes 
 Zarit Burden Interview PDQ-Carer 
Fixed Effects Estimates Estimate (Standard Error), Significance 
Age 
0.51 (±0.25), 
p = 0.068 
0.67 (±0.28), 
p = 0.039 * 
Neuroticism 
8.65 (±4.04), 
p = 0.058 
9.01 (±4.57), 
p = 0.077 
Midpoint 
-5.50 (±1.83), 
p = 0.0053 ** 
-3.97 (±2.89), 
p = 0.18 
Endpoint 
-7.50 (±1.83), 
p = 0.00028 *** 
-7.50 (±2.89), 
p = 0.015 * 
3-months Post-Intervention 
-6.20 (±1.83), 
p = 0.0019 ** 
-4.40 (±2.88), 
p = 0.14 
 
Significance: *K < 0.05. **K < 0.01. ***K < 0.001 
 
11.4.3 Participant Feedback 
The content of the intervention was rated highly by participants, with most reporting that they 
would participate again and encourage others to participate (Supplementary Figure 11.3). In 
qualitative feedback, participants stated that the most useful aspects of the program comprised 
relaxation and thought challenging. Participants indicated that they would be more assertive 
and practice better self-care as a result of the program. Several participants suggested a greater 
focus on practical aspects of caregiving, such as training in lifting their spouses after a fall or 
specific details of financial benefits available to caregivers. Feedback about the level of detail 
in the program was mixed: some participants felt rushed and would have preferred longer 
sessions or a greater number of sessions, whilst others felt that the material could have been 
more concisely delivered.  
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Figure 11.2 | Time Series of ZBI and PDQ-Carer Scores 
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11.5 Discussion 
We report the results of a pilot trial of manualised, cognitive-behavioural therapy for spousal 
caregivers of persons with Parkinson’s disease who have received subthalamic deep brain 
stimulation. We have previously shown that this cohort of caregivers is at risk of persistent 
burden, which is not modified by STN-DBS (Mosley et al., 2018a). However, the CBT 
intervention trialled in the present study significantly reduced caregiver burden, an effect that 
was maintained three-months after completion of the eight-week program. Likewise, caregiver 
anxiety symptoms were significantly reduced and this effect was maintained at three-month 
follow-up. Caregiver quality of life had improved at the end of the program but this effect was 
not sustained three-months later. The intervention was acceptable to participants and sessions 
were highly-rated.  
 
A novel aspect of this investigation is the inclusion of a specific group of caregivers who may 
face unique challenges after their spouse receives STN-DBS. The manualised CBT 
intervention was tailored to address specific challenges that may arise in the postoperative 
period, such as neuropsychiatric changes secondary to stimulation and withdrawal of 
dopaminergic medication, role changes in the relationship subsequent to relief of disability and 
progression of existing non-motor problems such as cognitive impairment. Additional 
strengths of this study include the mix of genders, the large age range of participants and the 
wide variation in the length of time since STN-DBS was carried out. This suggests that the 
intervention has promising generalisability amongst a range of caregivers. The manualised 
nature of the program means it can be extended to a larger group of caregivers and shared 
amongst clinics in a straightforward manner. Limitations include the small sample size and the 
uncontrolled nature of the investigation.  
 
The burden of two participants did not change following this program and it is interesting that 
these participants reported very high levels of burden at baseline, with significant comorbid 
anxiety and depressive symptoms. Neither of these participants were receiving 
pharmacological treatment for anxiety and depression. Further work will establish if this is a 
consistent association, whether there is a ‘ceiling’ of burden above which psychotherapy alone 
is less effective and whether the presence of significant co-morbid psychiatric symptoms at 
baseline requires a combined psychiatric and psychological approach. This investigation also 
did not find a significant effect of baseline neuroticism on response to psychotherapy and 
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further work in a larger sample will be required to establish if temperament has a moderating 
effect.  
 
In response to participant feedback, future modifications to the manualised program may also 
include more specific practical and financial advice, as well as the opportunity to provide extra 
sessions to caregivers who require a slower approach. Comparison with an active control, such 
as an educational module delivered alone, will also be necessary to demonstrate the specificity 
of psychotherapy. 
 
In summary, this study indicates that burden amongst caregivers of persons with Parkinson’s 
disease after STN-DBS is not intractable and can be ameliorated with a short course of 
manualised and tailored cognitive-behavioural therapy. Larger, controlled trials are justified in 
this population.  
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11.6 Supplementary Data 
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Chapter 12 
12 Conclusions 
‘Even though we've had our highs and lows it's given me my life back. I'd probably go through it all again, and 
that sounds stupid, but as long as I didn't have to put everyone else through the same - knowing that as long as I 
didn't have to do that, that'd be fine. But me myself going through that to get where I am now, yeah, definitely 
well worth the effort.’ 
DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic deep brain 
stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
12.1 Overview 
This study recruited a total of ninety-one persons with Parkinson’s disease and their caregivers 
to a longitudinal investigation of neuropsychiatric outcomes following subthalamic DBS for 
Parkinson’s disease. Each patient-caregiver dyad was followed for a total of six-months 
postoperatively and data was collected at multiple postoperative intervals, allowing causal 
inferences to be made upon the trajectory of symptoms and their correlates. Strengths of this 
study included its multimodal nature, incorporating questionnaire-derived data, 
neuropsychiatric assessment, qualitative interviews, computational tasks and sophisticated 
neuroimaging analyses. A further strength included the explicit incorporation of caregiver 
perspectives, recognising them both as partners in healthcare and as the ‘forgotten patient’. The 
findings of this investigation promise to improve the recognition and treatment of caregiver 
burden in Parkinson’s disease, contribute to a mechanistic understanding of neuropsychiatric 
symptoms after subthalamic DBS, as well as motivating new techniques for prospectively 
minimising neuropsychiatric side effects.  
12.1.1 Caregiver Burden is Mediated by Neuropsychiatric Symptoms 
Caregiver burden in Parkinson’s disease is strongly influenced by the neuropsychiatric features 
of this neurodegenerative disorder (Chapter 2) and, in our cohort, this was the case pre- and 
postoperatively, during which intervals impulsiveness, lack of empathy, depression, 
disinhibition and compulsivity led to increased burden (Chapter 5). Neuropsychiatric 
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symptoms directly attributable to subthalamic stimulation, such as mood elevation and 
impulsivity, also increased caregiver burden (Chapter 5). In severe cases, the impact of these 
symptoms was profound (Chapters 4 and 6) with lasting personal, relational and social 
impairment.  
12.1.2 Profiles of Caregiver Burden are Stable Longitudinally 
Although stimulation-dependent neuropsychiatric symptoms increase caregiver burden, at a 
cohort-level, longitudinal trajectories of caregiver burden and caregiver appraisal of 
neuropsychiatric symptoms were stable and were not moderated by subthalamic DBS. 
Therefore, if a person with Parkinson’s disease was judged by their caregiver to be impulsive, 
lacking in empathy and to have poor interpersonal relationships pre-DBS, then this burdened 
caregiver was likely to maintain this perspective post-DBS. The reverse was also true; those 
caregivers of patients with few (caregiver-appraised) neuropsychiatric symptoms at baseline 
were likely to remain unburdened and rate their spouses as symptom-free postoperatively. This 
emphasises that although STN-DBS can result in significant improvements in motor symptoms 
and quality of life amongst persons with Parkinson’s disease, the burden of caregivers may not 
change, which appears related to the prevalence of comorbid neuropsychiatric symptoms at 
baseline. It underscores the importance of seeking caregiver perspectives in the appraisal of 
surgical outcomes and the potential for detecting (and addressing) caregiver burden prior to 
neurosurgery based on the presence of neuropsychiatric comorbidity. 
12.1.3 Stimulation-Dependent Neuropsychiatric Symptoms Are Not Expected by 
Caregivers 
Unexpected and harmful neuropsychiatric symptoms occurred after STN-DBS, despite the 
oversight of a large and experienced movement disorders centre that followed best practice 
guidelines, including an embedded psychiatrist, preoperative psychiatric evaluation of all 
surgical candidates and a preoperative education programme delivered to spousal caregivers 
(Chapter 6). Our participants perceived that ill-preparedness impaired their capacity to respond 
and cope with neuropsychiatric symptoms, and often delayed their help-seeking responses, 
highlighting the importance of delivering preoperative education in a manner that is memorable 
and meaningful. 
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12.1.4 The Site and Distribution of Subthalamic Stimulation Influences 
Neuropsychiatric Outcomes 
The causal link between the site of subthalamic stimulation and the emergence of postoperative 
neuropsychiatric symptoms after STN-DBS was supported by empirical data (Chapter 7). By 
simulating a volume of activated tissue for each participant, the spread of charge from the 
active electrode contact was represented. Consistent with the known gradient of cortical 
representations within the STN, stimulation diffusion within more ventromedial aspects of this 
nucleus played an important role in mediating neuropsychiatric outcomes. This extends 
previous work on the importance of electrode targeting and stimulation titration for optimal 
motor outcome and corroborates existing data on the functional anatomy of this nucleus, 
derived from non-human primates and neuroimaging data in healthy subjects. Classification 
methods were able to identify ‘cases’ of neuropsychiatric impairment with reasonable 
accuracy, based purely on anatomical data derived from the modelling of electrode location 
and dispersion of the stimulation field. Data such as these could be used prospectively to guide 
DBS titration and enhance the safety profile of STN-DBS. 
12.1.5 Uncertainty Offers a Computational Understanding of Impulsivity after 
Subthalamic DBS 
Gambling behaviours in a virtual casino indexed postoperative changes in self-rated 
impulsivity in a sample of persons with Parkinson’s disease after STN-DBS (Chapter 8). In 
addition, participant-specific estimates of volatility (uncertainty about the tendency of a slot 
machine to pay out), as well as stochasticity in belief-to-choice mapping, increased after STN-
DBS. Notably, the greater the magnitude of these changes in model-based uncertainty, the 
greater the impulsivity amongst participants. This implicates the STN in the modulation of 
outcome certainty and lends further support to an account of impulsivity in which high 
subjective uncertainty leads to lack of predictability and thus increases a tendency for short-
term reward seeking and exploration. The potential of a naturalistic assessment of gambling 
behaviour to explain changes in impulsivity could be valuable in Parkinson’s disease, given 
the significant, but poorly quantified risks relating to surgical (neurostimulation) and medical 
(dopamine agonist) treatments.  
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12.1.6 Impulsivity and Gambling Behaviour in Parkinson’s Disease Co-Varies with the 
Structural Connectivity of ‘Choosing’ and ‘Stopping’ Networks 
The structural connectivity of distinct reward evaluation and response inhibition networks were 
found to underlie discrete aspects of impulsivity (Chapter 9). The contribution of each network 
and the relative influence of each hemisphere was dissociated by the neuropsychiatric construct 
or gambling behaviour under investigation, supporting the conceptualisation of impulsivity as 
a multifaceted construct. Furthermore, persons with a history of impulse-control behaviours 
(ICBs) could be differentiated from those without ICBs in the virtual casino when the 
interaction of betting behaviour, dopaminergic medication dosage and structural connectivity 
was examined. These findings demonstrate the potential of employing naturalistic paradigms 
and neuroimaging techniques in clinical settings to assist in the identification of those 
susceptible to harmful behaviours. 
12.1.7 Impulsivity and Gambling Behaviour after Subthalamic Deep Brain Stimulation 
Relates to the Structural Connectivity of the Stimulation Field 
Identifying persons with Parkinson’s disease at high risk of postoperative neuropsychiatric 
complications before they undertake STN-DBS has proved challenging. In this cohort, 
postoperative impulsivity and gambling behaviour co-varied with the structural connectivity of 
frontostriatal networks (reward evaluation and response inhibition) incorporating the field of 
stimulation. Notably, structural connectivity of these networks at baseline (prior to DBS) did 
not associate with postoperative behaviour, suggesting a primary role for the locus and 
distribution of stimulation in explaining this variance, and signifying that electrode placement 
and accurate stimulation titration are key drivers of these non-motor outcomes. Furthermore, 
individuals who developed postoperative changes in mood and clinically-significant impulsive 
behaviour (‘cases’) could be discriminated by the interaction of connectivity and betting 
behaviour in the virtual casino.  
12.1.8 Caregiver Burden and Caregiver Quality of Life Responds to a Course of 
Psychotherapy in a Pilot Trial 
A course of manualised cognitive behavioural therapy was developed and delivered to a small 
group of burdened caregivers in a pilot trial (Chapter 11). This program specifically targeted 
spousal caregivers of persons with Parkinson’s disease reporting high levels of burden before 
and after subthalamic DBS. In contrast to the cohort-level findings in Chapter 5 (where the 
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observed longitudinal profile of burdened caregivers remained unchanged) burden and quality 
of life did prove to be modifiable with psychotherapy amongst this smaller group. Moreover, 
benefits from psychotherapy were maintained at follow up.  
12.2 Limitations 
Limitations and caveats pertaining to the findings of each chapter have been presented with the 
relevant text. A more general limitation of this thesis pertains to its single-site nature, which 
necessarily constrains the generalisability of these findings. To some extent this is a necessary 
corollary of the intensive, frequent sampling of participants throughout the investigation, which 
would have been difficult to implement in a multi-site design without a large investigative 
team. However, there remains the possibility that local factors unique to the participant profile 
and neurological / neurosurgical treatment protocol could have influenced each result. 
However, our practice of placing our code and analyses into the public domain makes it 
possible for other centres to replicate our methods. 
12.3 Future Work 
12.3.1 Psychotherapy for Caregivers 
The promising pilot trial of psychotherapy will be extended to a larger group of caregivers 
reporting elevated burden and poor relationship quality prior to STN-DBS, as part of a 
controlled trial. The threshold for entry into the intervention will be determined by a 
psychiatrist conducting a formal preoperative psychiatric assessment, as part of an assessment 
of family functioning, in combination with formal rating scales. Comprehensive education 
regarding the role of DBS in the treatment of Parkinson’s disease will also be included, in order 
to prepare caregivers for potential neuropsychiatric complications and ensure that expectations 
about the benefit of DBS are realistic. However, this will be supplemented with modules 
addressing burnout, coping styles, relaxation, assertive communication, physical health and 
support, as detailed in Chapter 11. A control arm comprising education alone will be used as a 
comparator.  
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12.3.2 Prospective Prevention of Neuropsychiatric Symptoms 
The methods and knowledge developed in this thesis will be used prospectively to predict and 
prevent postoperative neuropsychiatric symptoms in persons with Parkinson’s disease 
undertaking STN-DBS. Following DBS device implantation and electrode localisation, the 
process of stimulation titration will be actively guided by the modelled distribution of the 
stimulation field in relation to the structure of the STN and key frontostriatal networks 
implicated in postoperative impulsivity. Importantly, the Lead-DBS toolbox is sufficiently 
streamlined to facilitate this process in real time, which will be a key factor in determining the 
acceptability of this approach amongst clinicians in the DBS team. Such a study could 
contribute to the evidence base supporting the routine use of these technologies in clinical 
practice.  
12.4 Summary 
Subthalamic deep brain stimulation is a transformative intervention that reduces suffering and 
improves quality of life for many people affected by Parkinson’s disease. However, 
Parkinson’s disease is a complex disorder and co-morbid neuropsychiatric symptoms can 
influence the postoperative trajectory of persons with Parkinson’s disease and the wellbeing of 
their family caregivers. This thesis has comprehensively examined the anatomical and 
computational underpinnings of stimulation-dependent neuropsychiatric symptoms after STN-
DBS and has characterised the impact of these symptoms on persons with Parkinson’s disease 
and their spouses. The state of the art techniques developed in this work promise to reduce the 
incidence of postoperative neuropsychiatric complications in Parkinson’s disease, but will also 
be applicable to other neuropsychiatric disorders in which the interaction of brain connectivity, 
behaviour and risk has yet to be quantified. 
 
It has been a pleasure to work on this project and once again I thank my supervisor Professor 
Michael Breakspear and the study participants for generously contributing their time and 
experiences to the advancement of scientific knowledge.  
 
 ‘I have a sense that while there's a lot of experience around, there's not a lot of firm, really solid knowledge 
about what happens once we start tweaking [adjusting the DBS]. It's very - there's a real trial and error aspect 
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to it, which I probably thought would be less the case - that it would be more known, more rigorous if I can put 
it that way. I understand that it's a fairly new technology, so we're part of that developing of that rigour.’ 
Spouse of DBS patient, quoted in: ‘A qualitative analysis of neuropsychiatric symptoms following subthalamic 
deep brain stimulation for Parkinson’s disease’ (Mosley et al., 2019b). 
 
.
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Appendix A 
13 Ethics Approval Letters (Appendix A) 
13.1 University of Queensland 
 
HREC approval University of Queensland 
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13.2 Royal Brisbane and Women’s Hospital 
 
HREC approval Royal Brisbane and Women’s Hospital 
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13.3 Uniting Care Health 
 
HREC approval Uniting Care Health 
  
 
 
 
 
 
 
The UnitingCare Health Human Research Ethics Committee is constituted and operates in accordance with the National Health and Medical Research Council’s 
Statement on Human Experimentation and Supplementary Notes 
 
 
  
8 May 2014  
 
Please quote our reference:  1406 
 
  
 
Dear Dr Mosley, 
 
RESEARCH PROPOSAL: Impulsivity and Caregiver Commitment after Deep brain Stimulation for Parkinson's disease 
INVESTIGATORS:  Dr Philip Mosley, Prof Michael Breakspear, Prof Wayne Hall, Dr Adrian Carter, Prof Peter Silburn, Dr Rodney 
Marsh, Dr Nadeeka Dissanayaka    
 
I am pleased to advise that the UnitingCare Health Human Research Ethics Committee has reviewed the abovenamed research proposal and 
at its meeting on 1 May 2014 granted ethical approval, subject to the following inclusions.  
 
• Approval letter from the Hospital Manager at St Andrew’s Hospital 
• A statement should be included in the PIS which advises that subjects will be told of any unforseen risks that may be identified. 
• An inclusion on the PIS alongside the other groups endorsing the project towards the end of the PIS to advise that the study has 
been reviewed and approved by the UCH HREC.  
 
Thank you for your response to our request, I am now able to approve your application. 
 
If your project involves inpatients or the use of hospital facilities, it will be necessary for you to obtain the approval of the Director of Medical 
Services of the relevant hospitals before commencement.  
 
It is a strict condition of approval that any departure from the protocol detailed in the proposal submitted for approval be reported 
immediately to the Committee. If there is any change to the status of the project, this should be reported also. 
 
Approval for the project is given subject to your agreement to UnitingCare Health requirements for the monitoring of research (see overleaf), 
which have been based on the Australian Health Ethics Committee guidelines. Please note the requirement to submit a report annually or at 
the completion of the project, as appropriate. 
 
With best wishes 
 
Yours sincerely 
 
 
Douglas Killer MBBS FRACP 
Executive Officer 
 
Ethics Committee Approval 
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Appendix B 
14 Qualitative Interview Schedule (Appendix B) 
14.1 Introduction 
i. Explain background and significance of the study 
ii. Explain that all responses given during the interview are confidential 
iii. Explain that some questions may cover sensitive material. If the participant feels 
uncomfortable, they may pause or decline to answer the question 
iv. Explain that participants may choose to withdraw from the study at any time without 
affecting their care 
14.2 Parkinson’s Disease and DBS 
i. When were you diagnosed with PD? 
ii. When did you undergo DBS? 
iii. How did PD affect you prior to DBS? 
iv. When did you first start to think about DBS? 
v. Why did you choose to have DBS? 
vi. What were your experiences after DBS? 
vii. Successful? 
viii. Side-effects? 
ix. Time course? 
x. Changes in stimulation? 
xi. What were you told about the likely benefits of DBS? 
xii. Before the surgery, did a health professional (neurologist, psychiatrist, nurse) discuss any 
side effects of the procedure? 
xiii. What did they tell you about? 
xiv. What did they tell you to do if you developed side effects? 
xv. Was there any information that you weren’t told that would have helped? 
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14.3 Screening for Impulsive Behaviours 
Correlate with the QUIP-RS completed in the neuropsychological arm of the investigation to 
identify any major impulse-control disorders 
14.3.1 General 
i. Since DBS have you found yourself acting more impulsively – i.e. on the spur of the 
moment? 
ii. Can you tell me more about this? 
iii. Have your interests changed after DBS? 
iv. Have other people told you that your personality has changed in any way? 
v. Do you think that your personality has changed? 
14.3.2 Pathological Gambling 
i. Since DBS have you gambled (including: casino, internet gambling, lotteries, scratch 
tickets, betting, slot or poker machines)?  
ii. How often and for how much money?  
iii. Do you think that you gamble too much?  
iv. Do others think that you gamble too much? 
v. Do you have difficulty controlling your gambling behaviours (such as increasing them over 
time, or having trouble cutting down or stopping them)? 
vi. Do you feel guilty or anxious about gambling? 
vii. Have you ever lied to your family (or your doctor) about how much you spend on 
gambling? 
14.3.3 Compulsive Buying 
i. Since DBS, have you had urges to go shopping or buy things? 
ii. Do you ever have trouble controlling how much you buy/spend? 
iii. How often do you think about shopping?  
iv. Do you ever buy things that you do not necessarily need or already have?  
v. Do you feel guilty or anxious about having bought useless things? 
vi. Do you feel restless or irritable if you do not buy something that you wanted? 
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vii. Do you ever buy things in order to feel better about yourself (e.g. to run away from 
problems, to break away from feelings of guilt or anxiety)? 
viii. Have you ever lied to your family (or your doctor) about how much you spend on shopping? 
14.3.4 Compulsive Eating 
i. Since DBS, have you experienced an issue with eating behaviours (such as eating larger 
amounts or different types of food than in the past, more rapidly than normal, until feeling 
uncomfortably full, or when not hungry)? 
ii. Are there any particular types of food you crave or have compulsions to eat? 
iii. Do you tend to eat a large amount of food in a very short time? 
iv. Do you feel that you lose control while you are eating (i.e. you feel that you are unable to 
stop eating or choose what you are eating)? 
v. Do you feel anxious, restless or agitated if food is not readily available when you have 
compulsions to eat? 
vi. Have you noticed any changes in your weight?  
vii. How much? 
14.3.5 Hypersexuality 
Some people with Parkinson’s disease can experience a change in their sexual drive or can 
develop new sexual interests (normalize the situation to make participant more comfortable). 
This could be an increase or decrease in thoughts about sex, engaging in sex, pornography etc. 
 
i. Have you noticed any changes in your interest in sex since DBS?  
ii. How would you describe your sex drive? 
iii. Do you ever feel that your sexual desire is excessive?  
iv. Do you think that you have an issue with this (such as having trouble keeping thoughts out 
of your mind or feeling guilty)?  
v. Do you have sexual fantasies very often?  
vi. Do you ever act, or have urges to act, on these sexual desires or fantasies? 
vii. Have you noticed any changes in your sexual behaviour since DBS? 
viii. Does anyone you are close to you worry about your sexual behaviour?  
ix. Have your sexual habits ever seriously interfered with your family or social life? 
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14.3.6 Punding and Hobbyism 
i. Do you have any specific hobbies or participate in other organised activities (e.g. writing, 
painting, gardening, home improvement)? 
ii. How often do you do these? 
iii. Since DBS, has your interest in these increased? 
iv. Do you ever spend a lot of time on specific tasks or activities? 
v. Repairing or dismantling things? 
vi. On the computer? 
vii. Using other technological gadgets  
viii. Working on projects?  
ix. Cleaning or tidying? 
x. Sorting, ordering, or arranging objects? 
xi. Walking or driving with no intended purpose? 
xii. Anything else you can think of? 
xiii. Do others think that you spend too much time doing any of these things? 
14.4 Chronology 
i. When did you first have a desire to engage in these behaviours or have these thoughts? 
ii. Do you think that they emerged before or after DBS? 
iii. Have you ever engaged in these behaviours before DBS? 
iv. What prevented you from engaging in these behaviours before DBS? 
v. Since DBS, has there been any change in the frequency of these behaviours or thoughts 
(i.e. are they getting better, worse or staying the same)? 
14.5 Impairment 
i. Do you think that these thoughts or behaviours are excessive or unreasonable? 
ii. Do they cause you distress or concern? 
iii. Do they cause anyone else distress or concern? 
iv. How has your family / partner / carer reacted? 
Have they caused: 
v. Financial hardship? 
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vi. Difficulties at work? 
vii. Interference with your normal routine? 
viii. Interference with social activities? 
ix. Difficulty with relationships? 
14.6 Treatment 
i. Have you spoken to anyone about these behaviours (partner or friend, GP, neurologist, 
psychologist or psychiatrist)? 
If no: 
ii. Why not?  
iii. Would you like to speak to someone about these behaviours? 
iv. Would you like to receive treatment for these behaviours? 
If yes:  
v. What did they say to do about it? 
vi. What treatment(s) have you received?  
vii. Adjusted or decreased PD medications? 
viii. Psychotherapy or counselling (psychologist or a psychiatrist)? 
ix. Prescribed new drugs?  
x. Behavioural therapy? 
xi. Adjusted DBS? 
xii. Other strategies? Please specify 
xiii. Did this treatment reduce or stop your engagement in these behaviours? 
xiv. Did this treatment reduce or stop your thoughts about these activities? 
xv. Did this treatment reduce or stop your interest in engaging in these activities? 
xvi. Have you ever tried to hide these behaviours from anyone (partner or friend, GP, 
neurologist, psychologist or psychiatrist)? 
xvii. Why? 
14.7 Autonomy and Responsibility 
i. Can you describe your thoughts or feelings when engaging in this behaviour? 
ii. Do you enjoy engaging in this behaviour?  
iii. Beforehand? 
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iv. During? 
v. After? 
vi. Do you feel that you have control over this behaviour? 
vii. What happens when you lose control over your behaviour? 
viii. Can you describe a recent time when you felt you lost control over this activity? 
ix. How did this make you feel?  
x. Do you avoid situations, people or places that will give you the urge of engaging in these 
behaviours? 
xi. Do you use other strategies to stop you from engaging in these behaviours or losing control 
(e.g. limits on financial transactions)? 
xii. Do you ever feel that you struggle to resist urges to engage in this behaviour? 
xiii. Do you wish to stop engaging in this behaviour? 
xiv. How often? 
xv. Why? 
xvi. Have there been any adverse consequences associated with this activity? 
xvii. Do you think about these consequences before engaging in the activity? 
xviii. How do you think it would make you feel if you weren’t able to go engage in the behaviour 
anymore? 
xix. Do you feel responsible for this behaviour and the harm that is caused by it? 
xx. Would you describe your behaviour as a compulsion? An addiction? 
14.8 Identity 
i. Where do you think these urges are coming from?  
ii. What do you think is driving this urge? 
iii. Do you ever feel that these behaviours, thoughts or desires are being imposed on you or are 
beyond your control? 
iv. Do you think that thoughts about these activities or the urge to engage in them are the 
product of your own free will? 
v. Do you ever feel that the DBS has caused you to have these thoughts or desires or to engage 
in these activities?  
vi. Is the behaviour consistent with the desires you had prior to DBS? 
vii. Do you think that your behaviour is consistent with who you really are or how you see 
yourself? 
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viii. Do you have a belief about how the mind and brain are related? Has your experience with 
DBS changed this? 
ix. What role do you think changes in your brain have on who you are, your thoughts and your 
interests? How has your experience of PD informed this? How has your experience of DBS 
informed this? 
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